_golden	chemical_id	chemical_name	comment_box_gold_reason	disease_id	disease_name	form_sentence	original_job_id	pmid	relation_pair_id	uniq_id	useless_column_gold	useless_column_gold_reason	verify_relationship_gold	verify_relationship_gold_reason
TRUE	D010672	"<span class=""chemical"">phenytoin</span>"		D011605	"<span class=""disease"">psychosis</span>"	"The case of a nonepileptic patient who developed <span class=""disease"">psychosis</span> following <span class=""chemical"">phenytoin</span> treatment for trigeminal neuralgia is described."	760841.0	14698717	14698717_D010672_D011605	bcv_easy_3152_job_760841_testq	"test
other
experiment"	ignore_this	yes_direct	The patient developed psychosis after receiving phenytoin.
TRUE	D001379	"<span class=""chemical"">azathioprine</span>"		D009369	"<span class=""disease"">cancers</span>"	"There have been several long-term studies of patients with rheumatoid arthritis treated with <span class=""chemical"">azathioprine</span> and cyclophosphamide and the incidence of most of the common <span class=""disease"">cancers</span> is not increased."	760841.0	3970039	3970039_D001379_D009369	bcv_easy_2200_job_760841_testq	"test
other
experiment"	ignore_this	no_relation	Azathioprine had no effect on cancer prevalence in the patients.
TRUE	D011433	"<span class=""chemical"">propranolol</span>"		D016584	"<span class=""disease"">panic disorders</span>"	"The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and <span class=""chemical"">propranolol</span> (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with <span class=""disease"">panic disorders</span> and agoraphobia were investigated in a double-blind, randomized and crossover design."	760841.0	6387529	6387529_D011433_D016584	bcv_easy_174_job_760841_testq	"test
other
experiment"	ignore_this	no_relation	The sentence says that the effects of diazepam and propranolol on patients was investigated. The sentence does not state what the effect was.
TRUE	D004837	"<span class=""chemical"">adrenaline</span>"		D001281	"<span class=""disease"">atrial fibrillation</span>"	"An increase in blood pressure, accompanied by <span class=""disease"">atrial fibrillation</span>, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing <span class=""chemical"">adrenaline</span> 0.225 mg, for correction of Dupuytren's contracture."	760841.0	9698967	9698967_D004837_D001281	bcv_easy_762_job_760841_testq	"test
other
experiment"	ignore_this	yes_direct	Giving mepivacaine and adrenaline together caused the male patient to experience atrial fibrillation.
TRUE	D007654	"<span class=""chemical"">ketoconazole</span>"		D006973	"<span class=""disease"">hypertension</span>"	"In both cases normal plasma and urinary free cortisol levels had been achieved following <span class=""chemical"">ketoconazole</span> therapy, yet continuous blood pressure monitoring demonstrated <span class=""disease"">hypertension</span> 31 (patient 1) and 52 weeks (patient 2) after treatment."	760841.0	2632720	2632720_D007654_D006973	bcv_easy_58_job_760841_testq	"test
other
experiment"	ignore_this	yes_direct	Long-term patient monitoring showed that both patients had hypertension after receiving ketoconazole therapy.
TRUE	D002945	"<span class=""chemical"">cisplatin</span>"		D064420	"<span class=""disease"">toxicity</span>"	"We initiated a phase I/II trial to determine the response and <span class=""disease"">toxicity</span> of escalating paclitaxel doses combined with fixed-dose <span class=""chemical"">cisplatin</span> with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma."	760841.0	8643971	8643971_D002945_D064420	bcv_easy_2217_job_760841_testq	"test
other
experiment"	ignore_this	no_relation	The sentence says that the response and toxicity of paclitaxel with cisplatin was studied, but does not say what the result was.
TRUE	D012964	"<span class=""chemical"">na</span>"		D012640	"<span class=""disease"">Seizure</span>"	"METHODS: Cholinergic convulsant sensitivity was examined in alcohol-<span class=""chemical"">na</span>  ve Withdrawal <span class=""disease"">Seizure</span>-Prone (WSP) and-Resistant (WSR) mice."	760841.0	12198388	12198388_D012964_D012640	bcv_easy_847_job_760841_testq	"test
other
experiment"	ignore_this	ner_mistake	"""na"" does not represent a chemical in this context. There seems to be an error with ""alcohol-na ve"" since ""ve"" is not a word."
TRUE	D014031	"<span class=""chemical"">tobramycin sulfate</span>"		D006311	"<span class=""disease"">ototoxicity</span>"	"Gentamicin sulfate and <span class=""chemical"">tobramycin sulfate</span> continue to demonstrate <span class=""disease"">ototoxicity</span> and nephrotoxicity in both animal and clinical studies."	760841.0	7420681	7420681_D014031_D006311	bcv_easy_2055_job_760841_testq	"test
other
experiment"	ignore_this	yes_direct	Tobramycin sulfate causes ototoxicity in animals and humans.
TRUE	D014700	"<span class=""chemical"">Verapamil</span>"		D006973	"<span class=""disease"">hypertensive</span>"	"<span class=""chemical"">Verapamil</span> withdrawal as a possible cause of myocardial infarction in a <span class=""disease"">hypertensive</span> woman with a normal coronary angiogram."	760841.0	3173179	3173179_D014700_D006973	bcv_easy_1910_job_760841_testq	"test
other
experiment"	ignore_this	no_relation	Verapamil was used by a woman with hypertension, but the sentence does not say that verapamil causes hypertension.
TRUE	D002110	"<span class=""chemical"">caffeine</span>"		D014693	"<span class=""disease"">ventricular fibrillation</span>"	"We describe a 25-year-old woman with pre-existing mitral valve prolapse who developed intractable <span class=""disease"">ventricular fibrillation</span> after consuming a ""natural energy"" guarana health drink containing a high concentration of <span class=""chemical"">caffeine</span>."	760841.0	11419773	11419773_D002110_D014693	bcv_easy_298_job_760841_testq	"test
other
experiment"	ignore_this	yes_direct	She developed ventricular fibrillation after consuming the health drink containing caffeine.
TRUE	D000082	"<span class=""chemical"">acetaminophen</span>"		D007676	"<span class=""disease"">ESRD</span>"	"The possibility that habitual use of <span class=""chemical"">acetaminophen</span> alone increases the risk of <span class=""disease"">ESRD</span> has not been clearly demonstrated, but cannot be dismissed."	760841.0	8669433	8669433_D000082_D007676	bcv_easy_698_job_760841_testq	"test
other
experiment"	ignore_this	no_relation	"The sentence says that it is not known whether acetaminophen causes ESRD, but that it is also not impossible. Therefore we do not know whether acetaminophen causes ESRD, and therefore the answer is that ""the sentence does not say that acetaminophen contributes to or causes ESRD""."
TRUE	D010862	"<span class=""chemical"">pilocarpine</span>"		D002544	"<span class=""disease"">Infarcts in substantia nigra pars reticulata</span>"	"<span class=""disease"">Infarcts in substantia nigra pars reticulata</span> were evoked by prolonged <span class=""chemical"">pilocarpine</span>-induced status epilepticus."	760841.0	8410052	8410052_D010862_D002544	bcv_easy_229_job_760841_testq	"test
other
experiment"	ignore_this	yes_indirect	"The infarcts were caused (""evoked"") by status epilepticus, which is another disease (a series of seizures). Therefore pilocarpine contributed to ""infarcts in substantia nigra pars reticulata"" through another disease."
TRUE	D000628	"<span class=""chemical"">aminophylline</span>"		D012131	"<span class=""disease"">respiratory failure</span>"	"The effects of <span class=""chemical"">aminophylline</span> on the ventricular fibrillation threshold during normal acid-base conditions and during <span class=""disease"">respiratory failure</span> were studied in anesthetized open chest dogs."	760841.0	234669	234669_D000628_D012131	bcv_easy_2792_job_760841_testq	"test
other
experiment"	ignore_this	no_relation	The sentence says that the effects were studied, but does not say if there were any effects.
TRUE	C027260	"<span class=""chemical"">4'-0-tetrahydropyranyladriamycin/Pirarubicin</span>"		D009369	"<span class=""disease"">tumors</span>"	"A Phase I study of intravenous (IV) bolus <span class=""chemical"">4'-0-tetrahydropyranyladriamycin</span> (<span class=""chemical"">Pirarubicin</span>) was done in 55 patients in good performance status with refractory <span class=""disease"">tumors</span>."	760841.0	2224762	2224762_C027260_D009369	bcv_easy_2221_job_760841_testq	"test
other
experiment"	ignore_this	no_relation	The study of Pirarubicin was done in patients with existing tumors, but there is no stated link between Pirarubicin and tumors.
TRUE	C558899	"<span class=""chemical"">lopinavir/ritonavir</span>"		D001919	"<span class=""disease"">bradycardia</span>"	"One of the twins developed complete heart block and dilated cardiomyopathy related to <span class=""chemical"">lopinavir/ritonavir</span> therapy, a boosted protease-inhibitor agent, while the other twin developed mild <span class=""disease"">bradycardia</span>."	760841.0	19820426	19820426_C558899_D001919	bcv_easy_1711_job_760841_testq	"test
other
experiment"	ignore_this	no_relation	The first twin used lopinavir/ritonavir, but it was the second twin who developed bradycardia.
TRUE	D011346	"<span class=""chemical"">prochlorperazine</span>"		D017109	"<span class=""disease"">akathisia</span>"	"Intravenous administration of <span class=""chemical"">prochlorperazine</span> by 15-minute infusion versus 2-minute bolus does not affect the incidence of <span class=""disease"">akathisia</span>: a prospective, randomized, controlled trial."	760841.0	11679859	11679859_D011346_D017109	bcv_easy_834_job_760841_testq	"test
other
experiment"	ignore_this	no_relation	Prochlorperazine has no effect on akathisia.
TRUE	D005283	"<span class=""chemical"">Fentanyl</span>"		D001919	"<span class=""disease"">bradycardia</span>"	"<span class=""chemical"">Fentanyl</span> did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and <span class=""disease"">bradycardia</span>."	760841.0	18544179	18544179_D005283_D001919	bcv_easy_2375_job_760841_testq	"test
other
experiment"	ignore_this	yes_direct	Fentanyl increased bradycardia.
TRUE	D003042	"<span class=""chemical"">cocaine</span>"		D005921	"<span class=""disease"">glomerulonephritis</span>"	"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic <span class=""disease"">glomerulonephritis</span>, and <span class=""chemical"">cocaine</span>-related acute renal failure."	760841.0	11391224	11391224_D003042_D005921	bcv_easy_814_job_760841_testq	"test
other
experiment"	ignore_this	ner_mistake	"The sentence gives a list of diseases. In this context, ""cocaine"" is part of ""cocaine-related acute renal failure"", and is therefore part of a larger concept discussing a disease."
TRUE	D015740	"<span class=""chemical"">CGRP</span>"		D008881	"<span class=""disease"">migraine</span>"	"Plasma <span class=""chemical"">CGRP</span> concentration increased significantly (P<0.01) during the <span class=""disease"">migraine</span> attack and returned to baseline after the cessation of the <span class=""disease"">migraine</span>."	760841.0	14659530	14659530_D015740_D008881	bcv_easy_349_job_760841_testq	"test
other
experiment"	ignore_this	ner_mistake	"Here ""CGRP"" is part of ""Plasma CGRP concentration"", which is not a chemical."
TRUE	D000082	"<span class=""chemical"">paracetamol</span>"		D007680|D014516|D001749	"<span class=""disease"">cancer of the renal pelvis, ureter or bladder</span>"	"The risk of developing renal papillary necrosis or <span class=""disease"">cancer of the renal pelvis, ureter or bladder</span> associated with consumption of either phenacetin or <span class=""chemical"">paracetamol</span> was calculated from data acquired by questionnaire from 381 cases and 808 controls."	760841.0	3412544	3412544_D000082_D007680|D014516|D001749	bcv_easy_94_job_760841_testq	"test
other
experiment"	ignore_this	no_relation	The risk of paracetamol for the cancers was calculated, but the sentence does not say if there is an actual risk or not.
TRUE	C106791	"<span class=""chemical"">telithromycin</span>"		D056486	"<span class=""disease"">toxic hepatitis/hepatitis</span>"	"Based on a score of 8 on the Naranjo adverse drug reaction probability scale, <span class=""chemical"">telithromycin</span> was the probable cause of acute <span class=""disease"">hepatitis</span> in this patient, and pathological findings suggested drug-induced <span class=""disease"">toxic hepatitis</span>."	760841.0	17919553	17919553_C106791_D056486	bcv_easy_2550_job_760841_testq	"test
other
experiment"	ignore_this	yes_direct	Telithromycin was the likely cause of hepatitis in the patient.
TRUE	D001920	"<span class=""chemical"">bradykinin</span>"		D006973	"<span class=""disease"">hypertension</span>"	"Role of activation of <span class=""chemical"">bradykinin</span> B2 receptors in disruption of the blood-brain barrier during acute <span class=""disease"">hypertension</span>."	760841.0	8955532	8955532_D001920_D006973	bcv_easy_1892_job_760841_testq	"test
other
experiment"	ignore_this	ner_mistake	"Here ""bradykinin"" is part of ""bradykinin B2 receptors"", because the activated receptors are disrupting the blood-brain barrier somehow."
TRUE	D013390	"<span class=""chemical"">suxamethonium</span>"		D001919	"<span class=""disease"">bradycardia</span>"	"Comparison of i.v. glycopyrrolate and atropine in the prevention of <span class=""disease"">bradycardia</span> and arrhythmias following repeated doses of <span class=""chemical"">suxamethonium</span> in children."	760841.0	6466532	6466532_D013390_D001919	bcv_easy_3049_job_760841_testq	"test
other
experiment"	ignore_this	yes_direct	Suxamethonium causes bradycardia, and the sentence says two other chemicals (glycopyrrolate and atropine) are being used to try and prevent the bradycardia.
TRUE	C060802	"<span class=""chemical"">fangchinoline</span>"		D013927	"<span class=""disease"">thrombosis</span>"	"Effects of tetrandrine and <span class=""chemical"">fangchinoline</span> on experimental <span class=""disease"">thrombosis</span> in mice and human platelet aggregation."	760841.0	10193204	10193204_C060802_D013927	bcv_easy_253_job_760841_testq	"test
other
experiment"	ignore_this	no_relation	The sentence is a fragment, and does not explicitly say that negative effects of fangchinoline exist, rather that the effects were tested.
TRUE	D004164	"<span class=""chemical"">bisphosphonate</span>"		D058186	"<span class=""disease"">acute renal failure</span>"	"Massive proteinuria and <span class=""disease"">acute renal failure</span> after oral <span class=""chemical"">bisphosphonate</span> (alendronate) administration in a patient with focal segmental glomerulosclerosis."	760841.0	18754075	18754075_D004164_D058186	bcv_easy_1641_job_760841_testq	"test
other
experiment"	ignore_this	yes_direct	Patient developed acute renal failure after taking bisphosphonate.
TRUE	D000082	"<span class=""chemical"">acetaminophen</span>"		D007676	"<span class=""disease"">chronic renal failure/ESRD</span>"	"However, three case control studies, one each in North Carolina, northern Maryland, and West Berlin, Germany, showed that habitual use of <span class=""chemical"">acetaminophen</span> is also associated with <span class=""disease"">chronic renal failure</span> and <span class=""disease"">ESRD</span>, with a relative risk in the range of 2 to 4."	760841.0	8669433	8669433_D000082_D007676	bcv_easy_695_job_760841_testq	"test
other
experiment"	ignore_this	yes_direct	Habitual use of acetaminophen causes chronic renal failure.
TRUE	D010755	"<span class=""chemical"">organophosphate</span>"		D020258	"<span class=""disease"">neurotoxic</span>"	"The correlation between neuropathic damage and inhibition of <span class=""disease"">neurotoxic</span> esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a <span class=""disease"">neurotoxic</span> <span class=""chemical"">organophosphate</span>."	760841.0	3714122	3714122_D010755_D020258	bcv_easy_1194_job_760841_testq	"test
other
experiment"	ignore_this	ner_mistake	"The rats were exposed to Mipafox (a chemical). The sentence says that Mipafox belongs to a category of chemicals called ""neurotoxic organophosphates"". Therefore ""neurotoxic organophosphate"" is not a disease and a chemical joined together, but rather a category of chemicals."
TRUE	D009569	"<span class=""chemical"">NO</span>"		D009437	"<span class=""disease"">neuropathic pain</span>"	"Therefore, concomitant administration of small doses of bradykinin receptor antagonists and <span class=""chemical"">NO</span> synthase inhibitors can be effective in alleviation of <span class=""disease"">neuropathic pain</span>, even in hospital care."	760841.0	19300402	19300402_D009569_D009437	bcv_easy_2907_job_760841_testq	"test
other
experiment"	ignore_this	ner_mistake	"The sentence says that administration of small doses of ""bradykinin receptor antagonists"" (a type of chemical) and ""NO synthase inhibitors"" (a type of chemical) is effective for treating neuropathic pain. Therefore ""NO"" is not a chemical in this context but rather a part of ""NO synthase inhibitors""."
TRUE	D003520	"<span class=""chemical"">cyclophosphamide</span>"		D006973	"<span class=""disease"">hypertension</span>"	"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional <span class=""chemical"">cyclophosphamide</span> as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, <span class=""disease"">hypertension</span>, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation."	760841.0	15325671	15325671_D003520_D006973	bcv_easy_2919_job_760841_testq	"test
other
experiment"	ignore_this	no_relation	An analysis was done to see if congestive heart failure had anything to do with some pretreatment characteristics, including hypertension. The sentence never says what the conclusions of the analysis were, or whether cyclophosphamide causes hypertension.
TRUE	C524754	"<span class=""chemical"">maltolyl p-coumarate</span>"		D009410	"<span class=""disease"">neuronal death</span>"	"Taking these in vitro and in vivo results together, our study suggests that <span class=""chemical"">maltolyl p-coumarate</span> is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread <span class=""disease"">neuronal death</span> and progressive decline of cognitive function."	760841.0	17600377	17600377_C524754_D009410	bcv_easy_1560_job_760841_testq	"test
other
experiment"	ignore_this	no_relation	"Maltolyl p-coumarate is treating Alzheimer's disease, and not causing one of the symptoms (""neuronal death"") of Alzheimer's disease."
TRUE	D000109	"<span class=""chemical"">acetylcholine</span>"		D014202	"<span class=""disease"">tremors</span>"	"Binding of nicotine to nicotinic <span class=""chemical"">acetylcholine</span> receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and <span class=""disease"">tremors</span>, to seizures and death."	760841.0	15275829	15275829_D000109_D014202	bcv_easy_1512_job_760841_testq	"test
other
experiment"	ignore_this	ner_mistake	"Here ""acetylcholine"" is part of ""nicotinic acetylcholine receptors"". Nicotinic acetylcholine receptors are a category of proteins, and are therefore not chemicals."
TRUE	D012964	"<span class=""chemical"">na</span>"		D006509	"<span class=""disease"">HBV infected/HBV mono-infected</span>"	"Thirty-five lamivudine-<span class=""chemical"">na</span>  ve <span class=""disease"">HBV infected</span> patients with or without HIV co-infection were studied: 15 chronic <span class=""disease"">HBV mono-infected</span> patients and 20 HBV-HIV co-infected patients."	760841.0	17854040	17854040_D012964_D006509	bcv_easy_1578_job_760841_testq	"test
other
experiment"	ignore_this	ner_mistake	"""na"" is not being used as a chemical in this context, because ""ve"" is not a word. There seems to be a missing letter between ""na"" and ""ve""."
TRUE	D004837	"<span class=""chemical"">epinephrine/EP</span>"		D013927	"<span class=""disease"">thrombosis</span>"	"The present study was undertaken to investigate the effects of TET and FAN on the experimental <span class=""disease"">thrombosis</span> induced by collagen plus <span class=""chemical"">epinephrine</span> (<span class=""chemical"">EP</span>) in mice, and platelet aggregation and blood coagulation in vitro."	760841.0	10193204	10193204_D004837_D013927	bcv_easy_262_job_760841_testq	"test
other
experiment"	ignore_this	yes_direct	"Thrombosis was ""induced by"" (caused by) collagen and epinephrine."
TRUE	D006854	"<span class=""chemical"">hydrocortisone</span>"		D009202	"<span class=""disease"">myocardial injury</span>"	"Effects of acetylsalicylic acid, dipyridamole, and <span class=""chemical"">hydrocortisone</span> on epinephrine-induced <span class=""disease"">myocardial injury</span> in dogs."	760841.0	983936	983936_D006854_D009202	bcv_easy_1098_job_760841_testq	"test
other
experiment"	ignore_this	no_relation	"Myocardial injury is caused by ""epinephrine"". We do not know what the effect of hydrocortisone on myocardial injury is."
TRUE	D002784	"<span class=""chemical"">cholesterol</span>"		D003072	"<span class=""disease"">cognitive dysfunctions</span>"	"Therefore, DCE may prove to be a useful remedy for the management of <span class=""disease"">cognitive dysfunctions</span> on account of its multifarious beneficial effects such as, memory improving property, <span class=""chemical"">cholesterol</span> lowering property and anticholinesterase activity."	760841.0	16755009	16755009_D002784_D003072	bcv_easy_978_job_760841_testq	"test
other
experiment"	ignore_this	ner_mistake	"The sentence lists some ""beneficial effects"" of DCE. ""Cholesterol lowering property"" is listed as one of the beneficial effects, and therefore ""cholesterol"" is part of ""cholesterol lowering property""."
TRUE	D012964	"<span class=""chemical"">sodium</span>"		D016055	"<span class=""disease"">volume retention</span>"	"Doxorubicin-induced nephropathy leads to epithelial <span class=""chemical"">sodium</span> channel (ENaC)-dependent <span class=""disease"">volume retention</span> and renal fibrosis."	760841.0	18768591	18768591_D012964_D016055	bcv_easy_1653_job_760841_testq	"test
other
experiment"	ignore_this	ner_mistake	"Here ""sodium"" is part of ""epithelial sodium channel"", which is a kind of protein channel."
TRUE	D002945	"<span class=""chemical"">cisplatin</span>"		D028361	"<span class=""disease"">mitochondrial toxicity</span>"	"In conclusion <span class=""disease"">mitochondrial toxicity</span> is an early common event both in paclitaxel and <span class=""chemical"">cisplatin</span> induced neurotoxicity."	760841.0	18809400	18809400_D002945_D028361	bcv_easy_2259_job_760841_testq	"test
other
experiment"	ignore_this	yes_indirect	Mitochondrial toxicity is an early event in neurotoxicity. The neurotoxicity was caused by cisplatin. Therefore cisplatin contributed to another disease, and the other disease (neurotoxicity) causes mitochondrial toxicity.
TRUE	D009020	"<span class=""chemical"">morphine</span>"		D059787	"<span class=""disease"">acute pain</span>"	"Enhancement of <span class=""chemical"">morphine</span> antinociception by dextromethorphan was seen in both males and females in the <span class=""disease"">acute pain</span> models, with the magnitude of this effect being greater in males."	760841.0	18221780	18221780_D009020_D059787	bcv_easy_1595_job_760841_testq	"test
other
experiment"	ignore_this	ner_mistake	"Here ""morphine"" is part of ""morphine antinociception"". Antinociception means ""reduced sensitivity to pain"". The first part of the sentence (""Enhancement of morphine antinociception by dextromethorphan"") means ""The ability of dextromethorphan to enhance morphine's ability to reduce pain"". We can tell because the sentence structure is ""Enhancement of [something] by [something else]""."
TRUE	D016202	"<span class=""chemical"">NMDA</span>"		D059787	"<span class=""disease"">acute pain</span>"	"These findings demonstrate a sexually-dimorphic interaction between <span class=""chemical"">NMDA</span> antagonists and morphine in a persistent pain model that can be distinguished from those observed in <span class=""disease"">acute pain</span> models."	760841.0	18221780	18221780_D016202_D059787	bcv_easy_1597_job_760841_testq	"test
other
experiment"	ignore_this	ner_mistake	"The sentence structure is ""interaction between [something] and [something else] in ..."". Therefore ""NMDA"" is part of ""NMDA antagonists"", which is different from just ""NMDA""."
TRUE	D000431	"<span class=""chemical"">alcohol</span>"		D005483	"<span class=""disease"">flushing of the face</span>"	"In less than 1 hour after the ingestion of <span class=""chemical"">alcohol</span>, he developed malaise with <span class=""disease"">flushing of the face</span>, tachycardia, and dyspnea."	760841.0	19657887	19657887_D000431_D005483	bcv_easy_1805_job_760841_testq	"test
other
experiment"	ignore_this	yes_direct	Ingesting alcohol causes your face to flush (but you already knew that!).
TRUE	D004298	"<span class=""chemical"">dopamine</span>"		D001919	"<span class=""disease"">bradycardia</span>"	"They suggest that, in normal conscious rats, the central tachycardia of bromocriptine appears to predominate and to mask the <span class=""disease"">bradycardia</span> of this agonist at peripheral <span class=""chemical"">dopamine</span> D2 receptors."	760841.0	10721819	10721819_D004298_D001919	bcv_easy_1391_job_760841_testq	"test
other
experiment"	ignore_this	ner_mistake	"Here ""dopamine"" is part of ""dopamine D2 receptors"", which is a kind of protein."
TRUE	D006220	"<span class=""chemical"">haloperidol</span>"		D011595	"<span class=""disease"">psychomotor agitation</span>"	"RESULTS: For the 60 patients who completed phase A, standard-dose <span class=""chemical"">haloperidol</span> was efficacious and superior to both low-dose <span class=""chemical"">haloperidol</span> and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on <span class=""disease"">psychomotor agitation</span>."	760841.0	9812111	9812111_D006220_D011595	bcv_easy_2042_job_760841_testq	"test
other
experiment"	ignore_this	no_relation	Haloperidol seemed to have a positive effect on psychomotor agitation.
TRUE	D005283	"<span class=""chemical"">fentanyl</span>"		D010149	"<span class=""disease"">postoperative pain</span>"	"CONCLUSION: As <span class=""chemical"">fentanyl</span> exacerbated postoperative nausea and vomiting without an improvement in <span class=""disease"">postoperative pain</span> and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery."	760841.0	18544179	18544179_D005283_D010149	bcv_easy_2381_job_760841_testq	"test
other
experiment"	ignore_this	no_relation	Fentanyl made postoperative nausea and vomiting worse, but did not improve postoperative pain. The sentence does not say that fentanyl originally caused the postoperative pain!
TRUE	D009582	"<span class=""chemical"">Nitrofurantoins</span>"		D000853	"<span class=""disease"">anophthalmia</span>"	"<span class=""chemical"">Nitrofurantoins</span> were associated with <span class=""disease"">anophthalmia</span> or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9)."	760841.0	19884587	19884587_D009582_D000853	bcv_easy_2185_job_760841_testq	"test
other
experiment"	ignore_this	yes_direct	Nitrofurantoins cause anophthalmia.
TRUE	D004177	"<span class=""chemical"">metamizol</span>"		D059350	"<span class=""disease"">chronic pain</span>"	"These findings show a significant interaction between morphine and <span class=""chemical"">metamizol</span> in chronically treated rats, suggesting that this combination could be useful for the treatment of <span class=""disease"">chronic pain</span>."	760841.0	12063090	12063090_D004177_D059350	bcv_easy_1462_job_760841_testq	"test
other
experiment"	ignore_this	no_relation	Metamizol is said to be useful for treating chronic pain.
TRUE	D007608	"<span class=""chemical"">kainic acid</span>"		D001930	"<span class=""disease"">hippocampal injury</span>"	"Estrogens protect ovariectomized rats from <span class=""disease"">hippocampal injury</span> induced by <span class=""chemical"">kainic acid</span>-induced status epilepticus (SE)."	760841.0	12757899	12757899_D007608_D001930	bcv_easy_1482_job_760841_testq	"test
other
experiment"	ignore_this	yes_indirect	Kainic acid causes status spilepticus (SE). SE in turn causes hippocampal injury.
TRUE	D008775	"<span class=""chemical"">methylprednisolone</span>"		D020250	"<span class=""disease"">nausea, vomiting</span>"	"CONCLUSIONS: The administration of <span class=""chemical"">methylprednisolone</span> and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including <span class=""disease"">nausea, vomiting</span>, and headache."	760841.0	17466854	17466854_D008775_D020250	bcv_easy_1538_job_760841_testq	"test
other
experiment"	ignore_this	yes_direct	Methylprednisolone causes nausea and vomiting as a side effect.
TRUE	D002220	"<span class=""chemical"">carbamazepine</span>"		D051437	"<span class=""disease"">renal failure</span>"	"We report a patient in whom hypersensitivity to <span class=""chemical"">carbamazepine</span> presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and <span class=""disease"">renal failure</span>."	760841.0	2522601	2522601_D002220_D051437	bcv_easy_1930_job_760841_testq	"test
other
experiment"	ignore_this	yes_direct	Carbamazepine caused many diseases in this patient.
TRUE	D019386	"<span class=""chemical"">alendronate</span>"		D011507	"<span class=""disease"">proteinuria</span>"	"Massive <span class=""disease"">proteinuria</span> and acute renal failure after oral bisphosphonate (<span class=""chemical"">alendronate</span>) administration in a patient with focal segmental glomerulosclerosis."	760841.0	18754075	18754075_D019386_D011507	bcv_easy_1645_job_760841_testq	"test
other
experiment"	ignore_this	yes_direct	Patient developed proteinuria after taking alendronate.
TRUE	D002443	"<span class=""chemical"">ceftriaxone</span>"		D056486	"<span class=""disease"">hepatitis</span>"	"Acute <span class=""disease"">hepatitis</span>, autoimmune hemolytic anemia, and erythroblastocytopenia induced by <span class=""chemical"">ceftriaxone</span>."	760841.0	9625142	9625142_D002443_D056486	bcv_easy_241_job_760841_testq	"test
other
experiment"	ignore_this	yes_direct	Induced means caused by.
TRUE	D009568	"<span class=""chemical"">nitrendipine</span>"		D006978	"<span class=""disease"">renovascular hypertension</span>"	"The effect of a 6-week treatment with the calcium channel blocker <span class=""chemical"">nitrendipine</span> or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip <span class=""disease"">renovascular hypertension</span>."	760841.0	1639466	1639466_D009568_D006978	bcv_easy_3086_job_760841_testq	"test
other
experiment"	ignore_this	no_relation	The sentence gives no conclusion regarding the result of the study.
TRUE	C030852	"<span class=""chemical"">vinorelbine</span>"		D002289	"<span class=""disease"">nonsmall cell lung carcinoma</span>"	"Gemcitabine plus <span class=""chemical"">vinorelbine</span> in <span class=""disease"">nonsmall cell lung carcinoma</span> patients age 70 years or older or patients who cannot receive cisplatin. Oncopaz Cooperative Group."	760841.0	10526274	10526274_C030852_D002289	bcv_easy_269_job_760841_testq	"test
other
experiment"	ignore_this	no_relation	The sentence says vinorelbine was used in patients with lung carcinoma, but does not say whether vinorelbine is treating or causing the cancer.
TRUE	D005283	"<span class=""chemical"">fentanyl</span>"		D016055	"<span class=""disease"">retention of urine</span>"	"Bladder <span class=""disease"">retention of urine</span> as a result of continuous intravenous infusion of <span class=""chemical"">fentanyl</span>: 2 case reports."	760841.0	11581460	11581460_D005283_D016055	bcv_easy_299_job_760841_testq	"test
other
experiment"	ignore_this	yes_direct	Using fentanyl caused retention or urine.
TRUE	D018817	"<span class=""chemical"">MDMA</span>"		D003072	"<span class=""disease"">impaired social and emotional judgement processes</span>"	"<span class=""chemical"">MDMA</span> polydrug users show process-specific central executive impairments coupled with <span class=""disease"">impaired social and emotional judgement processes</span>."	760841.0	16574712	16574712_D018817_D003072	bcv_easy_371_job_760841_testq	"test
other
experiment"	ignore_this	yes_direct	People who take MDMA (and other drugs) develop impaired social and emotional judgement processes.
	D011692	"<span class=""chemical"">puromycin aminonucleoside</span>"		D000860	"<span class=""disease"">hypoxia</span>"	"With this model, we were able to identify diffuse cortical <span class=""disease"">hypoxia</span> in the <span class=""chemical"">puromycin aminonucleoside</span>-induced nephrotic syndrome and focal and segmental <span class=""disease"">hypoxia</span> in the remnant kidney model."		15579441	15579441_D011692_D000860	bcv_easy_0				
	D011692	"<span class=""chemical"">puromycin aminonucleoside</span>"		D000860	"<span class=""disease"">hypoxia</span>"	"Expression of the <span class=""disease"">hypoxia</span>-responsive transgene increased throughout the observation period, reaching 2.2-fold at 2 weeks in the <span class=""chemical"">puromycin aminonucleoside</span> model and 2.6-fold at 4 weeks in the remnant kidney model, whereas that of vascular endothelial growth factor showed a mild decrease, reflecting distinct behaviors of the two genes."		15579441	15579441_D011692_D000860	bcv_easy_1				
	D015742	"<span class=""chemical"">propofol</span>"		D010146	"<span class=""disease"">pain</span>"	"Reduction of <span class=""disease"">pain</span> during induction with target-controlled <span class=""chemical"">propofol</span> and remifentanil."		18006530	18006530_D015742_D010146	bcv_easy_2				
	C071741	"<span class=""chemical"">remifentanil</span>"		D010146	"<span class=""disease"">pain</span>"	"Reduction of <span class=""disease"">pain</span> during induction with target-controlled propofol and <span class=""chemical"">remifentanil</span>."		18006530	18006530_C071741_D010146	bcv_easy_3				
	D015742	"<span class=""chemical"">propofol</span>"		D010146	"<span class=""disease"">Pain</span>"	"BACKGROUND: <span class=""disease"">Pain</span> on injection of <span class=""chemical"">propofol</span> is unpleasant."		18006530	18006530_D015742_D010146	bcv_easy_4				
	D015742	"<span class=""chemical"">propofol</span>"		D010146	"<span class=""disease"">pain</span>"	"We hypothesized that <span class=""chemical"">propofol</span> infusion <span class=""disease"">pain</span> might be prevented by infusing remifentanil before starting the <span class=""chemical"">propofol</span> infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used."		18006530	18006530_D015742_D010146	bcv_easy_5				
	C071741	"<span class=""chemical"">remifentanil</span>"		D010146	"<span class=""disease"">pain</span>"	"We hypothesized that propofol infusion <span class=""disease"">pain</span> might be prevented by infusing <span class=""chemical"">remifentanil</span> before starting the propofol infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used."		18006530	18006530_C071741_D010146	bcv_easy_6				
	C071741	"<span class=""chemical"">remifentanil</span>"		D010146	"<span class=""disease"">pain</span>"	"A prospective, randomized, double-blind, placebo-controlled trial was performed to determine the effect-site concentration (Ce) of <span class=""chemical"">remifentanil</span> to prevent the <span class=""disease"">pain</span> without producing complications."		18006530	18006530_C071741_D010146	bcv_easy_7				
	D015742	"<span class=""chemical"">propofol</span>"		D010146	"<span class=""disease"">pain</span>"	"Remifentanil-related complications were assessed during the remifentanil infusion, and <span class=""disease"">pain</span> caused by <span class=""chemical"">propofol</span> was evaluated using a four-point scale during the <span class=""chemical"">propofol</span> infusion."		18006530	18006530_D015742_D010146	bcv_easy_8				
	C071741	"<span class=""chemical"">Remifentanil</span>"		D010146	"<span class=""disease"">pain</span>"	"<span class=""chemical"">Remifentanil</span>-related complications were assessed during the <span class=""chemical"">remifentanil</span> infusion, and <span class=""disease"">pain</span> caused by propofol was evaluated using a four-point scale during the propofol infusion."		18006530	18006530_C071741_D010146	bcv_easy_9				
	D015742	"<span class=""chemical"">propofol</span>"		D010146	"<span class=""disease"">pain</span>"	"CONCLUSIONS: During induction of anaesthesia with TCI of <span class=""chemical"">propofol</span> and remifentanil, a significant reduction in <span class=""chemical"">propofol</span> infusion <span class=""disease"">pain</span> was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1)."		18006530	18006530_D015742_D010146	bcv_easy_10				
	C071741	"<span class=""chemical"">remifentanil</span>"		D010146	"<span class=""disease"">pain</span>"	"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and <span class=""chemical"">remifentanil</span>, a significant reduction in propofol infusion <span class=""disease"">pain</span> was achieved without significant complications by prior administration of <span class=""chemical"">remifentanil</span> at a target Ce of 4 ng ml(-1)."		18006530	18006530_C071741_D010146	bcv_easy_11				
	D011188	"<span class=""chemical"">potassium</span>"		D006973	"<span class=""disease"">hypertensive</span>"	"Diuretics, <span class=""chemical"">potassium</span> and arrhythmias in <span class=""disease"">hypertensive</span> coronary disease."		3732088	3732088_D011188_D006973	bcv_easy_12				
	D011188	"<span class=""chemical"">potassium</span>"		D003327	"<span class=""disease"">coronary disease</span>"	"Diuretics, <span class=""chemical"">potassium</span> and arrhythmias in hypertensive <span class=""disease"">coronary disease</span>."		3732088	3732088_D011188_D003327	bcv_easy_13				
	D011188	"<span class=""chemical"">potassium</span>"		D001145	"<span class=""disease"">arrhythmias</span>"	"Diuretics, <span class=""chemical"">potassium</span> and <span class=""disease"">arrhythmias</span> in hypertensive coronary disease."		3732088	3732088_D011188_D001145	bcv_easy_14				
	D011188	"<span class=""chemical"">potassium</span>"		D001145	"<span class=""disease"">cardiac arrhythmias</span>"	"It has been proposed that modest changes in plasma <span class=""chemical"">potassium</span> can alter the tendency towards <span class=""disease"">cardiac arrhythmias</span>."		3732088	3732088_D011188_D001145	bcv_easy_15				
	D002752	"<span class=""chemical"">chlorthalidone</span>"		D006973	"<span class=""disease"">hypertension</span>"	"Thus, myocardial electrical excitability was measured in patients with mild essential <span class=""disease"">hypertension</span> and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (<span class=""chemical"">chlorthalidone</span>) in a randomised study."		3732088	3732088_D002752_D006973	bcv_easy_16				
	D011188	"<span class=""chemical"">potassium</span>"		D006973	"<span class=""disease"">hypertension</span>"	"Thus, myocardial electrical excitability was measured in patients with mild essential <span class=""disease"">hypertension</span> and known coronary artery disease after 8 weeks of treatment with a <span class=""chemical"">potassium</span>-conserving diuretic (amiloride) and a similar period on a <span class=""chemical"">potassium</span>-losing diuretic (chlorthalidone) in a randomised study."		3732088	3732088_D011188_D006973	bcv_easy_17				
	D000584	"<span class=""chemical"">amiloride</span>"		D006973	"<span class=""disease"">hypertension</span>"	"Thus, myocardial electrical excitability was measured in patients with mild essential <span class=""disease"">hypertension</span> and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (<span class=""chemical"">amiloride</span>) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study."		3732088	3732088_D000584_D006973	bcv_easy_18				
	D000584	"<span class=""chemical"">amiloride</span>"		D003324	"<span class=""disease"">coronary artery disease</span>"	"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known <span class=""disease"">coronary artery disease</span> after 8 weeks of treatment with a potassium-conserving diuretic (<span class=""chemical"">amiloride</span>) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study."		3732088	3732088_D000584_D003324	bcv_easy_19				
	D002752	"<span class=""chemical"">chlorthalidone</span>"		D003324	"<span class=""disease"">coronary artery disease</span>"	"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known <span class=""disease"">coronary artery disease</span> after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (<span class=""chemical"">chlorthalidone</span>) in a randomised study."		3732088	3732088_D002752_D003324	bcv_easy_20				
	D011188	"<span class=""chemical"">potassium</span>"		D003324	"<span class=""disease"">coronary artery disease</span>"	"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known <span class=""disease"">coronary artery disease</span> after 8 weeks of treatment with a <span class=""chemical"">potassium</span>-conserving diuretic (amiloride) and a similar period on a <span class=""chemical"">potassium</span>-losing diuretic (chlorthalidone) in a randomised study."		3732088	3732088_D011188_D003324	bcv_easy_21				
	D000584	"<span class=""chemical"">amiloride</span>"		D018879	"<span class=""disease"">ventricular ectopic beats</span>"	"Compared to <span class=""chemical"">amiloride</span> treatment, the chlorthalidone phase was associated with an increased frequency of <span class=""disease"">ventricular ectopic beats</span> (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation."		3732088	3732088_D000584_D018879	bcv_easy_22				
	D002752	"<span class=""chemical"">chlorthalidone</span>"		D018879	"<span class=""disease"">ventricular ectopic beats</span>"	"Compared to amiloride treatment, the <span class=""chemical"">chlorthalidone</span> phase was associated with an increased frequency of <span class=""disease"">ventricular ectopic beats</span> (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation."		3732088	3732088_D002752_D018879	bcv_easy_23				
	D011188	"<span class=""chemical"">potassium</span>"		D017202	"<span class=""disease"">ischaemic heart disease</span>"	"The above results indicate that because <span class=""chemical"">potassium</span>-losing diuretic therapy can increase myocardial electrical excitability in patients with <span class=""disease"">ischaemic heart disease</span>, even minor falls in plasma <span class=""chemical"">potassium</span> concentrations are probably best avoided in such patients."		3732088	3732088_D011188_D017202	bcv_easy_24				
	D009569	"<span class=""chemical"">nitric oxide</span>"		D007674	"<span class=""disease"">nephropathy</span>"	"Association of <span class=""chemical"">nitric oxide</span> production and apoptosis in a model of experimental <span class=""disease"">nephropathy</span>."		11208990	11208990_D009569_D007674	bcv_easy_25				
	D004317	"<span class=""chemical"">ADR/adriamycin</span>"		D009404	"<span class=""disease"">nephrotic syndrome</span>"	"We have studied the role of NO and its association with apoptosis in an experimental model of <span class=""disease"">nephrotic syndrome</span> induced by a single injection of <span class=""chemical"">adriamycin</span> (<span class=""chemical"">ADR</span>)."		11208990	11208990_D004317_D009404	bcv_easy_26				
	D009569	"<span class=""chemical"">NO</span>"		D009404	"<span class=""disease"">nephrotic syndrome</span>"	"We have studied the role of <span class=""chemical"">NO</span> and its association with apoptosis in an experimental model of <span class=""disease"">nephrotic syndrome</span> induced by a single injection of adriamycin (ADR)."		11208990	11208990_D009569_D009404	bcv_easy_27				
	D004317	"<span class=""chemical"">ADR</span>"		C537346	"<span class=""disease"">mesangial proliferation</span>"	"RESULTS: Histopathological examination of the kidneys of rats treated with <span class=""chemical"">ADR</span> revealed focal areas of <span class=""disease"">mesangial proliferation</span> and mild tubulointerstitial inflammation."		11208990	11208990_D004317_C537346	bcv_easy_28				
	D004317	"<span class=""chemical"">ADR</span>"		D009395	"<span class=""disease"">tubulointerstitial inflammation</span>"	"RESULTS: Histopathological examination of the kidneys of rats treated with <span class=""chemical"">ADR</span> revealed focal areas of mesangial proliferation and mild <span class=""disease"">tubulointerstitial inflammation</span>."		11208990	11208990_D004317_D009395	bcv_easy_29				
	D009573	"<span class=""chemical"">nitrite</span>"		D007674	"<span class=""disease"">nephropathy</span>"	"Urine <span class=""chemical"">nitrite</span> levels were significantly increased in the ADR-<span class=""disease"">nephropathy</span> group (P < 0.05)."		11208990	11208990_D009573_D007674	bcv_easy_30				
	D010656	"<span class=""chemical"">phenylephrine</span>"		D007674	"<span class=""disease"">nephropathy</span>"	"In the IPRK <span class=""chemical"">phenylephrine</span> and acetylcholine related responses were significantly impaired in the ADR-<span class=""disease"">nephropathy</span> group."		11208990	11208990_D010656_D007674	bcv_easy_31				
	D000109	"<span class=""chemical"">acetylcholine</span>"		D007674	"<span class=""disease"">nephropathy</span>"	"In the IPRK phenylephrine and <span class=""chemical"">acetylcholine</span> related responses were significantly impaired in the ADR-<span class=""disease"">nephropathy</span> group."		11208990	11208990_D000109_D007674	bcv_easy_32				
	D009569	"<span class=""chemical"">NO</span>"		D009401	"<span class=""disease"">nephrosis</span>"	"CONCLUSION: We suggest that interactions between <span class=""chemical"">NO</span> and apoptosis are important in the pathogenesis of the ADR-induced <span class=""disease"">nephrosis</span>."		11208990	11208990_D009569_D009401	bcv_easy_33				
	D010042	"<span class=""chemical"">ouabain</span>"		D001145	"<span class=""disease"">arrhythmia</span>"	"This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism, using both aconitine-induced rat and <span class=""chemical"">ouabain</span>-induced guinea pig <span class=""disease"">arrhythmia</span> models."		19721134	19721134_D010042_D001145	bcv_easy_34				
	D000157	"<span class=""chemical"">aconitine</span>"		D001145	"<span class=""disease"">arrhythmia</span>"	"This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism, using both <span class=""chemical"">aconitine</span>-induced rat and ouabain-induced guinea pig <span class=""disease"">arrhythmia</span> models."		19721134	19721134_D000157_D001145	bcv_easy_35				
	D010862	"<span class=""chemical"">pilocarpine</span>"		D001145	"<span class=""disease"">arrhythmia</span>"	"This study was designed to evaluate the effects of <span class=""chemical"">pilocarpine</span> and explore the underlying ionic mechanism, using both aconitine-induced rat and ouabain-induced guinea pig <span class=""disease"">arrhythmia</span> models."		19721134	19721134_D010862_D001145	bcv_easy_36				
	D010862	"<span class=""chemical"">pilocarpine</span>"		D017180|D014693	"<span class=""disease"">ventricular tachycardia and fibrillation</span>"	"The current data showed that <span class=""chemical"">pilocarpine</span> significantly delayed onset of arrhythmias, decreased the time course of <span class=""disease"">ventricular tachycardia and fibrillation</span>, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs."		19721134	19721134_D010862_D017180|D014693	bcv_easy_37				
	D010862	"<span class=""chemical"">pilocarpine</span>"		D001145	"<span class=""disease"">arrhythmic/arrhythmias/arrhythmia</span>"	"The current data showed that <span class=""chemical"">pilocarpine</span> significantly delayed onset of <span class=""disease"">arrhythmias</span>, decreased the time course of ventricular tachycardia and fibrillation, reduced <span class=""disease"">arrhythmia</span> score, and increased the survival time of <span class=""disease"">arrhythmic</span> rats and guinea pigs."		19721134	19721134_D010862_D001145	bcv_easy_38				
	D010042	"<span class=""chemical"">ouabain</span>"		D001145	"<span class=""disease"">arrhythmic</span>"	"These data suggest that pilocarpine produced antiarrhythmic actions on <span class=""disease"">arrhythmic</span> rat and guinea pig models induced by aconitine or <span class=""chemical"">ouabain</span> via stimulating the cardiac M(3)-mAChR."		19721134	19721134_D010042_D001145	bcv_easy_39				
	D000157	"<span class=""chemical"">aconitine</span>"		D001145	"<span class=""disease"">arrhythmic</span>"	"These data suggest that pilocarpine produced antiarrhythmic actions on <span class=""disease"">arrhythmic</span> rat and guinea pig models induced by <span class=""chemical"">aconitine</span> or ouabain via stimulating the cardiac M(3)-mAChR."		19721134	19721134_D000157_D001145	bcv_easy_40				
	D010862	"<span class=""chemical"">pilocarpine</span>"		D001145	"<span class=""disease"">arrhythmic</span>"	"These data suggest that <span class=""chemical"">pilocarpine</span> produced antiarrhythmic actions on <span class=""disease"">arrhythmic</span> rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR."		19721134	19721134_D010862_D001145	bcv_easy_41				
	D000420	"<span class=""chemical"">salbutamol</span>"		D013617	"<span class=""disease"">atrial tachyarrhythmia</span>"	"Swallowing-induced <span class=""disease"">atrial tachyarrhythmia</span> triggered by <span class=""chemical"">salbutamol</span>: case report and review of the literature."		20552622	20552622_D000420_D013617	bcv_easy_42				
	D001262	"<span class=""chemical"">atenolol</span>"		D001145	"<span class=""disease"">arrhythmia</span>"	"The <span class=""disease"">arrhythmia</span> resolved after therapy with <span class=""chemical"">atenolol</span>, but recurred a year later."		20552622	20552622_D001262_D001145	bcv_easy_43				
	D001262	"<span class=""chemical"">atenolol</span>"		D001145	"<span class=""disease"">arrhythmia</span>"	"After stopping the beta-agonist, and after a week with the <span class=""chemical"">atenolol</span>, the <span class=""disease"">arrhythmia</span> disappeared."		20552622	20552622_D001262_D001145	bcv_easy_44				
	D000420	"<span class=""chemical"">Salbutamol</span>"		D013617	"<span class=""disease"">SIAT</span>"	"CONCLUSION: <span class=""chemical"">Salbutamol</span> is presented here as a possible trigger for <span class=""disease"">SIAT</span>."		20552622	20552622_D000420_D013617	bcv_easy_45				
	D000420	"<span class=""chemical"">salbutamol</span>"		D013610	"<span class=""disease"">tachycardia</span>"	"Although it is difficult to define causality in a case report, it is logical to think that a beta-agonist like <span class=""chemical"">salbutamol</span> (known to induce <span class=""disease"">tachycardia</span>) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta-blocker such as atenolol (that blocks the adrenergic activity) may relieve it."		20552622	20552622_D000420_D013610	bcv_easy_46				
	D001262	"<span class=""chemical"">atenolol</span>"		D013610	"<span class=""disease"">tachycardia</span>"	"Although it is difficult to define causality in a case report, it is logical to think that a beta-agonist like salbutamol (known to induce <span class=""disease"">tachycardia</span>) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta-blocker such as <span class=""chemical"">atenolol</span> (that blocks the adrenergic activity) may relieve it."		20552622	20552622_D001262_D013610	bcv_easy_47				
	D002119	"<span class=""chemical"">calcium carbon-ate</span>"		D053040	"<span class=""disease"">nephrolithiasis</span>"	"One case of acute hypercalcaemia and two of recurrent <span class=""disease"">nephrolithiasis</span> are reported in patients who had regularly consumed large amounts of <span class=""chemical"">calcium carbon-ate</span>-sodium bicarbonate powders for more than 20 years."		625456	625456_D002119_D053040	bcv_easy_48				
	D017693	"<span class=""chemical"">sodium bicarbonate</span>"		D006934	"<span class=""disease"">hypercalcaemia</span>"	"One case of acute <span class=""disease"">hypercalcaemia</span> and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-<span class=""chemical"">sodium bicarbonate</span> powders for more than 20 years."		625456	625456_D017693_D006934	bcv_easy_49				
	D002119	"<span class=""chemical"">calcium carbon-ate</span>"		D006934	"<span class=""disease"">hypercalcaemia</span>"	"One case of acute <span class=""disease"">hypercalcaemia</span> and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of <span class=""chemical"">calcium carbon-ate</span>-sodium bicarbonate powders for more than 20 years."		625456	625456_D002119_D006934	bcv_easy_50				
	D017693	"<span class=""chemical"">sodium bicarbonate</span>"		D053040	"<span class=""disease"">nephrolithiasis</span>"	"One case of acute hypercalcaemia and two of recurrent <span class=""disease"">nephrolithiasis</span> are reported in patients who had regularly consumed large amounts of calcium carbon-ate-<span class=""chemical"">sodium bicarbonate</span> powders for more than 20 years."		625456	625456_D017693_D053040	bcv_easy_51				
	C092292	"<span class=""chemical"">ziprasidone</span>"		D009459	"<span class=""disease"">Neuroleptic malignant syndrome</span>"	"<span class=""disease"">Neuroleptic malignant syndrome</span> induced by <span class=""chemical"">ziprasidone</span> on the second day of treatment."		17366349	17366349_C092292_D009459	bcv_easy_52				
	C092292	"<span class=""chemical"">ziprasidone</span>"		D009459	"<span class=""disease"">NMS/neuroleptic malignant syndrome</span>"	"We describe a case of <span class=""disease"">neuroleptic malignant syndrome</span> (<span class=""disease"">NMS</span>) associated with the use of <span class=""chemical"">ziprasidone</span>."		17366349	17366349_C092292_D009459	bcv_easy_53				
	C092292	"<span class=""chemical"">ziprasidone</span>"		D009459	"<span class=""disease"">NMS</span>"	"Although conventional neuroleptics are more frequently associated with <span class=""disease"">NMS</span>, atypical antipsychotic drugs like <span class=""chemical"">ziprasidone</span> may also be a cause."		17366349	17366349_C092292_D009459	bcv_easy_54				
	C092292	"<span class=""chemical"">ziprasidone</span>"		D009459	"<span class=""disease"">NMS</span>"	"The patient is a 24-year-old male with a history of schizophrenia who developed signs and symptoms of <span class=""disease"">NMS</span> after 2 days of treatment with an 80-mg/day dose of orally administrated <span class=""chemical"">ziprasidone</span>."		17366349	17366349_C092292_D009459	bcv_easy_55				
	C092292	"<span class=""chemical"">ziprasidone</span>"		D012559	"<span class=""disease"">schizophrenia</span>"	"The patient is a 24-year-old male with a history of <span class=""disease"">schizophrenia</span> who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated <span class=""chemical"">ziprasidone</span>."		17366349	17366349_C092292_D012559	bcv_easy_56				
	C092292	"<span class=""chemical"">ziprasidone</span>"		D009459	"<span class=""disease"">NMS</span>"	"This case is the earliest (second day of treatment) <span class=""disease"">NMS</span> due to <span class=""chemical"">ziprasidone</span> reported in the literature."		17366349	17366349_C092292_D009459	bcv_easy_57				
	D004317	"<span class=""chemical"">doxorubicin</span>"		D009202	"<span class=""disease"">cardiomyopathy</span>"	"Dose-effect and structure-function relationships in <span class=""chemical"">doxorubicin</span> <span class=""disease"">cardiomyopathy</span>."		7282516	7282516_D004317_D009202	bcv_easy_58				
	D004317	"<span class=""chemical"">doxorubicin/DXR/Adriamycin</span>"		D009202	"<span class=""disease"">cardiomyopathy/myocardial disease/CM</span>"	"The <span class=""disease"">cardiomyopathy</span> (<span class=""disease"">CM</span>) produced by the anticancer drug <span class=""chemical"">doxorubicin</span> (<span class=""chemical"">DXR</span>) (<span class=""chemical"">Adriamycin</span>) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of <span class=""disease"">myocardial disease</span>."		7282516	7282516_D004317_D009202	bcv_easy_59				
	D004317	"<span class=""chemical"">DXR</span>"		D009202	"<span class=""disease"">myocardial damage/CM</span>"	"In <span class=""chemical"">DXR</span>-<span class=""disease"">CM</span> <span class=""disease"">myocardial damage</span> is proportional to the degree of cytotoxic insult (<span class=""chemical"">DXR</span> dose) while myocardial function is preserved until a critical dose or degree of damage is reached, after which myocardial performance deteriorates rapidly."		7282516	7282516_D004317_D009202	bcv_easy_60				
	D002794	"<span class=""chemical"">choline</span>"		D000647	"<span class=""disease"">amnesia</span>"	"Daidzein activates <span class=""chemical"">choline</span> acetyltransferase from MC-IXC cells and improves drug-induced <span class=""disease"">amnesia</span>."		16428827	16428827_D002794_D000647	bcv_easy_61				
	C004742	"<span class=""chemical"">Daidzein</span>"		D000647	"<span class=""disease"">amnesia</span>"	"<span class=""chemical"">Daidzein</span> activates choline acetyltransferase from MC-IXC cells and improves drug-induced <span class=""disease"">amnesia</span>."		16428827	16428827_C004742_D000647	bcv_easy_62				
	D002794	"<span class=""chemical"">choline</span>"		D000544	"<span class=""disease"">AD/Alzheimer's disease</span>"	"The <span class=""chemical"">choline</span> acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of <span class=""disease"">Alzheimer's disease</span> (<span class=""disease"">AD</span>)."		16428827	16428827_D002794_D000544	bcv_easy_63				
	D000109	"<span class=""chemical"">ACh/acetylcholine</span>"		D000544	"<span class=""disease"">AD/Alzheimer's disease</span>"	"The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of <span class=""chemical"">acetylcholine</span> (<span class=""chemical"">ACh</span>), is an important factor in the treatment of <span class=""disease"">Alzheimer's disease</span> (<span class=""disease"">AD</span>)."		16428827	16428827_D000109_D000544	bcv_easy_64				
	C004742	"<span class=""chemical"">daidzein</span>"		D007859|D008569	"<span class=""disease"">impairments of learning and memory</span>"	"In order to investigate the effects of <span class=""chemical"">daidzein</span> from Pueraria thunbergiana on scopolamine-induced <span class=""disease"">impairments of learning and memory</span>, we conducted a series of in vivo tests."		16428827	16428827_C004742_D007859|D008569	bcv_easy_65				
	C004742	"<span class=""chemical"">daidzein</span>"		D000647	"<span class=""disease"">amnesia</span>"	"Administration of <span class=""chemical"">daidzein</span> (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced <span class=""disease"">amnesia</span>, according to the results of a Y-maze test."		16428827	16428827_C004742_D000647	bcv_easy_66				
	C004742	"<span class=""chemical"">daidzein</span>"		D000647	"<span class=""disease"">amnesia</span>"	"These results indicate that <span class=""chemical"">daidzein</span> might play a role in acetylcholine biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-induced <span class=""disease"">amnesia</span>."		16428827	16428827_C004742_D000647	bcv_easy_67				
	D000109	"<span class=""chemical"">acetylcholine</span>"		D000647	"<span class=""disease"">amnesia</span>"	"These results indicate that daidzein might play a role in <span class=""chemical"">acetylcholine</span> biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-induced <span class=""disease"">amnesia</span>."		16428827	16428827_D000109_D000647	bcv_easy_68				
	C065179	"<span class=""chemical"">Atorvastatin</span>"		D006973	"<span class=""disease"">hypertension</span>"	"<span class=""chemical"">Atorvastatin</span> prevented and reversed dexamethasone-induced <span class=""disease"">hypertension</span> in the rat."		16820346	16820346_C065179_D006973	bcv_easy_69				
	C065179	"<span class=""chemical"">atorvastatin/atorva</span>"		D006973	"<span class=""disease"">hypertension</span>"	"To assess the antioxidant effects of <span class=""chemical"">atorvastatin</span> (<span class=""chemical"">atorva</span>) on dexamethasone (dex)-induced <span class=""disease"">hypertension</span>, 60 male Sprague-Dawley rats were treated with <span class=""chemical"">atorva</span> 30 mg/kg/day or tap water for 15 days."		16820346	16820346_C065179_D006973	bcv_easy_70				
	D013481	"<span class=""chemical"">superoxide</span>"		D006973	"<span class=""disease"">hypertension</span>"	"Atorva reversed dex-induced <span class=""disease"">hypertension</span> (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma <span class=""chemical"">superoxide</span> (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001)."		16820346	16820346_D013481_D006973	bcv_easy_71				
	C065179	"<span class=""chemical"">Atorva</span>"		D006973	"<span class=""disease"">hypertension</span>"	"<span class=""chemical"">Atorva</span> reversed dex-induced <span class=""disease"">hypertension</span> (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 <span class=""chemical"">atorva</span> + dex, P < 0.0001)."		16820346	16820346_C065179_D006973	bcv_easy_72				
	C065179	"<span class=""chemical"">atorvastatin</span>"		D006973	"<span class=""disease"">hypertension</span>"	"Thus, <span class=""chemical"">atorvastatin</span> prevented and reversed dexamethasone-induced <span class=""disease"">hypertension</span> in the rat."		16820346	16820346_C065179_D006973	bcv_easy_73				
	D011241	"<span class=""chemical"">prednisone</span>"		D053609	"<span class=""disease"">lethargy</span>"	"Following short exposure to oral <span class=""chemical"">prednisone</span>, both boys developed <span class=""disease"">lethargy</span>, increasing somnolence, polydipsia, polyphagia, and polyuria."		3703509	3703509_D011241_D053609	bcv_easy_74				
	D011241	"<span class=""chemical"">prednisone</span>"		D006963	"<span class=""disease"">polyphagia</span>"	"Following short exposure to oral <span class=""chemical"">prednisone</span>, both boys developed lethargy, increasing somnolence, polydipsia, <span class=""disease"">polyphagia</span>, and polyuria."		3703509	3703509_D011241_D006963	bcv_easy_75				
	D011241	"<span class=""chemical"">prednisone</span>"		D011141	"<span class=""disease"">polyuria</span>"	"Following short exposure to oral <span class=""chemical"">prednisone</span>, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and <span class=""disease"">polyuria</span>."		3703509	3703509_D011241_D011141	bcv_easy_76				
	D011241	"<span class=""chemical"">prednisone</span>"		D059606	"<span class=""disease"">polydipsia</span>"	"Following short exposure to oral <span class=""chemical"">prednisone</span>, both boys developed lethargy, increasing somnolence, <span class=""disease"">polydipsia</span>, polyphagia, and polyuria."		3703509	3703509_D011241_D059606	bcv_easy_77				
	D011241	"<span class=""chemical"">prednisone</span>"		D006970	"<span class=""disease"">somnolence</span>"	"Following short exposure to oral <span class=""chemical"">prednisone</span>, both boys developed lethargy, increasing <span class=""disease"">somnolence</span>, polydipsia, polyphagia, and polyuria."		3703509	3703509_D011241_D006970	bcv_easy_78				
	D019344	"<span class=""chemical"">lactate</span>"		D007662	"<span class=""disease"">ketosis</span>"	"Nonketotic lactic acidosis was present in one and <span class=""disease"">ketosis</span> without a known serum <span class=""chemical"">lactate</span> level was present in the other."		3703509	3703509_D019344_D007662	bcv_easy_79				
	D019344	"<span class=""chemical"">lactate</span>"		D000140	"<span class=""disease"">lactic acidosis</span>"	"Nonketotic <span class=""disease"">lactic acidosis</span> was present in one and ketosis without a known serum <span class=""chemical"">lactate</span> level was present in the other."		3703509	3703509_D019344_D000140	bcv_easy_80				
	D009020	"<span class=""chemical"">morphine</span>"		D020760	"<span class=""disease"">spinal cord ischemia</span>"	"The activation of spinal N-methyl-D-aspartate receptors may contribute to degeneration of spinal motor neurons induced by neuraxial <span class=""chemical"">morphine</span> after a noninjurious interval of <span class=""disease"">spinal cord ischemia</span>."		15673851	15673851_D009020_D020760	bcv_easy_81				
	D016202	"<span class=""chemical"">N-methyl-D-aspartate</span>"		D020760	"<span class=""disease"">spinal cord ischemia</span>"	"The activation of spinal <span class=""chemical"">N-methyl-D-aspartate</span> receptors may contribute to degeneration of spinal motor neurons induced by neuraxial morphine after a noninjurious interval of <span class=""disease"">spinal cord ischemia</span>."		15673851	15673851_D016202_D020760	bcv_easy_82				
	D016202	"<span class=""chemical"">NMDA/N-methyl-d-aspartate</span>"		D001157	"<span class=""disease"">aortic occlusion</span>"	"We investigated the relationship between the degeneration of spinal motor neurons and activation of <span class=""chemical"">N-methyl-d-aspartate</span> (<span class=""chemical"">NMDA</span>) receptors after neuraxial morphine following a noninjurious interval of <span class=""disease"">aortic occlusion</span> in rats."		15673851	15673851_D016202_D001157	bcv_easy_83				
	D009020	"<span class=""chemical"">morphine</span>"		D001157	"<span class=""disease"">aortic occlusion</span>"	"We investigated the relationship between the degeneration of spinal motor neurons and activation of N-methyl-d-aspartate (NMDA) receptors after neuraxial <span class=""chemical"">morphine</span> following a noninjurious interval of <span class=""disease"">aortic occlusion</span> in rats."		15673851	15673851_D009020_D001157	bcv_easy_84				
	D016291	"<span class=""chemical"">MK-801</span>"		D020336	"<span class=""disease"">spastic paraparesis</span>"	"Second, we investigated the effect of IT <span class=""chemical"">MK-801</span> (30 mug) on the histopathologic changes in the spinal cord after morphine-induced <span class=""disease"">spastic paraparesis</span>."		15673851	15673851_D016291_D020336	bcv_easy_85				
	D016291	"<span class=""chemical"">MK-801</span>"		D020336	"<span class=""disease"">spastic paraparesis</span>"	"IT <span class=""chemical"">MK-801</span> significantly reduced the number of dark-stained alpha-motoneurons after morphine-induced <span class=""disease"">spastic paraparesis</span> compared with the saline group."		15673851	15673851_D016291_D020336	bcv_easy_86				
	D016202	"<span class=""chemical"">NMDA</span>"		D020336	"<span class=""disease"">spastic paraparesis</span>"	"These data indicate that IT morphine induces <span class=""disease"">spastic paraparesis</span> with a concomitant increase in CSF glutamate, which is involved in <span class=""chemical"">NMDA</span> receptor activation."		15673851	15673851_D016202_D020336	bcv_easy_87				
	D018698	"<span class=""chemical"">glutamate</span>"		D020336	"<span class=""disease"">spastic paraparesis</span>"	"These data indicate that IT morphine induces <span class=""disease"">spastic paraparesis</span> with a concomitant increase in CSF <span class=""chemical"">glutamate</span>, which is involved in NMDA receptor activation."		15673851	15673851_D018698_D020336	bcv_easy_88				
	D016202	"<span class=""chemical"">NMDA</span>"		D020258	"<span class=""disease"">neurotoxic</span>"	"We suggest that opioids may be <span class=""disease"">neurotoxic</span> in the setting of spinal cord ischemia via <span class=""chemical"">NMDA</span> receptor activation."		15673851	15673851_D016202_D020258	bcv_easy_89				
	D016202	"<span class=""chemical"">NMDA</span>"		D020760	"<span class=""disease"">spinal cord ischemia</span>"	"We suggest that opioids may be neurotoxic in the setting of <span class=""disease"">spinal cord ischemia</span> via <span class=""chemical"">NMDA</span> receptor activation."		15673851	15673851_D016202_D020760	bcv_easy_90				
	D011441	"<span class=""chemical"">PTU</span>"		D006111	"<span class=""disease"">Graves' disease</span>"	"<span class=""chemical"">PTU</span>-associated vasculitis in a girl with Turner Syndrome and <span class=""disease"">Graves' disease</span>."		16418614	16418614_D011441_D006111	bcv_easy_91				
	D011441	"<span class=""chemical"">PTU</span>"		D014424	"<span class=""disease"">Turner Syndrome</span>"	"<span class=""chemical"">PTU</span>-associated vasculitis in a girl with <span class=""disease"">Turner Syndrome</span> and Graves' disease."		16418614	16418614_D011441_D014424	bcv_easy_92				
	D011441	"<span class=""chemical"">PTU</span>"		D014657	"<span class=""disease"">vasculitis</span>"	"<span class=""chemical"">PTU</span>-associated <span class=""disease"">vasculitis</span> in a girl with Turner Syndrome and Graves' disease."		16418614	16418614_D011441_D014657	bcv_easy_93				
	D011441	"<span class=""chemical"">PTU/propylthiouracil</span>"		D014657	"<span class=""disease"">vasculitis</span>"	"The diagnosis of <span class=""chemical"">propylthiouracil</span> (<span class=""chemical"">PTU</span>)-associated <span class=""disease"">vasculitis</span> was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of <span class=""chemical"">PTU</span>."		16418614	16418614_D011441_D014657	bcv_easy_94				
	D002511	"<span class=""chemical"">cephalosporins</span>"		D000743	"<span class=""disease"">hemolytic anemia</span>"	"Second- and third-generation <span class=""chemical"">cephalosporins</span>, especially cefotetan, are increasingly associated with severe, sometimes fatal immune <span class=""disease"">hemolytic anemia</span>."		10411803	10411803_D002511_D000743	bcv_easy_95				
	D014147	"<span class=""chemical"">tramadol</span>"		D006212	"<span class=""disease"">hallucinations</span>"	"Nightmares and <span class=""disease"">hallucinations</span> after long-term intake of <span class=""chemical"">tramadol</span> combined with antidepressants."		8766220	8766220_D014147_D006212	bcv_easy_96				
	D014147	"<span class=""chemical"">Tramadol</span>"		D010146	"<span class=""disease"">pain</span>"	"<span class=""chemical"">Tramadol</span> is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer <span class=""disease"">pain</span> and chronic non malignant <span class=""disease"">pain</span>."		8766220	8766220_D014147_D010146	bcv_easy_97				
	D014147	"<span class=""chemical"">Tramadol</span>"		D009369	"<span class=""disease"">cancer</span>"	"<span class=""chemical"">Tramadol</span> is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat <span class=""disease"">cancer</span> pain and chronic non malignant pain."		8766220	8766220_D014147_D009369	bcv_easy_98				
	D004308	"<span class=""chemical"">dosulepine hydrochloride</span>"		D059350	"<span class=""disease"">chronic pain</span>"	"This drug was initiated in association with paroxetine and <span class=""chemical"">dosulepine hydrochloride</span> in a tetraparetic patient with <span class=""disease"">chronic pain</span>."		8766220	8766220_D004308_D059350	bcv_easy_99				
	D017374	"<span class=""chemical"">paroxetine</span>"		D059350	"<span class=""disease"">chronic pain</span>"	"This drug was initiated in association with <span class=""chemical"">paroxetine</span> and dosulepine hydrochloride in a tetraparetic patient with <span class=""disease"">chronic pain</span>."		8766220	8766220_D017374_D059350	bcv_easy_100				
	D014147	"<span class=""chemical"">tramadol</span>"		D006212	"<span class=""disease"">hallucinations</span>"	"Fifty-six days after initiation of the treatment the patient presented <span class=""disease"">hallucinations</span> that only stopped after the withdrawal of psycho-active drugs and <span class=""chemical"">tramadol</span>."		8766220	8766220_D014147_D006212	bcv_easy_101				
	D063325	"<span class=""chemical"">Tiapride</span>"		D004409	"<span class=""disease"">involuntary movements</span>"	"<span class=""chemical"">Tiapride</span> in levodopa-induced <span class=""disease"">involuntary movements</span>."		458486	458486_D063325_D004409	bcv_easy_102				
	C037689	"<span class=""chemical"">benzamide</span>"		D010300	"<span class=""disease"">idiopathic Parkinson's disease</span>"	"Tiapride, a substituted <span class=""chemical"">benzamide</span> derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with <span class=""disease"">idiopathic Parkinson's disease</span>."		458486	458486_C037689_D010300	bcv_easy_103				
	D008787	"<span class=""chemical"">metoclopramide</span>"		D004409	"<span class=""disease"">involuntary movements</span>"	"Tiapride, a substituted benzamide derivative closely related to <span class=""chemical"">metoclopramide</span>, reduced levodopa-induced peak dose <span class=""disease"">involuntary movements</span> in 16 patients with idiopathic Parkinson's disease."		458486	458486_D008787_D004409	bcv_easy_104				
	D008787	"<span class=""chemical"">metoclopramide</span>"		D010300	"<span class=""disease"">idiopathic Parkinson's disease</span>"	"Tiapride, a substituted benzamide derivative closely related to <span class=""chemical"">metoclopramide</span>, reduced levodopa-induced peak dose involuntary movements in 16 patients with <span class=""disease"">idiopathic Parkinson's disease</span>."		458486	458486_D008787_D010300	bcv_easy_105				
	D063325	"<span class=""chemical"">Tiapride</span>"		D010300	"<span class=""disease"">idiopathic Parkinson's disease</span>"	"<span class=""chemical"">Tiapride</span>, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with <span class=""disease"">idiopathic Parkinson's disease</span>."		458486	458486_D063325_D010300	bcv_easy_106				
	C037689	"<span class=""chemical"">benzamide</span>"		D004409	"<span class=""disease"">involuntary movements</span>"	"Tiapride, a substituted <span class=""chemical"">benzamide</span> derivative closely related to metoclopramide, reduced levodopa-induced peak dose <span class=""disease"">involuntary movements</span> in 16 patients with idiopathic Parkinson's disease."		458486	458486_C037689_D004409	bcv_easy_107				
	D063325	"<span class=""chemical"">Tiapride</span>"		D004409	"<span class=""disease"">involuntary movements</span>"	"<span class=""chemical"">Tiapride</span>, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose <span class=""disease"">involuntary movements</span> in 16 patients with idiopathic Parkinson's disease."		458486	458486_D063325_D004409	bcv_easy_108				
	D007980	"<span class=""chemical"">levodopa</span>"		D010300	"<span class=""disease"">idiopathic Parkinson's disease</span>"	"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced <span class=""chemical"">levodopa</span>-induced peak dose involuntary movements in 16 patients with <span class=""disease"">idiopathic Parkinson's disease</span>."		458486	458486_D007980_D010300	bcv_easy_109				
	D007980	"<span class=""chemical"">levodopa</span>"		D004421	"<span class=""disease"">dystonia</span>"	"Tiapride had no effect on <span class=""chemical"">levodopa</span>-induced early morning of ""off-period"" segmental <span class=""disease"">dystonia</span>."		458486	458486_D007980_D004421	bcv_easy_110				
	D063325	"<span class=""chemical"">Tiapride</span>"		D004421	"<span class=""disease"">dystonia</span>"	"<span class=""chemical"">Tiapride</span> had no effect on levodopa-induced early morning of ""off-period"" segmental <span class=""disease"">dystonia</span>."		458486	458486_D063325_D004421	bcv_easy_111				
	D004298	"<span class=""chemical"">dopamine</span>"		D004409	"<span class=""disease"">dyskinesias</span>"	"These results fail to support the notion that levodopa-induced <span class=""disease"">dyskinesias</span> are caused by overstimulation of a separate group of <span class=""chemical"">dopamine</span> receptors."		458486	458486_D004298_D004409	bcv_easy_112				
	D001379	"<span class=""chemical"">azathioprine</span>"		D008107	"<span class=""disease"">liver disease</span>"	"A 67-year-old patient, with primary polymyositis and without previous evidence of <span class=""disease"">liver disease</span>, developed clinical and biochemical features of severe cholestasis 3 months after initiation of <span class=""chemical"">azathioprine</span> therapy."		2051906	2051906_D001379_D008107	bcv_easy_113				
	D001379	"<span class=""chemical"">azathioprine</span>"		D017285	"<span class=""disease"">polymyositis</span>"	"A 67-year-old patient, with primary <span class=""disease"">polymyositis</span> and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of <span class=""chemical"">azathioprine</span> therapy."		2051906	2051906_D001379_D017285	bcv_easy_114				
	D007530	"<span class=""chemical"">isoflurane</span>"		D002779|D056486	"<span class=""disease"">cholestatic hepatitis</span>"	"Acute <span class=""disease"">cholestatic hepatitis</span> after exposure to <span class=""chemical"">isoflurane</span>."		11847945	11847945_D007530_D002779|D056486	bcv_easy_115				
	D007530	"<span class=""chemical"">isoflurane</span>"		D002779|D056486	"<span class=""disease"">cholestatic hepatitis</span>"	"OBJECTIVE: To report a case of acute <span class=""disease"">cholestatic hepatitis</span> following exposure to the inhalational anesthetic <span class=""chemical"">isoflurane</span>."		11847945	11847945_D007530_D002779|D056486	bcv_easy_116				
	D004177	"<span class=""chemical"">dipyrone</span>"		D000699	"<span class=""disease"">analgesia</span>"	"No other medications were involved except for <span class=""chemical"">dipyrone</span> for <span class=""disease"">analgesia</span>."		11847945	11847945_D004177_D000699	bcv_easy_117				
	D007530	"<span class=""chemical"">Isoflurane</span>"		D002779|D056486	"<span class=""disease"">cholestatic hepatitis</span>"	"CONCLUSIONS: <span class=""chemical"">Isoflurane</span>, a common anesthetic agent, can cause severe <span class=""disease"">cholestatic hepatitis</span>."		11847945	11847945_D007530_D002779|D056486	bcv_easy_118				
	D002110	"<span class=""chemical"">caffeine</span>"		D017180	"<span class=""disease"">ventricular tachycardia</span>"	"A case of <span class=""disease"">ventricular tachycardia</span> related to <span class=""chemical"">caffeine</span> pretreatment."		18997632	18997632_D002110_D017180	bcv_easy_119				
	D002110	"<span class=""chemical"">caffeine</span>"		D018879	"<span class=""disease"">ventricular ectopy</span>"	"Intravenous <span class=""chemical"">caffeine</span> is commonly used to improve seizure duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign <span class=""disease"">ventricular ectopy</span>."		18997632	18997632_D002110_D018879	bcv_easy_120				
	D002110	"<span class=""chemical"">caffeine</span>"		D012640	"<span class=""disease"">seizure</span>"	"Intravenous <span class=""chemical"">caffeine</span> is commonly used to improve <span class=""disease"">seizure</span> duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign ventricular ectopy."		18997632	18997632_D002110_D012640	bcv_easy_121				
	D002110	"<span class=""chemical"">caffeine</span>"		D017180	"<span class=""disease"">ventricular tachycardia</span>"	"We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of <span class=""disease"">ventricular tachycardia</span> after <span class=""chemical"">caffeine</span> administration."		18997632	18997632_D002110_D017180	bcv_easy_122				
	D002110	"<span class=""chemical"">caffeine</span>"		D001145	"<span class=""disease"">arrhythmia</span>"	"We describe a patient with no previous history of cardiac disease or <span class=""disease"">arrhythmia</span> who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after <span class=""chemical"">caffeine</span> administration."		18997632	18997632_D002110_D001145	bcv_easy_123				
	D002110	"<span class=""chemical"">caffeine</span>"		D006331	"<span class=""disease"">cardiac disease</span>"	"We describe a patient with no previous history of <span class=""disease"">cardiac disease</span> or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after <span class=""chemical"">caffeine</span> administration."		18997632	18997632_D002110_D006331	bcv_easy_124				
	D002110	"<span class=""chemical"">caffeine</span>"		D001145	"<span class=""disease"">ventricular arrhythmias</span>"	"Although intravenous <span class=""chemical"">caffeine</span> is generally well tolerated, the clinician should be aware of the potential for unpredictable and serious <span class=""disease"">ventricular arrhythmias</span>."		18997632	18997632_D002110_D001145	bcv_easy_125				
	C076029	"<span class=""chemical"">olanzapine</span>"		D001714	"<span class=""disease"">Hypomania</span>"	"<span class=""disease"">Hypomania</span>-like syndrome induced by <span class=""chemical"">olanzapine</span>."		10565806	10565806_C076029_D001714	bcv_easy_126				
	C076029	"<span class=""chemical"">olanzapine</span>"		D011618	"<span class=""disease"">psychotic disorder</span>"	"We report a female patient with a diagnosis of a not otherwise specified <span class=""disease"">psychotic disorder</span> (DSM-IV) who developed hypomania shortly after the introduction of <span class=""chemical"">olanzapine</span> treatment."		10565806	10565806_C076029_D011618	bcv_easy_127				
	C076029	"<span class=""chemical"">olanzapine</span>"		D001714	"<span class=""disease"">hypomania</span>"	"We report a female patient with a diagnosis of a not otherwise specified psychotic disorder (DSM-IV) who developed <span class=""disease"">hypomania</span> shortly after the introduction of <span class=""chemical"">olanzapine</span> treatment."		10565806	10565806_C076029_D001714	bcv_easy_128				
	D003520	"<span class=""chemical"">cyclophosphamide</span>"		D066126	"<span class=""disease"">cardiotoxicity</span>"	"Reduced <span class=""disease"">cardiotoxicity</span> and preserved antitumor efficacy of liposome-encapsulated doxorubicin and <span class=""chemical"">cyclophosphamide</span> compared with conventional doxorubicin and <span class=""chemical"">cyclophosphamide</span> in a randomized, multicenter trial of metastatic breast cancer."		11230490	11230490_D003520_D066126	bcv_easy_129				
	D004317	"<span class=""chemical"">doxorubicin</span>"		D001943	"<span class=""disease"">breast cancer</span>"	"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated <span class=""chemical"">doxorubicin</span> and cyclophosphamide compared with conventional <span class=""chemical"">doxorubicin</span> and cyclophosphamide in a randomized, multicenter trial of metastatic <span class=""disease"">breast cancer</span>."		11230490	11230490_D004317_D001943	bcv_easy_130				
	D003520	"<span class=""chemical"">cyclophosphamide</span>"		D001943	"<span class=""disease"">breast cancer</span>"	"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and <span class=""chemical"">cyclophosphamide</span> compared with conventional doxorubicin and <span class=""chemical"">cyclophosphamide</span> in a randomized, multicenter trial of metastatic <span class=""disease"">breast cancer</span>."		11230490	11230490_D003520_D001943	bcv_easy_131				
	D004317	"<span class=""chemical"">doxorubicin</span>"		D066126	"<span class=""disease"">cardiotoxicity</span>"	"Reduced <span class=""disease"">cardiotoxicity</span> and preserved antitumor efficacy of liposome-encapsulated <span class=""chemical"">doxorubicin</span> and cyclophosphamide compared with conventional <span class=""chemical"">doxorubicin</span> and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer."		11230490	11230490_D004317_D066126	bcv_easy_132				
	D003520	"<span class=""chemical"">cyclophosphamide</span>"		D066126	"<span class=""disease"">cardiotoxicity</span>"	"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with <span class=""chemical"">cyclophosphamide</span> significantly reduces doxorubicin <span class=""disease"">cardiotoxicity</span> while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC)."		11230490	11230490_D003520_D066126	bcv_easy_133				
	D004317	"<span class=""chemical"">Myocet/doxorubicin</span>"		D001943	"<span class=""disease"">breast cancer/MBC</span>"	"PURPOSE: To determine whether <span class=""chemical"">Myocet</span> (liposome-encapsulated <span class=""chemical"">doxorubicin</span>; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces <span class=""chemical"">doxorubicin</span> cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic <span class=""disease"">breast cancer</span> (<span class=""disease"">MBC</span>)."		11230490	11230490_D004317_D001943	bcv_easy_134				
	D003520	"<span class=""chemical"">cyclophosphamide</span>"		D001943	"<span class=""disease"">breast cancer/MBC</span>"	"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with <span class=""chemical"">cyclophosphamide</span> significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic <span class=""disease"">breast cancer</span> (<span class=""disease"">MBC</span>)."		11230490	11230490_D003520_D001943	bcv_easy_135				
	D004317	"<span class=""chemical"">Myocet/doxorubicin</span>"		D066126	"<span class=""disease"">cardiotoxicity</span>"	"PURPOSE: To determine whether <span class=""chemical"">Myocet</span> (liposome-encapsulated <span class=""chemical"">doxorubicin</span>; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces <span class=""chemical"">doxorubicin</span> <span class=""disease"">cardiotoxicity</span> while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC)."		11230490	11230490_D004317_D066126	bcv_easy_136				
	D004317	"<span class=""chemical"">Myocet/doxorubicin</span>"		D001943	"<span class=""disease"">MBC</span>"	"PATIENTS AND METHODS: Two hundred ninety-seven patients with <span class=""disease"">MBC</span> and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of <span class=""chemical"">Myocet</span> (M) or conventional <span class=""chemical"">doxorubicin</span> (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity."		11230490	11230490_D004317_D001943	bcv_easy_137				
	D004317	"<span class=""chemical"">Myocet/doxorubicin</span>"		D064420	"<span class=""disease"">toxicity</span>"	"PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of <span class=""chemical"">Myocet</span> (M) or conventional <span class=""chemical"">doxorubicin</span> (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable <span class=""disease"">toxicity</span>."		11230490	11230490_D004317_D064420	bcv_easy_138				
	D003520	"<span class=""chemical"">cyclophosphamide</span>"		D064420	"<span class=""disease"">toxicity</span>"	"PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of <span class=""chemical"">cyclophosphamide</span> (C), every 3 weeks until disease progression or unacceptable <span class=""disease"">toxicity</span>."		11230490	11230490_D003520_D064420	bcv_easy_139				
	D003520	"<span class=""chemical"">cyclophosphamide</span>"		D001943	"<span class=""disease"">MBC</span>"	"PATIENTS AND METHODS: Two hundred ninety-seven patients with <span class=""disease"">MBC</span> and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of <span class=""chemical"">cyclophosphamide</span> (C), every 3 weeks until disease progression or unacceptable toxicity."		11230490	11230490_D003520_D001943	bcv_easy_140				
	D003520	"<span class=""chemical"">cyclophosphamide</span>"		D001943	"<span class=""disease"">MBC</span>"	"CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with <span class=""chemical"">cyclophosphamide</span> as first-line therapy for <span class=""disease"">MBC</span>."		11230490	11230490_D003520_D001943	bcv_easy_141				
	D003520	"<span class=""chemical"">cyclophosphamide</span>"		D066126	"<span class=""disease"">cardiotoxicity</span>"	"CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing <span class=""disease"">cardiotoxicity</span> and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with <span class=""chemical"">cyclophosphamide</span> as first-line therapy for MBC."		11230490	11230490_D003520_D066126	bcv_easy_142				
	D004317	"<span class=""chemical"">Myocet/doxorubicin</span>"		D009503	"<span class=""disease"">neutropenia</span>"	"CONCLUSION: <span class=""chemical"">Myocet</span> improves the therapeutic index of <span class=""chemical"">doxorubicin</span> by significantly reducing cardiotoxicity and grade 4 <span class=""disease"">neutropenia</span> and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC."		11230490	11230490_D004317_D009503	bcv_easy_143				
	D004317	"<span class=""chemical"">Myocet/doxorubicin</span>"		D066126	"<span class=""disease"">cardiotoxicity</span>"	"CONCLUSION: <span class=""chemical"">Myocet</span> improves the therapeutic index of <span class=""chemical"">doxorubicin</span> by significantly reducing <span class=""disease"">cardiotoxicity</span> and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC."		11230490	11230490_D004317_D066126	bcv_easy_144				
	D003520	"<span class=""chemical"">cyclophosphamide</span>"		D009503	"<span class=""disease"">neutropenia</span>"	"CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 <span class=""disease"">neutropenia</span> and provides comparable antitumor efficacy, when used in combination with <span class=""chemical"">cyclophosphamide</span> as first-line therapy for MBC."		11230490	11230490_D003520_D009503	bcv_easy_145				
	D004317	"<span class=""chemical"">Myocet/doxorubicin</span>"		D001943	"<span class=""disease"">MBC</span>"	"CONCLUSION: <span class=""chemical"">Myocet</span> improves the therapeutic index of <span class=""chemical"">doxorubicin</span> by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for <span class=""disease"">MBC</span>."		11230490	11230490_D004317_D001943	bcv_easy_146				
	D008238	"<span class=""chemical"">LSD</span>"		D012559	"<span class=""disease"">schizophrenic</span>"	"Risperidone-associated, benign transient visual disturbances in <span class=""disease"">schizophrenic</span> patients with a past history of <span class=""chemical"">LSD</span> abuse."		12013711	12013711_D008238_D012559	bcv_easy_147				
	D018967	"<span class=""chemical"">Risperidone</span>"		D012559	"<span class=""disease"">schizophrenic</span>"	"<span class=""chemical"">Risperidone</span>-associated, benign transient visual disturbances in <span class=""disease"">schizophrenic</span> patients with a past history of LSD abuse."		12013711	12013711_D018967_D012559	bcv_easy_148				
	D018967	"<span class=""chemical"">Risperidone</span>"		D010468	"<span class=""disease"">visual disturbances</span>"	"<span class=""chemical"">Risperidone</span>-associated, benign transient <span class=""disease"">visual disturbances</span> in schizophrenic patients with a past history of LSD abuse."		12013711	12013711_D018967_D010468	bcv_easy_149				
	D008238	"<span class=""chemical"">LSD</span>"		D010468	"<span class=""disease"">visual disturbances</span>"	"Risperidone-associated, benign transient <span class=""disease"">visual disturbances</span> in schizophrenic patients with a past history of <span class=""chemical"">LSD</span> abuse."		12013711	12013711_D008238_D010468	bcv_easy_150				
	D018967	"<span class=""chemical"">risperidone</span>"		D001480	"<span class=""disease"">EPS</span>"	"Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed <span class=""disease"">EPS</span> with classic antipsychotics, were successfully treated with <span class=""chemical"">risperidone</span>."		12013711	12013711_D018967_D001480	bcv_easy_151				
	D008238	"<span class=""chemical"">LSD</span>"		D012559	"<span class=""disease"">schizophrenic</span>"	"Two <span class=""disease"">schizophrenic</span> patients, who had a prior history of <span class=""chemical"">LSD</span> abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone."		12013711	12013711_D008238_D012559	bcv_easy_152				
	D008238	"<span class=""chemical"">LSD</span>"		D001480	"<span class=""disease"">EPS</span>"	"Two schizophrenic patients, who had a prior history of <span class=""chemical"">LSD</span> abuse and who had previously developed <span class=""disease"">EPS</span> with classic antipsychotics, were successfully treated with risperidone."		12013711	12013711_D008238_D001480	bcv_easy_153				
	D018967	"<span class=""chemical"">risperidone</span>"		D012559	"<span class=""disease"">schizophrenic</span>"	"Two <span class=""disease"">schizophrenic</span> patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with <span class=""chemical"">risperidone</span>."		12013711	12013711_D018967_D012559	bcv_easy_154				
	D018967	"<span class=""chemical"">risperidone</span>"		D010468	"<span class=""disease"">visual disturbances</span>"	"They both reported short episodes of transient <span class=""disease"">visual disturbances</span>, which appeared immediately after starting treatment with <span class=""chemical"">risperidone</span>."		12013711	12013711_D018967_D010468	bcv_easy_155				
	D008238	"<span class=""chemical"">LSD</span>"		D010468	"<span class=""disease"">visual disturbances</span>"	"This imagery resembled <span class=""disease"">visual disturbances</span> previously experienced as ""flashbacks"" related to prior <span class=""chemical"">LSD</span> consumption."		12013711	12013711_D008238_D010468	bcv_easy_156				
	D018967	"<span class=""chemical"">Risperidone</span>"		D010468	"<span class=""disease"">visual disturbances</span>"	"<span class=""chemical"">Risperidone</span> administration was continued and the <span class=""disease"">visual disturbances</span> gradually wore off."		12013711	12013711_D018967_D010468	bcv_easy_157				
	D014635	"<span class=""chemical"">sodium valproate</span>"		D007177	"<span class=""disease"">syndrome of inappropriate secretion of antidiuretic hormone</span>"	"Contribution of <span class=""chemical"">sodium valproate</span> to the <span class=""disease"">syndrome of inappropriate secretion of antidiuretic hormone</span>."		11195262	11195262_D014635_D007177	bcv_easy_158				
	D014635	"<span class=""chemical"">sodium valproate/VPA</span>"		D007177	"<span class=""disease"">SIADH/syndrome of inappropriate secretion of antidiuretic hormone</span>"	"We report the case of a 62-year-old man who was administered <span class=""chemical"">sodium valproate</span> (<span class=""chemical"">VPA</span>) and who subsequently developed the <span class=""disease"">syndrome of inappropriate secretion of antidiuretic hormone</span> (<span class=""disease"">SIADH</span>)."		11195262	11195262_D014635_D007177	bcv_easy_159				
	D014635	"<span class=""chemical"">VPA</span>"		D004830	"<span class=""disease"">tonic-clonic convulsions</span>"	"He had been taking <span class=""chemical"">VPA</span> for treatment of idiopathic generalized <span class=""disease"">tonic-clonic convulsions</span> since he was 56 years old."		11195262	11195262_D014635_D004830	bcv_easy_160				
	D014635	"<span class=""chemical"">VPA</span>"		D002493	"<span class=""disease"">weakness of the central nervous system</span>"	"We consider this episode of SIADH to be the result of a combination of factors including a <span class=""disease"">weakness of the central nervous system</span> and the long-term administration of <span class=""chemical"">VPA</span>."		11195262	11195262_D014635_D002493	bcv_easy_161				
	D014635	"<span class=""chemical"">VPA</span>"		D007177	"<span class=""disease"">SIADH</span>"	"We consider this episode of <span class=""disease"">SIADH</span> to be the result of a combination of factors including a weakness of the central nervous system and the long-term administration of <span class=""chemical"">VPA</span>."		11195262	11195262_D014635_D007177	bcv_easy_162				
	D008794	"<span class=""chemical"">metrizoate</span>"		D014693	"<span class=""disease"">ventricular fibrillation</span>"	"Selective injection of iopentol, iohexol and <span class=""chemical"">metrizoate</span> into the left coronary artery of the dog. Induction of <span class=""disease"">ventricular fibrillation</span> and decrease of aortic pressure."		2980315	2980315_D008794_D014693	bcv_easy_163				
	C053571	"<span class=""chemical"">iopentol</span>"		D014693	"<span class=""disease"">ventricular fibrillation</span>"	"Selective injection of <span class=""chemical"">iopentol</span>, iohexol and metrizoate into the left coronary artery of the dog. Induction of <span class=""disease"">ventricular fibrillation</span> and decrease of aortic pressure."		2980315	2980315_C053571_D014693	bcv_easy_164				
	D007472	"<span class=""chemical"">iohexol</span>"		D014693	"<span class=""disease"">ventricular fibrillation</span>"	"Selective injection of iopentol, <span class=""chemical"">iohexol</span> and metrizoate into the left coronary artery of the dog. Induction of <span class=""disease"">ventricular fibrillation</span> and decrease of aortic pressure."		2980315	2980315_D007472_D014693	bcv_easy_165				
	D008794	"<span class=""chemical"">metrizoate</span>"		D014693	"<span class=""disease"">ventricular fibrillation</span>"	"Frequencies of <span class=""disease"">ventricular fibrillation</span> were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after <span class=""chemical"">metrizoate</span> (22%)."		2980315	2980315_D008794_D014693	bcv_easy_166				
	C053571	"<span class=""chemical"">iopentol</span>"		D014693	"<span class=""disease"">ventricular fibrillation</span>"	"Frequencies of <span class=""disease"">ventricular fibrillation</span> were significantly lower (p less than 0.05) after <span class=""chemical"">iopentol</span> (0%) and iohexol (3%) than after metrizoate (22%)."		2980315	2980315_C053571_D014693	bcv_easy_167				
	D007472	"<span class=""chemical"">iohexol</span>"		D014693	"<span class=""disease"">ventricular fibrillation</span>"	"Frequencies of <span class=""disease"">ventricular fibrillation</span> were significantly lower (p less than 0.05) after iopentol (0%) and <span class=""chemical"">iohexol</span> (3%) than after metrizoate (22%)."		2980315	2980315_D007472_D014693	bcv_easy_168				
	D012254	"<span class=""chemical"">ribavirin</span>"		D006526	"<span class=""disease"">hepatitis C</span>"	"Management strategies for <span class=""chemical"">ribavirin</span>-induced hemolytic anemia in the treatment of <span class=""disease"">hepatitis C</span>: clinical and economic implications."		11705128	11705128_D012254_D006526	bcv_easy_169				
	D016898	"<span class=""chemical"">interferon-alpha</span>"		D019698	"<span class=""disease"">chronic hepatitis C/CHC</span>"	"OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with <span class=""chemical"">interferon-alpha</span> monotherapy in the treatment of <span class=""disease"">chronic hepatitis C</span> (<span class=""disease"">CHC</span>)."		11705128	11705128_D016898_D019698	bcv_easy_170				
	D012254	"<span class=""chemical"">ribavirin</span>"		D019698	"<span class=""disease"">chronic hepatitis C/CHC</span>"	"OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/<span class=""chemical"">ribavirin</span> compared with interferon-alpha monotherapy in the treatment of <span class=""disease"">chronic hepatitis C</span> (<span class=""disease"">CHC</span>)."		11705128	11705128_D012254_D019698	bcv_easy_171				
	D002701	"<span class=""chemical"">chloramphenicol</span>"		D000741	"<span class=""disease"">aplastic anemia</span>"	"Fatal <span class=""disease"">aplastic anemia</span> following topical administration of ophthalmic <span class=""chemical"">chloramphenicol</span>."		7072798	7072798_D002701_D000741	bcv_easy_172				
	D002701	"<span class=""chemical"">chloramphenicol</span>"		D002386	"<span class=""disease"">cataract</span>"	"A 73-year-old woman died of aplastic anemia less than two months after undergoing <span class=""disease"">cataract</span> extraction and beginning topical therapy with <span class=""chemical"">chloramphenicol</span>."		7072798	7072798_D002701_D002386	bcv_easy_173				
	D002701	"<span class=""chemical"">chloramphenicol</span>"		D000741	"<span class=""disease"">aplastic anemia</span>"	"A 73-year-old woman died of <span class=""disease"">aplastic anemia</span> less than two months after undergoing cataract extraction and beginning topical therapy with <span class=""chemical"">chloramphenicol</span>."		7072798	7072798_D002701_D000741	bcv_easy_174				
	D002701	"<span class=""chemical"">chloramphenicol</span>"		D000741	"<span class=""disease"">aplastic anemia</span>"	"The pattern of the <span class=""disease"">aplastic anemia</span> was associated with an idiosyncratic response to <span class=""chemical"">chloramphenicol</span>."		7072798	7072798_D002701_D000741	bcv_easy_175				
	D002701	"<span class=""chemical"">chloramphenicol</span>"		D001855	"<span class=""disease"">bone marrow hypoplasia</span>"	"This was the second report of fatal aplastic anemia after topical treatment with <span class=""chemical"">chloramphenicol</span> for ocular conditions, although two cases of reversible <span class=""disease"">bone marrow hypoplasia</span> have also been reported."		7072798	7072798_D002701_D001855	bcv_easy_176				
	D002701	"<span class=""chemical"">chloramphenicol</span>"		D000741	"<span class=""disease"">aplastic anemia</span>"	"This was the second report of fatal <span class=""disease"">aplastic anemia</span> after topical treatment with <span class=""chemical"">chloramphenicol</span> for ocular conditions, although two cases of reversible bone marrow hypoplasia have also been reported."		7072798	7072798_D002701_D000741	bcv_easy_177				
	D002701	"<span class=""chemical"">chloramphenicol</span>"		D005128	"<span class=""disease"">ocular toxicity</span>"	"Any other suspected cases of <span class=""disease"">ocular toxicity</span> associated with topically applied <span class=""chemical"">chloramphenicol</span> should be reported to the National Registry of Drug-Induced Ocular Side Effects, Oregon Health Sciences University, Portland, OR 97201."		7072798	7072798_D002701_D005128	bcv_easy_178				
	D008727	"<span class=""chemical"">methotrexate</span>"		D009369	"<span class=""disease"">tumours</span>"	"Extensive experimental and limited clinical data have shown that lometrexol has activity against <span class=""disease"">tumours</span> which are refractory to other drugs, notably <span class=""chemical"">methotrexate</span>."		8958188	8958188_D008727_D009369	bcv_easy_179				
	C045894	"<span class=""chemical"">lometrexol</span>"		D009369	"<span class=""disease"">tumours</span>"	"Extensive experimental and limited clinical data have shown that <span class=""chemical"">lometrexol</span> has activity against <span class=""disease"">tumours</span> which are refractory to other drugs, notably methotrexate."		8958188	8958188_C045894_D009369	bcv_easy_180				
	C045894	"<span class=""chemical"">lometrexol</span>"		D064420	"<span class=""disease"">toxicities</span>"	"However, the initial clinical development of <span class=""chemical"">lometrexol</span> was curtailed because of severe and cumulative antiproliferative <span class=""disease"">toxicities</span>."		8958188	8958188_C045894_D064420	bcv_easy_181				
	C045894	"<span class=""chemical"">lometrexol</span>"		D064420	"<span class=""disease"">toxicity</span>"	"Preclinical murine studies demonstrated that the <span class=""disease"">toxicity</span> of <span class=""chemical"">lometrexol</span> can be prevented by low dose folic acid administration, i.e. for 7 days prior to and 7 days following a single bolus dose."		8958188	8958188_C045894_D064420	bcv_easy_182				
	D005492	"<span class=""chemical"">folic acid</span>"		D064420	"<span class=""disease"">toxicity</span>"	"Preclinical murine studies demonstrated that the <span class=""disease"">toxicity</span> of lometrexol can be prevented by low dose <span class=""chemical"">folic acid</span> administration, i.e. for 7 days prior to and 7 days following a single bolus dose."		8958188	8958188_D005492_D064420	bcv_easy_183				
	C045894	"<span class=""chemical"">lometrexol</span>"		D064420	"<span class=""disease"">toxicity</span>"	"This observation prompted a Phase I clinical study of <span class=""chemical"">lometrexol</span> given with folic acid supplementation which has confirmed that the <span class=""disease"">toxicity</span> of <span class=""chemical"">lometrexol</span> can be markedly reduced by folic acid supplementation."		8958188	8958188_C045894_D064420	bcv_easy_184				
	D005492	"<span class=""chemical"">folic acid</span>"		D064420	"<span class=""disease"">toxicity</span>"	"This observation prompted a Phase I clinical study of lometrexol given with <span class=""chemical"">folic acid</span> supplementation which has confirmed that the <span class=""disease"">toxicity</span> of lometrexol can be markedly reduced by <span class=""chemical"">folic acid</span> supplementation."		8958188	8958188_D005492_D064420	bcv_easy_185				
	D005492	"<span class=""chemical"">folate</span>"		D064420	"<span class=""disease"">toxicity</span>"	"There was no clear relationship between clinical <span class=""disease"">toxicity</span> and the extent of plasma <span class=""chemical"">folate</span> elevation."		8958188	8958188_D005492_D064420	bcv_easy_186				
	C045894	"<span class=""chemical"">lometrexol</span>"		D064420	"<span class=""disease"">toxicity</span>"	"Associated studies demonstrated that <span class=""chemical"">lometrexol</span> plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce <span class=""disease"">toxicity</span> by enhancing <span class=""chemical"">lometrexol</span> plasma clearance."		8958188	8958188_C045894_D064420	bcv_easy_187				
	D005492	"<span class=""chemical"">folic acid</span>"		D064420	"<span class=""disease"">toxicity</span>"	"Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by <span class=""chemical"">folic acid</span> administration indicating that supplementation is unlikely to reduce <span class=""disease"">toxicity</span> by enhancing lometrexol plasma clearance."		8958188	8958188_D005492_D064420	bcv_easy_188				
	D001058	"<span class=""chemical"">Apomorphine</span>"		D010300	"<span class=""disease"">Parkinson's disease</span>"	"<span class=""chemical"">Apomorphine</span>: an underutilized therapy for <span class=""disease"">Parkinson's disease</span>."		11009181	11009181_D001058_D010300	bcv_easy_189				
	D001058	"<span class=""chemical"">Apomorphine</span>"		D010300	"<span class=""disease"">Parkinson's disease</span>"	"<span class=""chemical"">Apomorphine</span> was the first dopaminergic drug ever used to treat symptoms of <span class=""disease"">Parkinson's disease</span>."		11009181	11009181_D001058_D010300	bcv_easy_190				
	D001058	"<span class=""chemical"">apomorphine</span>"		D010300	"<span class=""disease"">Parkinson's disease</span>"	"While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating <span class=""disease"">Parkinson's disease</span> by subcutaneous administration of <span class=""chemical"">apomorphine</span> has only recently become the subject of systematic study."		11009181	11009181_D001058_D010300	bcv_easy_191				
	D001058	"<span class=""chemical"">apomorphine</span>"		D004409	"<span class=""disease"">dyskinesias</span>"	"In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous <span class=""chemical"">apomorphine</span> infusions is associated with marked reductions of preexisting levodopa-induced <span class=""disease"">dyskinesias</span>."		11009181	11009181_D001058_D004409	bcv_easy_192				
	D001058	"<span class=""chemical"">apomorphine</span>"		D001523	"<span class=""disease"">psychiatric</span>"	"The main side effects of subcutaneous <span class=""chemical"">apomorphine</span> treatment are related to cutaneous tolerability problems, whereas sedation and <span class=""disease"">psychiatric</span> complications play a lesser role."		11009181	11009181_D001058_D001523	bcv_easy_193				
	D001058	"<span class=""chemical"">apomorphine</span>"		D010300	"<span class=""disease"">Parkinson's disease</span>"	"Given the marked degree of efficacy of subcutaneous <span class=""chemical"">apomorphine</span> treatment in fluctuating <span class=""disease"">Parkinson's disease</span>, this approach seems to deserve more widespread clinical use."		11009181	11009181_D001058_D010300	bcv_easy_194				
	D010400	"<span class=""chemical"">penicillin-G potassium</span>"		D004827	"<span class=""disease"">epileptic</span>"	"After a short period of basal activity recording, <span class=""disease"">epileptic</span> focus was induced by injecting 400IU/2 microl <span class=""chemical"">penicillin-G potassium</span> into the left lateral ventricle while the cortical activity was continuously recorded."		18657397	18657397_D010400_D004827	bcv_easy_195				
	D007649	"<span class=""chemical"">ketamine</span>"		D003866	"<span class=""disease"">depression</span>"	"Injections of <span class=""chemical"">ketamine</span> in doses from 100 microgram to 3 mg into the artery produced a <span class=""disease"">depression</span> of the SA nodal activity by a direct action."		921394	921394_D007649_D003866	bcv_easy_196				
	D008094	"<span class=""chemical"">lithium</span>"		D011141	"<span class=""disease"">polyuric</span>"	"He remained thirsty and <span class=""disease"">polyuric</span> despite cessation of <span class=""chemical"">lithium</span> and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion, with clear evidence of nephrogenic diabetes insipidus."		9226773	9226773_D008094_D011141	bcv_easy_197				
	D014667	"<span class=""chemical"">vasopressin</span>"		D011141	"<span class=""disease"">polyuric</span>"	"He remained thirsty and <span class=""disease"">polyuric</span> despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and <span class=""chemical"">vasopressin</span> secretion, with clear evidence of nephrogenic diabetes insipidus."		9226773	9226773_D014667_D011141	bcv_easy_198				
	D014667	"<span class=""chemical"">vasopressin</span>"		D018500	"<span class=""disease"">nephrogenic diabetes insipidus</span>"	"He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and <span class=""chemical"">vasopressin</span> secretion, with clear evidence of <span class=""disease"">nephrogenic diabetes insipidus</span>."		9226773	9226773_D014667_D018500	bcv_easy_199				
	D008094	"<span class=""chemical"">Lithium</span>"		D011141	"<span class=""disease"">polyuria</span>"	"<span class=""chemical"">Lithium</span> induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but <span class=""disease"">polyuria</span> persisted in this patient for ten years after <span class=""chemical"">lithium</span> was stopped."		9226773	9226773_D008094_D011141	bcv_easy_200				
	D014635	"<span class=""chemical"">Valproate</span>"		D006423	"<span class=""disease"">homonymous hemianopsia</span>"	"Complications were observed in two patients: one had a left <span class=""disease"">homonymous hemianopsia</span> after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with <span class=""chemical"">Valproate</span> 1000 mg/day."		19234905	19234905_D014635_D006423	bcv_easy_201				
	D004221	"<span class=""chemical"">Disulfiram</span>"		D009901|D010523	"<span class=""disease"">optic and peripheral neuropathy</span>"	"<span class=""chemical"">Disulfiram</span>-induced transient <span class=""disease"">optic and peripheral neuropathy</span>: a case report."		17786501	17786501_D004221_D009901|D010523	bcv_easy_202				
	D004221	"<span class=""chemical"">disulfiram</span>"		D009901|D010523	"<span class=""disease"">optic and peripheral neuropathy</span>"	"AIM: To report a case of <span class=""disease"">optic and peripheral neuropathy</span> after chronic use of <span class=""chemical"">disulfiram</span> for alcohol dependence management."		17786501	17786501_D004221_D009901|D010523	bcv_easy_203				
	D004221	"<span class=""chemical"">disulfiram</span>"		D000437	"<span class=""disease"">alcohol dependence</span>"	"AIM: To report a case of optic and peripheral neuropathy after chronic use of <span class=""chemical"">disulfiram</span> for <span class=""disease"">alcohol dependence</span> management."		17786501	17786501_D004221_D000437	bcv_easy_204				
	D004221	"<span class=""chemical"">disulfiram</span>"		D000437	"<span class=""disease"">alcohol dependence</span>"	"He had been taking <span class=""chemical"">disulfiram</span> for <span class=""disease"">alcohol dependence</span> for the preceding 3 years."		17786501	17786501_D004221_D000437	bcv_easy_205				
	D013390	"<span class=""chemical"">succinylcholine</span>"		D001049	"<span class=""disease"">apnoea</span>"	"The use of serum cholinesterase in <span class=""chemical"">succinylcholine</span> <span class=""disease"">apnoea</span>."		871943	871943_D013390_D001049	bcv_easy_206				
	D013390	"<span class=""chemical"">succinylcholine</span>"		D001049	"<span class=""disease"">apnoea</span>"	"Fifteen patients demonstrating unexpected prolonged <span class=""disease"">apnoea</span> lasting several hours after <span class=""chemical"">succinylcholine</span> have been treated by a new preparation of human serum cholinesterase."		871943	871943_D013390_D001049	bcv_easy_207				
	D013390	"<span class=""chemical"">succinylcholine</span>"		D001049	"<span class=""disease"">apnoea</span>"	"The use of serum cholinesterase in <span class=""chemical"">succinylcholine</span> <span class=""disease"">apnoea</span> provided considerable relief to both patient and anaesthetist."		871943	871943_D013390_D001049	bcv_easy_208				
	D015119	"<span class=""chemical"">epsilon-aminocaproic acid</span>"		D020225|D020227	"<span class=""disease"">sagittal and left transverse sinus thrombosis</span>"	"We describe a 42-year-old woman who developed superior <span class=""disease"">sagittal and left transverse sinus thrombosis</span> associated with prolonged <span class=""chemical"">epsilon-aminocaproic acid</span> therapy for menorrhagia."		2339463	2339463_D015119_D020225|D020227	bcv_easy_209				
	D015119	"<span class=""chemical"">epsilon-aminocaproic acid</span>"		D008595	"<span class=""disease"">menorrhagia</span>"	"We describe a 42-year-old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged <span class=""chemical"">epsilon-aminocaproic acid</span> therapy for <span class=""disease"">menorrhagia</span>."		2339463	2339463_D015119_D008595	bcv_easy_210				
	D015119	"<span class=""chemical"">epsilon-aminocaproic acid</span>"		D012851	"<span class=""disease"">cerebral sinus thrombosis</span>"	"Although increased risk of thromboembolic disease has been reported during treatment with <span class=""chemical"">epsilon-aminocaproic acid</span>, <span class=""disease"">cerebral sinus thrombosis</span> has not been previously described."		2339463	2339463_D015119_D012851	bcv_easy_211				
	D015119	"<span class=""chemical"">epsilon-aminocaproic acid</span>"		D013923	"<span class=""disease"">thromboembolic disease</span>"	"Although increased risk of <span class=""disease"">thromboembolic disease</span> has been reported during treatment with <span class=""chemical"">epsilon-aminocaproic acid</span>, cerebral sinus thrombosis has not been previously described."		2339463	2339463_D015119_D013923	bcv_easy_212				
	D015215	"<span class=""chemical"">azidothymidine</span>"		C565469	"<span class=""disease"">immunodeficient</span>"	"Sensitivity of erythroid progenitor colonies to erythropoietin in <span class=""chemical"">azidothymidine</span> treated <span class=""disease"">immunodeficient</span> mice."		2004015	2004015_D015215_C565469	bcv_easy_213				
	D015215	"<span class=""chemical"">AZT</span>"		D007938	"<span class=""disease"">leukaemia</span>"	"We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine <span class=""disease"">leukaemia</span> (MuLV) virus, to determine if <span class=""chemical"">AZT</span>-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO)."		2004015	2004015_D015215_D007938	bcv_easy_214				
	D015215	"<span class=""chemical"">AZT</span>"		D000163	"<span class=""disease"">AIDS</span>"	"We have used a murine model of <span class=""disease"">AIDS</span>, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if <span class=""chemical"">AZT</span>-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO)."		2004015	2004015_D015215_D000163	bcv_easy_215				
	D015215	"<span class=""chemical"">AZT</span>"		D007239	"<span class=""disease"">infection</span>"	"We have used a murine model of AIDS, <span class=""disease"">infection</span> of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if <span class=""chemical"">AZT</span>-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO)."		2004015	2004015_D015215_D007239	bcv_easy_216				
	C030299	"<span class=""chemical"">PHZ/phenylhydrazine</span>"		D000740	"<span class=""disease"">anaemia</span>"	"The mean plasma levels of EPO observed in AZT treated mice were appropriate for the degree of <span class=""disease"">anaemia</span> observed when compared with <span class=""chemical"">phenylhydrazine</span> (<span class=""chemical"">PHZ</span>) treated mice."		2004015	2004015_C030299_D000740	bcv_easy_217				
	C030299	"<span class=""chemical"">PHZ</span>"		D000740	"<span class=""disease"">anaemia</span>"	"The numbers of BFU-e and the percentage of bone marrow erythroblasts observed were comparable in AZT and <span class=""chemical"">PHZ</span> treated mice with similar degrees of <span class=""disease"">anaemia</span>."		2004015	2004015_C030299_D000740	bcv_easy_218				
	D015215	"<span class=""chemical"">AZT</span>"		D045262	"<span class=""disease"">reticulocytosis</span>"	"However, <span class=""disease"">reticulocytosis</span> was inappropriate for the degree of anaemia observed in <span class=""chemical"">AZT</span> treated infected mice."		2004015	2004015_D015215_D045262	bcv_easy_219				
	D016202	"<span class=""chemical"">NMDA/N-methyl-D-aspartate</span>"		D012559	"<span class=""disease"">schizophrenia</span>"	"The glutamatergic <span class=""chemical"">N-methyl-D-aspartate</span> (<span class=""chemical"">NMDA</span>) receptor has been implicated in the pathophysiology of <span class=""disease"">schizophrenia</span>."		20727411	20727411_D016202_D012559	bcv_easy_220				
	D016202	"<span class=""chemical"">NMDA</span>"		D012559	"<span class=""disease"">schizophrenia</span>"	"Administered to healthy volunteers, a subanesthetic dose of the non-competitive <span class=""chemical"">NMDA</span> receptor antagonist ketamine leads to psychopathological symptoms similar to those observed in <span class=""disease"">schizophrenia</span>."		20727411	20727411_D016202_D012559	bcv_easy_221				
	D007649	"<span class=""chemical"">ketamine</span>"		D012559	"<span class=""disease"">schizophrenia</span>"	"Administered to healthy volunteers, a subanesthetic dose of the non-competitive NMDA receptor antagonist <span class=""chemical"">ketamine</span> leads to psychopathological symptoms similar to those observed in <span class=""disease"">schizophrenia</span>."		20727411	20727411_D007649_D012559	bcv_easy_222				
	D007649	"<span class=""chemical"">ketamine</span>"		D012559	"<span class=""disease"">schizophrenia</span>"	"In patients with <span class=""disease"">schizophrenia</span>, <span class=""chemical"">ketamine</span> exacerbates the core symptoms of illness, supporting the hypothesis of a glutamatergic dysfunction."		20727411	20727411_D007649_D012559	bcv_easy_223				
	D007649	"<span class=""chemical"">ketamine</span>"		D018754	"<span class=""disease"">glutamatergic dysfunction</span>"	"In patients with schizophrenia, <span class=""chemical"">ketamine</span> exacerbates the core symptoms of illness, supporting the hypothesis of a <span class=""disease"">glutamatergic dysfunction</span>."		20727411	20727411_D007649_D018754	bcv_easy_224				
	D007649	"<span class=""chemical"">Ketamine</span>"		D011605	"<span class=""disease"">psychosis</span>"	"<span class=""chemical"">Ketamine</span> elicited <span class=""disease"">psychosis</span> like psychopathology."		20727411	20727411_D007649_D011605	bcv_easy_225				
	D007649	"<span class=""chemical"">Ketamine</span>"		D012559	"<span class=""disease"">schizophrenia</span>"	"<span class=""chemical"">Ketamine</span> induces activation changes in healthy subjects similar to those observed in patients with <span class=""disease"">schizophrenia</span>, particularly in frontal and temporal brain regions."		20727411	20727411_D007649_D012559	bcv_easy_226				
	D016202	"<span class=""chemical"">NMDA</span>"		D012559	"<span class=""disease"">schizophrenia</span>"	"Our results provide further support for the hypothesis of an <span class=""chemical"">NMDA</span> receptor dysfunction in the pathophysiology of <span class=""disease"">schizophrenia</span>."		20727411	20727411_D016202_D012559	bcv_easy_227				
	D007650	"<span class=""chemical"">Ketanserin</span>"		D009127	"<span class=""disease"">muscle rigidity</span>"	"<span class=""chemical"">Ketanserin</span> pretreatment reverses alfentanil-induced <span class=""disease"">muscle rigidity</span>."		3115150	3115150_D007650_D009127	bcv_easy_228				
	D007650	"<span class=""chemical"">ketanserin</span>"		D009127	"<span class=""disease"">muscle rigidity</span>"	"Systemic pretreatment with <span class=""chemical"">ketanserin</span>, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the <span class=""disease"">muscle rigidity</span> produced in rats by the potent short-acting opiate agonist alfentanil."		3115150	3115150_D007650_D009127	bcv_easy_229				
	D012701	"<span class=""chemical"">serotonin</span>"		D009127	"<span class=""disease"">muscle rigidity</span>"	"Systemic pretreatment with ketanserin, a relatively specific type-2 <span class=""chemical"">serotonin</span> receptor antagonist, significantly attenuated the <span class=""disease"">muscle rigidity</span> produced in rats by the potent short-acting opiate agonist alfentanil."		3115150	3115150_D012701_D009127	bcv_easy_230				
	D002707	"<span class=""chemical"">Chlordiazepoxide</span>"		D009127	"<span class=""disease"">rigidity</span>"	"<span class=""chemical"">Chlordiazepoxide</span> at doses up to 10 mg/kg failed to significantly influence the <span class=""disease"">rigidity</span> produced by alfentanil."		3115150	3115150_D002707_D009127	bcv_easy_231				
	D007650	"<span class=""chemical"">ketanserin</span>"		D009127	"<span class=""disease"">rigidity</span>"	"Despite the absence of <span class=""disease"">rigidity</span>, animals that received <span class=""chemical"">ketanserin</span> (greater than 0.31 mg/kg i.p.) followed by alfentanil were motionless, flaccid, and less responsive to external stimuli than were animals receiving alfentanil alone."		3115150	3115150_D007650_D009127	bcv_easy_232				
	D012701	"<span class=""chemical"">serotonin</span>"		D002318|D012131	"<span class=""disease"">cardiovascular, and respiratory depression</span>"	"Pretreatment with type-2 <span class=""chemical"">serotonin</span> antagonists may be clinically useful in attenuating opiate-induced rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, <span class=""disease"">cardiovascular, and respiratory depression</span>."		3115150	3115150_D012701_D002318|D012131	bcv_easy_233				
	D012701	"<span class=""chemical"">serotonin</span>"		D009127	"<span class=""disease"">rigidity</span>"	"Pretreatment with type-2 <span class=""chemical"">serotonin</span> antagonists may be clinically useful in attenuating opiate-induced <span class=""disease"">rigidity</span>, although further studies will be necessary to assess the interaction of possibly enhanced CNS, cardiovascular, and respiratory depression."		3115150	3115150_D012701_D009127	bcv_easy_234				
	D012254	"<span class=""chemical"">ribavirin</span>"		D000257	"<span class=""disease"">adenovirus disease</span>"	"Intravenous <span class=""chemical"">ribavirin</span> treatment for severe <span class=""disease"">adenovirus disease</span> in immunocompromised children."		12093990	12093990_D012254_D000257	bcv_easy_235				
	D012254	"<span class=""chemical"">Ribavirin</span>"		D018357	"<span class=""disease"">respiratory syncytial virus infection</span>"	"<span class=""chemical"">Ribavirin</span> is licensed in aerosol form for the treatment of <span class=""disease"">respiratory syncytial virus infection</span>, and orally in combination with interferon to treat hepatitis C."		12093990	12093990_D012254_D018357	bcv_easy_236				
	D012254	"<span class=""chemical"">Ribavirin</span>"		D006526	"<span class=""disease"">hepatitis C</span>"	"<span class=""chemical"">Ribavirin</span> is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat <span class=""disease"">hepatitis C</span>."		12093990	12093990_D012254_D006526	bcv_easy_237				
	D012254	"<span class=""chemical"">ribavirin</span>"		D006482	"<span class=""disease"">infection with hemorrhagic fever viruses</span>"	"Intravenous <span class=""chemical"">ribavirin</span> is the treatment of choice for <span class=""disease"">infection with hemorrhagic fever viruses</span>."		12093990	12093990_D012254_D006482	bcv_easy_238				
	D012254	"<span class=""chemical"">ribavirin</span>"		D000740	"<span class=""disease"">anemia</span>"	"The most common adverse effect of intravenous <span class=""chemical"">ribavirin</span> is reversible mild <span class=""disease"">anemia</span>."		12093990	12093990_D012254_D000740	bcv_easy_239				
	C059262	"<span class=""chemical"">cidofovir</span>"		D007674	"<span class=""disease"">nephrotoxicity</span>"	"The use of <span class=""chemical"">cidofovir</span> in severe adenovirus infection has been limited by adverse effects, the most significant of which is <span class=""disease"">nephrotoxicity</span>."		12093990	12093990_C059262_D007674	bcv_easy_240				
	C059262	"<span class=""chemical"">cidofovir</span>"		D000257	"<span class=""disease"">adenovirus infection</span>"	"The use of <span class=""chemical"">cidofovir</span> in severe <span class=""disease"">adenovirus infection</span> has been limited by adverse effects, the most significant of which is nephrotoxicity."		12093990	12093990_C059262_D000257	bcv_easy_241				
	D012254	"<span class=""chemical"">ribavirin</span>"		D000257	"<span class=""disease"">adenovirus disease</span>"	"OBJECTIVE: We report our experience with intravenous <span class=""chemical"">ribavirin</span> therapy for severe <span class=""disease"">adenovirus disease</span> in a series of immunocompromised children and review the literature."		12093990	12093990_D012254_D000257	bcv_easy_242				
	D012254	"<span class=""chemical"">ribavirin</span>"		D000257	"<span class=""disease"">adenovirus disease</span>"	"DESIGN/METHODS: We retrospectively reviewed the medical records of 5 children treated with intravenous <span class=""chemical"">ribavirin</span> for documented severe <span class=""disease"">adenovirus disease</span>."		12093990	12093990_D012254_D000257	bcv_easy_243				
	C059262	"<span class=""chemical"">cidofovir</span>"		D058186	"<span class=""disease"">progressive renal failure</span>"	"Use of <span class=""chemical"">cidofovir</span> in 1 child was associated with <span class=""disease"">progressive renal failure</span> and neutropenia."		12093990	12093990_C059262_D058186	bcv_easy_244				
	C059262	"<span class=""chemical"">cidofovir</span>"		D009503	"<span class=""disease"">neutropenia</span>"	"Use of <span class=""chemical"">cidofovir</span> in 1 child was associated with progressive renal failure and <span class=""disease"">neutropenia</span>."		12093990	12093990_C059262_D009503	bcv_easy_245				
	D012254	"<span class=""chemical"">ribavirin</span>"		D000257	"<span class=""disease"">adenovirus disease</span>"	"Although intravenous <span class=""chemical"">ribavirin</span> was not effective for all children with severe <span class=""disease"">adenovirus disease</span> in this series or in the literature, therapy is unlikely to be of benefit if begun late in the course of the infection."		12093990	12093990_D012254_D000257	bcv_easy_246				
	D012254	"<span class=""chemical"">ribavirin</span>"		D007239	"<span class=""disease"">infection</span>"	"Although intravenous <span class=""chemical"">ribavirin</span> was not effective for all children with severe adenovirus disease in this series or in the literature, therapy is unlikely to be of benefit if begun late in the course of the <span class=""disease"">infection</span>."		12093990	12093990_D012254_D007239	bcv_easy_247				
	D012254	"<span class=""chemical"">ribavirin</span>"		D000257	"<span class=""disease"">adenovirus disease</span>"	"CONCLUSIONS: Two of 5 children with severe <span class=""disease"">adenovirus disease</span> treated with intravenous <span class=""chemical"">ribavirin</span> recovered."		12093990	12093990_D012254_D000257	bcv_easy_248				
	D012254	"<span class=""chemical"">ribavirin</span>"		D000257	"<span class=""disease"">adenovirus disease</span>"	"Given the seriousness and increasing prevalence of <span class=""disease"">adenovirus disease</span> in certain hosts, especially children, a large, multicenter clinical trial of potentially useful anti-adenoviral therapies, such as intravenous <span class=""chemical"">ribavirin</span>, is clearly required to demonstrate the most effective and least toxic therapy."		12093990	12093990_D012254_D000257	bcv_easy_249				
	D014282	"<span class=""chemical"">trihexyphenidyl hydrochloride</span>"		D001919	"<span class=""disease"">Bradycardia</span>"	"<span class=""disease"">Bradycardia</span> due to <span class=""chemical"">trihexyphenidyl hydrochloride</span>."		3769769	3769769_D014282_D001919	bcv_easy_250				
	D014282	"<span class=""chemical"">trihexyphenidyl hydrochloride</span>"		D012559	"<span class=""disease"">schizophrenic</span>"	"A chronic <span class=""disease"">schizophrenic</span> patient was treated with an anticholinergic drug, <span class=""chemical"">trihexyphenidyl hydrochloride</span>."		3769769	3769769_D014282_D012559	bcv_easy_251				
	D004110	"<span class=""chemical"">diltiazem</span>"		D008133	"<span class=""disease"">Prolongation of the QT interval</span>"	"<span class=""disease"">Prolongation of the QT interval</span> related to cisapride-<span class=""chemical"">diltiazem</span> interaction."		9545159	9545159_D004110_D008133	bcv_easy_252				
	D020117	"<span class=""chemical"">cisapride</span>"		D008133	"<span class=""disease"">Prolongation of the QT interval</span>"	"<span class=""disease"">Prolongation of the QT interval</span> related to <span class=""chemical"">cisapride</span>-diltiazem interaction."		9545159	9545159_D020117_D008133	bcv_easy_253				
	D020117	"<span class=""chemical"">Cisapride</span>"		D015835	"<span class=""disease"">gastrointestinal motility disorders</span>"	"<span class=""chemical"">Cisapride</span>, a cytochrome P450 3A4 (CYP3A4) substrate, is widely prescribed for the treatment of <span class=""disease"">gastrointestinal motility disorders</span>."		9545159	9545159_D020117_D015835	bcv_easy_254				
	D001393	"<span class=""chemical"">azole</span>"		D008133	"<span class=""disease"">Prolongation of QT interval</span>"	"<span class=""disease"">Prolongation of QT interval</span>, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or <span class=""chemical"">azole</span> antifungal agents, but not with other CYP3A4 inhibitors."		9545159	9545159_D001393_D008133	bcv_easy_255				
	D001393	"<span class=""chemical"">azole</span>"		D016171	"<span class=""disease"">torsades de pointes</span>"	"Prolongation of QT interval, <span class=""disease"">torsades de pointes</span>, and sudden cardiac death have been reported after concomitant administration with erythromycin or <span class=""chemical"">azole</span> antifungal agents, but not with other CYP3A4 inhibitors."		9545159	9545159_D001393_D016171	bcv_easy_256				
	D004917	"<span class=""chemical"">erythromycin</span>"		D016757	"<span class=""disease"">sudden cardiac death</span>"	"Prolongation of QT interval, torsades de pointes, and <span class=""disease"">sudden cardiac death</span> have been reported after concomitant administration with <span class=""chemical"">erythromycin</span> or azole antifungal agents, but not with other CYP3A4 inhibitors."		9545159	9545159_D004917_D016757	bcv_easy_257				
	D004917	"<span class=""chemical"">erythromycin</span>"		D008133	"<span class=""disease"">Prolongation of QT interval</span>"	"<span class=""disease"">Prolongation of QT interval</span>, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with <span class=""chemical"">erythromycin</span> or azole antifungal agents, but not with other CYP3A4 inhibitors."		9545159	9545159_D004917_D008133	bcv_easy_258				
	D004917	"<span class=""chemical"">erythromycin</span>"		D016171	"<span class=""disease"">torsades de pointes</span>"	"Prolongation of QT interval, <span class=""disease"">torsades de pointes</span>, and sudden cardiac death have been reported after concomitant administration with <span class=""chemical"">erythromycin</span> or azole antifungal agents, but not with other CYP3A4 inhibitors."		9545159	9545159_D004917_D016171	bcv_easy_259				
	D001393	"<span class=""chemical"">azole</span>"		D016757	"<span class=""disease"">sudden cardiac death</span>"	"Prolongation of QT interval, torsades de pointes, and <span class=""disease"">sudden cardiac death</span> have been reported after concomitant administration with erythromycin or <span class=""chemical"">azole</span> antifungal agents, but not with other CYP3A4 inhibitors."		9545159	9545159_D001393_D016757	bcv_easy_260				
	D020117	"<span class=""chemical"">cisapride</span>"		D005764	"<span class=""disease"">gastroesophageal reflux disorder</span>"	"A possible drug interaction occurred in a 45-year-old woman who was taking <span class=""chemical"">cisapride</span> for <span class=""disease"">gastroesophageal reflux disorder</span> and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension."		9545159	9545159_D020117_D005764	bcv_easy_261				
	D020117	"<span class=""chemical"">cisapride</span>"		D006973	"<span class=""disease"">hypertension</span>"	"A possible drug interaction occurred in a 45-year-old woman who was taking <span class=""chemical"">cisapride</span> for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for <span class=""disease"">hypertension</span>."		9545159	9545159_D020117_D006973	bcv_easy_262				
	D004110	"<span class=""chemical"">diltiazem</span>"		D006973	"<span class=""disease"">hypertension</span>"	"A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and <span class=""chemical"">diltiazem</span>, an agent that has inhibitory effect on CYP3A4, for <span class=""disease"">hypertension</span>."		9545159	9545159_D004110_D006973	bcv_easy_263				
	D004110	"<span class=""chemical"">diltiazem</span>"		D005764	"<span class=""disease"">gastroesophageal reflux disorder</span>"	"A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for <span class=""disease"">gastroesophageal reflux disorder</span> and <span class=""chemical"">diltiazem</span>, an agent that has inhibitory effect on CYP3A4, for hypertension."		9545159	9545159_D004110_D005764	bcv_easy_264				
	D012459	"<span class=""chemical"">salicylates</span>"		D012202	"<span class=""disease"">Reye syndrome</span>"	"<span class=""disease"">Reye syndrome</span> may be disappearing from Australia despite a total lack of association with <span class=""chemical"">salicylates</span> or aspirin ingestion, since there were no cases found at The Children's Hospital in 1983, 1984, or 1985."		3670965	3670965_D012459_D012202	bcv_easy_265				
	D001241	"<span class=""chemical"">aspirin</span>"		D012202	"<span class=""disease"">Reye syndrome</span>"	"<span class=""disease"">Reye syndrome</span> may be disappearing from Australia despite a total lack of association with salicylates or <span class=""chemical"">aspirin</span> ingestion, since there were no cases found at The Children's Hospital in 1983, 1984, or 1985."		3670965	3670965_D001241_D012202	bcv_easy_266				
	D008687	"<span class=""chemical"">Metformin</span>"		D007674	"<span class=""disease"">nephropathy</span>"	"<span class=""chemical"">Metformin</span> prevents experimental gentamicin-induced <span class=""disease"">nephropathy</span> by a mitochondria-dependent pathway."		20164825	20164825_D008687_D007674	bcv_easy_267				
	D008687	"<span class=""chemical"">metformin</span>"		D014652	"<span class=""disease"">vascular dysfunction</span>"	"The antidiabetic drug <span class=""chemical"">metformin</span> can diminish apoptosis induced by oxidative stress in endothelial cells and prevent <span class=""disease"">vascular dysfunction</span> even in nondiabetic patients."		20164825	20164825_D008687_D014652	bcv_easy_268				
	D005839	"<span class=""chemical"">gentamicin</span>"		D064420	"<span class=""disease"">toxicity</span>"	"Here we tested whether it has a beneficial effect in a rat model of <span class=""chemical"">gentamicin</span> <span class=""disease"">toxicity</span>."		20164825	20164825_D005839_D064420	bcv_easy_269				
	D005839	"<span class=""chemical"">gentamicin</span>"		D058186	"<span class=""disease"">acute renal failure</span>"	"Metformin treatment fully blocked <span class=""chemical"">gentamicin</span>-mediated <span class=""disease"">acute renal failure</span>."		20164825	20164825_D005839_D058186	bcv_easy_270				
	D008687	"<span class=""chemical"">Metformin</span>"		D058186	"<span class=""disease"">acute renal failure</span>"	"<span class=""chemical"">Metformin</span> treatment fully blocked gentamicin-mediated <span class=""disease"">acute renal failure</span>."		20164825	20164825_D008687_D058186	bcv_easy_271				
	D008687	"<span class=""chemical"">metformin</span>"		D007674	"<span class=""disease"">kidney dysfunction</span>"	"These in vivo markers of <span class=""disease"">kidney dysfunction</span> and their correction by <span class=""chemical"">metformin</span> were complemented by in vitro studies of mitochondrial function."		20164825	20164825_D008687_D007674	bcv_easy_272				
	D008687	"<span class=""chemical"">metformin</span>"		D007674	"<span class=""disease"">nephrotoxicity</span>"	"Thus, our study suggests that pleiotropic effects of <span class=""chemical"">metformin</span> can lessen gentamicin <span class=""disease"">nephrotoxicity</span> and improve mitochondrial homeostasis."		20164825	20164825_D008687_D007674	bcv_easy_273				
	D003973	"<span class=""chemical"">diatrizoate</span>"		D014693	"<span class=""disease"">Ventricular fibrillation</span>"	"<span class=""disease"">Ventricular fibrillation</span> from <span class=""chemical"">diatrizoate</span> with and without chelating agents."		663266	663266_D003973_D014693	bcv_easy_274				
	C027278	"<span class=""chemical"">Renografin 76%/Hypaque 76%</span>"		D064420	"<span class=""disease"">toxicity</span>"	"The <span class=""disease"">toxicity</span> of <span class=""chemical"">Renografin 76%</span> was compared with that of <span class=""chemical"">Hypaque 76%</span> by selective injection of each into the right coronary artery of dogs."		663266	663266_C027278_D064420	bcv_easy_275				
	D003974	"<span class=""chemical"">Renografin</span>"		D014693	"<span class=""disease"">Ventricular fibrillation</span>"	"<span class=""disease"">Ventricular fibrillation</span> occurred significantly more often with <span class=""chemical"">Renografin</span>, suggesting that chelating agents contribute to toxicity in coronary angiography."		663266	663266_D003974_D014693	bcv_easy_276				
	D003974	"<span class=""chemical"">Renografin</span>"		D064420	"<span class=""disease"">toxicity</span>"	"Ventricular fibrillation occurred significantly more often with <span class=""chemical"">Renografin</span>, suggesting that chelating agents contribute to <span class=""disease"">toxicity</span> in coronary angiography."		663266	663266_D003974_D064420	bcv_easy_277				
	D000082	"<span class=""chemical"">paracetamol</span>"		D001749|D008113	"<span class=""disease"">bladder and liver tumours</span>"	"Induction by <span class=""chemical"">paracetamol</span> of <span class=""disease"">bladder and liver tumours</span> in the rat. Effects on hepatocyte fine structure."		4090988	4090988_D000082_D001749|D008113	bcv_easy_278				
	D000082	"<span class=""chemical"">paracetamol</span>"		D001749	"<span class=""disease"">bladder carcinomas</span>"	"Papillomas of the transitional epithelium of the bladder developed in all <span class=""chemical"">paracetamol</span>-treated groups, and three rats bore <span class=""disease"">bladder carcinomas</span>."		4090988	4090988_D000082_D001749	bcv_easy_279				
	D000082	"<span class=""chemical"">paracetamol</span>"		D010212	"<span class=""disease"">Papillomas</span>"	"<span class=""disease"">Papillomas</span> of the transitional epithelium of the bladder developed in all <span class=""chemical"">paracetamol</span>-treated groups, and three rats bore bladder carcinomas."		4090988	4090988_D000082_D010212	bcv_easy_280				
	D000082	"<span class=""chemical"">paracetamol</span>"		D006965	"<span class=""disease"">hyperplasia</span>"	"Additionally, 20 to 25% of <span class=""chemical"">paracetamol</span>-treated rats developed <span class=""disease"">hyperplasia</span> of the bladder epithelium, which was not coincident with the presence of bladder calculi."		4090988	4090988_D000082_D006965	bcv_easy_281				
	D000082	"<span class=""chemical"">paracetamol</span>"		D001744	"<span class=""disease"">bladder calculi</span>"	"Additionally, 20 to 25% of <span class=""chemical"">paracetamol</span>-treated rats developed hyperplasia of the bladder epithelium, which was not coincident with the presence of <span class=""disease"">bladder calculi</span>."		4090988	4090988_D000082_D001744	bcv_easy_282				
	D000082	"<span class=""chemical"">paracetamol</span>"		D009369	"<span class=""disease"">tumours</span>"	"A low yield of <span class=""disease"">tumours</span> at various other sites also arose following <span class=""chemical"">paracetamol</span> feeding."		4090988	4090988_D000082_D009369	bcv_easy_283				
	D000082	"<span class=""chemical"">paracetamol</span>"		D008113	"<span class=""disease"">hepatocarcinogens</span>"	"An electron microscope study of the livers of <span class=""chemical"">paracetamol</span>-treated rats revealed ultrastructural changes in the hepatocytes that resemble those that result from exposure to a variety of known <span class=""disease"">hepatocarcinogens</span>."		4090988	4090988_D000082_D008113	bcv_easy_284				
	D000638	"<span class=""chemical"">amiodarone</span>"		D056486	"<span class=""disease"">Hepatotoxicity</span>"	"<span class=""disease"">Hepatotoxicity</span> of <span class=""chemical"">amiodarone</span>."		3962737	3962737_D000638_D056486	bcv_easy_285				
	D000638	"<span class=""chemical"">Amiodarone</span>"		D013610	"<span class=""disease"">tachyarrhythmias</span>"	"<span class=""chemical"">Amiodarone</span> has proved very effective in the treatment of otherwise resistant cardiac <span class=""disease"">tachyarrhythmias</span>."		3962737	3962737_D000638_D013610	bcv_easy_286				
	D000638	"<span class=""chemical"">amiodarone</span>"		D002779|D056486	"<span class=""disease"">cholestatic hepatitis</span>"	"A patient with <span class=""disease"">cholestatic hepatitis</span> due to <span class=""chemical"">amiodarone</span> treatment is presented below and a review of the hepatotoxicity of <span class=""chemical"">amiodarone</span> is given."		3962737	3962737_D000638_D002779|D056486	bcv_easy_287				
	D000638	"<span class=""chemical"">amiodarone</span>"		D056486	"<span class=""disease"">hepatotoxicity</span>"	"A patient with cholestatic hepatitis due to <span class=""chemical"">amiodarone</span> treatment is presented below and a review of the <span class=""disease"">hepatotoxicity</span> of <span class=""chemical"">amiodarone</span> is given."		3962737	3962737_D000638_D056486	bcv_easy_288				
	D000638	"<span class=""chemical"">amiodarone</span>"		D008103	"<span class=""disease"">cirrhosis of the liver</span>"	"It is concluded that solid evidence exists of hepatic injury due to <span class=""chemical"">amiodarone</span> treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular <span class=""disease"">cirrhosis of the liver</span>."		3962737	3962737_D000638_D008103	bcv_easy_289				
	D000638	"<span class=""chemical"">amiodarone</span>"		D006519	"<span class=""disease"">alcoholic hepatitis</span>"	"It is concluded that solid evidence exists of hepatic injury due to <span class=""chemical"">amiodarone</span> treatment, including steatosis, alterations resembling <span class=""disease"">alcoholic hepatitis</span>, cholestatic hepatitis and micronodular cirrhosis of the liver."		3962737	3962737_D000638_D006519	bcv_easy_290				
	D000638	"<span class=""chemical"">amiodarone</span>"		D005234	"<span class=""disease"">steatosis</span>"	"It is concluded that solid evidence exists of hepatic injury due to <span class=""chemical"">amiodarone</span> treatment, including <span class=""disease"">steatosis</span>, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver."		3962737	3962737_D000638_D005234	bcv_easy_291				
	D000638	"<span class=""chemical"">amiodarone</span>"		D056486	"<span class=""disease"">hepatic injury</span>"	"It is concluded that solid evidence exists of <span class=""disease"">hepatic injury</span> due to <span class=""chemical"">amiodarone</span> treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver."		3962737	3962737_D000638_D056486	bcv_easy_292				
	D000638	"<span class=""chemical"">amiodarone</span>"		D002779|D056486	"<span class=""disease"">cholestatic hepatitis</span>"	"It is concluded that solid evidence exists of hepatic injury due to <span class=""chemical"">amiodarone</span> treatment, including steatosis, alterations resembling alcoholic hepatitis, <span class=""disease"">cholestatic hepatitis</span> and micronodular cirrhosis of the liver."		3962737	3962737_D000638_D002779|D056486	bcv_easy_293				
	D003401	"<span class=""chemical"">creatine</span>"		D008180	"<span class=""disease"">systemic lupus erythematosus</span>"	"Differential diagnosis of high serum <span class=""chemical"">creatine</span> kinase levels in <span class=""disease"">systemic lupus erythematosus</span>."		12739036	12739036_D003401_D008180	bcv_easy_294				
	D003520	"<span class=""chemical"">cyclophosphamide</span>"		D008180	"<span class=""disease"">systemic lupus erythematosus/SLE</span>"	"Since 1989, she had been suffering from <span class=""disease"">systemic lupus erythematosus</span> (<span class=""disease"">SLE</span>) with renal involvement and undergone periods of treatment with azathioprine and <span class=""chemical"">cyclophosphamide</span>."		12739036	12739036_D003520_D008180	bcv_easy_295				
	D003520	"<span class=""chemical"">cyclophosphamide</span>"		D007674	"<span class=""disease"">renal involvement</span>"	"Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with <span class=""disease"">renal involvement</span> and undergone periods of treatment with azathioprine and <span class=""chemical"">cyclophosphamide</span>."		12739036	12739036_D003520_D007674	bcv_easy_296				
	D001379	"<span class=""chemical"">azathioprine</span>"		D007674	"<span class=""disease"">renal involvement</span>"	"Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with <span class=""disease"">renal involvement</span> and undergone periods of treatment with <span class=""chemical"">azathioprine</span> and cyclophosphamide."		12739036	12739036_D001379_D007674	bcv_easy_297				
	D001379	"<span class=""chemical"">azathioprine</span>"		D008180	"<span class=""disease"">systemic lupus erythematosus/SLE</span>"	"Since 1989, she had been suffering from <span class=""disease"">systemic lupus erythematosus</span> (<span class=""disease"">SLE</span>) with renal involvement and undergone periods of treatment with <span class=""chemical"">azathioprine</span> and cyclophosphamide."		12739036	12739036_D001379_D008180	bcv_easy_298				
	D002738	"<span class=""chemical"">chloroquine/CQ</span>"		D018771	"<span class=""disease"">arthralgia</span>"	"Additional therapy with <span class=""chemical"">chloroquine</span> (<span class=""chemical"">CQ</span>) was started because of <span class=""disease"">arthralgia</span>."		12739036	12739036_D002738_D018771	bcv_easy_299				
	D013256	"<span class=""chemical"">steroids</span>"		D009220	"<span class=""disease"">Myositis</span>"	"<span class=""disease"">Myositis</span> was suspected, and the patient was treated with <span class=""chemical"">steroids</span>."		12739036	12739036_D013256_D009220	bcv_easy_300				
	D010068	"<span class=""chemical"">oxacillin</span>"		D018366	"<span class=""disease"">Cutaneous leucocytoclastic vasculitis</span>"	"<span class=""disease"">Cutaneous leucocytoclastic vasculitis</span> associated with <span class=""chemical"">oxacillin</span>."		11337188	11337188_D010068_D018366	bcv_easy_301				
	D010068	"<span class=""chemical"">oxacillin</span>"		D051437	"<span class=""disease"">renal failure</span>"	"A 67-year-old man who was treated with <span class=""chemical"">oxacillin</span> for one week because of Staphylococcus aureus bacteremia, developed <span class=""disease"">renal failure</span> and diffuse, symmetric, palpable purpuric lesions on his feet."		11337188	11337188_D010068_D051437	bcv_easy_302				
	D010068	"<span class=""chemical"">oxacillin</span>"		D013203|D016470	"<span class=""disease"">Staphylococcus aureus bacteremia</span>"	"A 67-year-old man who was treated with <span class=""chemical"">oxacillin</span> for one week because of <span class=""disease"">Staphylococcus aureus bacteremia</span>, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet."		11337188	11337188_D010068_D013203|D016470	bcv_easy_303				
	D010068	"<span class=""chemical"">oxacillin</span>"		D011693	"<span class=""disease"">purpuric lesions</span>"	"A 67-year-old man who was treated with <span class=""chemical"">oxacillin</span> for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable <span class=""disease"">purpuric lesions</span> on his feet."		11337188	11337188_D010068_D011693	bcv_easy_304				
	D010068	"<span class=""chemical"">Oxacillin</span>"		D018366	"<span class=""disease"">leucocytoclastic vasculitis</span>"	"<span class=""chemical"">Oxacillin</span> should be included among the drugs that can cause <span class=""disease"">leucocytoclastic vasculitis</span>."		11337188	11337188_D010068_D018366	bcv_easy_305				
	D013629	"<span class=""chemical"">tamoxifen</span>"		D001943	"<span class=""disease"">breast cancer</span>"	"Prevention of <span class=""disease"">breast cancer</span> with <span class=""chemical"">tamoxifen</span>: preliminary findings from the Italian randomised trial among hysterectomised women. Italian <span class=""chemical"">Tamoxifen</span> Prevention Study."		9672273	9672273_D013629_D001943	bcv_easy_306				
	D013629	"<span class=""chemical"">Tamoxifen</span>"		D016889	"<span class=""disease"">endometrial cancer</span>"	"BACKGROUND: <span class=""chemical"">Tamoxifen</span> is a candidate chemopreventive agent in breast cancer, although the drug may be associated with the development of <span class=""disease"">endometrial cancer</span>."		9672273	9672273_D013629_D016889	bcv_easy_307				
	D013629	"<span class=""chemical"">Tamoxifen</span>"		D001943	"<span class=""disease"">breast cancer</span>"	"BACKGROUND: <span class=""chemical"">Tamoxifen</span> is a candidate chemopreventive agent in <span class=""disease"">breast cancer</span>, although the drug may be associated with the development of endometrial cancer."		9672273	9672273_D013629_D001943	bcv_easy_308				
	D013629	"<span class=""chemical"">tamoxifen</span>"		D001943	"<span class=""disease"">breast cancer</span>"	"METHODS: In October, 1992, we started a double-blind placebo-controlled, randomised trial of <span class=""chemical"">tamoxifen</span> in women (mainly in Italy) who did not have <span class=""disease"">breast cancer</span> and who had had a hysterectomy."		9672273	9672273_D013629_D001943	bcv_easy_309				
	D013629	"<span class=""chemical"">tamoxifen</span>"		D001943	"<span class=""disease"">breast-cancer</span>"	"There is no difference in <span class=""disease"">breast-cancer</span> frequency between the placebo (22 cases) and <span class=""chemical"">tamoxifen</span> (19) arms."		9672273	9672273_D013629_D001943	bcv_easy_310				
	D013629	"<span class=""chemical"">tamoxifen</span>"		D001943	"<span class=""disease"">breast cancer</span>"	"There is a statistically significant reduction of <span class=""disease"">breast cancer</span> among women receiving <span class=""chemical"">tamoxifen</span> who also used hormone-replacement therapy during the trial: among 390 women on such therapy and allocated to placebo, we found eight cases of <span class=""disease"">breast cancer</span> compared with one case among 362 women allocated to <span class=""chemical"">tamoxifen</span>."		9672273	9672273_D013629_D001943	bcv_easy_311				
	D013629	"<span class=""chemical"">tamoxifen</span>"		D014652	"<span class=""disease"">vascular events</span>"	"Compared with the placebo group, there was a significantly increased risk of <span class=""disease"">vascular events</span> and hypertriglyceridaemia among women on <span class=""chemical"">tamoxifen</span>."		9672273	9672273_D013629_D014652	bcv_easy_312				
	D013629	"<span class=""chemical"">tamoxifen</span>"		D015228	"<span class=""disease"">hypertriglyceridaemia</span>"	"Compared with the placebo group, there was a significantly increased risk of vascular events and <span class=""disease"">hypertriglyceridaemia</span> among women on <span class=""chemical"">tamoxifen</span>."		9672273	9672273_D013629_D015228	bcv_easy_313				
	D013629	"<span class=""chemical"">tamoxifen</span>"		D001943	"<span class=""disease"">breast cancer</span>"	"INTERPRETATION: Although this preliminary analysis has low power, in this cohort of women at low-to-normal risk of <span class=""disease"">breast cancer</span>, the postulated protective effects of <span class=""chemical"">tamoxifen</span> are not yet apparent."		9672273	9672273_D013629_D001943	bcv_easy_314				
	D012701	"<span class=""chemical"">serotonin/5-HT</span>"		D020258	"<span class=""disease"">neurotoxic lesions</span>"	"Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain <span class=""chemical"">serotonin</span> (<span class=""chemical"">5-HT</span>) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced <span class=""chemical"">5-HT</span> <span class=""disease"">neurotoxic lesions</span> on functions in which <span class=""chemical"">5-HT</span> is involved, such as cognitive function."		16574713	16574713_D012701_D020258	bcv_easy_315				
	D018817	"<span class=""chemical"">MDMA</span>"		D008569	"<span class=""disease"">memory impairment</span>"	"In contrast, no evidence of <span class=""disease"">memory impairment</span> was observed in moderate <span class=""chemical"">MDMA</span> users."		16574713	16574713_D018817_D008569	bcv_easy_316				
	D018817	"<span class=""chemical"">MDMA</span>"		D008569	"<span class=""disease"">impaired memory functioning/memory impairments</span>"	"While the use of <span class=""chemical"">MDMA</span> in quantities that may be considered ""moderate"" is not associated with <span class=""disease"">impaired memory functioning</span>, heavy use of <span class=""chemical"">MDMA</span> use may lead to long lasting <span class=""disease"">memory impairments</span>."		16574713	16574713_D018817_D008569	bcv_easy_317				
	D003520	"<span class=""chemical"">Cyclophosphamide</span>"		D059265	"<span class=""disease"">visceral pain</span>"	"<span class=""chemical"">Cyclophosphamide</span>-induced cystitis in freely-moving conscious rats: behavioral approach to a new model of <span class=""disease"">visceral pain</span>."		10840460	10840460_D003520_D059265	bcv_easy_318				
	D000171	"<span class=""chemical"">acrolein</span>"		D003556	"<span class=""disease"">cystitis</span>"	"Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite <span class=""chemical"">acrolein</span>, was used to induce <span class=""disease"">cystitis</span>."		10840460	10840460_D000171_D003556	bcv_easy_319				
	D009020	"<span class=""chemical"">Morphine</span>"		D001523	"<span class=""disease"">behavioral disorders</span>"	"<span class=""chemical"">Morphine</span> dose-dependently reversed these <span class=""disease"">behavioral disorders</span>."		10840460	10840460_D009020_D001523	bcv_easy_320				
	D009020	"<span class=""chemical"">morphine</span>"		D004487	"<span class=""disease"">edema</span>"	"At the time of administration of <span class=""chemical"">morphine</span>, histological modifications of the bladder wall, such as chorionic and muscle layer <span class=""disease"">edema</span>, were observed."		10840460	10840460_D009020_D004487	bcv_easy_321				
	D003520	"<span class=""chemical"">CP</span>"		D010146	"<span class=""disease"">painful syndromes</span>"	"CONCLUSIONS: Overall, these results indicate that this experimental model of <span class=""chemical"">CP</span>-induced cystitis may be an interesting new behavioral model of inflammatory visceral pain, allowing a better understanding of these <span class=""disease"">painful syndromes</span> and thus a better therapeutic approach to them."		10840460	10840460_D003520_D010146	bcv_easy_322				
	D003520	"<span class=""chemical"">CP</span>"		D059265	"<span class=""disease"">visceral pain</span>"	"CONCLUSIONS: Overall, these results indicate that this experimental model of <span class=""chemical"">CP</span>-induced cystitis may be an interesting new behavioral model of inflammatory <span class=""disease"">visceral pain</span>, allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them."		10840460	10840460_D003520_D059265	bcv_easy_323				
	D005839	"<span class=""chemical"">gentamicin</span>"		D058186	"<span class=""disease"">acute renal failure</span>"	"In this study we postulated that during <span class=""disease"">acute renal failure</span> induced by <span class=""chemical"">gentamicin</span> the transient or dynamic response of blood vessels could be affected, and that antioxidants can prevent the changes in dynamic responses of blood vessels."		19893084	19893084_D005839_D058186	bcv_easy_324				
	D011899	"<span class=""chemical"">ranitidine</span>"		D007172	"<span class=""disease"">impotence</span>"	"Sixty percent of the males developed breast changes or <span class=""disease"">impotence</span> while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by <span class=""chemical"">ranitidine</span>."		6150641	6150641_D011899_D007172	bcv_easy_325				
	D002927	"<span class=""chemical"">cimetidine</span>"		D007172	"<span class=""disease"">impotence</span>"	"Sixty percent of the males developed breast changes or <span class=""disease"">impotence</span> while taking <span class=""chemical"">cimetidine</span> and in all cases these changes disappeared when <span class=""chemical"">cimetidine</span> was replaced by ranitidine."		6150641	6150641_D002927_D007172	bcv_easy_326				
	D002927	"<span class=""chemical"">cimetidine</span>"		D056486|D006402	"<span class=""disease"">hepatic or hematologic toxicity</span>"	"Treatment with high doses of <span class=""chemical"">cimetidine</span> (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with <span class=""disease"">hepatic or hematologic toxicity</span> or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with <span class=""chemical"">cimetidine</span> therapy."		6150641	6150641_D002927_D056486|D006402	bcv_easy_327				
	D011899	"<span class=""chemical"">ranitidine</span>"		D056486|D006402	"<span class=""disease"">hepatic or hematologic toxicity</span>"	"Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or <span class=""chemical"">ranitidine</span> (two to 31 months; median, 14 months) was not associated with <span class=""disease"">hepatic or hematologic toxicity</span> or alterations of serum gastrin concentrations, but <span class=""chemical"">ranitidine</span> therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy."		6150641	6150641_D011899_D056486|D006402	bcv_easy_328				
	D003404	"<span class=""chemical"">creatinine</span>"		D056486|D006402	"<span class=""disease"">hepatic or hematologic toxicity</span>"	"Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with <span class=""disease"">hepatic or hematologic toxicity</span> or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum <span class=""chemical"">creatinine</span> level than seen with cimetidine therapy."		6150641	6150641_D003404_D056486|D006402	bcv_easy_329				
	D007980	"<span class=""chemical"">Levodopa</span>"		D004421	"<span class=""disease"">dystonia</span>"	"<span class=""chemical"">Levodopa</span>-induced oromandibular <span class=""disease"">dystonia</span> in progressive supranuclear palsy."		12691807	12691807_D007980_D004421	bcv_easy_330				
	D007980	"<span class=""chemical"">Levodopa</span>"		D013494	"<span class=""disease"">progressive supranuclear palsy</span>"	"<span class=""chemical"">Levodopa</span>-induced oromandibular dystonia in <span class=""disease"">progressive supranuclear palsy</span>."		12691807	12691807_D007980_D013494	bcv_easy_331				
	D007980	"<span class=""chemical"">Levodopa</span>"		D019578	"<span class=""disease"">multiple system atrophy</span>"	"<span class=""chemical"">Levodopa</span>-induced dyskinesias have been reported in Parkinson's disease and <span class=""disease"">multiple system atrophy</span>."		12691807	12691807_D007980_D019578	bcv_easy_332				
	D007980	"<span class=""chemical"">Levodopa</span>"		D010300	"<span class=""disease"">Parkinson's disease</span>"	"<span class=""chemical"">Levodopa</span>-induced dyskinesias have been reported in <span class=""disease"">Parkinson's disease</span> and multiple system atrophy."		12691807	12691807_D007980_D010300	bcv_easy_333				
	D007980	"<span class=""chemical"">levodopa</span>"		D013494	"<span class=""disease"">PSP</span>"	"In this report we describe an unusual case of reversible <span class=""chemical"">levodopa</span>-induced Oromandibular dystonia (OMD) in a <span class=""disease"">PSP</span> patient to highlight the importance of recognizing this drug related complication in the management of <span class=""disease"">PSP</span>, and discuss the possible underlying pathophysiology."		12691807	12691807_D007980_D013494	bcv_easy_334				
	D012293	"<span class=""chemical"">rifampicin</span>"		D058186	"<span class=""disease"">Acute renal failure</span>"	"<span class=""disease"">Acute renal failure</span> subsequent to the administration of <span class=""chemical"">rifampicin</span>. A follow-up study of cases reported earlier."		982002	982002_D012293_D058186	bcv_easy_335				
	D012293	"<span class=""chemical"">rifampicin</span>"		D051437	"<span class=""disease"">renal failure</span>"	"The patients had developed transient <span class=""disease"">renal failure</span> after the intermittent administration of <span class=""chemical"">rifampicin</span>."		982002	982002_D012293_D051437	bcv_easy_336				
	D004977	"<span class=""chemical"">Ethambutol</span>"		D009901	"<span class=""disease"">optic neuropathy</span>"	"<span class=""chemical"">Ethambutol</span>-associated <span class=""disease"">optic neuropathy</span>."		16710500	16710500_D004977_D009901	bcv_easy_337				
	D004977	"<span class=""chemical"">Ethambutol</span>"		D014376	"<span class=""disease"">tuberculosis</span>"	"INTRODUCTION: <span class=""chemical"">Ethambutol</span> is used in the treatment of <span class=""disease"">tuberculosis</span>, which is still prevalent in Southeast Asia, and can be associated with permanent visual loss."		16710500	16710500_D004977_D014376	bcv_easy_338				
	D004977	"<span class=""chemical"">Ethambutol</span>"		D014786	"<span class=""disease"">visual loss</span>"	"INTRODUCTION: <span class=""chemical"">Ethambutol</span> is used in the treatment of tuberculosis, which is still prevalent in Southeast Asia, and can be associated with permanent <span class=""disease"">visual loss</span>."		16710500	16710500_D004977_D014786	bcv_easy_339				
	D004977	"<span class=""chemical"">ethambutol</span>"		D009901	"<span class=""disease"">optic neuropathy</span>"	"CLINICAL PICTURE: Three patients with <span class=""chemical"">ethambutol</span>-associated toxic <span class=""disease"">optic neuropathy</span> are described."		16710500	16710500_D004977_D009901	bcv_easy_340				
	D004977	"<span class=""chemical"">Ethambutol</span>"		D014786	"<span class=""disease"">visual loss</span>"	"CONCLUSIONS: <span class=""chemical"">Ethambutol</span> usage is associated with permanent <span class=""disease"">visual loss</span> and should be avoided if possible or used with caution and proper ophthalmological follow-up."		16710500	16710500_D004977_D014786	bcv_easy_341				
	D000082	"<span class=""chemical"">paracetamol</span>"		D017114	"<span class=""disease"">fulminant hepatic failure</span>"	"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived <span class=""disease"">fulminant hepatic failure</span> after <span class=""chemical"">paracetamol</span> overdose, whereas activities were increased equally in patients with <span class=""disease"">fulminant hepatic failure</span> due to viral hepatitis whether or not they survived."		7007443	7007443_D000082_D017114	bcv_easy_342				
	D000082	"<span class=""chemical"">paracetamol</span>"		D062787	"<span class=""disease"">overdose</span>"	"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after <span class=""chemical"">paracetamol</span> <span class=""disease"">overdose</span>, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived."		7007443	7007443_D000082_D062787	bcv_easy_343				
	D000082	"<span class=""chemical"">paracetamol</span>"		D006525	"<span class=""disease"">viral hepatitis</span>"	"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after <span class=""chemical"">paracetamol</span> overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to <span class=""disease"">viral hepatitis</span> whether or not they survived."		7007443	7007443_D000082_D006525	bcv_easy_344				
	C009166	"<span class=""chemical"">retinyl acetate</span>"		D063646	"<span class=""disease"">carcinogenic</span>"	"Co-<span class=""disease"">carcinogenic</span> effect of <span class=""chemical"">retinyl acetate</span> on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole."		3131282	3131282_C009166_D063646	bcv_easy_345				
	D002083	"<span class=""chemical"">butylated hydroxyanisole</span>"		D063646	"<span class=""disease"">carcinogenic</span>"	"Co-<span class=""disease"">carcinogenic</span> effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with <span class=""chemical"">butylated hydroxyanisole</span>."		3131282	3131282_D002083_D063646	bcv_easy_346				
	C009166	"<span class=""chemical"">retinyl acetate</span>"		D013274	"<span class=""disease"">forestomach carcinogenesis</span>"	"Co-carcinogenic effect of <span class=""chemical"">retinyl acetate</span> on <span class=""disease"">forestomach carcinogenesis</span> of male F344 rats induced with butylated hydroxyanisole."		3131282	3131282_C009166_D013274	bcv_easy_347				
	C009166	"<span class=""chemical"">retinyl acetate/RA</span>"		D013274	"<span class=""disease"">forestomach tumorigenesis</span>"	"The potential modifying effect of <span class=""chemical"">retinyl acetate</span> (<span class=""chemical"">RA</span>) on butylated hydroxyanisole (BHA)-induced rat <span class=""disease"">forestomach tumorigenesis</span> was examined."		3131282	3131282_C009166_D013274	bcv_easy_348				
	C009166	"<span class=""chemical"">RA</span>"		D013274	"<span class=""disease"">forestomach tumors</span>"	"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% <span class=""chemical"">RA</span> significantly (P less than 0.05) increased the incidence of <span class=""disease"">forestomach tumors</span> (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given <span class=""chemical"">RA</span>-free water."		3131282	3131282_C009166_D013274	bcv_easy_349				
	D002083	"<span class=""chemical"">BHA</span>"		D010212	"<span class=""disease"">squamous cell papilloma</span>"	"In groups given 2% <span class=""chemical"">BHA</span>, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (<span class=""disease"">squamous cell papilloma</span> and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water."		3131282	3131282_D002083_D010212	bcv_easy_350				
	C009166	"<span class=""chemical"">RA</span>"		D010212	"<span class=""disease"">squamous cell papilloma</span>"	"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% <span class=""chemical"">RA</span> significantly (P less than 0.05) increased the incidence of forestomach tumors (<span class=""disease"">squamous cell papilloma</span> and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given <span class=""chemical"">RA</span>-free water."		3131282	3131282_C009166_D010212	bcv_easy_351				
	C009166	"<span class=""chemical"">RA</span>"		D002277	"<span class=""disease"">carcinoma</span>"	"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% <span class=""chemical"">RA</span> significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and <span class=""disease"">carcinoma</span>) to 60% (9/15, 2 rats with <span class=""disease"">carcinoma</span>) from 15% (3/20, one rat with <span class=""disease"">carcinoma</span>) in the group given <span class=""chemical"">RA</span>-free water."		3131282	3131282_C009166_D002277	bcv_easy_352				
	D002083	"<span class=""chemical"">BHA</span>"		D002277	"<span class=""disease"">carcinoma</span>"	"In groups given 2% <span class=""chemical"">BHA</span>, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and <span class=""disease"">carcinoma</span>) to 60% (9/15, 2 rats with <span class=""disease"">carcinoma</span>) from 15% (3/20, one rat with <span class=""disease"">carcinoma</span>) in the group given RA-free water."		3131282	3131282_D002083_D002277	bcv_easy_353				
	C009166	"<span class=""chemical"">RA</span>"		D017573	"<span class=""disease"">epithelial hyperplasia</span>"	"In rats given 1% BHA, <span class=""chemical"">RA</span> co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the BHA-induced <span class=""disease"">epithelial hyperplasia</span>."		3131282	3131282_C009166_D017573	bcv_easy_354				
	C009166	"<span class=""chemical"">RA</span>"		D010212	"<span class=""disease"">papillomas</span>"	"Tumors, all <span class=""disease"">papillomas</span>, were induced in 3 rats (17%) with 0.25% <span class=""chemical"">RA</span> and in one rat (10%) with 0.05% <span class=""chemical"">RA</span> co-administration."		3131282	3131282_C009166_D010212	bcv_easy_355				
	C009166	"<span class=""chemical"">RA</span>"		D009369	"<span class=""disease"">Tumors</span>"	"<span class=""disease"">Tumors</span>, all papillomas, were induced in 3 rats (17%) with 0.25% <span class=""chemical"">RA</span> and in one rat (10%) with 0.05% <span class=""chemical"">RA</span> co-administration."		3131282	3131282_C009166_D009369	bcv_easy_356				
	C009166	"<span class=""chemical"">RA</span>"		D013274	"<span class=""disease"">forestomach carcinogenesis</span>"	"These findings indicate that <span class=""chemical"">RA</span> acted as a co-carcinogen in the BHA <span class=""disease"">forestomach carcinogenesis</span> of the rat."		3131282	3131282_C009166_D013274	bcv_easy_357				
	D003975	"<span class=""chemical"">diazepam</span>"		D001259	"<span class=""disease"">incoordination</span>"	"Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular <span class=""disease"">incoordination</span> by <span class=""chemical"">diazepam</span>, but NH4Ac treatment alone had no effect."		6323692	6323692_D003975_D001259	bcv_easy_358				
	D009020	"<span class=""chemical"">morphine</span>"		D001259	"<span class=""disease"">incoordination</span>"	"Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time <span class=""chemical"">morphine</span>-treated mice remained on a hot surface and similarly increased muscular <span class=""disease"">incoordination</span> by diazepam, but NH4Ac treatment alone had no effect."		6323692	6323692_D009020_D001259	bcv_easy_359				
	C018824	"<span class=""chemical"">ammonium acetate/NH4Ac</span>"		D001259	"<span class=""disease"">incoordination</span>"	"Pretreatment with <span class=""chemical"">ammonium acetate</span> (<span class=""chemical"">NH4Ac</span>) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular <span class=""disease"">incoordination</span> by diazepam, but <span class=""chemical"">NH4Ac</span> treatment alone had no effect."		6323692	6323692_C018824_D001259	bcv_easy_360				
	D002395	"<span class=""chemical"">catecholamine</span>"		D003866	"<span class=""disease"">depression</span>"	"Addition of excess calcium reversed the <span class=""disease"">depression</span> in both tissues, but calcium-independent <span class=""chemical"">catecholamine</span> release by acetaldehyde was not blocked by NH4Ac."		6323692	6323692_D002395_D003866	bcv_easy_361				
	C018824	"<span class=""chemical"">NH4Ac</span>"		D003866	"<span class=""disease"">depression</span>"	"Addition of excess calcium reversed the <span class=""disease"">depression</span> in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by <span class=""chemical"">NH4Ac</span>."		6323692	6323692_C018824_D003866	bcv_easy_362				
	D000079	"<span class=""chemical"">acetaldehyde</span>"		D003866	"<span class=""disease"">depression</span>"	"Addition of excess calcium reversed the <span class=""disease"">depression</span> in both tissues, but calcium-independent catecholamine release by <span class=""chemical"">acetaldehyde</span> was not blocked by NH4Ac."		6323692	6323692_D000079_D003866	bcv_easy_363				
	D002118	"<span class=""chemical"">calcium</span>"		D003866	"<span class=""disease"">depression</span>"	"Addition of excess <span class=""chemical"">calcium</span> reversed the <span class=""disease"">depression</span> in both tissues, but <span class=""chemical"">calcium</span>-independent catecholamine release by acetaldehyde was not blocked by NH4Ac."		6323692	6323692_D002118_D003866	bcv_easy_364				
	C018824	"<span class=""chemical"">NH4Ac</span>"		D000699	"<span class=""disease"">analgesia</span>"	"Both verapamil (10 mg/kg i.p.) and <span class=""chemical"">NH4Ac</span> pretreatment enhanced morphine <span class=""disease"">analgesia</span>- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor <span class=""chemical"">NH4Ac</span> affected the convulsant action of metrazol."		6323692	6323692_C018824_D000699	bcv_easy_365				
	D003975	"<span class=""chemical"">diazepam</span>"		D000699	"<span class=""disease"">analgesia</span>"	"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine <span class=""disease"">analgesia</span>- and <span class=""chemical"">diazepam</span>-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol."		6323692	6323692_D003975_D000699	bcv_easy_366				
	D009020	"<span class=""chemical"">morphine</span>"		D001259	"<span class=""disease"">incoordination</span>"	"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced <span class=""chemical"">morphine</span> analgesia- and diazepam-induced muscular <span class=""disease"">incoordination</span> and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol."		6323692	6323692_D009020_D001259	bcv_easy_367				
	D000661	"<span class=""chemical"">amphetamine</span>"		D000699	"<span class=""disease"">analgesia</span>"	"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine <span class=""disease"">analgesia</span>- and diazepam-induced muscular incoordination and antagonized <span class=""chemical"">amphetamine</span>-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol."		6323692	6323692_D000661_D000699	bcv_easy_368				
	D014700	"<span class=""chemical"">verapamil</span>"		D000699	"<span class=""disease"">analgesia</span>"	"Both <span class=""chemical"">verapamil</span> (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine <span class=""disease"">analgesia</span>- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither <span class=""chemical"">verapamil</span> nor NH4Ac affected the convulsant action of metrazol."		6323692	6323692_D014700_D000699	bcv_easy_369				
	C018824	"<span class=""chemical"">NH4Ac</span>"		D001259	"<span class=""disease"">incoordination</span>"	"Both verapamil (10 mg/kg i.p.) and <span class=""chemical"">NH4Ac</span> pretreatment enhanced morphine analgesia- and diazepam-induced muscular <span class=""disease"">incoordination</span> and antagonized amphetamine-induced motor activity, and neither verapamil nor <span class=""chemical"">NH4Ac</span> affected the convulsant action of metrazol."		6323692	6323692_C018824_D001259	bcv_easy_370				
	D010433	"<span class=""chemical"">metrazol</span>"		D001259	"<span class=""disease"">incoordination</span>"	"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular <span class=""disease"">incoordination</span> and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of <span class=""chemical"">metrazol</span>."		6323692	6323692_D010433_D001259	bcv_easy_371				
	D003975	"<span class=""chemical"">diazepam</span>"		D001259	"<span class=""disease"">incoordination</span>"	"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and <span class=""chemical"">diazepam</span>-induced muscular <span class=""disease"">incoordination</span> and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol."		6323692	6323692_D003975_D001259	bcv_easy_372				
	D014700	"<span class=""chemical"">verapamil</span>"		D001259	"<span class=""disease"">incoordination</span>"	"Both <span class=""chemical"">verapamil</span> (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular <span class=""disease"">incoordination</span> and antagonized amphetamine-induced motor activity, and neither <span class=""chemical"">verapamil</span> nor NH4Ac affected the convulsant action of metrazol."		6323692	6323692_D014700_D001259	bcv_easy_373				
	D009020	"<span class=""chemical"">morphine</span>"		D000699	"<span class=""disease"">analgesia</span>"	"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced <span class=""chemical"">morphine</span> <span class=""disease"">analgesia</span>- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol."		6323692	6323692_D009020_D000699	bcv_easy_374				
	D000661	"<span class=""chemical"">amphetamine</span>"		D001259	"<span class=""disease"">incoordination</span>"	"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular <span class=""disease"">incoordination</span> and antagonized <span class=""chemical"">amphetamine</span>-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol."		6323692	6323692_D000661_D001259	bcv_easy_375				
	D010433	"<span class=""chemical"">metrazol</span>"		D000699	"<span class=""disease"">analgesia</span>"	"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine <span class=""disease"">analgesia</span>- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of <span class=""chemical"">metrazol</span>."		6323692	6323692_D010433_D000699	bcv_easy_376				
	D002118	"<span class=""chemical"">calcium</span>"		D022124	"<span class=""disease"">hyperammonemia</span>"	"The data suggest that <span class=""disease"">hyperammonemia</span> exerts a <span class=""chemical"">calcium</span> channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics."		6323692	6323692_D002118_D022124	bcv_easy_377				
	D001556	"<span class=""chemical"">alpha-benzene hexachloride</span>"		D006528	"<span class=""disease"">hepatoma</span>"	"Changes in peroxisomes in preneoplastic liver and <span class=""disease"">hepatoma</span> of mice induced by <span class=""chemical"">alpha-benzene hexachloride</span>."		85485	85485_D001556_D006528	bcv_easy_378				
	D001556	"<span class=""chemical"">alpha-benzene hexachloride</span>"		D006528	"<span class=""disease"">hepatomas</span>"	"Peroxisomes in <span class=""disease"">hepatomas</span> and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm <span class=""chemical"">alpha-benzene hexachloride</span> were examined histochemically and electron microscopically."		85485	85485_D001556_D006528	bcv_easy_379				
	D001556	"<span class=""chemical"">alpha-benzene hexachloride</span>"		D017093	"<span class=""disease"">liver lesions</span>"	"Peroxisomes in hepatomas and hyperplastic preneoplastic <span class=""disease"">liver lesions</span> induced in mice by 500 ppm <span class=""chemical"">alpha-benzene hexachloride</span> were examined histochemically and electron microscopically."		85485	85485_D001556_D017093	bcv_easy_380				
	C012282	"<span class=""chemical"">ethyl-alpha-p-chlorophenoxyisobutyrate</span>"		D009369	"<span class=""disease"">tumor/tumors</span>"	"Although most of the hepatomas were well-differentiated <span class=""disease"">tumors</span> and contained a considerable number of peroxisomes, the <span class=""disease"">tumor</span> cells did not respond to <span class=""chemical"">ethyl-alpha-p-chlorophenoxyisobutyrate</span> with proliferation of peroxisomes."		85485	85485_C012282_D009369	bcv_easy_381				
	C012282	"<span class=""chemical"">ethyl-alpha-p-chlorophenoxyisobutyrate</span>"		D006528	"<span class=""disease"">hepatomas</span>"	"Although most of the <span class=""disease"">hepatomas</span> were well-differentiated tumors and contained a considerable number of peroxisomes, the tumor cells did not respond to <span class=""chemical"">ethyl-alpha-p-chlorophenoxyisobutyrate</span> with proliferation of peroxisomes."		85485	85485_C012282_D006528	bcv_easy_382				
	D013792	"<span class=""chemical"">thalidomide</span>"		D002292	"<span class=""disease"">renal cell carcinoma</span>"	"A phase II study of <span class=""chemical"">thalidomide</span> in advanced metastatic <span class=""disease"">renal cell carcinoma</span>."		12448656	12448656_D013792_D002292	bcv_easy_383				
	D013792	"<span class=""chemical"">thalidomide</span>"		D002292	"<span class=""disease"">renal cell cancer</span>"	"OBJECTIVES: To evaluate the toxicity and activity of <span class=""chemical"">thalidomide</span> in patients with advanced metastatic <span class=""disease"">renal cell cancer</span> and to measure changes of one angiogenic factor, vascular endothelial growth factor (VEGF)165, with therapy."		12448656	12448656_D013792_D002292	bcv_easy_384				
	D013792	"<span class=""chemical"">thalidomide</span>"		D064420	"<span class=""disease"">toxicity</span>"	"OBJECTIVES: To evaluate the <span class=""disease"">toxicity</span> and activity of <span class=""chemical"">thalidomide</span> in patients with advanced metastatic renal cell cancer and to measure changes of one angiogenic factor, vascular endothelial growth factor (VEGF)165, with therapy."		12448656	12448656_D013792_D064420	bcv_easy_385				
	D013792	"<span class=""chemical"">thalidomide</span>"		D002292	"<span class=""disease"">renal cell carcinoma</span>"	"CONCLUSION: These results are consistent with a low level of activity of <span class=""chemical"">thalidomide</span> in <span class=""disease"">renal cell carcinoma</span>."		12448656	12448656_D013792_D002292	bcv_easy_386				
	D013792	"<span class=""chemical"">thalidomide</span>"		D002292	"<span class=""disease"">renal cell carcinoma</span>"	"The dose-response relationship, if any, of <span class=""chemical"">thalidomide</span> for <span class=""disease"">renal cell carcinoma</span> is unclear."		12448656	12448656_D013792_D002292	bcv_easy_387				
	D003276	"<span class=""chemical"">oral contraception</span>"		D002819	"<span class=""disease"">Chorea</span>"	"<span class=""disease"">Chorea</span> associated with <span class=""chemical"">oral contraception</span>."		3123611	3123611_D003276_D002819	bcv_easy_388				
	D003276	"<span class=""chemical"">oral contraceptives</span>"		D002819	"<span class=""disease"">chorea</span>"	"Three patients developed <span class=""disease"">chorea</span> while receiving <span class=""chemical"">oral contraceptives</span>."		3123611	3123611_D003276_D002819	bcv_easy_389				
	D003276	"<span class=""chemical"">oral contraception</span>"		D002819	"<span class=""disease"">chorea</span>"	"The third patient had acute amphetamine-induced <span class=""disease"">chorea</span> after prolonged <span class=""chemical"">oral contraception</span>."		3123611	3123611_D003276_D002819	bcv_easy_390				
	D008012	"<span class=""chemical"">lignocaine</span>"		D011128	"<span class=""disease"">Cauda equina syndrome</span>"	"<span class=""disease"">Cauda equina syndrome</span> after spinal anaesthesia with hyperbaric 5% <span class=""chemical"">lignocaine</span>: a review of six cases of <span class=""disease"">cauda equina syndrome</span> reported to the Swedish Pharmaceutical Insurance 1993-1997."		10225068	10225068_D008012_D011128	bcv_easy_391				
	D008012	"<span class=""chemical"">lignocaine</span>"		D020258	"<span class=""disease"">neurotoxicity</span>"	"Three of the cases were most likely caused by direct <span class=""disease"">neurotoxicity</span> of hyperbaric 5% <span class=""chemical"">lignocaine</span>."		10225068	10225068_D008012_D020258	bcv_easy_392				
	D013999	"<span class=""chemical"">timolol</span>"		D007008	"<span class=""disease"">hypokalemia</span>"	"Amelioration of bendrofluazide-induced <span class=""disease"">hypokalemia</span> by <span class=""chemical"">timolol</span>."		326460	326460_D013999_D007008	bcv_easy_393				
	D013999	"<span class=""chemical"">timolol</span>"		D007008	"<span class=""disease"">hypokalemia</span>"	"The beta adrenergic blocking drug, <span class=""chemical"">timolol</span>, tended to correct the <span class=""disease"">hypokalemia</span> of short-term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant."		326460	326460_D013999_D007008	bcv_easy_394				
	D008619	"<span class=""chemical"">mepivacaine</span>"		D009135	"<span class=""disease"">muscle damage</span>"	"In addition to <span class=""disease"">muscle damage</span>, severe damage was also seen in harderian glands, especially after exposure to <span class=""chemical"">mepivacaine</span> and lidocaine plus epinephrine."		4038130	4038130_D008619_D009135	bcv_easy_395				
	D004837	"<span class=""chemical"">epinephrine</span>"		D009135	"<span class=""disease"">muscle damage</span>"	"In addition to <span class=""disease"">muscle damage</span>, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus <span class=""chemical"">epinephrine</span>."		4038130	4038130_D004837_D009135	bcv_easy_396				
	D008012	"<span class=""chemical"">lidocaine</span>"		D009135	"<span class=""disease"">muscle damage</span>"	"In addition to <span class=""disease"">muscle damage</span>, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and <span class=""chemical"">lidocaine</span> plus epinephrine."		4038130	4038130_D008012_D009135	bcv_easy_397				
	D008774	"<span class=""chemical"">methylphenidate</span>"		D061218	"<span class=""disease"">treatment-resistant depression</span>"	"An 82-year-old man with <span class=""disease"">treatment-resistant depression</span> and early Alzheimer's disease was started on <span class=""chemical"">methylphenidate</span>."		12907924	12907924_D008774_D061218	bcv_easy_398				
	D008774	"<span class=""chemical"">methylphenidate</span>"		D000544	"<span class=""disease"">Alzheimer's disease</span>"	"An 82-year-old man with treatment-resistant depression and early <span class=""disease"">Alzheimer's disease</span> was started on <span class=""chemical"">methylphenidate</span>."		12907924	12907924_D008774_D000544	bcv_easy_399				
	D016666	"<span class=""chemical"">fluvoxamine</span>"		D009771	"<span class=""disease"">obsessive-compulsive behavior</span>"	"Significant <span class=""disease"">obsessive-compulsive behavior</span> ensued but diminished over several weeks when methylphenidate was replaced by <span class=""chemical"">fluvoxamine</span>."		12907924	12907924_D016666_D009771	bcv_easy_400				
	D007069	"<span class=""chemical"">ifosfamide</span>"		D001002	"<span class=""disease"">anuria</span>"	"Lethal <span class=""disease"">anuria</span> complicating high dose <span class=""chemical"">ifosfamide</span> chemotherapy in a breast cancer patient with an impaired renal function."		2320800	2320800_D007069_D001002	bcv_easy_401				
	D007069	"<span class=""chemical"">ifosfamide</span>"		D007674	"<span class=""disease"">impaired renal function</span>"	"Lethal anuria complicating high dose <span class=""chemical"">ifosfamide</span> chemotherapy in a breast cancer patient with an <span class=""disease"">impaired renal function</span>."		2320800	2320800_D007069_D007674	bcv_easy_402				
	D007069	"<span class=""chemical"">ifosfamide</span>"		D001943	"<span class=""disease"">breast cancer</span>"	"Lethal anuria complicating high dose <span class=""chemical"">ifosfamide</span> chemotherapy in a <span class=""disease"">breast cancer</span> patient with an impaired renal function."		2320800	2320800_D007069_D001943	bcv_easy_403				
	D007069	"<span class=""chemical"">ifosfamide</span>"		D001002	"<span class=""disease"">anuria</span>"	"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with <span class=""disease"">anuria</span>, the day after 5 g/m2 bolus <span class=""chemical"">ifosfamide</span>."		2320800	2320800_D007069_D001002	bcv_easy_404				
	D007069	"<span class=""chemical"">ifosfamide</span>"		D001943	"<span class=""disease"">breast cancer</span>"	"A sixty-year-old woman with advanced <span class=""disease"">breast cancer</span>, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus <span class=""chemical"">ifosfamide</span>."		2320800	2320800_D007069_D001943	bcv_easy_405				
	D007069	"<span class=""chemical"">ifosfamide</span>"		D051437	"<span class=""disease"">renal failure</span>"	"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal <span class=""disease"">renal failure</span> with anuria, the day after 5 g/m2 bolus <span class=""chemical"">ifosfamide</span>."		2320800	2320800_D007069_D051437	bcv_easy_406				
	D002945	"<span class=""chemical"">cisplatin</span>"		D001943	"<span class=""disease"">breast cancer</span>"	"A sixty-year-old woman with advanced <span class=""disease"">breast cancer</span>, previously treated with <span class=""chemical"">cisplatin</span>, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide."		2320800	2320800_D002945_D001943	bcv_easy_407				
	D002945	"<span class=""chemical"">cisplatin</span>"		D051437	"<span class=""disease"">renal failure</span>"	"A sixty-year-old woman with advanced breast cancer, previously treated with <span class=""chemical"">cisplatin</span>, developed an irreversible lethal <span class=""disease"">renal failure</span> with anuria, the day after 5 g/m2 bolus ifosfamide."		2320800	2320800_D002945_D051437	bcv_easy_408				
	D002945	"<span class=""chemical"">cisplatin</span>"		D001002	"<span class=""disease"">anuria</span>"	"A sixty-year-old woman with advanced breast cancer, previously treated with <span class=""chemical"">cisplatin</span>, developed an irreversible lethal renal failure with <span class=""disease"">anuria</span>, the day after 5 g/m2 bolus ifosfamide."		2320800	2320800_D002945_D001002	bcv_easy_409				
	D007069	"<span class=""chemical"">Ifosfamide</span>"		D007674	"<span class=""disease"">nephrotoxic/tubulopathies</span>"	"<span class=""chemical"">Ifosfamide</span> is a known <span class=""disease"">nephrotoxic</span> drug with demonstrated <span class=""disease"">tubulopathies</span>."		2320800	2320800_D007069_D007674	bcv_easy_410				
	D007069	"<span class=""chemical"">ifosfamide</span>"		D001002	"<span class=""disease"">anuria</span>"	"We strongly suspect that this lethal <span class=""disease"">anuria</span> was mainly due to <span class=""chemical"">ifosfamide</span>, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension."		2320800	2320800_D007069_D001002	bcv_easy_411				
	D002945	"<span class=""chemical"">cisplatin</span>"		D001002	"<span class=""disease"">anuria</span>"	"We strongly suspect that this lethal <span class=""disease"">anuria</span> was mainly due to ifosfamide, occurring in a patient having received previous <span class=""chemical"">cisplatin</span> chemotherapy and with poor kidney perfusion due to transient hypotension."		2320800	2320800_D002945_D001002	bcv_easy_412				
	D007069	"<span class=""chemical"">ifosfamide</span>"		D007022	"<span class=""disease"">hypotension</span>"	"We strongly suspect that this lethal anuria was mainly due to <span class=""chemical"">ifosfamide</span>, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient <span class=""disease"">hypotension</span>."		2320800	2320800_D007069_D007022	bcv_easy_413				
	D002945	"<span class=""chemical"">cisplatin</span>"		D007022	"<span class=""disease"">hypotension</span>"	"We strongly suspect that this lethal anuria was mainly due to ifosfamide, occurring in a patient having received previous <span class=""chemical"">cisplatin</span> chemotherapy and with poor kidney perfusion due to transient <span class=""disease"">hypotension</span>."		2320800	2320800_D002945_D007022	bcv_easy_414				
	D007069	"<span class=""chemical"">ifosfamide</span>"		D007674	"<span class=""disease"">nephrotoxic</span>"	"We recommend careful use of <span class=""chemical"">ifosfamide</span> in patients pretreated with <span class=""disease"">nephrotoxic</span> chemotherapy and inadequate renal perfusion."		2320800	2320800_D007069_D007674	bcv_easy_415				
	D007608	"<span class=""chemical"">kainate</span>"		D010146	"<span class=""disease"">pain</span>"	"Two prodrugs of potent and selective GluR5 <span class=""chemical"">kainate</span> receptor antagonists actives in three animal models of <span class=""disease"">pain</span>."		15974569	15974569_D007608_D010146	bcv_easy_416				
	D002211	"<span class=""chemical"">capsaicin</span>"		D010146	"<span class=""disease"">pain</span>"	"Their ester prodrugs 6 and 8 were orally active in three models of <span class=""disease"">pain</span>: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and <span class=""chemical"">capsaicin</span>-induced mechanical hyperalgesia."		15974569	15974569_D002211_D010146	bcv_easy_417				
	D002351	"<span class=""chemical"">carrageenan</span>"		D010146	"<span class=""disease"">pain</span>"	"Their ester prodrugs 6 and 8 were orally active in three models of <span class=""disease"">pain</span>: reversal of formalin-induced paw licking, <span class=""chemical"">carrageenan</span>-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia."		15974569	15974569_D002351_D010146	bcv_easy_418				
	D005557	"<span class=""chemical"">formalin</span>"		D006930	"<span class=""disease"">thermal hyperalgesia/mechanical hyperalgesia</span>"	"Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of <span class=""chemical"">formalin</span>-induced paw licking, carrageenan-induced <span class=""disease"">thermal hyperalgesia</span>, and capsaicin-induced <span class=""disease"">mechanical hyperalgesia</span>."		15974569	15974569_D005557_D006930	bcv_easy_419				
	D005557	"<span class=""chemical"">formalin</span>"		D010146	"<span class=""disease"">pain</span>"	"Their ester prodrugs 6 and 8 were orally active in three models of <span class=""disease"">pain</span>: reversal of <span class=""chemical"">formalin</span>-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia."		15974569	15974569_D005557_D010146	bcv_easy_420				
	D003276	"<span class=""chemical"">oral contraceptives</span>"		D008113	"<span class=""disease"">liver tumors</span>"	"Etiologic factors in the pathogenesis of <span class=""disease"">liver tumors</span> associated with <span class=""chemical"">oral contraceptives</span>."		188339	188339_D003276_D008113	bcv_easy_421				
	D003276	"<span class=""chemical"">oral contraceptive</span>"		D008113	"<span class=""disease"">liver tumors</span>"	"Within the last several years, previously rare <span class=""disease"">liver tumors</span> have been seen in young women using <span class=""chemical"">oral contraceptive</span> steroids."		188339	188339_D003276_D008113	bcv_easy_422				
	D013256	"<span class=""chemical"">steroids</span>"		D008113	"<span class=""disease"">liver tumors</span>"	"Within the last several years, previously rare <span class=""disease"">liver tumors</span> have been seen in young women using oral contraceptive <span class=""chemical"">steroids</span>."		188339	188339_D013256_D008113	bcv_easy_423				
	D003276	"<span class=""chemical"">Oral Contraceptives</span>"		D008113	"<span class=""disease"">Liver Tumors</span>"	"The Registry for <span class=""disease"">Liver Tumors</span> Associated with <span class=""chemical"">Oral Contraceptives</span> at the University of California, Irvine, has clearly identified 27 cases."		188339	188339_D003276_D008113	bcv_easy_424				
	C032151	"<span class=""chemical"">cibenzoline</span>"		D001145	"<span class=""disease"">ventricular arrhythmias</span>"	"Antiarrhythmic plasma concentrations of <span class=""chemical"">cibenzoline</span> on canine <span class=""disease"">ventricular arrhythmias</span>."		2435991	2435991_C032151_D001145	bcv_easy_425				
	D004071	"<span class=""chemical"">digitalis</span>"		D001145	"<span class=""disease"">arrhythmia/ventricular arrhythmias</span>"	"Using two-stage coronary ligation-, <span class=""chemical"">digitalis</span>-, and adrenaline-induced canine <span class=""disease"">ventricular arrhythmias</span>, antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each <span class=""disease"">arrhythmia</span> model was determined."		2435991	2435991_D004071_D001145	bcv_easy_426				
	C032151	"<span class=""chemical"">cibenzoline</span>"		D001145	"<span class=""disease"">arrhythmia/ventricular arrhythmias</span>"	"Using two-stage coronary ligation-, digitalis-, and adrenaline-induced canine <span class=""disease"">ventricular arrhythmias</span>, antiarrhythmic effects of <span class=""chemical"">cibenzoline</span> were examined and the minimum effective plasma concentration for each <span class=""disease"">arrhythmia</span> model was determined."		2435991	2435991_C032151_D001145	bcv_easy_427				
	D004071	"<span class=""chemical"">digitalis</span>"		D001145	"<span class=""disease"">arrhythmias</span>"	"Cibenzoline suppressed all the <span class=""disease"">arrhythmias</span>, and the minimum effective plasma concentrations for <span class=""disease"">arrhythmias</span> induced by 24-h coronary ligation, 48-h coronary ligation, <span class=""chemical"">digitalis</span>, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7)."		2435991	2435991_D004071_D001145	bcv_easy_428				
	C032151	"<span class=""chemical"">Cibenzoline</span>"		D001145	"<span class=""disease"">arrhythmias</span>"	"<span class=""chemical"">Cibenzoline</span> suppressed all the <span class=""disease"">arrhythmias</span>, and the minimum effective plasma concentrations for <span class=""disease"">arrhythmias</span> induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7)."		2435991	2435991_C032151_D001145	bcv_easy_429				
	C032151	"<span class=""chemical"">cibenzoline</span>"		D003866	"<span class=""disease"">depressive</span>"	"Because <span class=""chemical"">cibenzoline</span> had only weak hypotensive and sinus node <span class=""disease"">depressive</span> effects and was found to be orally active when given to coronary ligation arrhythmia dogs, its clinical usefulness is expected."		2435991	2435991_C032151_D003866	bcv_easy_430				
	C032151	"<span class=""chemical"">cibenzoline</span>"		D001145	"<span class=""disease"">arrhythmia</span>"	"Because <span class=""chemical"">cibenzoline</span> had only weak hypotensive and sinus node depressive effects and was found to be orally active when given to coronary ligation <span class=""disease"">arrhythmia</span> dogs, its clinical usefulness is expected."		2435991	2435991_C032151_D001145	bcv_easy_431				
	C032151	"<span class=""chemical"">cibenzoline</span>"		D007022	"<span class=""disease"">hypotensive</span>"	"Because <span class=""chemical"">cibenzoline</span> had only weak <span class=""disease"">hypotensive</span> and sinus node depressive effects and was found to be orally active when given to coronary ligation arrhythmia dogs, its clinical usefulness is expected."		2435991	2435991_C032151_D007022	bcv_easy_432				
	D003520	"<span class=""chemical"">Cyclophosphamide</span>"		D001749	"<span class=""disease"">bladder cancer</span>"	"<span class=""chemical"">Cyclophosphamide</span> associated <span class=""disease"">bladder cancer</span>--a highly aggressive disease: analysis of 12 cases."		8911359	8911359_D003520_D001749	bcv_easy_433				
	D003520	"<span class=""chemical"">cyclophosphamide</span>"		D014523	"<span class=""disease"">urothelial cancer</span>"	"PURPOSE: We gained knowledge of the etiology, treatment and prevention of <span class=""chemical"">cyclophosphamide</span> associated <span class=""disease"">urothelial cancer</span>."		8911359	8911359_D003520_D014523	bcv_easy_434				
	D003520	"<span class=""chemical"">cyclophosphamide</span>"		D001749	"<span class=""disease"">bladder cancer</span>"	"MATERIALS AND METHODS: The medical records of 6 men and 6 women (mean age 55 years) with <span class=""chemical"">cyclophosphamide</span> associated <span class=""disease"">bladder cancer</span> were reviewed."		8911359	8911359_D003520_D001749	bcv_easy_435				
	D003520	"<span class=""chemical"">Cyclophosphamide</span>"		D001749	"<span class=""disease"">bladder tumor</span>"	"CONCLUSIONS: <span class=""chemical"">Cyclophosphamide</span> associated <span class=""disease"">bladder tumor</span> is an aggressive disease."		8911359	8911359_D003520_D001749	bcv_easy_436				
	D005680	"<span class=""chemical"">GABA</span>"		D012133	"<span class=""disease"">respiratory paralysis</span>"	"<span class=""chemical"">GABA</span> involvement in naloxone induced reversal of <span class=""disease"">respiratory paralysis</span> produced by thiopental."		2893236	2893236_D005680_D012133	bcv_easy_437				
	D013874	"<span class=""chemical"">thiopental</span>"		D012133	"<span class=""disease"">respiratory paralysis</span>"	"GABA involvement in naloxone induced reversal of <span class=""disease"">respiratory paralysis</span> produced by <span class=""chemical"">thiopental</span>."		2893236	2893236_D013874_D012133	bcv_easy_438				
	D009270	"<span class=""chemical"">naloxone</span>"		D012133	"<span class=""disease"">respiratory paralysis</span>"	"GABA involvement in <span class=""chemical"">naloxone</span> induced reversal of <span class=""disease"">respiratory paralysis</span> produced by thiopental."		2893236	2893236_D009270_D012133	bcv_easy_439				
	D013874	"<span class=""chemical"">thiopental</span>"		D012133	"<span class=""disease"">respiratory paralysis</span>"	"In this study naloxone reversed <span class=""disease"">respiratory paralysis</span> induced by <span class=""chemical"">thiopental</span> in rats."		2893236	2893236_D013874_D012133	bcv_easy_440				
	D009270	"<span class=""chemical"">naloxone</span>"		D012133	"<span class=""disease"">respiratory paralysis</span>"	"In this study <span class=""chemical"">naloxone</span> reversed <span class=""disease"">respiratory paralysis</span> induced by thiopental in rats."		2893236	2893236_D009270_D012133	bcv_easy_441				
	D013874	"<span class=""chemical"">thiopental</span>"		D012131	"<span class=""disease"">respiratory arrest</span>"	"50 mg/kg, i.v. <span class=""chemical"">thiopental</span> produced <span class=""disease"">respiratory arrest</span> with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain."		2893236	2893236_D013874_D012131	bcv_easy_442				
	D000596	"<span class=""chemical"">amino acids</span>"		D012131	"<span class=""disease"">respiratory arrest</span>"	"50 mg/kg, i.v. thiopental produced <span class=""disease"">respiratory arrest</span> with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the <span class=""chemical"">amino acids</span> studied in four regions of rat brain."		2893236	2893236_D000596_D012131	bcv_easy_443				
	D018698	"<span class=""chemical"">glutamate</span>"		D012131	"<span class=""disease"">respiratory arrest</span>"	"50 mg/kg, i.v. thiopental produced <span class=""disease"">respiratory arrest</span> with further increase in GABA and decrease in <span class=""chemical"">glutamate</span> again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain."		2893236	2893236_D018698_D012131	bcv_easy_444				
	D005680	"<span class=""chemical"">GABA</span>"		D012131	"<span class=""disease"">respiratory arrest</span>"	"50 mg/kg, i.v. thiopental produced <span class=""disease"">respiratory arrest</span> with further increase in <span class=""chemical"">GABA</span> and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain."		2893236	2893236_D005680_D012131	bcv_easy_445				
	D005680	"<span class=""chemical"">GABA</span>"		D012133	"<span class=""disease"">respiratory paralysis</span>"	"Naloxone (2.5 mg/kg, i.v.) reversed <span class=""disease"">respiratory paralysis</span>, glutamate and <span class=""chemical"">GABA</span> levels to control values in brain stem and cortex with no changes in caudate or cerebellum."		2893236	2893236_D005680_D012133	bcv_easy_446				
	D009270	"<span class=""chemical"">Naloxone</span>"		D012133	"<span class=""disease"">respiratory paralysis</span>"	"<span class=""chemical"">Naloxone</span> (2.5 mg/kg, i.v.) reversed <span class=""disease"">respiratory paralysis</span>, glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum."		2893236	2893236_D009270_D012133	bcv_easy_447				
	D018698	"<span class=""chemical"">glutamate</span>"		D012133	"<span class=""disease"">respiratory paralysis</span>"	"Naloxone (2.5 mg/kg, i.v.) reversed <span class=""disease"">respiratory paralysis</span>, <span class=""chemical"">glutamate</span> and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum."		2893236	2893236_D018698_D012133	bcv_easy_448				
	D013874	"<span class=""chemical"">thiopental</span>"		D012133	"<span class=""disease"">respiratory paralysis</span>"	"These data suggest naloxone reverses <span class=""disease"">respiratory paralysis</span> produced by <span class=""chemical"">thiopental</span> and involves GABA in its action."		2893236	2893236_D013874_D012133	bcv_easy_449				
	D005680	"<span class=""chemical"">GABA</span>"		D012133	"<span class=""disease"">respiratory paralysis</span>"	"These data suggest naloxone reverses <span class=""disease"">respiratory paralysis</span> produced by thiopental and involves <span class=""chemical"">GABA</span> in its action."		2893236	2893236_D005680_D012133	bcv_easy_450				
	D009270	"<span class=""chemical"">naloxone</span>"		D012133	"<span class=""disease"">respiratory paralysis</span>"	"These data suggest <span class=""chemical"">naloxone</span> reverses <span class=""disease"">respiratory paralysis</span> produced by thiopental and involves GABA in its action."		2893236	2893236_D009270_D012133	bcv_easy_451				
	D009543	"<span class=""chemical"">nifedipine</span>"		D013684	"<span class=""disease"">telangiectasia</span>"	"Photodistributed <span class=""chemical"">nifedipine</span>-induced facial <span class=""disease"">telangiectasia</span>."		8251368	8251368_D009543_D013684	bcv_easy_452				
	D009543	"<span class=""chemical"">nifedipine/Adalat</span>"		D013684	"<span class=""disease"">telangiectasia</span>"	"Five months after starting <span class=""chemical"">nifedipine</span> (<span class=""chemical"">Adalat</span>), two patients developed photodistributed facial <span class=""disease"">telangiectasia</span>, which became more noticeable with time."		8251368	8251368_D009543_D013684	bcv_easy_453				
	D017311	"<span class=""chemical"">amlodipine</span>"		D013684	"<span class=""disease"">telangiectasia</span>"	"One commenced the closely related drug <span class=""chemical"">amlodipine</span> 3 years later, with recurrence of <span class=""disease"">telangiectasia</span>."		8251368	8251368_D017311_D013684	bcv_easy_454				
	D007980	"<span class=""chemical"">L-dopa</span>"		D003128	"<span class=""disease"">coma</span>"	"Reversal of ammonia <span class=""disease"">coma</span> in rats by <span class=""chemical"">L-dopa</span>: a peripheral effect."		761833	761833_D007980_D003128	bcv_easy_455				
	D000641	"<span class=""chemical"">ammonia</span>"		D003128	"<span class=""disease"">coma</span>"	"Reversal of <span class=""chemical"">ammonia</span> <span class=""disease"">coma</span> in rats by L-dopa: a peripheral effect."		761833	761833_D000641_D003128	bcv_easy_456				
	D000643	"<span class=""chemical"">NH4CL</span>"		D003128	"<span class=""disease"">coma</span>"	"Ammonia <span class=""disease"">coma</span> was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1.7 mmol <span class=""chemical"">NH4CL</span>."		761833	761833_D000643_D003128	bcv_easy_457				
	D000641	"<span class=""chemical"">Ammonia</span>"		D003128	"<span class=""disease"">coma</span>"	"<span class=""chemical"">Ammonia</span> <span class=""disease"">coma</span> was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1.7 mmol NH4CL."		761833	761833_D000641_D003128	bcv_easy_458				
	D064751	"<span class=""chemical"">ammonium salt</span>"		D003128	"<span class=""disease"">coma</span>"	"This <span class=""disease"">coma</span> was prevented with 1.68 mmol L-dopa given by gastric intubation 15 minutes before the <span class=""chemical"">ammonium salt</span> injection."		761833	761833_D064751_D003128	bcv_easy_459				
	D007980	"<span class=""chemical"">L-dopa</span>"		D003128	"<span class=""disease"">coma</span>"	"This <span class=""disease"">coma</span> was prevented with 1.68 mmol <span class=""chemical"">L-dopa</span> given by gastric intubation 15 minutes before the ammonium salt injection."		761833	761833_D007980_D003128	bcv_easy_460				
	D004298	"<span class=""chemical"">dopamine</span>"		D003128	"<span class=""disease"">coma</span>"	"Intraventricular infusion of <span class=""chemical"">dopamine</span> sufficient to raise the brain <span class=""chemical"">dopamine</span> to the same extent did not prevent the ammonia <span class=""disease"">coma</span> nor affect the blood and brain ammonia concentrations."		761833	761833_D004298_D003128	bcv_easy_461				
	D000641	"<span class=""chemical"">ammonia</span>"		D003128	"<span class=""disease"">coma</span>"	"Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the <span class=""chemical"">ammonia</span> <span class=""disease"">coma</span> nor affect the blood and brain <span class=""chemical"">ammonia</span> concentrations."		761833	761833_D000641_D003128	bcv_easy_462				
	D007980	"<span class=""chemical"">L-dopa</span>"		D003128	"<span class=""disease"">coma</span>"	"Bilateral nephrectomy eliminated the beneficial effect of <span class=""chemical"">L-dopa</span> on blood and brain ammonia and the ammonia <span class=""disease"">coma</span> was not prevented."		761833	761833_D007980_D003128	bcv_easy_463				
	D000641	"<span class=""chemical"">ammonia</span>"		D003128	"<span class=""disease"">coma</span>"	"Bilateral nephrectomy eliminated the beneficial effect of L-dopa on blood and brain <span class=""chemical"">ammonia</span> and the <span class=""chemical"">ammonia</span> <span class=""disease"">coma</span> was not prevented."		761833	761833_D000641_D003128	bcv_easy_464				
	D004298	"<span class=""chemical"">dopamine</span>"		D003128	"<span class=""disease"">coma</span>"	"Thus, the reduction in blood and brain ammonia and the prevention of ammonia <span class=""disease"">coma</span> after L-dopa, can be accounted for by the peripheral effect of <span class=""chemical"">dopamine</span> on renal function rather than its central action."		761833	761833_D004298_D003128	bcv_easy_465				
	D007980	"<span class=""chemical"">L-dopa</span>"		D003128	"<span class=""disease"">coma</span>"	"Thus, the reduction in blood and brain ammonia and the prevention of ammonia <span class=""disease"">coma</span> after <span class=""chemical"">L-dopa</span>, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action."		761833	761833_D007980_D003128	bcv_easy_466				
	D000641	"<span class=""chemical"">ammonia</span>"		D003128	"<span class=""disease"">coma</span>"	"Thus, the reduction in blood and brain <span class=""chemical"">ammonia</span> and the prevention of <span class=""chemical"">ammonia</span> <span class=""disease"">coma</span> after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action."		761833	761833_D000641_D003128	bcv_easy_467				
	D007980	"<span class=""chemical"">L-dopa</span>"		D001927	"<span class=""disease"">encephalopathic</span>"	"These results provide a reasonable explanation for the beneficial effects observed in some <span class=""disease"">encephalopathic</span> patients receiving <span class=""chemical"">L-dopa</span>."		761833	761833_D007980_D001927	bcv_easy_468				
	D014700	"<span class=""chemical"">verapamil</span>"		D007022	"<span class=""disease"">hypotension</span>"	"Three patients with ischaemic heart disease developed profound cardiac failure, <span class=""disease"">hypotension</span> and bradycardia during combined therapy with <span class=""chemical"">verapamil</span> and beta-adrenergic blocking drugs."		6127992	6127992_D014700_D007022	bcv_easy_469				
	D000319	"<span class=""chemical"">beta-adrenergic blocking drugs</span>"		D017202	"<span class=""disease"">ischaemic heart disease</span>"	"Three patients with <span class=""disease"">ischaemic heart disease</span> developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and <span class=""chemical"">beta-adrenergic blocking drugs</span>."		6127992	6127992_D000319_D017202	bcv_easy_470				
	D000319	"<span class=""chemical"">beta-adrenergic blocking drugs</span>"		D006333	"<span class=""disease"">cardiac failure</span>"	"Three patients with ischaemic heart disease developed profound <span class=""disease"">cardiac failure</span>, hypotension and bradycardia during combined therapy with verapamil and <span class=""chemical"">beta-adrenergic blocking drugs</span>."		6127992	6127992_D000319_D006333	bcv_easy_471				
	D000319	"<span class=""chemical"">beta-adrenergic blocking drugs</span>"		D001919	"<span class=""disease"">bradycardia</span>"	"Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and <span class=""disease"">bradycardia</span> during combined therapy with verapamil and <span class=""chemical"">beta-adrenergic blocking drugs</span>."		6127992	6127992_D000319_D001919	bcv_easy_472				
	D014700	"<span class=""chemical"">verapamil</span>"		D006333	"<span class=""disease"">cardiac failure</span>"	"Three patients with ischaemic heart disease developed profound <span class=""disease"">cardiac failure</span>, hypotension and bradycardia during combined therapy with <span class=""chemical"">verapamil</span> and beta-adrenergic blocking drugs."		6127992	6127992_D014700_D006333	bcv_easy_473				
	D000319	"<span class=""chemical"">beta-adrenergic blocking drugs</span>"		D007022	"<span class=""disease"">hypotension</span>"	"Three patients with ischaemic heart disease developed profound cardiac failure, <span class=""disease"">hypotension</span> and bradycardia during combined therapy with verapamil and <span class=""chemical"">beta-adrenergic blocking drugs</span>."		6127992	6127992_D000319_D007022	bcv_easy_474				
	D014700	"<span class=""chemical"">verapamil</span>"		D017202	"<span class=""disease"">ischaemic heart disease</span>"	"Three patients with <span class=""disease"">ischaemic heart disease</span> developed profound cardiac failure, hypotension and bradycardia during combined therapy with <span class=""chemical"">verapamil</span> and beta-adrenergic blocking drugs."		6127992	6127992_D014700_D017202	bcv_easy_475				
	D014700	"<span class=""chemical"">verapamil</span>"		D001919	"<span class=""disease"">bradycardia</span>"	"Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and <span class=""disease"">bradycardia</span> during combined therapy with <span class=""chemical"">verapamil</span> and beta-adrenergic blocking drugs."		6127992	6127992_D014700_D001919	bcv_easy_476				
	C033706	"<span class=""chemical"">tiazofurin</span>"		D001927	"<span class=""disease"">cerebral lesions</span>"	"Reversible <span class=""disease"">cerebral lesions</span> associated with <span class=""chemical"">tiazofurin</span> usage: MR demonstration."		3183120	3183120_C033706_D001927	bcv_easy_477				
	D006220	"<span class=""chemical"">Haloperidol</span>"		D010300	"<span class=""disease"">parkinsonian</span>"	"<span class=""chemical"">Haloperidol</span> (1 mg/kg ip) induced <span class=""disease"">parkinsonian</span>-like muscle rigidity, measured as an increased resistance of a rat's hind foot to passive flexion and extension at the ankle joint."		12231232	12231232_D006220_D010300	bcv_easy_478				
	C095756	"<span class=""chemical"">AIDA</span>"		D009127	"<span class=""disease"">muscle rigidity</span>"	"<span class=""chemical"">AIDA</span> in doses of 7.5-15 microg/0.5 microl diminished the haloperidol-induced <span class=""disease"">muscle rigidity</span>."		12231232	12231232_C095756_D009127	bcv_easy_479				
	D015320	"<span class=""chemical"">tachykinins</span>"		D053201	"<span class=""disease"">bladder hyperactivity</span>"	"Prostaglandin E2-induced <span class=""disease"">bladder hyperactivity</span> in normal, conscious rats: involvement of <span class=""chemical"">tachykinins</span>?"		7752389	7752389_D015320_D053201	bcv_easy_480				
	D011453	"<span class=""chemical"">Prostanoids</span>"		D053201	"<span class=""disease"">bladder hyperactivity</span>"	"<span class=""chemical"">Prostanoids</span> may, via release of tachykinins, contribute to both urge and <span class=""disease"">bladder hyperactivity</span> seen in inflammatory conditions of the lower urinary tract."		7752389	7752389_D011453_D053201	bcv_easy_481				
	D015320	"<span class=""chemical"">tachykinins</span>"		D053201	"<span class=""disease"">bladder hyperactivity</span>"	"Prostanoids may, via release of <span class=""chemical"">tachykinins</span>, contribute to both urge and <span class=""disease"">bladder hyperactivity</span> seen in inflammatory conditions of the lower urinary tract."		7752389	7752389_D015320_D053201	bcv_easy_482				
	D000588	"<span class=""chemical"">amine</span>"		D002389	"<span class=""disease"">catatonia</span>"	"Effects of <span class=""chemical"">amine</span> pretreatment on ketamine <span class=""disease"">catatonia</span> in pinealectomized or hypophysectomized animals."		6540303	6540303_D000588_D002389	bcv_easy_483				
	D002395	"<span class=""chemical"">catecholamines</span>"		D002389	"<span class=""disease"">catatonia</span>"	"The present studies were designed to clarify the role of <span class=""chemical"">catecholamines</span> and pineal idolamines on ketamine-induced <span class=""disease"">catatonia</span> in the intact, pinealectomized or hypophysectomized chick and rat."		6540303	6540303_D002395_D002389	bcv_easy_484				
	D004298	"<span class=""chemical"">dopamine</span>"		D002389	"<span class=""disease"">catatonia</span>"	"In the pinealectomized chick, pretreatment with <span class=""chemical"">dopamine</span> increased the duration of <span class=""disease"">catatonia</span> (DOC) after ketamine, but pretreatment with norepinephrine did not."		6540303	6540303_D004298_D002389	bcv_easy_485				
	D009638	"<span class=""chemical"">norepinephrine</span>"		D002389	"<span class=""disease"">catatonia</span>"	"In the pinealectomized chick, pretreatment with dopamine increased the duration of <span class=""disease"">catatonia</span> (DOC) after ketamine, but pretreatment with <span class=""chemical"">norepinephrine</span> did not."		6540303	6540303_D009638_D002389	bcv_easy_486				
	D004298	"<span class=""chemical"">dopamine</span>"		D002389	"<span class=""disease"">catatonia</span>"	"Furthermore, <span class=""chemical"">dopamine</span> appeared to act on systems more closely involved with the induction of ketamine <span class=""disease"">catatonia</span> rather than directly on the pituitary."		6540303	6540303_D004298_D002389	bcv_easy_487				
	D000583	"<span class=""chemical"">amikacin</span>"		D007674	"<span class=""disease"">nephrotoxicity</span>"	"Factors associated with <span class=""disease"">nephrotoxicity</span> and clinical outcome in patients receiving <span class=""chemical"">amikacin</span>."		3950060	3950060_D000583_D007674	bcv_easy_488				
	D000583	"<span class=""chemical"">amikacin</span>"		D007674	"<span class=""disease"">nephrotoxicity</span>"	"Data from 60 patients treated with <span class=""chemical"">amikacin</span> were analyzed for factors associated with <span class=""disease"">nephrotoxicity</span>."		3950060	3950060_D000583_D007674	bcv_easy_489				
	D006495	"<span class=""chemical"">low-molecular weight heparin</span>"		D013927	"<span class=""disease"">thrombosis</span>"	"BACKGROUND: Unfractionated heparin sodium (UFH) or <span class=""chemical"">low-molecular weight heparin</span> (LMWH) is used in anticoagulant protocols at several institutions to prevent <span class=""disease"">thrombosis</span> after liver transplantation."		18589141	18589141_D006495_D013927	bcv_easy_490				
	D006493	"<span class=""chemical"">Unfractionated heparin sodium/UFH</span>"		D013927	"<span class=""disease"">thrombosis</span>"	"BACKGROUND: <span class=""chemical"">Unfractionated heparin sodium</span> (<span class=""chemical"">UFH</span>) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent <span class=""disease"">thrombosis</span> after liver transplantation."		18589141	18589141_D006493_D013927	bcv_easy_491				
	D000324	"<span class=""chemical"">ACTH</span>"		D004421	"<span class=""disease"">dystonia</span>"	"A <span class=""disease"">dystonia</span>-like syndrome after neuropeptide (MSH/<span class=""chemical"">ACTH</span>) stimulation of the rat locus ceruleus."		2840807	2840807_D000324_D004421	bcv_easy_492				
	D009074	"<span class=""chemical"">MSH</span>"		D004421	"<span class=""disease"">dystonia</span>"	"A <span class=""disease"">dystonia</span>-like syndrome after neuropeptide (<span class=""chemical"">MSH</span>/ACTH) stimulation of the rat locus ceruleus."		2840807	2840807_D009074_D004421	bcv_easy_493				
	D000324	"<span class=""chemical"">ACTH</span>"		D003866	"<span class=""disease"">depression</span>"	"However, it is not certain as to the following: (a) what receptors were stimulated by the <span class=""chemical"">ACTH</span> N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term <span class=""disease"">depression</span> at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder."		2840807	2840807_D000324_D003866	bcv_easy_494				
	D000324	"<span class=""chemical"">ACTH</span>"		D009069	"<span class=""disease"">movement disorder</span>"	"However, it is not certain as to the following: (a) what receptors were stimulated by the <span class=""chemical"">ACTH</span> N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the <span class=""disease"">movement disorder</span>; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder."		2840807	2840807_D000324_D009069	bcv_easy_495				
	D010396	"<span class=""chemical"">Penicillamine</span>"		D005921	"<span class=""disease"">glomerulonephritis</span>"	"<span class=""chemical"">Penicillamine</span>-induced rapidly progressive <span class=""disease"">glomerulonephritis</span> in a patient with rheumatoid arthritis."		8267029	8267029_D010396_D005921	bcv_easy_496				
	D010396	"<span class=""chemical"">Penicillamine</span>"		D001172	"<span class=""disease"">rheumatoid arthritis</span>"	"<span class=""chemical"">Penicillamine</span>-induced rapidly progressive glomerulonephritis in a patient with <span class=""disease"">rheumatoid arthritis</span>."		8267029	8267029_D010396_D001172	bcv_easy_497				
	D010396	"<span class=""chemical"">D-penicillamine</span>"		D001172	"<span class=""disease"">rheumatoid arthritis</span>"	"A 67-year-old woman with <span class=""disease"">rheumatoid arthritis</span> presented rapidly progressive glomerulonephritis (RPGN) after 5 months of <span class=""chemical"">D-penicillamine</span> (250 mg/day) treatment."		8267029	8267029_D010396_D001172	bcv_easy_498				
	D010396	"<span class=""chemical"">D-penicillamine</span>"		D005921	"<span class=""disease"">glomerulonephritis/RPGN</span>"	"A 67-year-old woman with rheumatoid arthritis presented rapidly progressive <span class=""disease"">glomerulonephritis</span> (<span class=""disease"">RPGN</span>) after 5 months of <span class=""chemical"">D-penicillamine</span> (250 mg/day) treatment."		8267029	8267029_D010396_D005921	bcv_easy_499				
	D010396	"<span class=""chemical"">D-penicillamine</span>"		D005921	"<span class=""disease"">RPGN</span>"	"This new case of <span class=""disease"">RPGN</span> in the course of <span class=""chemical"">D-penicillamine</span> treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and proteinuria in these patients."		8267029	8267029_D010396_D005921	bcv_easy_500				
	D010396	"<span class=""chemical"">D-penicillamine</span>"		D011507	"<span class=""disease"">proteinuria</span>"	"This new case of RPGN in the course of <span class=""chemical"">D-penicillamine</span> treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and <span class=""disease"">proteinuria</span> in these patients."		8267029	8267029_D010396_D011507	bcv_easy_501				
	D015215	"<span class=""chemical"">3'-azido-2',3'-deoxythymidine/zidovudine/AZT</span>"		D002311	"<span class=""disease"">DCM</span>"	"METHODS AND RESULTS: In order to investigate whether the HAART component <span class=""chemical"">zidovudine</span> (<span class=""chemical"">3'-azido-2',3'-deoxythymidine</span>; <span class=""chemical"">AZT</span>) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of <span class=""disease"">DCM</span>, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of <span class=""chemical"">AZT</span> (0, 0.07, 0.2, and 0.7 mg/ml)."		17943461	17943461_D015215_D002311	bcv_easy_502				
	D015215	"<span class=""chemical"">AZT</span>"		D002311	"<span class=""disease"">cardiac dilation</span>"	"In contrast, <span class=""chemical"">AZT</span>-treated FasL Tg mice developed <span class=""disease"">cardiac dilation</span> and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles."		17943461	17943461_D015215_D002311	bcv_easy_503				
	D012964	"<span class=""chemical"">sodium</span>"		D007022	"<span class=""disease"">hypotension</span>"	"Renal blood flow (RBF) increased during fenoldopam-induced <span class=""disease"">hypotension</span> 11 +/- 7 per cent and decreased 21 +/- 8 per cent during <span class=""chemical"">sodium</span> nitroprusside-induced <span class=""disease"">hypotension</span> (P less than 0.01)."		1969772	1969772_D012964_D007022	bcv_easy_504				
	D004298	"<span class=""chemical"">dopamine</span>"		D007022	"<span class=""disease"">hypotension</span>"	"Fenoldopam is a selective <span class=""chemical"">dopamine</span>-1 (DA1) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced <span class=""disease"">hypotension</span>."		1969772	1969772_D004298_D007022	bcv_easy_505				
	D009270	"<span class=""chemical"">Naloxone</span>"		D062787	"<span class=""disease"">overdose</span>"	"<span class=""chemical"">Naloxone</span> reversal of hypotension due to captopril <span class=""disease"">overdose</span>."		1928887	1928887_D009270_D062787	bcv_easy_506				
	D009270	"<span class=""chemical"">Naloxone</span>"		D007022	"<span class=""disease"">hypotension</span>"	"<span class=""chemical"">Naloxone</span> reversal of <span class=""disease"">hypotension</span> due to captopril overdose."		1928887	1928887_D009270_D007022	bcv_easy_507				
	D002216	"<span class=""chemical"">captopril</span>"		D062787	"<span class=""disease"">overdose</span>"	"Naloxone reversal of hypotension due to <span class=""chemical"">captopril</span> <span class=""disease"">overdose</span>."		1928887	1928887_D002216_D062787	bcv_easy_508				
	D009270	"<span class=""chemical"">naloxone</span>"		D007022	"<span class=""disease"">hypotensive</span>"	"The opioid antagonist <span class=""chemical"">naloxone</span> has been shown to block or reverse the <span class=""disease"">hypotensive</span> actions of captopril."		1928887	1928887_D009270_D007022	bcv_easy_509				
	D009270	"<span class=""chemical"">naloxone</span>"		D062787	"<span class=""disease"">overdose</span>"	"We report a case of an intentional captopril <span class=""disease"">overdose</span>, manifested by marked hypotension, that resolved promptly with the administration of <span class=""chemical"">naloxone</span>."		1928887	1928887_D009270_D062787	bcv_easy_510				
	D009270	"<span class=""chemical"">naloxone</span>"		D007022	"<span class=""disease"">hypotension</span>"	"We report a case of an intentional captopril overdose, manifested by marked <span class=""disease"">hypotension</span>, that resolved promptly with the administration of <span class=""chemical"">naloxone</span>."		1928887	1928887_D009270_D007022	bcv_easy_511				
	D002216	"<span class=""chemical"">captopril</span>"		D062787	"<span class=""disease"">overdose</span>"	"We report a case of an intentional <span class=""chemical"">captopril</span> <span class=""disease"">overdose</span>, manifested by marked hypotension, that resolved promptly with the administration of naloxone."		1928887	1928887_D002216_D062787	bcv_easy_512				
	D009270	"<span class=""chemical"">naloxone</span>"		D007022	"<span class=""disease"">hypotension</span>"	"To our knowledge, this is the first reported case of captopril-induced <span class=""disease"">hypotension</span> treated with <span class=""chemical"">naloxone</span>."		1928887	1928887_D009270_D007022	bcv_easy_513				
	D009270	"<span class=""chemical"">naloxone</span>"		D007022	"<span class=""disease"">hypotension</span>"	"Our experience demonstrates a possible role of <span class=""chemical"">naloxone</span> in the reversal of <span class=""disease"">hypotension</span> resulting from captopril."		1928887	1928887_D009270_D007022	bcv_easy_514				
	D004317	"<span class=""chemical"">Doxorubicin</span>"		D009369	"<span class=""disease"">tumor</span>"	"<span class=""chemical"">Doxorubicin</span> is an anti-<span class=""disease"">tumor</span> agent that represses cardiac-specific gene expression and induces myocardial cell apoptosis."		14975762	14975762_D004317_D009369	bcv_easy_515				
	D004317	"<span class=""chemical"">doxorubicin</span>"		D006333	"<span class=""disease"">heart failure</span>"	"These findings demonstrate that overexpression of p300 protects cardiac myocytes from <span class=""chemical"">doxorubicin</span>-induced apoptosis and reduces the extent of acute <span class=""disease"">heart failure</span> in adult mice in vivo."		14975762	14975762_D004317_D006333	bcv_easy_516				
	D010755	"<span class=""chemical"">organophosphorus</span>"		D009422	"<span class=""disease"">neuropathy</span>"	"Dose-related beneficial and adverse effects of dietary corticosterone on <span class=""chemical"">organophosphorus</span>-induced delayed <span class=""disease"">neuropathy</span> in chickens."		3961813	3961813_D010755_D009422	bcv_easy_517				
	D003345	"<span class=""chemical"">corticosterone</span>"		D009422	"<span class=""disease"">neuropathy</span>"	"Dose-related beneficial and adverse effects of dietary <span class=""chemical"">corticosterone</span> on organophosphorus-induced delayed <span class=""disease"">neuropathy</span> in chickens."		3961813	3961813_D003345_D009422	bcv_easy_518				
	D007531	"<span class=""chemical"">DFP</span>"		D009422	"<span class=""disease"">neuropathy</span>"	"Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on TOTP-induced <span class=""disease"">neuropathy</span>, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or <span class=""chemical"">DFP</span>."		3961813	3961813_D007531_D009422	bcv_easy_519				
	D003345	"<span class=""chemical"">corticosterone</span>"		D009422	"<span class=""disease"">neuropathy</span>"	"Although low concentrations (less than or equal to 50 ppm) of <span class=""chemical"">corticosterone</span> had beneficial effects on TOTP-induced <span class=""disease"">neuropathy</span>, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP."		3961813	3961813_D003345_D009422	bcv_easy_520				
	D010755	"<span class=""chemical"">organophosphorous</span>"		D020258	"<span class=""disease"">Neurotoxic</span>"	"<span class=""disease"">Neurotoxic</span> esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given <span class=""chemical"">organophosphorous</span> compounds."		3961813	3961813_D010755_D020258	bcv_easy_521				
	C025541	"<span class=""chemical"">TOTP</span>"		D020258	"<span class=""disease"">Neurotoxic</span>"	"<span class=""disease"">Neurotoxic</span> esterase activities 24 hr after <span class=""chemical"">TOTP</span> or DFP were less than 20% of values measured in chickens not given organophosphorous compounds."		3961813	3961813_C025541_D020258	bcv_easy_522				
	D007531	"<span class=""chemical"">DFP</span>"		D020258	"<span class=""disease"">Neurotoxic</span>"	"<span class=""disease"">Neurotoxic</span> esterase activities 24 hr after TOTP or <span class=""chemical"">DFP</span> were less than 20% of values measured in chickens not given organophosphorous compounds."		3961813	3961813_D007531_D020258	bcv_easy_523				
	D007531	"<span class=""chemical"">DFP</span>"		D009410	"<span class=""disease"">Degenerating myelinated fibers</span>"	"<span class=""disease"">Degenerating myelinated fibers</span> were also evident in distal levels of the peripheral nerves of chickens given TOTP or <span class=""chemical"">DFP</span>."		3961813	3961813_D007531_D009410	bcv_easy_524				
	C025541	"<span class=""chemical"">TOTP</span>"		D009410	"<span class=""disease"">Degenerating myelinated fibers</span>"	"<span class=""disease"">Degenerating myelinated fibers</span> were also evident in distal levels of the peripheral nerves of chickens given <span class=""chemical"">TOTP</span> or DFP."		3961813	3961813_C025541_D009410	bcv_easy_525				
	D000082	"<span class=""chemical"">paracetamol</span>"		D008107	"<span class=""disease"">liver disease</span>"	"On average, age-specific mortality rates were slightly higher for the 101 patients whose <span class=""chemical"">paracetamol</span>-induced liver injury had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of <span class=""disease"">liver disease</span>, whereas suicides were frequent in both groups."		20735774	20735774_D000082_D008107	bcv_easy_526				
	D013256	"<span class=""chemical"">Steroid</span>"		D005902	"<span class=""disease"">open angle glaucoma</span>"	"<span class=""chemical"">Steroid</span> treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and <span class=""disease"">open angle glaucoma</span>."		7843916	7843916_D013256_D005902	bcv_easy_527				
	D013256	"<span class=""chemical"">Steroid</span>"		D005901	"<span class=""disease"">corticosteroid glaucoma</span>"	"<span class=""chemical"">Steroid</span> treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for <span class=""disease"">corticosteroid glaucoma</span> and open angle glaucoma."		7843916	7843916_D013256_D005901	bcv_easy_528				
	D008094	"<span class=""chemical"">lithium</span>"		D054537	"<span class=""disease"">atrioventricular block</span>"	"Complete <span class=""disease"">atrioventricular block</span> secondary to <span class=""chemical"">lithium</span> therapy."		18441470	18441470_D008094_D054537	bcv_easy_529				
	D008094	"<span class=""chemical"">lithium</span>"		D012804	"<span class=""disease"">Sinus node dysfunction</span>"	"<span class=""disease"">Sinus node dysfunction</span> has been reported most frequently among the adverse cardiovascular effects of <span class=""chemical"">lithium</span>."		18441470	18441470_D008094_D012804	bcv_easy_530				
	D008094	"<span class=""chemical"">lithium</span>"		D054537	"<span class=""disease"">atrioventricular (AV) block</span>"	"In the present case, complete <span class=""disease"">atrioventricular (AV) block</span> with syncopal attacks developed secondary to <span class=""chemical"">lithium</span> therapy, necessitating permanent pacemaker implantation."		18441470	18441470_D008094_D054537	bcv_easy_531				
	D008094	"<span class=""chemical"">lithium</span>"		D013575	"<span class=""disease"">syncopal attacks</span>"	"In the present case, complete atrioventricular (AV) block with <span class=""disease"">syncopal attacks</span> developed secondary to <span class=""chemical"">lithium</span> therapy, necessitating permanent pacemaker implantation."		18441470	18441470_D008094_D013575	bcv_easy_532				
	D008094	"<span class=""chemical"">lithium</span>"		D013575	"<span class=""disease"">syncopal attacks</span>"	"Serum <span class=""chemical"">lithium</span> levels remained under or within the therapeutic range during the <span class=""disease"">syncopal attacks</span>."		18441470	18441470_D008094_D013575	bcv_easy_533				
	D015725	"<span class=""chemical"">fluconazole</span>"		D009202	"<span class=""disease"">cardiomyopathy</span>"	"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral <span class=""chemical"">fluconazole</span> The patient had no other risk factors for TDP, including coronary artery disease, <span class=""disease"">cardiomyopathy</span>, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of <span class=""chemical"">fluconazole</span> and TDP."		11302406	11302406_D015725_D009202	bcv_easy_534				
	D015725	"<span class=""chemical"">fluconazole</span>"		D003324	"<span class=""disease"">coronary artery disease</span>"	"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral <span class=""chemical"">fluconazole</span> The patient had no other risk factors for TDP, including <span class=""disease"">coronary artery disease</span>, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of <span class=""chemical"">fluconazole</span> and TDP."		11302406	11302406_D015725_D003324	bcv_easy_535				
	D015725	"<span class=""chemical"">fluconazole</span>"		D006333	"<span class=""disease"">congestive heart failure</span>"	"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral <span class=""chemical"">fluconazole</span> The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, <span class=""disease"">congestive heart failure</span>, and electrolyte abnormalities There was a temporal association between the initiation of <span class=""chemical"">fluconazole</span> and TDP."		11302406	11302406_D015725_D006333	bcv_easy_536				
	D015725	"<span class=""chemical"">fluconazole</span>"		D018879	"<span class=""disease"">premature ventricular contractions</span>"	"The TDP resolved when <span class=""chemical"">fluconazole</span> was discontinued; however, the patient continued to have <span class=""disease"">premature ventricular contractions</span> and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of <span class=""chemical"">fluconazole</span> and the development of TDP."		11302406	11302406_D015725_D018879	bcv_easy_537				
	D015725	"<span class=""chemical"">fluconazole</span>"		D017180	"<span class=""disease"">ventricular tachycardia/NSVT</span>"	"The TDP resolved when <span class=""chemical"">fluconazole</span> was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained <span class=""disease"">ventricular tachycardia</span> (<span class=""disease"">NSVT</span>) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of <span class=""chemical"">fluconazole</span> and the development of TDP."		11302406	11302406_D015725_D017180	bcv_easy_538				
	D011188	"<span class=""chemical"">potassium</span>"		D003866	"<span class=""disease"">depression</span>"	"The possible mechanism is <span class=""disease"">depression</span> of rapidly activating delayed rectifier <span class=""chemical"">potassium</span> currents."		11302406	11302406_D011188_D003866	bcv_easy_539				
	D015725	"<span class=""chemical"">fluconazole</span>"		D018879	"<span class=""disease"">premature ventricular contractions</span>"	"In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and <span class=""disease"">premature ventricular contractions</span> followed by normalization of QT interval after the drug was stopped strongly suggests <span class=""chemical"">fluconazole</span> as the etiology."		11302406	11302406_D015725_D018879	bcv_easy_540				
	D015725	"<span class=""chemical"">fluconazole</span>"		D008133	"<span class=""disease"">QT prolongation</span>"	"In our patient, there was no other etiology identified that could explain <span class=""disease"">QT prolongation</span> or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests <span class=""chemical"">fluconazole</span> as the etiology."		11302406	11302406_D015725_D008133	bcv_easy_541				
	D015725	"<span class=""chemical"">fluconazole</span>"		D017180	"<span class=""disease"">NSVT</span>"	"In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of <span class=""disease"">NSVT</span> and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests <span class=""chemical"">fluconazole</span> as the etiology."		11302406	11302406_D015725_D017180	bcv_easy_542				
	D015725	"<span class=""chemical"">fluconazole</span>"		D008133	"<span class=""disease"">prolongation of the QT interval</span>"	"CONCLUSIONS: Clinicians should be aware that <span class=""chemical"">fluconazole</span>, even at low doses, may cause <span class=""disease"">prolongation of the QT interval</span>, leading to TDP."		11302406	11302406_D015725_D008133	bcv_easy_543				
	D015725	"<span class=""chemical"">fluconazole</span>"		D001145	"<span class=""disease"">ventricular arrhythmias</span>"	"Serial electrocardiographic monitoring may be considered when <span class=""chemical"">fluconazole</span> is administered in patients who are at risk for <span class=""disease"">ventricular arrhythmias</span>."		11302406	11302406_D015725_D001145	bcv_easy_544				
	D011433	"<span class=""chemical"">propranolol</span>"		D007565	"<span class=""disease"">jaundice</span>"	"A 43-year-old woman had severe <span class=""disease"">jaundice</span> and itching 1 month after receiving methimazole (10 mg tid) and <span class=""chemical"">propranolol</span> (20 mg tid) for treatment of hyperthyroidism."		14982270	14982270_D011433_D007565	bcv_easy_545				
	D008713	"<span class=""chemical"">methimazole</span>"		D011537	"<span class=""disease"">itching</span>"	"A 43-year-old woman had severe jaundice and <span class=""disease"">itching</span> 1 month after receiving <span class=""chemical"">methimazole</span> (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism."		14982270	14982270_D008713_D011537	bcv_easy_546				
	D008713	"<span class=""chemical"">methimazole</span>"		D007565	"<span class=""disease"">jaundice</span>"	"A 43-year-old woman had severe <span class=""disease"">jaundice</span> and itching 1 month after receiving <span class=""chemical"">methimazole</span> (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism."		14982270	14982270_D008713_D007565	bcv_easy_547				
	D011433	"<span class=""chemical"">propranolol</span>"		D006980	"<span class=""disease"">hyperthyroidism</span>"	"A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and <span class=""chemical"">propranolol</span> (20 mg tid) for treatment of <span class=""disease"">hyperthyroidism</span>."		14982270	14982270_D011433_D006980	bcv_easy_548				
	D011433	"<span class=""chemical"">propranolol</span>"		D011537	"<span class=""disease"">itching</span>"	"A 43-year-old woman had severe jaundice and <span class=""disease"">itching</span> 1 month after receiving methimazole (10 mg tid) and <span class=""chemical"">propranolol</span> (20 mg tid) for treatment of hyperthyroidism."		14982270	14982270_D011433_D011537	bcv_easy_549				
	D008713	"<span class=""chemical"">methimazole</span>"		D006980	"<span class=""disease"">hyperthyroidism</span>"	"A 43-year-old woman had severe jaundice and itching 1 month after receiving <span class=""chemical"">methimazole</span> (10 mg tid) and propranolol (20 mg tid) for treatment of <span class=""disease"">hyperthyroidism</span>."		14982270	14982270_D008713_D006980	bcv_easy_550				
	D011433	"<span class=""chemical"">propranolol</span>"		D002779	"<span class=""disease"">cholestasis</span>"	"Methimazole-induced <span class=""disease"">cholestasis</span> was diagnosed, and <span class=""chemical"">propranolol</span> therapy was resumed."		14982270	14982270_D011433_D002779	bcv_easy_551				
	D005047	"<span class=""chemical"">Etoposide</span>"		D009203	"<span class=""disease"">myocardial infarction</span>"	"<span class=""chemical"">Etoposide</span>-related <span class=""disease"">myocardial infarction</span>."		7619765	7619765_D005047_D009203	bcv_easy_552				
	D005047	"<span class=""chemical"">etoposide</span>"		D003327	"<span class=""disease"">coronary heart disease</span>"	"The occurrence of a myocardial infarction is reported after chemotherapy containing <span class=""chemical"">etoposide</span>, in a man with no risk factors for <span class=""disease"">coronary heart disease</span>."		7619765	7619765_D005047_D003327	bcv_easy_553				
	D005047	"<span class=""chemical"">etoposide</span>"		D009203	"<span class=""disease"">myocardial infarction</span>"	"The occurrence of a <span class=""disease"">myocardial infarction</span> is reported after chemotherapy containing <span class=""chemical"">etoposide</span>, in a man with no risk factors for coronary heart disease."		7619765	7619765_D005047_D009203	bcv_easy_554				
	D001971	"<span class=""chemical"">bromocriptine</span>"		D011605	"<span class=""disease"">psychosis</span>"	"Postpartum <span class=""disease"">psychosis</span> induced by <span class=""chemical"">bromocriptine</span>."		3686155	3686155_D001971_D011605	bcv_easy_555				
	D001971	"<span class=""chemical"">bromocriptine</span>"		D007775	"<span class=""disease"">inhibition of lactation</span>"	"Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis, having received <span class=""chemical"">bromocriptine</span> for <span class=""disease"">inhibition of lactation</span>."		3686155	3686155_D001971_D007775	bcv_easy_556				
	D001971	"<span class=""chemical"">bromocriptine</span>"		D001523	"<span class=""disease"">psychiatric</span>"	"Two multigravida patients with no prior <span class=""disease"">psychiatric</span> history were seen with postpartum psychosis, having received <span class=""chemical"">bromocriptine</span> for inhibition of lactation."		3686155	3686155_D001971_D001523	bcv_easy_557				
	D001971	"<span class=""chemical"">bromocriptine</span>"		D011605	"<span class=""disease"">psychosis</span>"	"Two multigravida patients with no prior psychiatric history were seen with postpartum <span class=""disease"">psychosis</span>, having received <span class=""chemical"">bromocriptine</span> for inhibition of lactation."		3686155	3686155_D001971_D011605	bcv_easy_558				
	D001971	"<span class=""chemical"">Bromocriptine</span>"		D011605	"<span class=""disease"">psychosis</span>"	"<span class=""chemical"">Bromocriptine</span> given in high doses has been associated with <span class=""disease"">psychosis</span> in patients receiving the drug for Parkinson's disease."		3686155	3686155_D001971_D011605	bcv_easy_559				
	D001971	"<span class=""chemical"">Bromocriptine</span>"		D010300	"<span class=""disease"">Parkinson's disease</span>"	"<span class=""chemical"">Bromocriptine</span> given in high doses has been associated with psychosis in patients receiving the drug for <span class=""disease"">Parkinson's disease</span>."		3686155	3686155_D001971_D010300	bcv_easy_560				
	D001971	"<span class=""chemical"">bromocriptine</span>"		D011605	"<span class=""disease"">psychosis</span>"	"These cases demonstrate that <span class=""chemical"">bromocriptine</span> may cause <span class=""disease"">psychosis</span> even when given in low doses."		3686155	3686155_D001971_D011605	bcv_easy_561				
	D015080	"<span class=""chemical"">Mesna</span>"		D006417	"<span class=""disease"">hematuria</span>"	"The frequency and predictability of <span class=""disease"">hematuria</span> are not precise, and at least daily monitoring by urine Hematest is essential, adding <span class=""chemical"">Mesna</span> to the infusate in patients with persistent <span class=""disease"">hematuria</span>."		1899352	1899352_D015080_D006417	bcv_easy_562				
	D003042	"<span class=""chemical"">cocaine</span>"		D012640	"<span class=""disease"">seizure</span>"	"OBJECTIVE: The objective of this study was to determine the prevalence of positive plasma drug screening for <span class=""chemical"">cocaine</span> or amphetamine in adult emergency department <span class=""disease"">seizure</span> patients."		11185967	11185967_D003042_D012640	bcv_easy_563				
	D000661	"<span class=""chemical"">amphetamine</span>"		D012640	"<span class=""disease"">seizure</span>"	"OBJECTIVE: The objective of this study was to determine the prevalence of positive plasma drug screening for cocaine or <span class=""chemical"">amphetamine</span> in adult emergency department <span class=""disease"">seizure</span> patients."		11185967	11185967_D000661_D012640	bcv_easy_564				
	D000431	"<span class=""chemical"">alcohol</span>"		D012640	"<span class=""disease"">seizure</span>"	"Patient demographics, history of underlying drug or <span class=""chemical"">alcohol</span>-related <span class=""disease"">seizure</span> disorder, estimated time from <span class=""disease"">seizure</span> to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers."		11185967	11185967_D000431_D012640	bcv_easy_565				
	D000431	"<span class=""chemical"">alcohol</span>"		D019970|D019969	"<span class=""disease"">cocaine or amphetamine abuse</span>"	"Patient demographics, history of underlying drug or <span class=""chemical"">alcohol</span>-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of <span class=""disease"">cocaine or amphetamine abuse</span>, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers."		11185967	11185967_D000431_D019970|D019969	bcv_easy_566				
	D003042	"<span class=""chemical"">cocaine</span>"		D012640	"<span class=""disease"">seizure</span>"	"CONCLUSIONS: During this study period, routine plasma screening for <span class=""chemical"">cocaine</span> and amphetamines in adult <span class=""disease"">seizure</span> patients had a low yield."		11185967	11185967_D003042_D012640	bcv_easy_567				
	D000662	"<span class=""chemical"">amphetamines</span>"		D012640	"<span class=""disease"">seizure</span>"	"CONCLUSIONS: During this study period, routine plasma screening for cocaine and <span class=""chemical"">amphetamines</span> in adult <span class=""disease"">seizure</span> patients had a low yield."		11185967	11185967_D000662_D012640	bcv_easy_568				
	D007538	"<span class=""chemical"">isoniazid</span>"		D009901	"<span class=""disease"">Bilateral optic neuropathy</span>"	"<span class=""disease"">Bilateral optic neuropathy</span> due to combined ethambutol and <span class=""chemical"">isoniazid</span> treatment."		384871	384871_D007538_D009901	bcv_easy_569				
	D004977	"<span class=""chemical"">ethambutol</span>"		D009901	"<span class=""disease"">Bilateral optic neuropathy</span>"	"<span class=""disease"">Bilateral optic neuropathy</span> due to combined <span class=""chemical"">ethambutol</span> and isoniazid treatment."		384871	384871_D004977_D009901	bcv_easy_570				
	D004977	"<span class=""chemical"">ethambutol</span>"		D064420	"<span class=""disease"">toxicity</span>"	"The hazards of optic nerve <span class=""disease"">toxicity</span> due to <span class=""chemical"">ethambutol</span> are known."		384871	384871_D004977_D064420	bcv_easy_571				
	C400082	"<span class=""chemical"">bortezomib</span>"		D009101	"<span class=""disease"">myeloma</span>"	"DSMM XI study: dose definition for intravenous cyclophosphamide in combination with <span class=""chemical"">bortezomib</span>/dexamethasone for remission induction in patients with newly diagnosed <span class=""disease"">myeloma</span>."		19274460	19274460_C400082_D009101	bcv_easy_572				
	D003520	"<span class=""chemical"">cyclophosphamide</span>"		D009101	"<span class=""disease"">myeloma</span>"	"DSMM XI study: dose definition for intravenous <span class=""chemical"">cyclophosphamide</span> in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed <span class=""disease"">myeloma</span>."		19274460	19274460_D003520_D009101	bcv_easy_573				
	D003907	"<span class=""chemical"">dexamethasone</span>"		D009101	"<span class=""disease"">myeloma</span>"	"DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/<span class=""chemical"">dexamethasone</span> for remission induction in patients with newly diagnosed <span class=""disease"">myeloma</span>."		19274460	19274460_D003907_D009101	bcv_easy_574				
	C400082	"<span class=""chemical"">bortezomib</span>"		D009101	"<span class=""disease"">MM/multiple myeloma</span>"	"A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with <span class=""chemical"">bortezomib</span> and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed <span class=""disease"">multiple myeloma</span> (<span class=""disease"">MM</span>)."		19274460	19274460_C400082_D009101	bcv_easy_575				
	D003520	"<span class=""chemical"">cyclophosphamide</span>"		D009101	"<span class=""disease"">MM/multiple myeloma</span>"	"A clinical trial was initiated to evaluate the recommended dose of <span class=""chemical"">cyclophosphamide</span> in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed <span class=""disease"">multiple myeloma</span> (<span class=""disease"">MM</span>)."		19274460	19274460_D003520_D009101	bcv_easy_576				
	D003907	"<span class=""chemical"">dexamethasone</span>"		D009101	"<span class=""disease"">MM/multiple myeloma</span>"	"A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and <span class=""chemical"">dexamethasone</span> as induction treatment before stem cell transplantation for younger patients with newly diagnosed <span class=""disease"">multiple myeloma</span> (<span class=""disease"">MM</span>)."		19274460	19274460_D003907_D009101	bcv_easy_577				
	C400082	"<span class=""chemical"">bortezomib</span>"		D009101	"<span class=""disease"">MM</span>"	"The results suggest that <span class=""chemical"">bortezomib</span> in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed <span class=""disease"">MM</span> that warrants further investigation."		19274460	19274460_C400082_D009101	bcv_easy_578				
	D003520	"<span class=""chemical"">cyclophosphamide</span>"		D009101	"<span class=""disease"">MM</span>"	"The results suggest that bortezomib in combination with <span class=""chemical"">cyclophosphamide</span> at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed <span class=""disease"">MM</span> that warrants further investigation."		19274460	19274460_D003520_D009101	bcv_easy_579				
	D003907	"<span class=""chemical"">dexamethasone</span>"		D009101	"<span class=""disease"">MM</span>"	"The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and <span class=""chemical"">dexamethasone</span> is an effective induction treatment for patients with newly diagnosed <span class=""disease"">MM</span> that warrants further investigation."		19274460	19274460_D003907_D009101	bcv_easy_580				
	D006854	"<span class=""chemical"">hydrocortisone</span>"		D016534	"<span class=""disease"">increased cardiac output</span>"	"The rise in resting blood pressure with <span class=""chemical"">hydrocortisone</span> is associated with an <span class=""disease"">increased cardiac output</span> (presumably due to increased blood volume).(ABSTRACT TRUNCATED AT 250 WORDS)"		2722224	2722224_D006854_D016534	bcv_easy_581				
	D002216	"<span class=""chemical"">captopril</span>"		D011507	"<span class=""disease"">proteinuria</span>"	"Effect of <span class=""chemical"">captopril</span> on pre-existing and aminonucleoside-induced <span class=""disease"">proteinuria</span> in spontaneously hypertensive rats."		6454943	6454943_D002216_D011507	bcv_easy_582				
	D011692	"<span class=""chemical"">aminonucleoside</span>"		D006973	"<span class=""disease"">hypertensive</span>"	"Effect of captopril on pre-existing and <span class=""chemical"">aminonucleoside</span>-induced proteinuria in spontaneously <span class=""disease"">hypertensive</span> rats."		6454943	6454943_D011692_D006973	bcv_easy_583				
	D002216	"<span class=""chemical"">captopril</span>"		D006973	"<span class=""disease"">hypertensive</span>"	"Effect of <span class=""chemical"">captopril</span> on pre-existing and aminonucleoside-induced proteinuria in spontaneously <span class=""disease"">hypertensive</span> rats."		6454943	6454943_D002216_D006973	bcv_easy_584				
	D002216	"<span class=""chemical"">captopril</span>"		D011507	"<span class=""disease"">Proteinuria</span>"	"<span class=""disease"">Proteinuria</span> is a side effect of <span class=""chemical"">captopril</span> treatment in hypertensive patients."		6454943	6454943_D002216_D011507	bcv_easy_585				
	D002216	"<span class=""chemical"">captopril</span>"		D006973	"<span class=""disease"">hypertensive</span>"	"Proteinuria is a side effect of <span class=""chemical"">captopril</span> treatment in <span class=""disease"">hypertensive</span> patients."		6454943	6454943_D002216_D006973	bcv_easy_586				
	D002216	"<span class=""chemical"">captopril</span>"		D007674	"<span class=""disease"">renal abnormality</span>"	"The possibility of reproducing the same <span class=""disease"">renal abnormality</span> with <span class=""chemical"">captopril</span> was examined in SHR."		6454943	6454943_D002216_D007674	bcv_easy_587				
	D002216	"<span class=""chemical"">captopril</span>"		D011507	"<span class=""disease"">proteinuria</span>"	"Oral administration of <span class=""chemical"">captopril</span> at 100 mg/kg for 14 days failed to aggravate <span class=""disease"">proteinuria</span> pre-existing in SHR."		6454943	6454943_D002216_D011507	bcv_easy_588				
	D002216	"<span class=""chemical"">captopril</span>"		D011507	"<span class=""disease"">proteinuria</span>"	"Also, <span class=""chemical"">captopril</span> treatment failed to potentiate or facilitate development of massive <span class=""disease"">proteinuria</span> invoked by puromycin aminonucleoside in SHR."		6454943	6454943_D002216_D011507	bcv_easy_589				
	D010672	"<span class=""chemical"">diphenylhydantoin</span>"		D064420	"<span class=""disease"">toxicity</span>"	"Transient hemiparesis: a rare manifestation of <span class=""chemical"">diphenylhydantoin</span> <span class=""disease"">toxicity</span>. Report of two cases."		430165	430165_D010672_D064420	bcv_easy_590				
	D010672	"<span class=""chemical"">diphenylhydantoin</span>"		D010291	"<span class=""disease"">hemiparesis</span>"	"Transient <span class=""disease"">hemiparesis</span>: a rare manifestation of <span class=""chemical"">diphenylhydantoin</span> toxicity. Report of two cases."		430165	430165_D010672_D010291	bcv_easy_591				
	D010672	"<span class=""chemical"">diphenylhydantoin/DPH</span>"		D002526	"<span class=""disease"">cerebellar dysfunction</span>"	"Among the common side effects of <span class=""chemical"">diphenylhydantoin</span> (<span class=""chemical"">DPH</span>) overdose, the most frequently encountered neurological signs are those of <span class=""disease"">cerebellar dysfunction</span>."		430165	430165_D010672_D002526	bcv_easy_592				
	D010672	"<span class=""chemical"">diphenylhydantoin/DPH</span>"		D062787	"<span class=""disease"">overdose</span>"	"Among the common side effects of <span class=""chemical"">diphenylhydantoin</span> (<span class=""chemical"">DPH</span>) <span class=""disease"">overdose</span>, the most frequently encountered neurological signs are those of cerebellar dysfunction."		430165	430165_D010672_D062787	bcv_easy_593				
	D010672	"<span class=""chemical"">DPH</span>"		D062787	"<span class=""disease"">overdose</span>"	"Two patients are presented who suffered progressive hemiparesis due to <span class=""chemical"">DPH</span> <span class=""disease"">overdose</span>."		430165	430165_D010672_D062787	bcv_easy_594				
	D010672	"<span class=""chemical"">DPH</span>"		D010291	"<span class=""disease"">hemiparesis</span>"	"Two patients are presented who suffered progressive <span class=""disease"">hemiparesis</span> due to <span class=""chemical"">DPH</span> overdose."		430165	430165_D010672_D010291	bcv_easy_595				
	D010672	"<span class=""chemical"">DPH</span>"		D064420	"<span class=""disease"">toxicity</span>"	"It is assumed that patients with some cerebral damage are liable to manifest <span class=""chemical"">DPH</span> <span class=""disease"">toxicity</span> as focal neurological signs."		430165	430165_D010672_D064420	bcv_easy_596				
	D010672	"<span class=""chemical"">DPH</span>"		D001927	"<span class=""disease"">cerebral damage</span>"	"It is assumed that patients with some <span class=""disease"">cerebral damage</span> are liable to manifest <span class=""chemical"">DPH</span> toxicity as focal neurological signs."		430165	430165_D010672_D001927	bcv_easy_597				
	D010665	"<span class=""chemical"">Phenylpropanolamine/Dexatrim</span>"		D009203	"<span class=""disease"">myocardial infarction</span>"	"Case report: <span class=""chemical"">Dexatrim</span> (<span class=""chemical"">Phenylpropanolamine</span>) as a cause of <span class=""disease"">myocardial infarction</span>."		12734532	12734532_D010665_D009203	bcv_easy_598				
	D010665	"<span class=""chemical"">PPA</span>"		D062787	"<span class=""disease"">overdose</span>"	"Several reports have linked the abuse of <span class=""chemical"">PPA</span> with myocardial injury, especially when <span class=""disease"">overdose</span> is involved."		12734532	12734532_D010665_D062787	bcv_easy_599				
	D005996	"<span class=""chemical"">Glyceryl trinitrate</span>"		D020325	"<span class=""disease"">migraine with aura</span>"	"<span class=""chemical"">Glyceryl trinitrate</span> induces attacks of migraine without aura in sufferers of <span class=""disease"">migraine with aura</span>."		10524660	10524660_D005996_D020325	bcv_easy_600				
	D005996	"<span class=""chemical"">Glyceryl trinitrate</span>"		D020326	"<span class=""disease"">migraine without aura</span>"	"<span class=""chemical"">Glyceryl trinitrate</span> induces attacks of <span class=""disease"">migraine without aura</span> in sufferers of migraine with aura."		10524660	10524660_D005996_D020326	bcv_easy_601				
	D009569	"<span class=""chemical"">nitric oxide/NO</span>"		D010146	"<span class=""disease"">pain</span>"	"In recent years, increasing evidence has suggested that the messenger molecule <span class=""chemical"">nitric oxide</span> (<span class=""chemical"">NO</span>) is involved in <span class=""disease"">pain</span> mechanisms of migraine without aura."		10524660	10524660_D009569_D010146	bcv_easy_602				
	D009569	"<span class=""chemical"">nitric oxide/NO</span>"		D020326	"<span class=""disease"">migraine without aura</span>"	"In recent years, increasing evidence has suggested that the messenger molecule <span class=""chemical"">nitric oxide</span> (<span class=""chemical"">NO</span>) is involved in pain mechanisms of <span class=""disease"">migraine without aura</span>."		10524660	10524660_D009569_D020326	bcv_easy_603				
	D005996	"<span class=""chemical"">glyceryl trinitrate/GTN</span>"		D020325	"<span class=""disease"">migraine with aura</span>"	"In order to clarify whether the same is true for <span class=""disease"">migraine with aura</span>, in the present study we examined the headache response to intravenous infusion of <span class=""chemical"">glyceryl trinitrate</span> (<span class=""chemical"">GTN</span>) (0.5 microg/kg/min for 20 min) in 12 sufferers of <span class=""disease"">migraine with aura</span>."		10524660	10524660_D005996_D020325	bcv_easy_604				
	D005996	"<span class=""chemical"">GTN</span>"		D008881	"<span class=""disease"">migraineurs</span>"	"Headache was more severe in <span class=""disease"">migraineurs</span> than in the controls during and immediately after <span class=""chemical"">GTN</span> infusion (p=0.037) as well as during the following 11 h (p = 0.008)."		10524660	10524660_D005996_D008881	bcv_easy_605				
	D005996	"<span class=""chemical"">GTN</span>"		D008881	"<span class=""disease"">migraineurs</span>"	"In the controls, the <span class=""chemical"">GTN</span>-induced headache gradually disappeared, whereas in <span class=""disease"">migraineurs</span> peak headache intensity occurred at a mean time of 240 min post-infusion."		10524660	10524660_D005996_D008881	bcv_easy_606				
	D009569	"<span class=""chemical"">NO</span>"		D010146	"<span class=""disease"">pain</span>"	"The results therefore suggest that <span class=""chemical"">NO</span> is involved in the <span class=""disease"">pain</span> mechanisms of migraine with aura."		10524660	10524660_D009569_D010146	bcv_easy_607				
	D009569	"<span class=""chemical"">NO</span>"		D020325	"<span class=""disease"">migraine with aura</span>"	"The results therefore suggest that <span class=""chemical"">NO</span> is involved in the pain mechanisms of <span class=""disease"">migraine with aura</span>."		10524660	10524660_D009569_D020325	bcv_easy_608				
	D009569	"<span class=""chemical"">NO</span>"		D003866	"<span class=""disease"">depression</span>"	"Since cortical spreading <span class=""disease"">depression</span> has been shown to liberate <span class=""chemical"">NO</span> in animals, this finding may help our understanding of the coupling between cortical spreading <span class=""disease"">depression</span> and headache in migraine with aura."		10524660	10524660_D009569_D003866	bcv_easy_609				
	D009569	"<span class=""chemical"">NO</span>"		D006261	"<span class=""disease"">headache</span>"	"Since cortical spreading depression has been shown to liberate <span class=""chemical"">NO</span> in animals, this finding may help our understanding of the coupling between cortical spreading depression and <span class=""disease"">headache</span> in migraine with aura."		10524660	10524660_D009569_D006261	bcv_easy_610				
	D009569	"<span class=""chemical"">NO</span>"		D020325	"<span class=""disease"">migraine with aura</span>"	"Since cortical spreading depression has been shown to liberate <span class=""chemical"">NO</span> in animals, this finding may help our understanding of the coupling between cortical spreading depression and headache in <span class=""disease"">migraine with aura</span>."		10524660	10524660_D009569_D020325	bcv_easy_611				
	D020123	"<span class=""chemical"">RAPA</span>"		D064420	"<span class=""disease"">toxicity</span>"	"BACKGROUND: The aim of this study is to evaluate the effects of <span class=""chemical"">RAPA</span> conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) <span class=""disease"">toxicity</span>."		11063349	11063349_D020123_D064420	bcv_easy_612				
	D016572	"<span class=""chemical"">CsA/cyclosporine</span>"		D064420	"<span class=""disease"">toxicity</span>"	"BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing <span class=""chemical"">cyclosporine</span> (<span class=""chemical"">CsA</span>) or tacrolimus (Tac) <span class=""disease"">toxicity</span>."		11063349	11063349_D016572_D064420	bcv_easy_613				
	D016559	"<span class=""chemical"">Tac/tacrolimus</span>"		D064420	"<span class=""disease"">toxicity</span>"	"BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or <span class=""chemical"">tacrolimus</span> (<span class=""chemical"">Tac</span>) <span class=""disease"">toxicity</span>."		11063349	11063349_D016559_D064420	bcv_easy_614				
	D016559	"<span class=""chemical"">Tac</span>"		D056486	"<span class=""disease"">hepatotoxicity</span>"	"The indications for switch were chronic CsA or <span class=""chemical"">Tac</span> nephrotoxicity (12), acute CsA or <span class=""chemical"">Tac</span> toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and <span class=""disease"">hepatotoxicity</span> in 1."		11063349	11063349_D016559_D056486	bcv_easy_615				
	D016572	"<span class=""chemical"">CsA</span>"		D056486	"<span class=""disease"">hepatotoxicity</span>"	"The indications for switch were chronic <span class=""chemical"">CsA</span> or Tac nephrotoxicity (12), acute <span class=""chemical"">CsA</span> or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and <span class=""disease"">hepatotoxicity</span> in 1."		11063349	11063349_D016572_D056486	bcv_easy_616				
	D016572	"<span class=""chemical"">CsA</span>"		D007674	"<span class=""disease"">nephrotoxicity</span>"	"The indications for switch were chronic <span class=""chemical"">CsA</span> or Tac <span class=""disease"">nephrotoxicity</span> (12), acute <span class=""chemical"">CsA</span> or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1."		11063349	11063349_D016572_D007674	bcv_easy_617				
	D016572	"<span class=""chemical"">CsA</span>"		D008232	"<span class=""disease"">PTLD/posttransplant lymphoproliferative disorder</span>"	"The indications for switch were chronic <span class=""chemical"">CsA</span> or Tac nephrotoxicity (12), acute <span class=""chemical"">CsA</span> or Tac toxicity (3), severe facial dysmorphism (2), <span class=""disease"">posttransplant lymphoproliferative disorder</span> (<span class=""disease"">PTLD</span>) in remission (2), and hepatotoxicity in 1."		11063349	11063349_D016572_D008232	bcv_easy_618				
	D016572	"<span class=""chemical"">CsA</span>"		D064420	"<span class=""disease"">toxicity</span>"	"The indications for switch were chronic <span class=""chemical"">CsA</span> or Tac nephrotoxicity (12), acute <span class=""chemical"">CsA</span> or Tac <span class=""disease"">toxicity</span> (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1."		11063349	11063349_D016572_D064420	bcv_easy_619				
	D016559	"<span class=""chemical"">Tac</span>"		D064420	"<span class=""disease"">toxicity</span>"	"The indications for switch were chronic CsA or <span class=""chemical"">Tac</span> nephrotoxicity (12), acute CsA or <span class=""chemical"">Tac</span> <span class=""disease"">toxicity</span> (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1."		11063349	11063349_D016559_D064420	bcv_easy_620				
	D016559	"<span class=""chemical"">Tac</span>"		D008232	"<span class=""disease"">PTLD/posttransplant lymphoproliferative disorder</span>"	"The indications for switch were chronic CsA or <span class=""chemical"">Tac</span> nephrotoxicity (12), acute CsA or <span class=""chemical"">Tac</span> toxicity (3), severe facial dysmorphism (2), <span class=""disease"">posttransplant lymphoproliferative disorder</span> (<span class=""disease"">PTLD</span>) in remission (2), and hepatotoxicity in 1."		11063349	11063349_D016559_D008232	bcv_easy_621				
	D016559	"<span class=""chemical"">Tac</span>"		D007674	"<span class=""disease"">nephrotoxicity</span>"	"The indications for switch were chronic CsA or <span class=""chemical"">Tac</span> <span class=""disease"">nephrotoxicity</span> (12), acute CsA or <span class=""chemical"">Tac</span> toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1."		11063349	11063349_D016559_D007674	bcv_easy_622				
	D003404	"<span class=""chemical"">creatinine</span>"		D007674	"<span class=""disease"">nephrotoxicity</span>"	"RESULTS: In the 12 patients switched because of chronic <span class=""disease"">nephrotoxicity</span> there was a significant decrease in serum <span class=""chemical"">creatinine</span> [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months]."		11063349	11063349_D003404_D007674	bcv_easy_623				
	D020123	"<span class=""chemical"">RAPA</span>"		D008232	"<span class=""disease"">PTLD</span>"	"<span class=""chemical"">RAPA</span> was discontinued in four patients, because of pneumonia in two, <span class=""disease"">PTLD</span> in one, and oral aphtous ulcers in one."		11063349	11063349_D020123_D008232	bcv_easy_624				
	D020123	"<span class=""chemical"">RAPA</span>"		D013281	"<span class=""disease"">aphtous ulcers</span>"	"<span class=""chemical"">RAPA</span> was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral <span class=""disease"">aphtous ulcers</span> in one."		11063349	11063349_D020123_D013281	bcv_easy_625				
	D020123	"<span class=""chemical"">RAPA</span>"		D011014	"<span class=""disease"">pneumonia</span>"	"<span class=""chemical"">RAPA</span> was discontinued in four patients, because of <span class=""disease"">pneumonia</span> in two, PTLD in one, and oral aphtous ulcers in one."		11063349	11063349_D020123_D011014	bcv_easy_626				
	D020123	"<span class=""chemical"">RAPA</span>"		D011020	"<span class=""disease"">Pneumocystis carinii pneumonia</span>"	"However, when converting patients to <span class=""chemical"">RAPA</span> drug levels should be monitored to avoid over-immunosuppression and adequate antiviral and <span class=""disease"">Pneumocystis carinii pneumonia</span> prophylaxis should be given."		11063349	11063349_D020123_D011020	bcv_easy_627				
	D018021	"<span class=""chemical"">LiCl</span>"		D012640	"<span class=""disease"">seizures</span>"	"Tacrine, administered in <span class=""chemical"">LiCl</span> pre-treated rats, induces electrocorticographic <span class=""disease"">seizures</span> and delayed hippocampal damage."		19944736	19944736_D018021_D012640	bcv_easy_628				
	D013619	"<span class=""chemical"">Tacrine</span>"		D012640	"<span class=""disease"">seizures</span>"	"<span class=""chemical"">Tacrine</span>, administered in LiCl pre-treated rats, induces electrocorticographic <span class=""disease"">seizures</span> and delayed hippocampal damage."		19944736	19944736_D013619_D012640	bcv_easy_629				
	D013619	"<span class=""chemical"">Tacrine</span>"		D001930	"<span class=""disease"">hippocampal damage</span>"	"<span class=""chemical"">Tacrine</span>, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed <span class=""disease"">hippocampal damage</span>."		19944736	19944736_D013619_D001930	bcv_easy_630				
	D018021	"<span class=""chemical"">LiCl</span>"		D001930	"<span class=""disease"">hippocampal damage</span>"	"Tacrine, administered in <span class=""chemical"">LiCl</span> pre-treated rats, induces electrocorticographic seizures and delayed <span class=""disease"">hippocampal damage</span>."		19944736	19944736_D018021_D001930	bcv_easy_631				
	D013619	"<span class=""chemical"">tacrine</span>"		D004827	"<span class=""disease"">epileptic</span>"	"All the animals treated with <span class=""chemical"">tacrine</span>-loaded nanoparticles showed an earlier outcome of CNS adverse symptoms, i.e. <span class=""disease"">epileptic</span> onset, with respect to those animals treated with the free compound (10 min vs. 22 min respectively)."		19944736	19944736_D013619_D004827	bcv_easy_632				
	D013619	"<span class=""chemical"">tacrine</span>"		D001930	"<span class=""disease"">damage of neuronal cells</span>"	"In addition, <span class=""chemical"">tacrine</span>-loaded nanoparticles administration induced <span class=""disease"">damage of neuronal cells</span> in CA1 field of the hippocampus in all treated animals, while the saline solution of <span class=""chemical"">tacrine</span> only in 60% of animals."		19944736	19944736_D013619_D001930	bcv_easy_633				
	D008094	"<span class=""chemical"">lithium</span>"		D004827	"<span class=""disease"">epilepsy</span>"	"In conclusion, the evaluation of time-to-onset of symptoms and the severity of neurodegenerative processes induced by the tacrine-<span class=""chemical"">lithium</span> model of <span class=""disease"">epilepsy</span> in the rat, could be used to evaluate preliminarily the capability of a drug delivery system to trespass (or not) the BBB in vivo."		19944736	19944736_D008094_D004827	bcv_easy_634				
	D013619	"<span class=""chemical"">tacrine</span>"		D004827	"<span class=""disease"">epilepsy</span>"	"In conclusion, the evaluation of time-to-onset of symptoms and the severity of neurodegenerative processes induced by the <span class=""chemical"">tacrine</span>-lithium model of <span class=""disease"">epilepsy</span> in the rat, could be used to evaluate preliminarily the capability of a drug delivery system to trespass (or not) the BBB in vivo."		19944736	19944736_D013619_D004827	bcv_easy_635				
	D000082	"<span class=""chemical"">paracetamol</span>"		D014581	"<span class=""disease"">urticaria</span>"	"Tolerability of nimesulide and <span class=""chemical"">paracetamol</span> in patients with NSAID-induced <span class=""disease"">urticaria</span>/angioedema."		11694026	11694026_D000082_D014581	bcv_easy_636				
	C012655	"<span class=""chemical"">nimesulide</span>"		D014581	"<span class=""disease"">urticaria</span>"	"Tolerability of <span class=""chemical"">nimesulide</span> and paracetamol in patients with NSAID-induced <span class=""disease"">urticaria</span>/angioedema."		11694026	11694026_C012655_D014581	bcv_easy_637				
	D000082	"<span class=""chemical"">paracetamol</span>"		D000799	"<span class=""disease"">angioedema</span>"	"Tolerability of nimesulide and <span class=""chemical"">paracetamol</span> in patients with NSAID-induced urticaria/<span class=""disease"">angioedema</span>."		11694026	11694026_D000082_D000799	bcv_easy_638				
	C012655	"<span class=""chemical"">nimesulide</span>"		D000799	"<span class=""disease"">angioedema</span>"	"Tolerability of <span class=""chemical"">nimesulide</span> and paracetamol in patients with NSAID-induced urticaria/<span class=""disease"">angioedema</span>."		11694026	11694026_C012655_D000799	bcv_easy_639				
	D000082	"<span class=""chemical"">paracetamol</span>"		D014581	"<span class=""disease"">urticaria</span>"	"In this study we investigated tolerability and reliability of nimesulide and <span class=""chemical"">paracetamol</span> in a very large number of patients with an exclusive well-documented history of NSAID-induced <span class=""disease"">urticaria</span>/angioedema."		11694026	11694026_D000082_D014581	bcv_easy_640				
	C012655	"<span class=""chemical"">nimesulide</span>"		D014581	"<span class=""disease"">urticaria</span>"	"In this study we investigated tolerability and reliability of <span class=""chemical"">nimesulide</span> and paracetamol in a very large number of patients with an exclusive well-documented history of NSAID-induced <span class=""disease"">urticaria</span>/angioedema."		11694026	11694026_C012655_D014581	bcv_easy_641				
	D000082	"<span class=""chemical"">paracetamol</span>"		D000799	"<span class=""disease"">angioedema</span>"	"In this study we investigated tolerability and reliability of nimesulide and <span class=""chemical"">paracetamol</span> in a very large number of patients with an exclusive well-documented history of NSAID-induced urticaria/<span class=""disease"">angioedema</span>."		11694026	11694026_D000082_D000799	bcv_easy_642				
	C012655	"<span class=""chemical"">nimesulide</span>"		D000799	"<span class=""disease"">angioedema</span>"	"In this study we investigated tolerability and reliability of <span class=""chemical"">nimesulide</span> and paracetamol in a very large number of patients with an exclusive well-documented history of NSAID-induced urticaria/<span class=""disease"">angioedema</span>."		11694026	11694026_C012655_D000799	bcv_easy_643				
	D000082	"<span class=""chemical"">paracetamol</span>"		D014581	"<span class=""disease"">urticaria</span>"	"A single-placebo-controlled oral challenge procedure with nimesulide or <span class=""chemical"">paracetamol</span> was applied to 829 patients with a history of NSAID-induced <span class=""disease"">urticaria</span>/angioedema."		11694026	11694026_D000082_D014581	bcv_easy_644				
	C012655	"<span class=""chemical"">nimesulide</span>"		D014581	"<span class=""disease"">urticaria</span>"	"A single-placebo-controlled oral challenge procedure with <span class=""chemical"">nimesulide</span> or paracetamol was applied to 829 patients with a history of NSAID-induced <span class=""disease"">urticaria</span>/angioedema."		11694026	11694026_C012655_D014581	bcv_easy_645				
	D000082	"<span class=""chemical"">paracetamol</span>"		D000799	"<span class=""disease"">angioedema</span>"	"A single-placebo-controlled oral challenge procedure with nimesulide or <span class=""chemical"">paracetamol</span> was applied to 829 patients with a history of NSAID-induced urticaria/<span class=""disease"">angioedema</span>."		11694026	11694026_D000082_D000799	bcv_easy_646				
	C012655	"<span class=""chemical"">nimesulide</span>"		D000799	"<span class=""disease"">angioedema</span>"	"A single-placebo-controlled oral challenge procedure with <span class=""chemical"">nimesulide</span> or paracetamol was applied to 829 patients with a history of NSAID-induced urticaria/<span class=""disease"">angioedema</span>."		11694026	11694026_C012655_D000799	bcv_easy_647				
	D000082	"<span class=""chemical"">paracetamol</span>"		D014581	"<span class=""disease"">urticaria</span>"	"Taken together, our results confirm the good tolerability of nimesulide and <span class=""chemical"">paracetamol</span> in patients who experienced <span class=""disease"">urticaria</span>/angioedema caused by NSAIDs."		11694026	11694026_D000082_D014581	bcv_easy_648				
	C012655	"<span class=""chemical"">nimesulide</span>"		D014581	"<span class=""disease"">urticaria</span>"	"Taken together, our results confirm the good tolerability of <span class=""chemical"">nimesulide</span> and paracetamol in patients who experienced <span class=""disease"">urticaria</span>/angioedema caused by NSAIDs."		11694026	11694026_C012655_D014581	bcv_easy_649				
	D000082	"<span class=""chemical"">paracetamol</span>"		D000799	"<span class=""disease"">angioedema</span>"	"Taken together, our results confirm the good tolerability of nimesulide and <span class=""chemical"">paracetamol</span> in patients who experienced urticaria/<span class=""disease"">angioedema</span> caused by NSAIDs."		11694026	11694026_D000082_D000799	bcv_easy_650				
	C012655	"<span class=""chemical"">nimesulide</span>"		D000799	"<span class=""disease"">angioedema</span>"	"Taken together, our results confirm the good tolerability of <span class=""chemical"">nimesulide</span> and paracetamol in patients who experienced urticaria/<span class=""disease"">angioedema</span> caused by NSAIDs."		11694026	11694026_C012655_D000799	bcv_easy_651				
	D004997	"<span class=""chemical"">ethinylestradiol</span>"		D054556	"<span class=""disease"">venous thromboembolism</span>"	"Absolute and attributable risk of <span class=""disease"">venous thromboembolism</span> in women on combined cyproterone acetate and <span class=""chemical"">ethinylestradiol</span>."		12851669	12851669_D004997_D054556	bcv_easy_652				
	D017373	"<span class=""chemical"">cyproterone acetate</span>"		D054556	"<span class=""disease"">venous thromboembolism</span>"	"Absolute and attributable risk of <span class=""disease"">venous thromboembolism</span> in women on combined <span class=""chemical"">cyproterone acetate</span> and ethinylestradiol."		12851669	12851669_D017373_D054556	bcv_easy_653				
	D003277	"<span class=""chemical"">combined oral contraceptives/COCs</span>"		D054556	"<span class=""disease"">venous thromboembolism/VTE</span>"	"OBJECTIVE: To achieve absolute risk estimates of <span class=""disease"">venous thromboembolism</span> (<span class=""disease"">VTE</span>) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on <span class=""chemical"">combined oral contraceptives</span> (<span class=""chemical"">COCs</span>)."		12851669	12851669_D003277_D054556	bcv_easy_654				
	D004997	"<span class=""chemical"">EE/ethinylestradiol</span>"		D054556	"<span class=""disease"">venous thromboembolism/VTE</span>"	"OBJECTIVE: To achieve absolute risk estimates of <span class=""disease"">venous thromboembolism</span> (<span class=""disease"">VTE</span>) among women on cyproterone acetate plus <span class=""chemical"">ethinylestradiol</span> (CPA/<span class=""chemical"">EE</span>), and among women on combined oral contraceptives (COCs)."		12851669	12851669_D004997_D054556	bcv_easy_655				
	D017373	"<span class=""chemical"">CPA/cyproterone acetate</span>"		D054556	"<span class=""disease"">venous thromboembolism/VTE</span>"	"OBJECTIVE: To achieve absolute risk estimates of <span class=""disease"">venous thromboembolism</span> (<span class=""disease"">VTE</span>) among women on <span class=""chemical"">cyproterone acetate</span> plus ethinylestradiol (<span class=""chemical"">CPA</span>/EE), and among women on combined oral contraceptives (COCs)."		12851669	12851669_D017373_D054556	bcv_easy_656				
	D003277	"<span class=""chemical"">COCs</span>"		D054556	"<span class=""disease"">VTE</span>"	"RESULTS: During the time frame of the study, 330 women were found to have had <span class=""disease"">VTE</span> while on <span class=""chemical"">COCs</span>."		12851669	12851669_D003277_D054556	bcv_easy_657				
	D017373	"<span class=""chemical"">CPA</span>"		D054556	"<span class=""disease"">VTE</span>"	"The corresponding absolute risk of <span class=""disease"">VTE</span> was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on <span class=""chemical"">CPA</span>/EE."		12851669	12851669_D017373_D054556	bcv_easy_658				
	D016912	"<span class=""chemical"">levonorgestrel</span>"		D054556	"<span class=""disease"">VTE</span>"	"The corresponding absolute risk of <span class=""disease"">VTE</span> was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on <span class=""chemical"">levonorgestrel</span>-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/EE."		12851669	12851669_D016912_D054556	bcv_easy_659				
	D003277	"<span class=""chemical"">COCs</span>"		D054556	"<span class=""disease"">VTE</span>"	"The corresponding absolute risk of <span class=""disease"">VTE</span> was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on <span class=""chemical"">COCs</span>, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing <span class=""chemical"">COCs</span>, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/EE."		12851669	12851669_D003277_D054556	bcv_easy_660				
	D004997	"<span class=""chemical"">EE</span>"		D054556	"<span class=""disease"">VTE</span>"	"The corresponding absolute risk of <span class=""disease"">VTE</span> was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/<span class=""chemical"">EE</span>."		12851669	12851669_D004997_D054556	bcv_easy_661				
	D017373	"<span class=""chemical"">CPA</span>"		D054556	"<span class=""disease"">VTE</span>"	"CONCLUSION: Our results suggest the absolute risk of <span class=""disease"">VTE</span> among Danish women on COCs is similar to that among women taking <span class=""chemical"">CPA</span>/EE."		12851669	12851669_D017373_D054556	bcv_easy_662				
	D004997	"<span class=""chemical"">EE</span>"		D054556	"<span class=""disease"">VTE</span>"	"CONCLUSION: Our results suggest the absolute risk of <span class=""disease"">VTE</span> among Danish women on COCs is similar to that among women taking CPA/<span class=""chemical"">EE</span>."		12851669	12851669_D004997_D054556	bcv_easy_663				
	D003277	"<span class=""chemical"">COCs</span>"		D054556	"<span class=""disease"">VTE</span>"	"CONCLUSION: Our results suggest the absolute risk of <span class=""disease"">VTE</span> among Danish women on <span class=""chemical"">COCs</span> is similar to that among women taking CPA/EE."		12851669	12851669_D003277_D054556	bcv_easy_664				
	D011718	"<span class=""chemical"">pyrazinamide</span>"		D000857	"<span class=""disease"">dysosmia</span>"	"Recurrent <span class=""disease"">dysosmia</span> induced by <span class=""chemical"">pyrazinamide</span>."		19674115	19674115_D011718_D000857	bcv_easy_665				
	D011718	"<span class=""chemical"">Pyrazinamide</span>"		D033461	"<span class=""disease"">hyperuricemia</span>"	"<span class=""chemical"">Pyrazinamide</span> can have adverse effects such as hepatic toxicity, <span class=""disease"">hyperuricemia</span> or digestive disorders."		19674115	19674115_D011718_D033461	bcv_easy_666				
	D011718	"<span class=""chemical"">Pyrazinamide</span>"		D056486	"<span class=""disease"">hepatic toxicity</span>"	"<span class=""chemical"">Pyrazinamide</span> can have adverse effects such as <span class=""disease"">hepatic toxicity</span>, hyperuricemia or digestive disorders."		19674115	19674115_D011718_D056486	bcv_easy_667				
	D011718	"<span class=""chemical"">pyrazinamide</span>"		D000857	"<span class=""disease"">olfactory disorder</span>"	"We report a case of reversible <span class=""disease"">olfactory disorder</span> related to <span class=""chemical"">pyrazinamide</span> in a woman, with a positive rechallenge."		19674115	19674115_D011718_D000857	bcv_easy_668				
	D011718	"<span class=""chemical"">pyrazinamide</span>"		D000857	"<span class=""disease"">Dysosmia</span>"	"<span class=""disease"">Dysosmia</span> disappeared completely after <span class=""chemical"">pyrazinamide</span> withdrawal and recurred after its rechallenge."		19674115	19674115_D011718_D000857	bcv_easy_669				
	D008625	"<span class=""chemical"">Tiopronin</span>"		D009393	"<span class=""disease"">nephritis</span>"	"A strong association has been found between <span class=""disease"">nephritis</span> and dermatitis due to <span class=""chemical"">Tiopronin</span> (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35."		3084782	3084782_D008625_D009393	bcv_easy_670				
	D010396	"<span class=""chemical"">D-Penicillamine</span>"		D009393	"<span class=""disease"">nephritis</span>"	"A strong association has been found between <span class=""disease"">nephritis</span> and dermatitis due to Tiopronin (a <span class=""chemical"">D-Penicillamine</span> like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35."		3084782	3084782_D010396_D009393	bcv_easy_671				
	D010396	"<span class=""chemical"">D-Penicillamine</span>"		D003872	"<span class=""disease"">dermatitis</span>"	"A strong association has been found between nephritis and <span class=""disease"">dermatitis</span> due to Tiopronin (a <span class=""chemical"">D-Penicillamine</span> like compound) and class I antigens B35-Cw4, and between <span class=""disease"">dermatitis</span> due to gold thiosulphate and B35."		3084782	3084782_D010396_D003872	bcv_easy_672				
	D008625	"<span class=""chemical"">Tiopronin</span>"		D003872	"<span class=""disease"">dermatitis</span>"	"A strong association has been found between nephritis and <span class=""disease"">dermatitis</span> due to <span class=""chemical"">Tiopronin</span> (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between <span class=""disease"">dermatitis</span> due to gold thiosulphate and B35."		3084782	3084782_D008625_D003872	bcv_easy_673				
	D006046	"<span class=""chemical"">gold</span>"		D009393	"<span class=""disease"">nephritis</span>"	"A strong association has been found between <span class=""disease"">nephritis</span> and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to <span class=""chemical"">gold</span> thiosulphate and B35."		3084782	3084782_D006046_D009393	bcv_easy_674				
	D006046	"<span class=""chemical"">gold</span>"		D003872	"<span class=""disease"">dermatitis</span>"	"A strong association has been found between nephritis and <span class=""disease"">dermatitis</span> due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between <span class=""disease"">dermatitis</span> due to <span class=""chemical"">gold</span> thiosulphate and B35."		3084782	3084782_D006046_D003872	bcv_easy_675				
	D008625	"<span class=""chemical"">Tiopronin</span>"		D009393	"<span class=""disease"">nephritis</span>"	"Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the <span class=""chemical"">Tiopronin</span> related <span class=""disease"">nephritis</span> group."		3084782	3084782_D008625_D009393	bcv_easy_676				
	D008625	"<span class=""chemical"">Tiopronin</span>"		D001172	"<span class=""disease"">RA</span>"	"Compared to healthy controls a lower DR5 frequency was observed in patients with <span class=""disease"">RA</span> except for the <span class=""chemical"">Tiopronin</span> related nephritis group."		3084782	3084782_D008625_D001172	bcv_easy_677				
	D064704	"<span class=""chemical"">levofloxacin</span>"		D012852	"<span class=""disease"">sinusitis</span>"	"Open-label assessment of <span class=""chemical"">levofloxacin</span> for the treatment of acute bacterial <span class=""disease"">sinusitis</span> in adults."		9564988	9564988_D064704_D012852	bcv_easy_678				
	D064704	"<span class=""chemical"">levofloxacin</span>"		D012852	"<span class=""disease"">sinusitis</span>"	"PURPOSE: To evaluate the efficacy and safety of <span class=""chemical"">levofloxacin</span> (500 mg orally once daily for 10 to 14 days) in treating adult outpatients with acute bacterial <span class=""disease"">sinusitis</span>."		9564988	9564988_D064704_D012852	bcv_easy_679				
	D064704	"<span class=""chemical"">levofloxacin</span>"		D012852	"<span class=""disease"">sinusitis</span>"	"CONCLUSION: The results of this study indicate that <span class=""chemical"">levofloxacin</span> 500 mg once daily is an effective and safe treatment for acute bacterial <span class=""disease"">sinusitis</span>."		9564988	9564988_D064704_D012852	bcv_easy_680				
	D002220	"<span class=""chemical"">carbamazepine</span>"		D012640	"<span class=""disease"">seizures</span>"	"Chronic <span class=""chemical"">carbamazepine</span> inhibits the development of local anesthetic <span class=""disease"">seizures</span> kindled by cocaine and lidocaine."		2790457	2790457_D002220_D012640	bcv_easy_681				
	D008012	"<span class=""chemical"">lidocaine</span>"		D012640	"<span class=""disease"">seizures</span>"	"Chronic carbamazepine inhibits the development of local anesthetic <span class=""disease"">seizures</span> kindled by cocaine and <span class=""chemical"">lidocaine</span>."		2790457	2790457_D008012_D012640	bcv_easy_682				
	D002220	"<span class=""chemical"">CBZ/carbamazepine</span>"		D012640	"<span class=""disease"">seizures</span>"	"The effects of <span class=""chemical"">carbamazepine</span> (<span class=""chemical"">CBZ</span>) treatment on local anesthetic-kindled <span class=""disease"">seizures</span> and lethality were evaluated in different stages of the kindling process and under different methods of <span class=""chemical"">CBZ</span> administration."		2790457	2790457_D002220_D012640	bcv_easy_683				
	D002220	"<span class=""chemical"">CBZ</span>"		D012640	"<span class=""disease"">seizures</span>"	"Chronic oral <span class=""chemical"">CBZ</span> inhibited the development of both lidocaine- and cocaine-induced <span class=""disease"">seizures</span>, but had little effect on the fully developed local anesthetic <span class=""disease"">seizures</span>."		2790457	2790457_D002220_D012640	bcv_easy_684				
	D008012	"<span class=""chemical"">lidocaine</span>"		D012640	"<span class=""disease"">seizures</span>"	"Chronic oral CBZ inhibited the development of both <span class=""chemical"">lidocaine</span>- and cocaine-induced <span class=""disease"">seizures</span>, but had little effect on the fully developed local anesthetic <span class=""disease"">seizures</span>."		2790457	2790457_D008012_D012640	bcv_easy_685				
	D002220	"<span class=""chemical"">CBZ</span>"		D012640	"<span class=""disease"">seizure</span>"	"Chronic <span class=""chemical"">CBZ</span> also decreased the incidence of <span class=""disease"">seizure</span>-related mortality in the cocaine-injected rats."		2790457	2790457_D002220_D012640	bcv_easy_686				
	D002220	"<span class=""chemical"">CBZ</span>"		D012640	"<span class=""disease"">seizures</span>"	"Acute <span class=""chemical"">CBZ</span> over a range of doses (15-50 mg/kg) had no effect on completed lidocaine-kindled or acute cocaine-induced <span class=""disease"">seizures</span>."		2790457	2790457_D002220_D012640	bcv_easy_687				
	D008012	"<span class=""chemical"">lidocaine</span>"		D012640	"<span class=""disease"">seizures</span>"	"Acute CBZ over a range of doses (15-50 mg/kg) had no effect on completed <span class=""chemical"">lidocaine</span>-kindled or acute cocaine-induced <span class=""disease"">seizures</span>."		2790457	2790457_D008012_D012640	bcv_easy_688				
	D002220	"<span class=""chemical"">CBZ</span>"		D012640	"<span class=""disease"">seizures</span>"	"Repeated i.p. injection of <span class=""chemical"">CBZ</span> (15 mg/kg) also was without effect on the development of lidocaine- or cocaine-kindled <span class=""disease"">seizures</span>."		2790457	2790457_D002220_D012640	bcv_easy_689				
	D008012	"<span class=""chemical"">lidocaine</span>"		D012640	"<span class=""disease"">seizures</span>"	"Repeated i.p. injection of CBZ (15 mg/kg) also was without effect on the development of <span class=""chemical"">lidocaine</span>- or cocaine-kindled <span class=""disease"">seizures</span>."		2790457	2790457_D008012_D012640	bcv_easy_690				
	D002220	"<span class=""chemical"">CBZ</span>"		D012640	"<span class=""disease"">seizures/seizure</span>"	"The differential effects of <span class=""chemical"">CBZ</span> depending upon stage of <span class=""disease"">seizure</span> development suggest that distinct mechanisms underlie the development versus maintenance of local anesthetic-kindled <span class=""disease"">seizures</span>."		2790457	2790457_D002220_D012640	bcv_easy_691				
	D003520	"<span class=""chemical"">CYP</span>"		D001745	"<span class=""disease"">bladder inflammation</span>"	"The data suggest that in VIP(-/-) mice with <span class=""disease"">bladder inflammation</span>, inflammatory mediators are increased above that observed in WT with <span class=""chemical"">CYP</span>."		18483878	18483878_D003520_D001745	bcv_easy_692				
	D000583	"<span class=""chemical"">amikacin</span>"		D007674	"<span class=""disease"">nephrotoxicity</span>"	"An evaluation of <span class=""chemical"">amikacin</span> <span class=""disease"">nephrotoxicity</span> in the hematology/oncology population."		18356633	18356633_D000583_D007674	bcv_easy_693				
	D000583	"<span class=""chemical"">Amikacin</span>"		D009503	"<span class=""disease"">febrile neutropenia</span>"	"<span class=""chemical"">Amikacin</span> is an aminoglycoside commonly used to provide empirical double gram-negative treatment for <span class=""disease"">febrile neutropenia</span> and other suspected infections."		18356633	18356633_D000583_D009503	bcv_easy_694				
	D000617	"<span class=""chemical"">aminoglycoside</span>"		D009503	"<span class=""disease"">febrile neutropenia</span>"	"Amikacin is an <span class=""chemical"">aminoglycoside</span> commonly used to provide empirical double gram-negative treatment for <span class=""disease"">febrile neutropenia</span> and other suspected infections."		18356633	18356633_D000617_D009503	bcv_easy_695				
	D000617	"<span class=""chemical"">aminoglycoside</span>"		D007239	"<span class=""disease"">infections</span>"	"Amikacin is an <span class=""chemical"">aminoglycoside</span> commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected <span class=""disease"">infections</span>."		18356633	18356633_D000617_D007239	bcv_easy_696				
	D000583	"<span class=""chemical"">Amikacin</span>"		D007239	"<span class=""disease"">infections</span>"	"<span class=""chemical"">Amikacin</span> is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected <span class=""disease"">infections</span>."		18356633	18356633_D000583_D007239	bcv_easy_697				
	D000583	"<span class=""chemical"">amikacin</span>"		D007674	"<span class=""disease"">nephrotoxicity</span>"	"To evaluate <span class=""chemical"">amikacin</span>-associated <span class=""disease"">nephrotoxicity</span> in an adult hematology/oncology population, a prospective, randomized, open-label trial was conducted at a university-affiliated medical center."		18356633	18356633_D000583_D007674	bcv_easy_698				
	D000617	"<span class=""chemical"">aminoglycoside</span>"		D006402|D009369	"<span class=""disease"">hematologic/oncologic disorder</span>"	"Forty patients with a diagnosis consistent with a <span class=""disease"">hematologic/oncologic disorder</span> that required treatment with an <span class=""chemical"">aminoglycoside</span> were randomized to either conventional or extended-interval amikacin."		18356633	18356633_D000617_D006402|D009369	bcv_easy_699				
	D000583	"<span class=""chemical"">amikacin</span>"		D006402|D009369	"<span class=""disease"">hematologic/oncologic disorder</span>"	"Forty patients with a diagnosis consistent with a <span class=""disease"">hematologic/oncologic disorder</span> that required treatment with an aminoglycoside were randomized to either conventional or extended-interval <span class=""chemical"">amikacin</span>."		18356633	18356633_D000583_D006402|D009369	bcv_easy_700				
	D003404	"<span class=""chemical"">creatinine</span>"		D007674	"<span class=""disease"">nephrotoxicity</span>"	"The occurrence of <span class=""disease"">nephrotoxicity</span> by means of an increase in serum <span class=""chemical"">creatinine</span> and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed."		18356633	18356633_D003404_D007674	bcv_easy_701				
	D000583	"<span class=""chemical"">amikacin</span>"		D007674	"<span class=""disease"">nephrotoxicity</span>"	"The occurrence of <span class=""disease"">nephrotoxicity</span> by means of an increase in serum creatinine and evaluation of efficacy via <span class=""chemical"">amikacin</span> serum concentrations with respective pathogens were assessed."		18356633	18356633_D000583_D007674	bcv_easy_702				
	D002119	"<span class=""chemical"">Calcium carbonate</span>"		D064420	"<span class=""disease"">toxicity</span>"	"<span class=""chemical"">Calcium carbonate</span> <span class=""disease"">toxicity</span>: the updated milk-alkali syndrome; report of 3 cases and review of the literature."		16006300	16006300_D002119_D064420	bcv_easy_703				
	D002118	"<span class=""chemical"">calcium</span>"		D006934	"<span class=""disease"">milk-alkali syndrome/hypercalcemia</span>"	"METHODS: We report the clinical and laboratory data in 3 patients who presented with severe <span class=""disease"">hypercalcemia</span> (corrected serum <span class=""chemical"">calcium</span> > or = 14 mg/dL) and review the pertinent literature on <span class=""disease"">milk-alkali syndrome</span>."		16006300	16006300_D002118_D006934	bcv_easy_704				
	C097949	"<span class=""chemical"">1,25-dihydroxyvitamin D</span>"		D058186	"<span class=""disease"">acute renal insufficiency</span>"	"RESULTS: The 3 patients had <span class=""disease"">acute renal insufficiency</span>, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and <span class=""chemical"">1,25-dihydroxyvitamin D</span> concentrations."		16006300	16006300_C097949_D058186	bcv_easy_705				
	C097949	"<span class=""chemical"">1,25-dihydroxyvitamin D</span>"		D000471	"<span class=""disease"">metabolic alkalosis</span>"	"RESULTS: The 3 patients had acute renal insufficiency, relative <span class=""disease"">metabolic alkalosis</span>, and low parathyroid hormone (PTH), PTH-related peptide, and <span class=""chemical"">1,25-dihydroxyvitamin D</span> concentrations."		16006300	16006300_C097949_D000471	bcv_easy_706				
	C019248	"<span class=""chemical"">pamidronate</span>"		D006996	"<span class=""disease"">hypocalcemia</span>"	"The 2 patients with the higher serum calcium concentrations received <span class=""chemical"">pamidronate</span> intravenously (60 and 30 mg, respectively), which caused severe <span class=""disease"">hypocalcemia</span>."		16006300	16006300_C019248_D006996	bcv_easy_707				
	D002118	"<span class=""chemical"">calcium</span>"		D006996	"<span class=""disease"">hypocalcemia</span>"	"The 2 patients with the higher serum <span class=""chemical"">calcium</span> concentrations received pamidronate intravenously (60 and 30 mg, respectively), which caused severe <span class=""disease"">hypocalcemia</span>."		16006300	16006300_D002118_D006996	bcv_easy_708				
	C019248	"<span class=""chemical"">Pamidronate</span>"		D006996	"<span class=""disease"">hypocalcemia</span>"	"<span class=""chemical"">Pamidronate</span> treatment is associated with considerable risk for <span class=""disease"">hypocalcemia</span>, even in cases of initially severe hypercalcemia."		16006300	16006300_C019248_D006996	bcv_easy_709				
	C019248	"<span class=""chemical"">Pamidronate</span>"		D006934	"<span class=""disease"">hypercalcemia</span>"	"<span class=""chemical"">Pamidronate</span> treatment is associated with considerable risk for hypocalcemia, even in cases of initially severe <span class=""disease"">hypercalcemia</span>."		16006300	16006300_C019248_D006934	bcv_easy_710				
	D010634	"<span class=""chemical"">phenobarbital</span>"		D063646	"<span class=""disease"">carcinogenic</span>"	"Anti-<span class=""disease"">carcinogenic</span> action of <span class=""chemical"">phenobarbital</span> given simultaneously with diethylnitrosamine in the rat."		3780814	3780814_D010634_D063646	bcv_easy_711				
	D004052	"<span class=""chemical"">diethylnitrosamine</span>"		D063646	"<span class=""disease"">carcinogenic</span>"	"Anti-<span class=""disease"">carcinogenic</span> action of phenobarbital given simultaneously with <span class=""chemical"">diethylnitrosamine</span> in the rat."		3780814	3780814_D004052_D063646	bcv_easy_712				
	D010634	"<span class=""chemical"">PB/phenobarbital</span>"		D063646	"<span class=""disease"">carcinogenesis</span>"	"The present work has been planned in order to elucidate the effect of <span class=""chemical"">phenobarbital</span> (<span class=""chemical"">PB</span>: 15 mg per rat of ingested dose) on <span class=""disease"">carcinogenesis</span> when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day)."		3780814	3780814_D010634_D063646	bcv_easy_713				
	D004052	"<span class=""chemical"">diethylnitrosamine/DEN</span>"		D063646	"<span class=""disease"">carcinogenesis</span>"	"The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on <span class=""disease"">carcinogenesis</span> when it is administered simultaneously with <span class=""chemical"">diethylnitrosamine</span> (<span class=""chemical"">DEN</span>: 10 mg/kg/day)."		3780814	3780814_D004052_D063646	bcv_easy_714				
	D010634	"<span class=""chemical"">PB</span>"		D063646	"<span class=""disease"">hepatocarcinogenesis</span>"	"Wistar rats (180 g) were treated by DEN alone or by DEN + <span class=""chemical"">PB</span> during 2, 4 and 6 weeks according to our schedule for <span class=""disease"">hepatocarcinogenesis</span>."		3780814	3780814_D010634_D063646	bcv_easy_715				
	D004052	"<span class=""chemical"">DEN</span>"		D063646	"<span class=""disease"">hepatocarcinogenesis</span>"	"Wistar rats (180 g) were treated by <span class=""chemical"">DEN</span> alone or by <span class=""chemical"">DEN</span> + PB during 2, 4 and 6 weeks according to our schedule for <span class=""disease"">hepatocarcinogenesis</span>."		3780814	3780814_D004052_D063646	bcv_easy_716				
	D010634	"<span class=""chemical"">PB</span>"		D011230	"<span class=""disease"">preneoplastic foci</span>"	"After the end of the treatment, the number and the size of induced PAS positive <span class=""disease"">preneoplastic foci</span> was significantly reduced when <span class=""chemical"">PB</span> was given simultaneously with DEN for 4 and 6 weeks."		3780814	3780814_D010634_D011230	bcv_easy_717				
	D004052	"<span class=""chemical"">DEN</span>"		D011230	"<span class=""disease"">preneoplastic foci</span>"	"After the end of the treatment, the number and the size of induced PAS positive <span class=""disease"">preneoplastic foci</span> was significantly reduced when PB was given simultaneously with <span class=""chemical"">DEN</span> for 4 and 6 weeks."		3780814	3780814_D004052_D011230	bcv_easy_718				
	D004052	"<span class=""chemical"">DEN</span>"		D009369	"<span class=""disease"">tumor</span>"	"In <span class=""chemical"">DEN</span> + PB treated rats, the survival was prolonged and the <span class=""disease"">tumor</span> incidence decreased as compared with the results obtained by <span class=""chemical"">DEN</span> alone."		3780814	3780814_D004052_D009369	bcv_easy_719				
	D010634	"<span class=""chemical"">PB</span>"		D009369	"<span class=""disease"">tumor</span>"	"In DEN + <span class=""chemical"">PB</span> treated rats, the survival was prolonged and the <span class=""disease"">tumor</span> incidence decreased as compared with the results obtained by DEN alone."		3780814	3780814_D010634_D009369	bcv_easy_720				
	D010634	"<span class=""chemical"">PB</span>"		D063646	"<span class=""disease"">carcinogenesis</span>"	"It is concluded that <span class=""chemical"">PB</span>, which promotes <span class=""disease"">carcinogenesis</span> when administered after the DEN treatment, reduces the carcinogen effect when given simultaneously with DEN."		3780814	3780814_D010634_D063646	bcv_easy_721				
	D004052	"<span class=""chemical"">DEN</span>"		D063646	"<span class=""disease"">carcinogenesis</span>"	"It is concluded that PB, which promotes <span class=""disease"">carcinogenesis</span> when administered after the <span class=""chemical"">DEN</span> treatment, reduces the carcinogen effect when given simultaneously with <span class=""chemical"">DEN</span>."		3780814	3780814_D004052_D063646	bcv_easy_722				
	D013835	"<span class=""chemical"">thiamine pyrophosphate/TPP</span>"		D014899	"<span class=""disease"">Wernicke's encephalopathy</span>"	"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed <span class=""disease"">Wernicke's encephalopathy</span> when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for <span class=""chemical"">thiamine pyrophosphate</span> (<span class=""chemical"">TPP</span>)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome."		3762968	3762968_D013835_D014899	bcv_easy_723				
	D013835	"<span class=""chemical"">thiamine pyrophosphate/TPP</span>"		D020915	"<span class=""disease"">Wernicke-Korsakoff syndrome</span>"	"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for <span class=""chemical"">thiamine pyrophosphate</span> (<span class=""chemical"">TPP</span>)], as previously reported in postalcoholic <span class=""disease"">Wernicke-Korsakoff syndrome</span>."		3762968	3762968_D013835_D020915	bcv_easy_724				
	D013831	"<span class=""chemical"">thiamine</span>"		D014899	"<span class=""disease"">Wernicke's encephalopathy</span>"	"We studied a <span class=""chemical"">thiamine</span>-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed <span class=""disease"">Wernicke's encephalopathy</span> when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome."		3762968	3762968_D013831_D014899	bcv_easy_725				
	D014042	"<span class=""chemical"">tolazamide</span>"		D020915	"<span class=""disease"">Wernicke-Korsakoff syndrome</span>"	"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with <span class=""chemical"">tolazamide</span>, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic <span class=""disease"">Wernicke-Korsakoff syndrome</span>."		3762968	3762968_D014042_D020915	bcv_easy_726				
	D013831	"<span class=""chemical"">thiamine</span>"		D020915	"<span class=""disease"">Wernicke-Korsakoff syndrome</span>"	"We studied a <span class=""chemical"">thiamine</span>-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic <span class=""disease"">Wernicke-Korsakoff syndrome</span>."		3762968	3762968_D013831_D020915	bcv_easy_727				
	D013831	"<span class=""chemical"">thiamine</span>"		D003920	"<span class=""disease"">diabetic</span>"	"We studied a <span class=""chemical"">thiamine</span>-dependent enzyme, transketolase, from fibroblasts of a <span class=""disease"">diabetic</span> patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome."		3762968	3762968_D013831_D003920	bcv_easy_728				
	D013835	"<span class=""chemical"">thiamine pyrophosphate/TPP</span>"		D003920	"<span class=""disease"">diabetic</span>"	"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a <span class=""disease"">diabetic</span> patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for <span class=""chemical"">thiamine pyrophosphate</span> (<span class=""chemical"">TPP</span>)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome."		3762968	3762968_D013835_D003920	bcv_easy_729				
	D014042	"<span class=""chemical"">tolazamide</span>"		D003920	"<span class=""disease"">diabetic</span>"	"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a <span class=""disease"">diabetic</span> patient who developed Wernicke's encephalopathy when treated with <span class=""chemical"">tolazamide</span>, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome."		3762968	3762968_D014042_D003920	bcv_easy_730				
	D013835	"<span class=""chemical"">TPP</span>"		D003920	"<span class=""disease"">diabetic</span>"	"We found that the above-mentioned patient and one of the <span class=""disease"">diabetic</span> kindreds with no history of Wernicke's encephalopathy had abnormal transketolase as determined by its Km for <span class=""chemical"">TPP</span>."		3762968	3762968_D013835_D003920	bcv_easy_731				
	D013835	"<span class=""chemical"">TPP</span>"		D014899	"<span class=""disease"">Wernicke's encephalopathy</span>"	"We found that the above-mentioned patient and one of the diabetic kindreds with no history of <span class=""disease"">Wernicke's encephalopathy</span> had abnormal transketolase as determined by its Km for <span class=""chemical"">TPP</span>."		3762968	3762968_D013835_D014899	bcv_easy_732				
	D014042	"<span class=""chemical"">tolazamide</span>"		D020915	"<span class=""disease"">Wernicke-Korsakoff syndrome</span>"	"These data suggest a similarity between postalcoholic <span class=""disease"">Wernicke-Korsakoff syndrome</span> and the patient with <span class=""chemical"">tolazamide</span>-induced Wernicke's encephalopathy from the standpoint of transketolase abnormality."		3762968	3762968_D014042_D020915	bcv_easy_733				
	D007649	"<span class=""chemical"">ketamine</span>"		D002375	"<span class=""disease"">Catalepsy</span>"	"<span class=""disease"">Catalepsy</span> induced by combinations of <span class=""chemical"">ketamine</span> and morphine: potentiation, antagonism, tolerance and cross-tolerance in the rat."		2716967	2716967_D007649_D002375	bcv_easy_734				
	D009020	"<span class=""chemical"">morphine</span>"		D002375	"<span class=""disease"">Catalepsy</span>"	"<span class=""disease"">Catalepsy</span> induced by combinations of ketamine and <span class=""chemical"">morphine</span>: potentiation, antagonism, tolerance and cross-tolerance in the rat."		2716967	2716967_D009020_D002375	bcv_easy_735				
	D007649	"<span class=""chemical"">ketamine</span>"		D002375	"<span class=""disease"">catalepsy</span>"	"Previous studies demonstrated that both <span class=""chemical"">ketamine</span> and morphine induced analgesia and <span class=""disease"">catalepsy</span> in the rat."		2716967	2716967_D007649_D002375	bcv_easy_736				
	D009020	"<span class=""chemical"">morphine</span>"		D002375	"<span class=""disease"">catalepsy</span>"	"Previous studies demonstrated that both ketamine and <span class=""chemical"">morphine</span> induced analgesia and <span class=""disease"">catalepsy</span> in the rat."		2716967	2716967_D009020_D002375	bcv_easy_737				
	D007649	"<span class=""chemical"">ketamine</span>"		D000699	"<span class=""disease"">analgesia</span>"	"Previous studies demonstrated that both <span class=""chemical"">ketamine</span> and morphine induced <span class=""disease"">analgesia</span> and catalepsy in the rat."		2716967	2716967_D007649_D000699	bcv_easy_738				
	D007649	"<span class=""chemical"">ketamine</span>"		D002375	"<span class=""disease"">cataleptic</span>"	"Pre-treatment with <span class=""chemical"">ketamine</span> produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to <span class=""chemical"">ketamine</span> but rather augmented the <span class=""disease"">cataleptic</span> response; this augmentation was attributed to residual morphine in the brain."		2716967	2716967_D007649_D002375	bcv_easy_739				
	D009020	"<span class=""chemical"">morphine</span>"		D002375	"<span class=""disease"">cataleptic</span>"	"Pre-treatment with ketamine produced cross-tolerance to <span class=""chemical"">morphine</span>, whereas pretreatment with <span class=""chemical"">morphine</span> did not induce cross-tolerance to ketamine but rather augmented the <span class=""disease"">cataleptic</span> response; this augmentation was attributed to residual <span class=""chemical"">morphine</span> in the brain."		2716967	2716967_D009020_D002375	bcv_easy_740				
	D009020	"<span class=""chemical"">morphine</span>"		D009127	"<span class=""disease"">rigidity</span>"	"Latency to the loss of righting reflex, <span class=""disease"">rigidity</span> and behavior on recovery, reflected the relative predominance of ketamine or <span class=""chemical"">morphine</span> in each combination."		2716967	2716967_D009020_D009127	bcv_easy_741				
	D007649	"<span class=""chemical"">ketamine</span>"		D009127	"<span class=""disease"">rigidity</span>"	"Latency to the loss of righting reflex, <span class=""disease"">rigidity</span> and behavior on recovery, reflected the relative predominance of <span class=""chemical"">ketamine</span> or morphine in each combination."		2716967	2716967_D007649_D009127	bcv_easy_742				
	D009270	"<span class=""chemical"">Naloxone</span>"		D002375	"<span class=""disease"">cataleptic</span>"	"<span class=""chemical"">Naloxone</span> inhibited the induced <span class=""disease"">cataleptic</span> effects."		2716967	2716967_D009270_D002375	bcv_easy_743				
	D009270	"<span class=""chemical"">naloxone</span>"		D002375	"<span class=""disease"">catalepsy</span>"	"While the mutual potentiation, antagonism and tolerance suggest common mechanisms for the induced <span class=""disease"">catalepsy</span>, differences in latency, rigidity and behavior, asymmetry of cross-tolerance and a widely-different ID50 for <span class=""chemical"">naloxone</span> would argue against an action at a single opioid site."		2716967	2716967_D009270_D002375	bcv_easy_744				
	D009270	"<span class=""chemical"">naloxone</span>"		D009127	"<span class=""disease"">rigidity</span>"	"While the mutual potentiation, antagonism and tolerance suggest common mechanisms for the induced catalepsy, differences in latency, <span class=""disease"">rigidity</span> and behavior, asymmetry of cross-tolerance and a widely-different ID50 for <span class=""chemical"">naloxone</span> would argue against an action at a single opioid site."		2716967	2716967_D009270_D009127	bcv_easy_745				
	D000809	"<span class=""chemical"">angiotensin</span>"		D051437	"<span class=""disease"">decreased renal function</span>"	"Predictors of <span class=""disease"">decreased renal function</span> in patients with heart failure during <span class=""chemical"">angiotensin</span>-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)"		10539815	10539815_D000809_D051437	bcv_easy_746				
	D000809	"<span class=""chemical"">angiotensin</span>"		D006333	"<span class=""disease"">heart failure</span>"	"Predictors of decreased renal function in patients with <span class=""disease"">heart failure</span> during <span class=""chemical"">angiotensin</span>-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)"		10539815	10539815_D000809_D006333	bcv_easy_747				
	D000809	"<span class=""chemical"">angiotensin</span>"		D018487	"<span class=""disease"">left ventricular dysfunction</span>"	"Predictors of decreased renal function in patients with heart failure during <span class=""chemical"">angiotensin</span>-converting enzyme inhibitor therapy: results from the studies of <span class=""disease"">left ventricular dysfunction</span> (SOLVD)"		10539815	10539815_D000809_D018487	bcv_easy_748				
	D000809	"<span class=""chemical"">angiotensin</span>"		D051437	"<span class=""disease"">decreased renal function</span>"	"BACKGROUND: Although <span class=""chemical"">angiotensin</span>-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause <span class=""disease"">decreased renal function</span>."		10539815	10539815_D000809_D051437	bcv_easy_749				
	D000809	"<span class=""chemical"">angiotensin</span>"		D006333	"<span class=""disease"">CHF/congestive heart failure</span>"	"BACKGROUND: Although <span class=""chemical"">angiotensin</span>-converting enzyme inhibitor therapy reduces mortality rates in patients with <span class=""disease"">congestive heart failure</span> (<span class=""disease"">CHF</span>), it may also cause decreased renal function."		10539815	10539815_D000809_D006333	bcv_easy_750				
	D000809	"<span class=""chemical"">angiotensin</span>"		D051437	"<span class=""disease"">reduction in renal function</span>"	"OBJECTIVE: To quantify specific clinical predictors of <span class=""disease"">reduction in renal function</span> in patients with CHF who are prescribed <span class=""chemical"">angiotensin</span>-converting enzyme inhibitor therapy."		10539815	10539815_D000809_D051437	bcv_easy_751				
	D000809	"<span class=""chemical"">angiotensin</span>"		D006333	"<span class=""disease"">CHF</span>"	"OBJECTIVE: To quantify specific clinical predictors of reduction in renal function in patients with <span class=""disease"">CHF</span> who are prescribed <span class=""chemical"">angiotensin</span>-converting enzyme inhibitor therapy."		10539815	10539815_D000809_D006333	bcv_easy_752				
	D004656	"<span class=""chemical"">enalapril</span>"		D018487	"<span class=""disease"">Left Ventricular Dysfunction</span>"	"METHOD: We analyzed data from the Studies of <span class=""disease"">Left Ventricular Dysfunction</span> (SOLVD), a randomized, double-blind, placebo-controlled trial of <span class=""chemical"">enalapril</span> for the treatment of CHF."		10539815	10539815_D004656_D018487	bcv_easy_753				
	D004656	"<span class=""chemical"">enalapril</span>"		D006333	"<span class=""disease"">CHF</span>"	"METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of <span class=""chemical"">enalapril</span> for the treatment of <span class=""disease"">CHF</span>."		10539815	10539815_D004656_D006333	bcv_easy_754				
	D003404	"<span class=""chemical"">creatinine</span>"		D051437	"<span class=""disease"">Decreased renal function</span>"	"<span class=""disease"">Decreased renal function</span> was defined as a rise in serum <span class=""chemical"">creatinine</span> >/=0.5 mg/dL (44 micromol/L) from baseline."		10539815	10539815_D003404_D051437	bcv_easy_755				
	D003404	"<span class=""chemical"">creatinine</span>"		D003920	"<span class=""disease"">diabetes</span>"	"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline <span class=""chemical"">creatinine</span>, low systolic blood pressure (<100 mm Hg), history of hypertension, <span class=""disease"">diabetes</span>, and use of antiplatelet, diuretic, and beta-blocker therapy."		10539815	10539815_D003404_D003920	bcv_easy_756				
	D004232	"<span class=""chemical"">diuretic</span>"		D006973	"<span class=""disease"">hypertension</span>"	"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of <span class=""disease"">hypertension</span>, diabetes, and use of antiplatelet, <span class=""chemical"">diuretic</span>, and beta-blocker therapy."		10539815	10539815_D004232_D006973	bcv_easy_757				
	D004232	"<span class=""chemical"">diuretic</span>"		D003920	"<span class=""disease"">diabetes</span>"	"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, <span class=""disease"">diabetes</span>, and use of antiplatelet, <span class=""chemical"">diuretic</span>, and beta-blocker therapy."		10539815	10539815_D004232_D003920	bcv_easy_758				
	D003404	"<span class=""chemical"">creatinine</span>"		D006973	"<span class=""disease"">hypertension</span>"	"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline <span class=""chemical"">creatinine</span>, low systolic blood pressure (<100 mm Hg), history of <span class=""disease"">hypertension</span>, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy."		10539815	10539815_D003404_D006973	bcv_easy_759				
	D004656	"<span class=""chemical"">enalapril</span>"		D051437	"<span class=""disease"">decreased renal function</span>"	"RESULTS: Patients randomly assigned to <span class=""chemical"">enalapril</span> had a 33% greater likelihood of <span class=""disease"">decreased renal function</span> than controls (P =.003)."		10539815	10539815_D004656_D051437	bcv_easy_760				
	D004656	"<span class=""chemical"">enalapril</span>"		D003920	"<span class=""disease"">diabetes</span>"	"By multivariate analysis, in both the placebo and <span class=""chemical"">enalapril</span> groups older age, diuretic therapy, and <span class=""disease"">diabetes</span> were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective."		10539815	10539815_D004656_D003920	bcv_easy_761				
	D004232	"<span class=""chemical"">diuretic</span>"		D051437	"<span class=""disease"">decreased renal function</span>"	"By multivariate analysis, in both the placebo and enalapril groups older age, <span class=""chemical"">diuretic</span> therapy, and diabetes were associated with <span class=""disease"">decreased renal function</span>, whereas beta-blocker therapy and higher ejection fraction were renoprotective."		10539815	10539815_D004232_D051437	bcv_easy_762				
	D004656	"<span class=""chemical"">enalapril</span>"		D051437	"<span class=""disease"">decreased renal function</span>"	"By multivariate analysis, in both the placebo and <span class=""chemical"">enalapril</span> groups older age, diuretic therapy, and diabetes were associated with <span class=""disease"">decreased renal function</span>, whereas beta-blocker therapy and higher ejection fraction were renoprotective."		10539815	10539815_D004656_D051437	bcv_easy_763				
	D004232	"<span class=""chemical"">diuretic</span>"		D003920	"<span class=""disease"">diabetes</span>"	"By multivariate analysis, in both the placebo and enalapril groups older age, <span class=""chemical"">diuretic</span> therapy, and <span class=""disease"">diabetes</span> were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective."		10539815	10539815_D004232_D003920	bcv_easy_764				
	D004656	"<span class=""chemical"">enalapril</span>"		D051437	"<span class=""disease"">decreased renal function</span>"	"Older age was associated with a greater risk of developing <span class=""disease"">decreased renal function</span> in both groups, but significantly more so in the <span class=""chemical"">enalapril</span> group (<span class=""chemical"">enalapril</span>: risk ratio [RR] 1.42 per 10 years, 95% confidence interval [CI] 1.32-1.52 with <span class=""chemical"">enalapril</span>; placebo: RR 1.18, 95% CI 1.12-1.25)."		10539815	10539815_D004656_D051437	bcv_easy_765				
	D004232	"<span class=""chemical"">Diuretic</span>"		D051437	"<span class=""disease"">decreased renal function</span>"	"<span class=""chemical"">Diuretic</span> therapy was likewise associated with a greater risk of <span class=""disease"">decreased renal function</span> in the enalapril group (RR 1.89, 95% CI 1.70-2.08) than in the placebo group (RR 1.35, 95% CI 1.09-1.66)."		10539815	10539815_D004232_D051437	bcv_easy_766				
	D004656	"<span class=""chemical"">enalapril</span>"		D051437	"<span class=""disease"">decreased renal function</span>"	"Diuretic therapy was likewise associated with a greater risk of <span class=""disease"">decreased renal function</span> in the <span class=""chemical"">enalapril</span> group (RR 1.89, 95% CI 1.70-2.08) than in the placebo group (RR 1.35, 95% CI 1.09-1.66)."		10539815	10539815_D004656_D051437	bcv_easy_767				
	D004656	"<span class=""chemical"">enalapril</span>"		D003920	"<span class=""disease"">diabetes</span>"	"Conversely, <span class=""chemical"">enalapril</span> had a relative renoprotective effect (RR 1.33, 95% CI 1.13-1.53) compared with placebo (RR 1.96, 95% CI 1.57-2.44) in patients with <span class=""disease"">diabetes</span>."		10539815	10539815_D004656_D003920	bcv_easy_768				
	D004656	"<span class=""chemical"">Enalapril</span>"		D051437	"<span class=""disease"">decreased renal function</span>"	"CONCLUSIONS: <span class=""chemical"">Enalapril</span> use caused a 33% increase in the risk of <span class=""disease"">decreased renal function</span> in patients with CHF."		10539815	10539815_D004656_D051437	bcv_easy_769				
	D004656	"<span class=""chemical"">Enalapril</span>"		D006333	"<span class=""disease"">CHF</span>"	"CONCLUSIONS: <span class=""chemical"">Enalapril</span> use caused a 33% increase in the risk of decreased renal function in patients with <span class=""disease"">CHF</span>."		10539815	10539815_D004656_D006333	bcv_easy_770				
	D004656	"<span class=""chemical"">enalapril</span>"		D003920	"<span class=""disease"">Diabetes</span>"	"<span class=""disease"">Diabetes</span> was associated with an increased risk of renal impairment in all patients with CHF, but this risk was reduced in the <span class=""chemical"">enalapril</span> group compared with the placebo group."		10539815	10539815_D004656_D003920	bcv_easy_771				
	D004656	"<span class=""chemical"">enalapril</span>"		D051437	"<span class=""disease"">renal impairment</span>"	"Diabetes was associated with an increased risk of <span class=""disease"">renal impairment</span> in all patients with CHF, but this risk was reduced in the <span class=""chemical"">enalapril</span> group compared with the placebo group."		10539815	10539815_D004656_D051437	bcv_easy_772				
	D004656	"<span class=""chemical"">enalapril</span>"		D006333	"<span class=""disease"">CHF</span>"	"Diabetes was associated with an increased risk of renal impairment in all patients with <span class=""disease"">CHF</span>, but this risk was reduced in the <span class=""chemical"">enalapril</span> group compared with the placebo group."		10539815	10539815_D004656_D006333	bcv_easy_773				
	D007501	"<span class=""chemical"">Iron</span>"		D010300	"<span class=""disease"">Parkinson's disease</span>"	"<span class=""chemical"">Iron</span> accumulation is considered to be involved in the pathogenesis of <span class=""disease"">Parkinson's disease</span>."		17490790	17490790_D007501_D010300	bcv_easy_774				
	D007501	"<span class=""chemical"">iron</span>"		D009410	"<span class=""disease"">degeneration of dopaminergic neurons</span>"	"To demonstrate the relationship between peripheral <span class=""chemical"">iron</span> overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' <span class=""chemical"">iron</span> staining, and high performance liquid chromatography-electrochemical detection to study the <span class=""disease"">degeneration of dopaminergic neurons</span> and increased <span class=""chemical"">iron</span> content in the SN of iron dextran overloaded animals."		17490790	17490790_D007501_D009410	bcv_easy_775				
	D014443	"<span class=""chemical"">tyrosine</span>"		D009410	"<span class=""disease"">degeneration of dopaminergic neurons</span>"	"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, <span class=""chemical"">tyrosine</span> hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the <span class=""disease"">degeneration of dopaminergic neurons</span> and increased iron content in the SN of iron dextran overloaded animals."		17490790	17490790_D014443_D009410	bcv_easy_776				
	D007501	"<span class=""chemical"">iron</span>"		D009410	"<span class=""disease"">degeneration of dopaminergic neurons</span>"	"These results suggest that peripheral iron dextran can increase the <span class=""chemical"">iron</span> level in the SN, where excessive <span class=""chemical"">iron</span> causes the <span class=""disease"">degeneration of dopaminergic neurons</span>."		17490790	17490790_D007501_D009410	bcv_easy_777				
	D008727	"<span class=""chemical"">methotrexate</span>"		D002544	"<span class=""disease"">cerebrovascular accident</span>"	"BACKGROUND: A transient leukoencephalopathy mimicking <span class=""disease"">cerebrovascular accident</span> has been described as a complication of chemotherapy, most commonly in recipients of intrathecal <span class=""chemical"">methotrexate</span> for childhood leukaemia."		17682013	17682013_D008727_D002544	bcv_easy_778				
	D008727	"<span class=""chemical"">methotrexate</span>"		D056784	"<span class=""disease"">leukoencephalopathy</span>"	"BACKGROUND: A transient <span class=""disease"">leukoencephalopathy</span> mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal <span class=""chemical"">methotrexate</span> for childhood leukaemia."		17682013	17682013_D008727_D056784	bcv_easy_779				
	D008727	"<span class=""chemical"">methotrexate</span>"		D007938	"<span class=""disease"">leukaemia</span>"	"BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal <span class=""chemical"">methotrexate</span> for childhood <span class=""disease"">leukaemia</span>."		17682013	17682013_D008727_D007938	bcv_easy_780				
	D008727	"<span class=""chemical"">methotrexate</span>"		D056784	"<span class=""disease"">leukoencephalopathy</span>"	"RESULTS: We identified 27 reports of toxic <span class=""disease"">leukoencephalopathy</span> in patients treated with <span class=""chemical"">methotrexate</span> (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine."		17682013	17682013_D008727_D056784	bcv_easy_781				
	C017367	"<span class=""chemical"">carmofur</span>"		D056784	"<span class=""disease"">leukoencephalopathy</span>"	"RESULTS: We identified 27 reports of toxic <span class=""disease"">leukoencephalopathy</span> in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative <span class=""chemical"">carmofur</span>, and capecitabine."		17682013	17682013_C017367_D056784	bcv_easy_782				
	D005472	"<span class=""chemical"">5-fluorouracil</span>"		D056784	"<span class=""disease"">leukoencephalopathy</span>"	"RESULTS: We identified 27 reports of toxic <span class=""disease"">leukoencephalopathy</span> in patients treated with methotrexate (intrathecal, systemic), <span class=""chemical"">5-fluorouracil</span> and its derivative carmofur, and capecitabine."		17682013	17682013_D005472_D056784	bcv_easy_783				
	C110904	"<span class=""chemical"">capecitabine</span>"		D056784	"<span class=""disease"">leukoencephalopathy</span>"	"RESULTS: We identified 27 reports of toxic <span class=""disease"">leukoencephalopathy</span> in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and <span class=""chemical"">capecitabine</span>."		17682013	17682013_C110904_D056784	bcv_easy_784				
	D005283	"<span class=""chemical"">fentanyl</span>"		D009127	"<span class=""disease"">rigidity</span>"	"Post-operative <span class=""disease"">rigidity</span> after <span class=""chemical"">fentanyl</span> administration."		3780697	3780697_D005283_D009127	bcv_easy_785				
	D005283	"<span class=""chemical"">fentanyl</span>"		D012131	"<span class=""disease"">respiratory failure</span>"	"A case of thoraco-abdominal rigidity leading to <span class=""disease"">respiratory failure</span> is described in the post-operative period in an elderly patient who received a moderate dose of <span class=""chemical"">fentanyl</span>."		3780697	3780697_D005283_D012131	bcv_easy_786				
	D005283	"<span class=""chemical"">fentanyl</span>"		D009127	"<span class=""disease"">rigidity</span>"	"A case of thoraco-abdominal <span class=""disease"">rigidity</span> leading to respiratory failure is described in the post-operative period in an elderly patient who received a moderate dose of <span class=""chemical"">fentanyl</span>."		3780697	3780697_D005283_D009127	bcv_easy_787				
	D004967	"<span class=""chemical"">estrogen</span>"		D063646	"<span class=""disease"">carcinogenesis</span>"	"The mechanistic details of tumor angiogenesis induction, during <span class=""chemical"">estrogen</span> <span class=""disease"">carcinogenesis</span>, are still unknown."		9214597	9214597_D004967_D063646	bcv_easy_788				
	D004958	"<span class=""chemical"">E2</span>"		D009369	"<span class=""disease"">tumor</span>"	"The high <span class=""disease"">tumor</span> angiogenic potential was associated with an elevated VEGF/VPF protein expression in the <span class=""chemical"">E2</span> exposed pituitary of ovariectomized (OVEX) rats."		9214597	9214597_D004958_D009369	bcv_easy_789				
	D004317	"<span class=""chemical"">adriamycin</span>"		D028361	"<span class=""disease"">Structural and functional impairment of mitochondria</span>"	"<span class=""disease"">Structural and functional impairment of mitochondria</span> in <span class=""chemical"">adriamycin</span>-induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression."		9952311	9952311_D004317_D028361	bcv_easy_790				
	D004317	"<span class=""chemical"">ADR/adriamycin</span>"		D002318	"<span class=""disease"">cardiovascular toxicity</span>"	"The use of <span class=""chemical"">adriamycin</span> (<span class=""chemical"">ADR</span>) in cancer chemotherapy has been limited due to its cumulative <span class=""disease"">cardiovascular toxicity</span>."		9952311	9952311_D004317_D002318	bcv_easy_791				
	D004317	"<span class=""chemical"">ADR/adriamycin</span>"		D009369	"<span class=""disease"">cancer</span>"	"The use of <span class=""chemical"">adriamycin</span> (<span class=""chemical"">ADR</span>) in <span class=""disease"">cancer</span> chemotherapy has been limited due to its cumulative cardiovascular toxicity."		9952311	9952311_D004317_D009369	bcv_easy_792				
	D004317	"<span class=""chemical"">ADR</span>"		D001145	"<span class=""disease"">cardiovascular arrhythmias</span>"	"Our results indicated that 1) treatment of mice with <span class=""chemical"">ADR</span> caused <span class=""disease"">cardiovascular arrhythmias</span> characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment."		9952311	9952311_D004317_D001145	bcv_easy_793				
	D004317	"<span class=""chemical"">ADR</span>"		D001919	"<span class=""disease"">bradycardia</span>"	"Our results indicated that 1) treatment of mice with <span class=""chemical"">ADR</span> caused cardiovascular arrhythmias characterized by <span class=""disease"">bradycardia</span>, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment."		9952311	9952311_D004317_D001919	bcv_easy_794				
	D004317	"<span class=""chemical"">ADR</span>"		D004487	"<span class=""disease"">swelling</span>"	"Our results indicated that 1) treatment of mice with <span class=""chemical"">ADR</span> caused cardiovascular arrhythmias characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent <span class=""disease"">swelling</span>, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment."		9952311	9952311_D004317_D004487	bcv_easy_795				
	D004317	"<span class=""chemical"">ADR</span>"		D028361	"<span class=""disease"">mitochondrial structural and functional impairment</span>"	"Knowing that heart mitochondria represent almost 40% of heart muscle by weight, we conclude that the deteriorating effects of <span class=""chemical"">ADR</span> on cardiovascular function involve <span class=""disease"">mitochondrial structural and functional impairment</span>."		9952311	9952311_D004317_D028361	bcv_easy_796				
	D016685	"<span class=""chemical"">Mitomycin C</span>"		D006463	"<span class=""disease"">hemolytic uremic syndrome</span>"	"<span class=""chemical"">Mitomycin C</span> associated <span class=""disease"">hemolytic uremic syndrome</span>."		3108839	3108839_D016685_D006463	bcv_easy_797				
	D016685	"<span class=""chemical"">Mitomycin C</span>"		D006463	"<span class=""disease"">Hemolytic Uremic Syndrome/HUS</span>"	"<span class=""chemical"">Mitomycin C</span> associated <span class=""disease"">Hemolytic Uremic Syndrome</span> (<span class=""disease"">HUS</span>) is a potentially fatal but uncommon condition that is not yet widely recognised."		3108839	3108839_D016685_D006463	bcv_easy_798				
	D016685	"<span class=""chemical"">mitomycin C</span>"		D000743	"<span class=""disease"">hemolytic anemia</span>"	"It consists of microangiopathic <span class=""disease"">hemolytic anemia</span>, thrombocytopenia and progressive renal failure associated with <span class=""chemical"">mitomycin C</span> treatment and affects about 10% of patients treated with this agent."		3108839	3108839_D016685_D000743	bcv_easy_799				
	D016685	"<span class=""chemical"">mitomycin C</span>"		D051437	"<span class=""disease"">renal failure</span>"	"It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive <span class=""disease"">renal failure</span> associated with <span class=""chemical"">mitomycin C</span> treatment and affects about 10% of patients treated with this agent."		3108839	3108839_D016685_D051437	bcv_easy_800				
	D016685	"<span class=""chemical"">mitomycin C</span>"		D013921	"<span class=""disease"">thrombocytopenia</span>"	"It consists of microangiopathic hemolytic anemia, <span class=""disease"">thrombocytopenia</span> and progressive renal failure associated with <span class=""chemical"">mitomycin C</span> treatment and affects about 10% of patients treated with this agent."		3108839	3108839_D016685_D013921	bcv_easy_801				
	D016685	"<span class=""chemical"">mitomycin C</span>"		D011654	"<span class=""disease"">pulmonary edema</span>"	"The renal failure usually develops about 8-10 mth after start of <span class=""chemical"">mitomycin C</span> treatment and the mortality is approximately 60% from renal failure or <span class=""disease"">pulmonary edema</span>."		3108839	3108839_D016685_D011654	bcv_easy_802				
	D016685	"<span class=""chemical"">mitomycin C</span>"		D051437	"<span class=""disease"">renal failure</span>"	"The <span class=""disease"">renal failure</span> usually develops about 8-10 mth after start of <span class=""chemical"">mitomycin C</span> treatment and the mortality is approximately 60% from <span class=""disease"">renal failure</span> or pulmonary edema."		3108839	3108839_D016685_D051437	bcv_easy_803				
	D016685	"<span class=""chemical"">mitomycin C</span>"		D013274	"<span class=""disease"">gastric adenocarcinoma</span>"	"We describe the clinical course and pathological findings in a 65 yr-old man with <span class=""disease"">gastric adenocarcinoma</span> who developed renal failure and thrombocytopenia while on treatment with <span class=""chemical"">mitomycin C</span> and died in pulmonary edema."		3108839	3108839_D016685_D013274	bcv_easy_804				
	D016685	"<span class=""chemical"">mitomycin C</span>"		D011654	"<span class=""disease"">pulmonary edema</span>"	"We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with <span class=""chemical"">mitomycin C</span> and died in <span class=""disease"">pulmonary edema</span>."		3108839	3108839_D016685_D011654	bcv_easy_805				
	D016685	"<span class=""chemical"">mitomycin C</span>"		D051437	"<span class=""disease"">renal failure</span>"	"We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed <span class=""disease"">renal failure</span> and thrombocytopenia while on treatment with <span class=""chemical"">mitomycin C</span> and died in pulmonary edema."		3108839	3108839_D016685_D051437	bcv_easy_806				
	D016685	"<span class=""chemical"">mitomycin C</span>"		D013921	"<span class=""disease"">thrombocytopenia</span>"	"We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and <span class=""disease"">thrombocytopenia</span> while on treatment with <span class=""chemical"">mitomycin C</span> and died in pulmonary edema."		3108839	3108839_D016685_D013921	bcv_easy_807				
	D017035	"<span class=""chemical"">Pravastatin</span>"		D009135	"<span class=""disease"">myopathy</span>"	"<span class=""chemical"">Pravastatin</span>-associated <span class=""disease"">myopathy</span>. Report of a case."		7604176	7604176_D017035_D009135	bcv_easy_808				
	D017035	"<span class=""chemical"">pravastatin</span>"		D009220	"<span class=""disease"">inflammatory myopathy</span>"	"A case of acute <span class=""disease"">inflammatory myopathy</span> associated with the use of <span class=""chemical"">pravastatin</span>, a new hydrophilic 3-hydroxy-3 methylglutaril coenzyme A reductase inhibitor, is reported."		7604176	7604176_D017035_D009220	bcv_easy_809				
	D017035	"<span class=""chemical"">pravastatin</span>"		D006937	"<span class=""disease"">hypercholesterolemia</span>"	"He assumed <span class=""chemical"">pravastatin</span> (20 mg/day) because of <span class=""disease"">hypercholesterolemia</span>."		7604176	7604176_D017035_D006937	bcv_easy_810				
	D017035	"<span class=""chemical"">pravastatin</span>"		D009135	"<span class=""disease"">myopathy</span>"	"He was admitted with acute <span class=""disease"">myopathy</span> of the lower limbs which resolved in a few days after <span class=""chemical"">pravastatin</span> discontinuation."		7604176	7604176_D017035_D009135	bcv_easy_811				
	D008148	"<span class=""chemical"">lovastatin</span>"		D009135	"<span class=""disease"">myopathy</span>"	"While <span class=""chemical"">lovastatin</span> and simvastatin have been associated with toxic <span class=""disease"">myopathy</span>, pravastatin-associated <span class=""disease"">myopathy</span> could represent a distinct, inflammatory entity."		7604176	7604176_D008148_D009135	bcv_easy_812				
	D017035	"<span class=""chemical"">pravastatin</span>"		D009135	"<span class=""disease"">myopathy</span>"	"While lovastatin and simvastatin have been associated with toxic <span class=""disease"">myopathy</span>, <span class=""chemical"">pravastatin</span>-associated <span class=""disease"">myopathy</span> could represent a distinct, inflammatory entity."		7604176	7604176_D017035_D009135	bcv_easy_813				
	D019821	"<span class=""chemical"">simvastatin</span>"		D009135	"<span class=""disease"">myopathy</span>"	"While lovastatin and <span class=""chemical"">simvastatin</span> have been associated with toxic <span class=""disease"">myopathy</span>, pravastatin-associated <span class=""disease"">myopathy</span> could represent a distinct, inflammatory entity."		7604176	7604176_D019821_D009135	bcv_easy_814				
	D017963	"<span class=""chemical"">azithromycin</span>"		D006606	"<span class=""disease"">hiccups</span>"	"Possible <span class=""chemical"">azithromycin</span>-associated <span class=""disease"">hiccups</span>."		15985056	15985056_D017963_D006606	bcv_easy_815				
	D017963	"<span class=""chemical"">azithromycin</span>"		D006606	"<span class=""disease"">hiccups</span>"	"OBJECTIVE: To report a case of persistent <span class=""disease"">hiccups</span> associated by <span class=""chemical"">azithromycin</span> therapy."		15985056	15985056_D017963_D006606	bcv_easy_816				
	D017963	"<span class=""chemical"">azithromycin</span>"		D006606	"<span class=""disease"">hiccups</span>"	"CASE SUMMARY: A 76-year-old man presented with persistent <span class=""disease"">hiccups</span> after beginning <span class=""chemical"">azithromycin</span> for the treatment of pharyngitis."		15985056	15985056_D017963_D006606	bcv_easy_817				
	D017963	"<span class=""chemical"">azithromycin</span>"		D010612	"<span class=""disease"">pharyngitis</span>"	"CASE SUMMARY: A 76-year-old man presented with persistent hiccups after beginning <span class=""chemical"">azithromycin</span> for the treatment of <span class=""disease"">pharyngitis</span>."		15985056	15985056_D017963_D010612	bcv_easy_818				
	D017963	"<span class=""chemical"">azithromycin</span>"		D006606	"<span class=""disease"">hiccups</span>"	"Discontinuation of <span class=""chemical"">azithromycin</span> and therapy with baclofen finally resolved <span class=""disease"">hiccups</span>."		15985056	15985056_D017963_D006606	bcv_easy_819				
	D001418	"<span class=""chemical"">baclofen</span>"		D006606	"<span class=""disease"">hiccups</span>"	"Discontinuation of azithromycin and therapy with <span class=""chemical"">baclofen</span> finally resolved <span class=""disease"">hiccups</span>."		15985056	15985056_D001418_D006606	bcv_easy_820				
	D008775	"<span class=""chemical"">methylprednisolone</span>"		D006606	"<span class=""disease"">hiccups</span>"	"Corticosteroids (dexamethasone and <span class=""chemical"">methylprednisolone</span>), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of <span class=""disease"">hiccups</span>."		15985056	15985056_D008775_D006606	bcv_easy_821				
	D001569	"<span class=""chemical"">benzodiazepines</span>"		D006606	"<span class=""disease"">hiccups</span>"	"Corticosteroids (dexamethasone and methylprednisolone), <span class=""chemical"">benzodiazepines</span> (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of <span class=""disease"">hiccups</span>."		15985056	15985056_D001569_D006606	bcv_easy_822				
	D003907	"<span class=""chemical"">dexamethasone</span>"		D006606	"<span class=""disease"">hiccups</span>"	"Corticosteroids (<span class=""chemical"">dexamethasone</span> and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of <span class=""disease"">hiccups</span>."		15985056	15985056_D003907_D006606	bcv_easy_823				
	D008874	"<span class=""chemical"">midazolam</span>"		D006606	"<span class=""disease"">hiccups</span>"	"Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (<span class=""chemical"">midazolam</span>) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of <span class=""disease"">hiccups</span>."		15985056	15985056_D008874_D006606	bcv_easy_824				
	D018942	"<span class=""chemical"">macrolide</span>"		D006606	"<span class=""disease"">hiccups</span>"	"Few cases of drug-induced <span class=""disease"">hiccups</span> have been reported related to <span class=""chemical"">macrolide</span> antimicrobials."		15985056	15985056_D018942_D006606	bcv_easy_825				
	D018942	"<span class=""chemical"">macrolides</span>"		D006606	"<span class=""disease"">hiccups</span>"	"Using the Naranjo adverse effect reaction probability scale this event could be classified as possible (score 5 points), mostly because of the close temporal sequence, previous reports on this reaction with other <span class=""chemical"">macrolides</span> and the absence of any alternative explanation for <span class=""disease"">hiccups</span>."		15985056	15985056_D018942_D006606	bcv_easy_826				
	D017963	"<span class=""chemical"">azithromycin</span>"		D006606	"<span class=""disease"">hiccups</span>"	"Our hypothesis is that a vagal mechanism mediated by <span class=""chemical"">azithromycin</span> could be the pathogenesis of <span class=""disease"">hiccups</span> in our patient."		15985056	15985056_D017963_D006606	bcv_easy_827				
	D018942	"<span class=""chemical"">macrolide</span>"		D006606	"<span class=""disease"">hiccups</span>"	"However, <span class=""chemical"">macrolide</span> antimicrobials have been reported to be associated with <span class=""disease"">hiccups</span> and vagal mechanism could explain the development of this side-effect."		15985056	15985056_D018942_D006606	bcv_easy_828				
	D006220	"<span class=""chemical"">haloperidol</span>"		D006948	"<span class=""disease"">hyperactivity</span>"	"Calcitonin injection resulted in a potentiation of <span class=""chemical"">haloperidol</span>-induced catalepsy and a partial prevention of apomorphine-induced <span class=""disease"">hyperactivity</span>."		6293644	6293644_D006220_D006948	bcv_easy_829				
	D001058	"<span class=""chemical"">apomorphine</span>"		D002375	"<span class=""disease"">catalepsy</span>"	"Calcitonin injection resulted in a potentiation of haloperidol-induced <span class=""disease"">catalepsy</span> and a partial prevention of <span class=""chemical"">apomorphine</span>-induced hyperactivity."		6293644	6293644_D001058_D002375	bcv_easy_830				
	D010396	"<span class=""chemical"">D-penicillamine</span>"		D017285	"<span class=""disease"">polymyositis</span>"	"A case of <span class=""disease"">polymyositis</span> in a patient with primary biliary cirrhosis treated with <span class=""chemical"">D-penicillamine</span>."		8268147	8268147_D010396_D017285	bcv_easy_831				
	D010396	"<span class=""chemical"">D-penicillamine</span>"		D008105	"<span class=""disease"">primary biliary cirrhosis</span>"	"A case of polymyositis in a patient with <span class=""disease"">primary biliary cirrhosis</span> treated with <span class=""chemical"">D-penicillamine</span>."		8268147	8268147_D010396_D008105	bcv_easy_832				
	D010396	"<span class=""chemical"">D-penicillamine</span>"		D012216	"<span class=""disease"">rheumatologic diseases</span>"	"Although <span class=""chemical"">D-penicillamine</span> has been used for many <span class=""disease"">rheumatologic diseases</span>, toxicity limits its usefulness in many patients."		8268147	8268147_D010396_D012216	bcv_easy_833				
	D010396	"<span class=""chemical"">D-penicillamine</span>"		D064420	"<span class=""disease"">toxicity</span>"	"Although <span class=""chemical"">D-penicillamine</span> has been used for many rheumatologic diseases, <span class=""disease"">toxicity</span> limits its usefulness in many patients."		8268147	8268147_D010396_D064420	bcv_easy_834				
	D010396	"<span class=""chemical"">D-penicillamine</span>"		D003882	"<span class=""disease"">dermatomyositis</span>"	"Polymyositis/<span class=""disease"">dermatomyositis</span> can develop as one of the autoimmune complications of <span class=""chemical"">D-penicillamine</span> treatment, but its exact pathogenesis remains unclear."		8268147	8268147_D010396_D003882	bcv_easy_835				
	D010396	"<span class=""chemical"">D-penicillamine</span>"		D017285	"<span class=""disease"">Polymyositis</span>"	"<span class=""disease"">Polymyositis</span>/dermatomyositis can develop as one of the autoimmune complications of <span class=""chemical"">D-penicillamine</span> treatment, but its exact pathogenesis remains unclear."		8268147	8268147_D010396_D017285	bcv_easy_836				
	D010396	"<span class=""chemical"">D-penicillamine</span>"		D017285	"<span class=""disease"">polymyositis</span>"	"We report a patient with primary biliary cirrhosis, who developed <span class=""disease"">polymyositis</span> while receiving <span class=""chemical"">D-penicillamine</span> therapy."		8268147	8268147_D010396_D017285	bcv_easy_837				
	D010396	"<span class=""chemical"">D-penicillamine</span>"		D008105	"<span class=""disease"">primary biliary cirrhosis</span>"	"We report a patient with <span class=""disease"">primary biliary cirrhosis</span>, who developed polymyositis while receiving <span class=""chemical"">D-penicillamine</span> therapy."		8268147	8268147_D010396_D008105	bcv_easy_838				
	D010396	"<span class=""chemical"">D-penicillamine</span>"		D003882	"<span class=""disease"">dermatomyositis</span>"	"Patients receiving <span class=""chemical"">D-penicillamine</span> therapy should be followed carefully for the development of autoimmune complications like polymyositis/<span class=""disease"">dermatomyositis</span>."		8268147	8268147_D010396_D003882	bcv_easy_839				
	D010396	"<span class=""chemical"">D-penicillamine</span>"		D017285	"<span class=""disease"">polymyositis</span>"	"Patients receiving <span class=""chemical"">D-penicillamine</span> therapy should be followed carefully for the development of autoimmune complications like <span class=""disease"">polymyositis</span>/dermatomyositis."		8268147	8268147_D010396_D017285	bcv_easy_840				
	D011692	"<span class=""chemical"">Puromycin aminonucleoside/PAN</span>"		D011507	"<span class=""disease"">proteinuria</span>"	"METHODS: <span class=""chemical"">Puromycin aminonucleoside</span> (<span class=""chemical"">PAN</span>) was administered to Sprague Dawley rats to induce <span class=""disease"">proteinuria</span>."		10193809	10193809_D011692_D011507	bcv_easy_841				
	D007980	"<span class=""chemical"">levodopa</span>"		D018476	"<span class=""disease"">bradykinesia</span>"	"Pallidal stimulation improves <span class=""disease"">bradykinesia</span> and rigidity to a minor extent; however, its strength seems to be in improving <span class=""chemical"">levodopa</span>-induced dyskinesias."		15096016	15096016_D007980_D018476	bcv_easy_842				
	D007980	"<span class=""chemical"">levodopa</span>"		D009127	"<span class=""disease"">rigidity</span>"	"Pallidal stimulation improves bradykinesia and <span class=""disease"">rigidity</span> to a minor extent; however, its strength seems to be in improving <span class=""chemical"">levodopa</span>-induced dyskinesias."		15096016	15096016_D007980_D009127	bcv_easy_843				
	D002939	"<span class=""chemical"">Ciprofloxacin</span>"		D009369	"<span class=""disease"">cancer</span>"	"<span class=""chemical"">Ciprofloxacin</span>-induced nephrotoxicity in patients with <span class=""disease"">cancer</span>."		8494478	8494478_D002939_D009369	bcv_easy_844				
	D002939	"<span class=""chemical"">ciprofloxacin</span>"		D009369	"<span class=""disease"">cancer</span>"	"Five patients with <span class=""disease"">cancer</span> who developed acute renal failure that followed treatment with <span class=""chemical"">ciprofloxacin</span> are described and an additional 15 cases reported in the literature are reviewed."		8494478	8494478_D002939_D009369	bcv_easy_845				
	D004837	"<span class=""chemical"">epinephrine</span>"		D017202	"<span class=""disease"">myocardial ischemia</span>"	"Mechanisms of <span class=""disease"">myocardial ischemia</span> induced by <span class=""chemical"">epinephrine</span>: comparison with exercise-induced ischemia."		3413271	3413271_D004837_D017202	bcv_easy_846				
	D004837	"<span class=""chemical"">epinephrine</span>"		D003324	"<span class=""disease"">coronary artery disease</span>"	"The role of <span class=""chemical"">epinephrine</span> in eliciting myocardial ischemia was examined in patients with <span class=""disease"">coronary artery disease</span>."		3413271	3413271_D004837_D003324	bcv_easy_847				
	D004837	"<span class=""chemical"">epinephrine</span>"		D017202	"<span class=""disease"">myocardial ischemia</span>"	"The role of <span class=""chemical"">epinephrine</span> in eliciting <span class=""disease"">myocardial ischemia</span> was examined in patients with coronary artery disease."		3413271	3413271_D004837_D017202	bcv_easy_848				
	D010100	"<span class=""chemical"">oxygen</span>"		D007511	"<span class=""disease"">ischemia</span>"	"Objective signs of <span class=""disease"">ischemia</span> and factors increasing myocardial <span class=""chemical"">oxygen</span> consumption were compared during epinephrine infusion and supine bicycle exercise."		3413271	3413271_D010100_D007511	bcv_easy_849				
	D004837	"<span class=""chemical"">epinephrine</span>"		D003866	"<span class=""disease"">depression</span>"	"Both <span class=""chemical"">epinephrine</span> and exercise produced myocardial ischemia as evidenced by ST segment <span class=""disease"">depression</span> and angina."		3413271	3413271_D004837_D003866	bcv_easy_850				
	D004837	"<span class=""chemical"">epinephrine</span>"		D000787	"<span class=""disease"">angina</span>"	"Both <span class=""chemical"">epinephrine</span> and exercise produced myocardial ischemia as evidenced by ST segment depression and <span class=""disease"">angina</span>."		3413271	3413271_D004837_D000787	bcv_easy_851				
	D004837	"<span class=""chemical"">epinephrine</span>"		D017202	"<span class=""disease"">myocardial ischemia</span>"	"Both <span class=""chemical"">epinephrine</span> and exercise produced <span class=""disease"">myocardial ischemia</span> as evidenced by ST segment depression and angina."		3413271	3413271_D004837_D017202	bcv_easy_852				
	D004837	"<span class=""chemical"">epinephrine</span>"		D017202	"<span class=""disease"">myocardial ischemia</span>"	"However, the mechanisms of <span class=""disease"">myocardial ischemia</span> induced by <span class=""chemical"">epinephrine</span> were significantly different from those of exercise."		3413271	3413271_D004837_D017202	bcv_easy_853				
	D004837	"<span class=""chemical"">epinephrine</span>"		D017202	"<span class=""disease"">myocardial ischemia</span>"	"Exercise-induced <span class=""disease"">myocardial ischemia</span> was marked predominantly by increased heart rate and rate-pressure product with a minor contribution of end-diastolic volume, while <span class=""chemical"">epinephrine</span>-induced ischemia was characterized by a marked increase in contractility and a less pronounced increase in heart rate and rate-pressure product."		3413271	3413271_D004837_D017202	bcv_easy_854				
	D004298	"<span class=""chemical"">dopamine</span>"		D002375	"<span class=""disease"">catalepsy</span>"	"Blockade of both D-1 and D-2 <span class=""chemical"">dopamine</span> receptors may induce <span class=""disease"">catalepsy</span> in mice."		1687392	1687392_D004298_D002375	bcv_easy_855				
	D004298	"<span class=""chemical"">dopamine</span>"		D002375	"<span class=""disease"">catalepsy</span>"	"The <span class=""disease"">catalepsy</span> induced by <span class=""chemical"">dopamine</span> antagonists has been tested and the possible <span class=""chemical"">dopamine</span> subtypes involved in <span class=""disease"">catalepsy</span> was determined."		1687392	1687392_D004298_D002375	bcv_easy_856				
	C534628	"<span class=""chemical"">SCH 23390</span>"		D002375	"<span class=""disease"">catalepsy</span>"	"Dopamine antagonist fluphenazine, D-1 antagonist <span class=""chemical"">SCH 23390</span> or D-2 antagonist sulpiride induced <span class=""disease"">catalepsy</span>."		1687392	1687392_C534628_D002375	bcv_easy_857				
	D005476	"<span class=""chemical"">fluphenazine</span>"		D002375	"<span class=""disease"">catalepsy</span>"	"Dopamine antagonist <span class=""chemical"">fluphenazine</span>, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced <span class=""disease"">catalepsy</span>."		1687392	1687392_D005476_D002375	bcv_easy_858				
	D004298	"<span class=""chemical"">Dopamine</span>"		D002375	"<span class=""disease"">catalepsy</span>"	"<span class=""chemical"">Dopamine</span> antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced <span class=""disease"">catalepsy</span>."		1687392	1687392_D004298_D002375	bcv_easy_859				
	C534628	"<span class=""chemical"">SCH 23390</span>"		D002375	"<span class=""disease"">catalepsy</span>"	"Combination of <span class=""chemical"">SCH 23390</span> with sulpiride did not induce <span class=""disease"">catalepsy</span> potentiation."		1687392	1687392_C534628_D002375	bcv_easy_860				
	C534628	"<span class=""chemical"">SCH 23390</span>"		D002375	"<span class=""disease"">catalepsy</span>"	"D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the <span class=""disease"">catalepsy</span> induced by fluphenazine, <span class=""chemical"">SCH 23390</span> or sulpiride."		1687392	1687392_C534628_D002375	bcv_easy_861				
	D005476	"<span class=""chemical"">fluphenazine</span>"		D002375	"<span class=""disease"">catalepsy</span>"	"D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the <span class=""disease"">catalepsy</span> induced by <span class=""chemical"">fluphenazine</span>, SCH 23390 or sulpiride."		1687392	1687392_D005476_D002375	bcv_easy_862				
	D015647	"<span class=""chemical"">SKF 38393</span>"		D002375	"<span class=""disease"">catalepsy</span>"	"D-1 agonist <span class=""chemical"">SKF 38393</span> or D-2 agonist quinpirole decreased the <span class=""disease"">catalepsy</span> induced by fluphenazine, SCH 23390 or sulpiride."		1687392	1687392_D015647_D002375	bcv_easy_863				
	D019257	"<span class=""chemical"">quinpirole</span>"		D002375	"<span class=""disease"">catalepsy</span>"	"D-1 agonist SKF 38393 or D-2 agonist <span class=""chemical"">quinpirole</span> decreased the <span class=""disease"">catalepsy</span> induced by fluphenazine, SCH 23390 or sulpiride."		1687392	1687392_D019257_D002375	bcv_easy_864				
	D019257	"<span class=""chemical"">quinpirole</span>"		D002375	"<span class=""disease"">catalepsy</span>"	"Combination of SKF 38393 with <span class=""chemical"">quinpirole</span> did not cause potentiated inhibitory effect on <span class=""disease"">catalepsy</span> induced by dopamine antagonists."		1687392	1687392_D019257_D002375	bcv_easy_865				
	D004298	"<span class=""chemical"">dopamine</span>"		D002375	"<span class=""disease"">catalepsy</span>"	"Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on <span class=""disease"">catalepsy</span> induced by <span class=""chemical"">dopamine</span> antagonists."		1687392	1687392_D004298_D002375	bcv_easy_866				
	D015647	"<span class=""chemical"">SKF 38393</span>"		D002375	"<span class=""disease"">catalepsy</span>"	"Combination of <span class=""chemical"">SKF 38393</span> with quinpirole did not cause potentiated inhibitory effect on <span class=""disease"">catalepsy</span> induced by dopamine antagonists."		1687392	1687392_D015647_D002375	bcv_easy_867				
	D004041	"<span class=""chemical"">fat</span>"		D009765	"<span class=""disease"">obese</span>"	"High <span class=""chemical"">fat</span> diet-fed <span class=""disease"">obese</span> rats are highly sensitive to doxorubicin-induced cardiotoxicity."		18674790	18674790_D004041_D009765	bcv_easy_868				
	D004317	"<span class=""chemical"">doxorubicin</span>"		D009765	"<span class=""disease"">obese</span>"	"High fat diet-fed <span class=""disease"">obese</span> rats are highly sensitive to <span class=""chemical"">doxorubicin</span>-induced cardiotoxicity."		18674790	18674790_D004317_D009765	bcv_easy_869				
	D004041	"<span class=""chemical"">fat</span>"		D066126	"<span class=""disease"">cardiotoxicity</span>"	"High <span class=""chemical"">fat</span> diet-fed obese rats are highly sensitive to doxorubicin-induced <span class=""disease"">cardiotoxicity</span>."		18674790	18674790_D004041_D066126	bcv_easy_870				
	D004041	"<span class=""chemical"">fat</span>"		D009765	"<span class=""disease"">obesity</span>"	"In the current study, we investigated whether a physiological intervention by feeding 40% high <span class=""chemical"">fat</span> diet (HFD), which induces <span class=""disease"">obesity</span> in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity."		18674790	18674790_D004041_D009765	bcv_easy_871				
	D004317	"<span class=""chemical"">doxorubicin</span>"		D009765	"<span class=""disease"">obesity</span>"	"In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces <span class=""disease"">obesity</span> in male Sprague-Dawley rats (250-275 g), sensitizes to <span class=""chemical"">doxorubicin</span>-induced cardiotoxicity."		18674790	18674790_D004317_D009765	bcv_easy_872				
	D004041	"<span class=""chemical"">fat</span>"		D066126	"<span class=""disease"">cardiotoxicity</span>"	"In the current study, we investigated whether a physiological intervention by feeding 40% high <span class=""chemical"">fat</span> diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced <span class=""disease"">cardiotoxicity</span>."		18674790	18674790_D004041_D066126	bcv_easy_873				
	D004317	"<span class=""chemical"">doxorubicin</span>"		D009765	"<span class=""disease"">obese/OB</span>"	"A LD(10) dose (8 mg <span class=""chemical"">doxorubicin</span>/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the <span class=""disease"">obese</span> (<span class=""disease"">OB</span>) rats in the absence of any significant renal or hepatic toxicity."		18674790	18674790_D004317_D009765	bcv_easy_874				
	D004317	"<span class=""chemical"">doxorubicin</span>"		D006331	"<span class=""disease"">cardiac dysfunction</span>"	"A LD(10) dose (8 mg <span class=""chemical"">doxorubicin</span>/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, <span class=""disease"">cardiac dysfunction</span>, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity."		18674790	18674790_D004317_D006331	bcv_easy_875				
	D004317	"<span class=""chemical"">doxorubicin</span>"		D007674|D056486	"<span class=""disease"">renal or hepatic toxicity</span>"	"A LD(10) dose (8 mg <span class=""chemical"">doxorubicin</span>/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant <span class=""disease"">renal or hepatic toxicity</span>."		18674790	18674790_D004317_D007674|D056486	bcv_easy_876				
	C010013	"<span class=""chemical"">doxorubicinol</span>"		D009765	"<span class=""disease"">OB</span>"	"Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and <span class=""chemical"">doxorubicinol</span> (toxic metabolite) in the normal diet-fed (ND) and <span class=""disease"">OB</span> hearts."		18674790	18674790_C010013_D009765	bcv_easy_877				
	D004317	"<span class=""chemical"">Doxorubicin</span>"		D009765	"<span class=""disease"">OB</span>"	"<span class=""chemical"">Doxorubicin</span> toxicokinetics studies revealed no change in accumulation of <span class=""chemical"">doxorubicin</span> and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and <span class=""disease"">OB</span> hearts."		18674790	18674790_D004317_D009765	bcv_easy_878				
	D000244	"<span class=""chemical"">ADP</span>"		D009765	"<span class=""disease"">OB</span>"	"Mechanistic studies revealed that <span class=""disease"">OB</span> rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in <span class=""disease"">OB</span>), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/<span class=""chemical"">ADP</span> ratio after doxorubicin administration."		18674790	18674790_D000244_D009765	bcv_easy_879				
	D004317	"<span class=""chemical"">doxorubicin</span>"		D009765	"<span class=""disease"">OB</span>"	"Mechanistic studies revealed that <span class=""disease"">OB</span> rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in <span class=""disease"">OB</span>), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after <span class=""chemical"">doxorubicin</span> administration."		18674790	18674790_D004317_D009765	bcv_easy_880				
	D000255	"<span class=""chemical"">ATP</span>"		D009765	"<span class=""disease"">OB</span>"	"Mechanistic studies revealed that <span class=""disease"">OB</span> rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in <span class=""disease"">OB</span>), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac <span class=""chemical"">ATP</span> levels accompanied by decreased <span class=""chemical"">ATP</span>/ADP ratio after doxorubicin administration."		18674790	18674790_D000255_D009765	bcv_easy_881				
	D000249	"<span class=""chemical"">AMP</span>"		D009765	"<span class=""disease"">OB</span>"	"Mechanistic studies revealed that <span class=""disease"">OB</span> rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in <span class=""disease"">OB</span>), (5) decreased mitochondrial <span class=""chemical"">AMP</span>-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration."		18674790	18674790_D000249_D009765	bcv_easy_882				
	D004317	"<span class=""chemical"">doxorubicin</span>"		D009765	"<span class=""disease"">obese</span>"	"In conclusion, HFD-induced <span class=""disease"">obese</span> rats are highly sensitized to <span class=""chemical"">doxorubicin</span>-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway."		18674790	18674790_D004317_D009765	bcv_easy_883				
	D000255	"<span class=""chemical"">ATP</span>"		D009765	"<span class=""disease"">obese</span>"	"In conclusion, HFD-induced <span class=""disease"">obese</span> rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial <span class=""chemical"">ATP</span> generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway."		18674790	18674790_D000255_D009765	bcv_easy_884				
	D000255	"<span class=""chemical"">ATP</span>"		D066126	"<span class=""disease"">cardiotoxicity</span>"	"In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced <span class=""disease"">cardiotoxicity</span> by substantially downregulating cardiac mitochondrial <span class=""chemical"">ATP</span> generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway."		18674790	18674790_D000255_D066126	bcv_easy_885				
	D017311	"<span class=""chemical"">amlodipine</span>"		D006973	"<span class=""disease"">hypertension</span>"	"Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and <span class=""chemical"">amlodipine</span> versus <span class=""chemical"">amlodipine</span> monotherapy in Indian adults with stage II <span class=""disease"">hypertension</span>."		18201582	18201582_D017311_D006973	bcv_easy_886				
	C084178	"<span class=""chemical"">telmisartan</span>"		D006973	"<span class=""disease"">hypertension</span>"	"Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of <span class=""chemical"">telmisartan</span> and amlodipine versus amlodipine monotherapy in Indian adults with stage II <span class=""disease"">hypertension</span>."		18201582	18201582_C084178_D006973	bcv_easy_887				
	D017311	"<span class=""chemical"">amlodipine</span>"		D006973	"<span class=""disease"">hypertension</span>"	"OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + <span class=""chemical"">amlodipine</span> 5 mg (T+A) compared with <span class=""chemical"">amlodipine</span> 5-mg monotherapy (A) in adult Indian patients with stage II <span class=""disease"">hypertension</span>."		18201582	18201582_D017311_D006973	bcv_easy_888				
	C084178	"<span class=""chemical"">telmisartan</span>"		D006973	"<span class=""disease"">hypertension</span>"	"OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of <span class=""chemical"">telmisartan</span> 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II <span class=""disease"">hypertension</span>."		18201582	18201582_C084178_D006973	bcv_easy_889				
	D007980	"<span class=""chemical"">L-dopa</span>"		D020734	"<span class=""disease"">parkinsonian</span>"	"Cortical motor overactivation in <span class=""disease"">parkinsonian</span> patients with <span class=""chemical"">L-dopa</span>-induced peak-dose dyskinesia."		9549528	9549528_D007980_D020734	bcv_easy_890				
	D007980	"<span class=""chemical"">L-dopa</span>"		D020734	"<span class=""disease"">parkinsonian</span>"	"We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of <span class=""disease"">parkinsonian</span> patients on <span class=""chemical"">L-dopa</span> medication, the first one without <span class=""chemical"">L-dopa</span> induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects."		9549528	9549528_D007980_D020734	bcv_easy_891				
	D007980	"<span class=""chemical"">L-dopa</span>"		D006948	"<span class=""disease"">hyperkinetic</span>"	"These results are compatible with the hypothesis that an <span class=""disease"">hyperkinetic</span> abnormal involuntary movement, like <span class=""chemical"">L-dopa</span>-induced peak dose dyskinesia, is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop."		9549528	9549528_D007980_D006948	bcv_easy_892				
	D007660	"<span class=""chemical"">ketoprofen</span>"		D017542	"<span class=""disease"">aneurysmal</span>"	"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either <span class=""chemical"">ketoprofen</span>, 100 mg, three times a day (<span class=""chemical"">ketoprofen</span> group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of <span class=""disease"">aneurysmal</span> SAH."		10414674	10414674_D007660_D017542	bcv_easy_893				
	D007660	"<span class=""chemical"">ketoprofen</span>"		D013345	"<span class=""disease"">aneurysmal subarachnoid hemorrhage/SAH</span>"	"Patients with <span class=""disease"">aneurysmal subarachnoid hemorrhage</span> (<span class=""disease"">SAH</span>) were randomized to receive either <span class=""chemical"">ketoprofen</span>, 100 mg, three times a day (<span class=""chemical"">ketoprofen</span> group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal <span class=""disease"">SAH</span>."		10414674	10414674_D007660_D013345	bcv_easy_894				
	D000082	"<span class=""chemical"">acetaminophen</span>"		D013345	"<span class=""disease"">aneurysmal subarachnoid hemorrhage/SAH</span>"	"Patients with <span class=""disease"">aneurysmal subarachnoid hemorrhage</span> (<span class=""disease"">SAH</span>) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, <span class=""chemical"">acetaminophen</span>, 1 g, three times a day (<span class=""chemical"">acetaminophen</span> group, n = 9) starting immediately after the diagnosis of aneurysmal <span class=""disease"">SAH</span>."		10414674	10414674_D000082_D013345	bcv_easy_895				
	D000082	"<span class=""chemical"">acetaminophen</span>"		D017542	"<span class=""disease"">aneurysmal</span>"	"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, <span class=""chemical"">acetaminophen</span>, 1 g, three times a day (<span class=""chemical"">acetaminophen</span> group, n = 9) starting immediately after the diagnosis of <span class=""disease"">aneurysmal</span> SAH."		10414674	10414674_D000082_D017542	bcv_easy_896				
	D000244	"<span class=""chemical"">adenosine diphosphate</span>"		D001791	"<span class=""disease"">platelet aggregation</span>"	"Maximal <span class=""disease"">platelet aggregation</span> induced by 6 microM of <span class=""chemical"">adenosine diphosphate</span> decreased after administration of ketoprofen."		10414674	10414674_D000244_D001791	bcv_easy_897				
	D007660	"<span class=""chemical"">ketoprofen</span>"		D001791	"<span class=""disease"">platelet aggregation</span>"	"Maximal <span class=""disease"">platelet aggregation</span> induced by 6 microM of adenosine diphosphate decreased after administration of <span class=""chemical"">ketoprofen</span>."		10414674	10414674_D007660_D001791	bcv_easy_898				
	D000082	"<span class=""chemical"">acetaminophen</span>"		D001791	"<span class=""disease"">platelet aggregation</span>"	"In contrast, maximal <span class=""disease"">platelet aggregation</span> increased in the <span class=""chemical"">acetaminophen</span> group on the third postoperative day as compared with the pretreatment <span class=""disease"">platelet aggregation</span> results (P < .05)."		10414674	10414674_D000082_D001791	bcv_easy_899				
	D007660	"<span class=""chemical"">ketoprofen</span>"		D006406	"<span class=""disease"">hematoma</span>"	"One patient in the <span class=""chemical"">ketoprofen</span> group developed a postoperative intracranial <span class=""disease"">hematoma</span>."		10414674	10414674_D007660_D006406	bcv_easy_900				
	D007660	"<span class=""chemical"">Ketoprofen</span>"		D013345	"<span class=""disease"">SAH</span>"	"<span class=""chemical"">Ketoprofen</span> but not acetaminophen impaired platelet function in patients with <span class=""disease"">SAH</span>."		10414674	10414674_D007660_D013345	bcv_easy_901				
	D000082	"<span class=""chemical"">acetaminophen</span>"		D013345	"<span class=""disease"">SAH</span>"	"Ketoprofen but not <span class=""chemical"">acetaminophen</span> impaired platelet function in patients with <span class=""disease"">SAH</span>."		10414674	10414674_D000082_D013345	bcv_easy_902				
	D007660	"<span class=""chemical"">ketoprofen</span>"		D006470	"<span class=""disease"">hemorrhage</span>"	"If <span class=""chemical"">ketoprofen</span> is used before surgery on cerebral artery aneurysms, it may pose an additional risk factor for <span class=""disease"">hemorrhage</span>."		10414674	10414674_D007660_D006470	bcv_easy_903				
	D007660	"<span class=""chemical"">ketoprofen</span>"		D002532	"<span class=""disease"">artery aneurysms</span>"	"If <span class=""chemical"">ketoprofen</span> is used before surgery on cerebral <span class=""disease"">artery aneurysms</span>, it may pose an additional risk factor for hemorrhage."		10414674	10414674_D007660_D002532	bcv_easy_904				
	D015215	"<span class=""chemical"">AZT/azidothymidine</span>"		D009190	"<span class=""disease"">myelodysplasia</span>"	"Lifetime treatment of mice with <span class=""chemical"">azidothymidine</span> (<span class=""chemical"">AZT</span>) produces <span class=""disease"">myelodysplasia</span>."		9209318	9209318_D015215_D009190	bcv_easy_905				
	D015215	"<span class=""chemical"">AZT</span>"		D000163	"<span class=""disease"">AIDS</span>"	"<span class=""chemical"">AZT</span> has induced a macrocytic anemia in <span class=""disease"">AIDS</span> patients on long term <span class=""chemical"">AZT</span> therapy."		9209318	9209318_D015215_D000163	bcv_easy_906				
	D015215	"<span class=""chemical"">AZT</span>"		D009190	"<span class=""disease"">myelodysplastic syndrome</span>"	"Above mentioned <span class=""chemical"">AZT</span> incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells, which is known to be seen commonly in the <span class=""disease"">myelodysplastic syndrome</span>."		9209318	9209318_D015215_D009190	bcv_easy_907				
	D006221	"<span class=""chemical"">halothane</span>"		D056486	"<span class=""disease"">hepatic injury</span>"	"Two halogenated anesthetics, enflurane and isoflurane, have been associated with an allergic-type <span class=""disease"">hepatic injury</span> both alone and following previous exposure to <span class=""chemical"">halothane</span>."		7647582	7647582_D006221_D056486	bcv_easy_908				
	D007530	"<span class=""chemical"">isoflurane</span>"		D056486	"<span class=""disease"">hepatic injury</span>"	"Two halogenated anesthetics, enflurane and <span class=""chemical"">isoflurane</span>, have been associated with an allergic-type <span class=""disease"">hepatic injury</span> both alone and following previous exposure to halothane."		7647582	7647582_D007530_D056486	bcv_easy_909				
	D004737	"<span class=""chemical"">enflurane</span>"		D056486	"<span class=""disease"">hepatic injury</span>"	"Two halogenated anesthetics, <span class=""chemical"">enflurane</span> and isoflurane, have been associated with an allergic-type <span class=""disease"">hepatic injury</span> both alone and following previous exposure to halothane."		7647582	7647582_D004737_D056486	bcv_easy_910				
	D006221	"<span class=""chemical"">Halothane</span>"		D056486	"<span class=""disease"">hepatitis</span>"	"<span class=""chemical"">Halothane</span> <span class=""disease"">hepatitis</span> appears to involve an aberrant immune response."		7647582	7647582_D006221_D056486	bcv_easy_911				
	D006221	"<span class=""chemical"">halothane</span>"		D056486	"<span class=""disease"">hepatitis</span>"	"An antibody response to a protein-bound biotransformation product (trifluoroacetyl adduct) has been detected on <span class=""chemical"">halothane</span> <span class=""disease"">hepatitis</span> patients."		7647582	7647582_D006221_D056486	bcv_easy_912				
	D014269	"<span class=""chemical"">trifluoroacetyl</span>"		D056486	"<span class=""disease"">hepatitis</span>"	"An antibody response to a protein-bound biotransformation product (<span class=""chemical"">trifluoroacetyl</span> adduct) has been detected on halothane <span class=""disease"">hepatitis</span> patients."		7647582	7647582_D014269_D056486	bcv_easy_913				
	D006221	"<span class=""chemical"">halothane</span>"		D004342	"<span class=""disease"">hypersensitivity</span>"	"This study was performed to determine cross-reactivity between enflurane and isoflurane with the <span class=""disease"">hypersensitivity</span> induced by <span class=""chemical"">halothane</span>."		7647582	7647582_D006221_D004342	bcv_easy_914				
	D007530	"<span class=""chemical"">isoflurane</span>"		D004342	"<span class=""disease"">hypersensitivity</span>"	"This study was performed to determine cross-reactivity between enflurane and <span class=""chemical"">isoflurane</span> with the <span class=""disease"">hypersensitivity</span> induced by halothane."		7647582	7647582_D007530_D004342	bcv_easy_915				
	D004737	"<span class=""chemical"">enflurane</span>"		D004342	"<span class=""disease"">hypersensitivity</span>"	"This study was performed to determine cross-reactivity between <span class=""chemical"">enflurane</span> and isoflurane with the <span class=""disease"">hypersensitivity</span> induced by halothane."		7647582	7647582_D004737_D004342	bcv_easy_916				
	D004737	"<span class=""chemical"">enflurane</span>"		D056486	"<span class=""disease"">hepatitis</span>"	"This supports and extends previous evidence for a mechanism by which <span class=""chemical"">enflurane</span> and/or isoflurane could produce a hypersensitivity condition similar to that of halothane <span class=""disease"">hepatitis</span> either alone or subsequent to halothane administration."		7647582	7647582_D004737_D056486	bcv_easy_917				
	D007530	"<span class=""chemical"">isoflurane</span>"		D056486	"<span class=""disease"">hepatitis</span>"	"This supports and extends previous evidence for a mechanism by which enflurane and/or <span class=""chemical"">isoflurane</span> could produce a hypersensitivity condition similar to that of halothane <span class=""disease"">hepatitis</span> either alone or subsequent to halothane administration."		7647582	7647582_D007530_D056486	bcv_easy_918				
	D006221	"<span class=""chemical"">halothane</span>"		D056486	"<span class=""disease"">hepatitis</span>"	"This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a hypersensitivity condition similar to that of <span class=""chemical"">halothane</span> <span class=""disease"">hepatitis</span> either alone or subsequent to <span class=""chemical"">halothane</span> administration."		7647582	7647582_D006221_D056486	bcv_easy_919				
	D004737	"<span class=""chemical"">enflurane</span>"		D004342	"<span class=""disease"">hypersensitivity</span>"	"This supports and extends previous evidence for a mechanism by which <span class=""chemical"">enflurane</span> and/or isoflurane could produce a <span class=""disease"">hypersensitivity</span> condition similar to that of halothane hepatitis either alone or subsequent to halothane administration."		7647582	7647582_D004737_D004342	bcv_easy_920				
	D007530	"<span class=""chemical"">isoflurane</span>"		D004342	"<span class=""disease"">hypersensitivity</span>"	"This supports and extends previous evidence for a mechanism by which enflurane and/or <span class=""chemical"">isoflurane</span> could produce a <span class=""disease"">hypersensitivity</span> condition similar to that of halothane hepatitis either alone or subsequent to halothane administration."		7647582	7647582_D007530_D004342	bcv_easy_921				
	D006221	"<span class=""chemical"">halothane</span>"		D004342	"<span class=""disease"">hypersensitivity</span>"	"This supports and extends previous evidence for a mechanism by which enflurane and/or isoflurane could produce a <span class=""disease"">hypersensitivity</span> condition similar to that of <span class=""chemical"">halothane</span> hepatitis either alone or subsequent to <span class=""chemical"">halothane</span> administration."		7647582	7647582_D006221_D004342	bcv_easy_922				
	C422649	"<span class=""chemical"">etoricoxib</span>"		D001172	"<span class=""disease"">rheumatoid arthritis</span>"	"Gastrointestinal tolerability of <span class=""chemical"">etoricoxib</span> in <span class=""disease"">rheumatoid arthritis</span> patients: results of the <span class=""chemical"">etoricoxib</span> vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II)."		17965424	17965424_C422649_D001172	bcv_easy_923				
	D004008	"<span class=""chemical"">diclofenac sodium</span>"		D001172	"<span class=""disease"">rheumatoid arthritis</span>"	"Gastrointestinal tolerability of etoricoxib in <span class=""disease"">rheumatoid arthritis</span> patients: results of the etoricoxib vs <span class=""chemical"">diclofenac sodium</span> gastrointestinal tolerability and effectiveness trial (EDGE-II)."		17965424	17965424_D004008_D001172	bcv_easy_924				
	C422649	"<span class=""chemical"">etoricoxib</span>"		D001172	"<span class=""disease"">rheumatoid arthritis/RA</span>"	"OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of <span class=""chemical"">etoricoxib</span> and diclofenac in patients with <span class=""disease"">rheumatoid arthritis</span> (<span class=""disease"">RA</span>)."		17965424	17965424_C422649_D001172	bcv_easy_925				
	D004008	"<span class=""chemical"">diclofenac</span>"		D001172	"<span class=""disease"">rheumatoid arthritis/RA</span>"	"OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and <span class=""chemical"">diclofenac</span> in patients with <span class=""disease"">rheumatoid arthritis</span> (<span class=""disease"">RA</span>)."		17965424	17965424_D004008_D001172	bcv_easy_926				
	C422649	"<span class=""chemical"">etoricoxib</span>"		D001172	"<span class=""disease"">RA</span>"	"PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with <span class=""disease"">RA</span> were enrolled and received <span class=""chemical"">etoricoxib</span> 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054)."		17965424	17965424_C422649_D001172	bcv_easy_927				
	D004008	"<span class=""chemical"">diclofenac</span>"		D001172	"<span class=""disease"">RA</span>"	"PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with <span class=""disease"">RA</span> were enrolled and received etoricoxib 90 mg daily (n = 2032) or <span class=""chemical"">diclofenac</span> 75 mg twice daily (n = 2054)."		17965424	17965424_D004008_D001172	bcv_easy_928				
	D004008	"<span class=""chemical"">diclofenac</span>"		D005767	"<span class=""disease"">GI AEs</span>"	"The cumulative discontinuation rate due to <span class=""disease"">GI AEs</span> was significantly lower with etoricoxib than <span class=""chemical"">diclofenac</span> (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001))."		17965424	17965424_D004008_D005767	bcv_easy_929				
	C422649	"<span class=""chemical"">etoricoxib</span>"		D005767	"<span class=""disease"">GI AEs</span>"	"The cumulative discontinuation rate due to <span class=""disease"">GI AEs</span> was significantly lower with <span class=""chemical"">etoricoxib</span> than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001))."		17965424	17965424_C422649_D005767	bcv_easy_930				
	D004008	"<span class=""chemical"">diclofenac</span>"		D004487	"<span class=""disease"">oedema</span>"	"The incidence of discontinuations for hypertension-related and <span class=""disease"">oedema</span>-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with <span class=""chemical"">diclofenac</span> (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for <span class=""disease"">oedema</span>)."		17965424	17965424_D004008_D004487	bcv_easy_931				
	C422649	"<span class=""chemical"">etoricoxib</span>"		D006973	"<span class=""disease"">hypertension</span>"	"The incidence of discontinuations for <span class=""disease"">hypertension</span>-related and oedema-related AEs were significantly higher with <span class=""chemical"">etoricoxib</span> (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for <span class=""disease"">hypertension</span> and p<0.01 for oedema)."		17965424	17965424_C422649_D006973	bcv_easy_932				
	C422649	"<span class=""chemical"">etoricoxib</span>"		D004487	"<span class=""disease"">oedema</span>"	"The incidence of discontinuations for hypertension-related and <span class=""disease"">oedema</span>-related AEs were significantly higher with <span class=""chemical"">etoricoxib</span> (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for <span class=""disease"">oedema</span>)."		17965424	17965424_C422649_D004487	bcv_easy_933				
	D004008	"<span class=""chemical"">diclofenac</span>"		D006973	"<span class=""disease"">hypertension</span>"	"The incidence of discontinuations for <span class=""disease"">hypertension</span>-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with <span class=""chemical"">diclofenac</span> (1.5% and 0.4% respectively; p<0.001 for <span class=""disease"">hypertension</span> and p<0.01 for oedema)."		17965424	17965424_D004008_D006973	bcv_easy_934				
	D004008	"<span class=""chemical"">diclofenac</span>"		D005767	"<span class=""disease"">GI AEs</span>"	"CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to <span class=""disease"">GI AEs</span> compared with <span class=""chemical"">diclofenac</span> 150 mg."		17965424	17965424_D004008_D005767	bcv_easy_935				
	C422649	"<span class=""chemical"">Etoricoxib</span>"		D005767	"<span class=""disease"">GI AEs</span>"	"CONCLUSIONS: <span class=""chemical"">Etoricoxib</span> 90 mg demonstrated a significantly lower risk for discontinuing treatment due to <span class=""disease"">GI AEs</span> compared with diclofenac 150 mg."		17965424	17965424_C422649_D005767	bcv_easy_936				
	C422649	"<span class=""chemical"">etoricoxib</span>"		D005767	"<span class=""disease"">GI AEs</span>"	"Discontinuations from renovascular AEs, although less common than discontinuations from <span class=""disease"">GI AEs</span>, were significantly higher with <span class=""chemical"">etoricoxib</span>."		17965424	17965424_C422649_D005767	bcv_easy_937				
	D004317	"<span class=""chemical"">adriamycin</span>"		D066126	"<span class=""disease"">Cardiotoxic</span>"	"<span class=""disease"">Cardiotoxic</span> and possible leukemogenic effects of <span class=""chemical"">adriamycin</span> in nonhuman primates."		6769133	6769133_D004317_D066126	bcv_easy_938				
	D004317	"<span class=""chemical"">adriamycin</span>"		D006333	"<span class=""disease"">congestive heart failure</span>"	"8 of the 10 monkeys developed <span class=""disease"">congestive heart failure</span> at an average cumulative <span class=""chemical"">adriamycin</span> dose (310 mg/m2) well below that considered the safe upper limit (550 mg/m2) in man."		6769133	6769133_D004317_D006333	bcv_easy_939				
	D018943	"<span class=""chemical"">anthracycline</span>"		D001768	"<span class=""disease"">myocardial lesions</span>"	"Histologically, the <span class=""disease"">myocardial lesions</span> resembled those found in human <span class=""chemical"">anthracycline</span>-induced cardiomyopathy."		6769133	6769133_D018943_D001768	bcv_easy_940				
	D004317	"<span class=""chemical"">adriamycin</span>"		D015470	"<span class=""disease"">acute myeloblastic leukemia</span>"	"1 of the 10 monkeys developed <span class=""disease"">acute myeloblastic leukemia</span> after receiving 324 mg/m2 of <span class=""chemical"">adriamycin</span>; the 10th monkey is alive and well 26 months after the last dose of drug."		6769133	6769133_D004317_D015470	bcv_easy_941				
	D004317	"<span class=""chemical"">adriamycin</span>"		D007938	"<span class=""disease"">leukemia</span>"	"Our results suggest that <span class=""chemical"">adriamycin</span> is a more potent cardiotoxin in monkeys than in man, and that <span class=""disease"">leukemia</span> may be a consequence of prolonged treatment with this drug."		6769133	6769133_D004317_D007938	bcv_easy_942				
	D008315	"<span class=""chemical"">malondialdehyde</span>"		D002545	"<span class=""disease"">cerebral ischemia</span>"	"Time dependence of plasma <span class=""chemical"">malondialdehyde</span>, oxypurines, and nucleosides during incomplete <span class=""disease"">cerebral ischemia</span> in the rat."		7710775	7710775_D008315_D002545	bcv_easy_943				
	D009705	"<span class=""chemical"">nucleosides</span>"		D002545	"<span class=""disease"">cerebral ischemia</span>"	"Time dependence of plasma malondialdehyde, oxypurines, and <span class=""chemical"">nucleosides</span> during incomplete <span class=""disease"">cerebral ischemia</span> in the rat."		7710775	7710775_D009705_D002545	bcv_easy_944				
	D009705	"<span class=""chemical"">nucleosides</span>"		D007511	"<span class=""disease"">ischemia</span>"	"During <span class=""disease"">ischemia</span>, a time-dependent increase of plasma oxypurines and <span class=""chemical"">nucleosides</span> was observed."		7710775	7710775_D009705_D007511	bcv_easy_945				
	D008315	"<span class=""chemical"">malondialdehyde</span>"		D007511	"<span class=""disease"">ischemia</span>"	"Plasma <span class=""chemical"">malondialdehyde</span>, which was present in minimal amount at zero time (0.058 mumol/liter plasma; SD 0.015), increased after 5 min of <span class=""disease"">ischemia</span>, resulting in a fivefold increase after 30 min of carotid occlusion (0.298 mumol/liter plasma; SD 0.078)."		7710775	7710775_D008315_D007511	bcv_easy_946				
	D001241	"<span class=""chemical"">acetylsalicylate</span>"		D007511	"<span class=""disease"">ischemia</span>"	"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor <span class=""chemical"">acetylsalicylate</span> intravenously immediately before <span class=""disease"">ischemia</span>, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during <span class=""disease"">ischemia</span>, although in this latter group malondialdehyde was significantly higher."		7710775	7710775_D001241_D007511	bcv_easy_947				
	D008315	"<span class=""chemical"">malondialdehyde</span>"		D007511	"<span class=""disease"">ischemia</span>"	"Increased plasma <span class=""chemical"">malondialdehyde</span> was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before <span class=""disease"">ischemia</span>, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during <span class=""disease"">ischemia</span>, although in this latter group <span class=""chemical"">malondialdehyde</span> was significantly higher."		7710775	7710775_D008315_D007511	bcv_easy_948				
	D008315	"<span class=""chemical"">malondialdehyde</span>"		D007022	"<span class=""disease"">hypotensive</span>"	"Increased plasma <span class=""chemical"">malondialdehyde</span> was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the <span class=""disease"">hypotensive</span> drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group <span class=""chemical"">malondialdehyde</span> was significantly higher."		7710775	7710775_D008315_D007022	bcv_easy_949				
	D009599	"<span class=""chemical"">nitroprusside</span>"		D007511	"<span class=""disease"">ischemia</span>"	"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before <span class=""disease"">ischemia</span>, the other receiving 650 micrograms/kg b.w. of the hypotensive drug <span class=""chemical"">nitroprusside</span> at a flow rate of 103 microliters/min intravenously during <span class=""disease"">ischemia</span>, although in this latter group malondialdehyde was significantly higher."		7710775	7710775_D009599_D007511	bcv_easy_950				
	D001241	"<span class=""chemical"">acetylsalicylate</span>"		D007022	"<span class=""disease"">hypotensive</span>"	"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor <span class=""chemical"">acetylsalicylate</span> intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the <span class=""disease"">hypotensive</span> drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher."		7710775	7710775_D001241_D007022	bcv_easy_951				
	D009599	"<span class=""chemical"">nitroprusside</span>"		D007022	"<span class=""disease"">hypotensive</span>"	"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the <span class=""disease"">hypotensive</span> drug <span class=""chemical"">nitroprusside</span> at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher."		7710775	7710775_D009599_D007022	bcv_easy_952				
	D008315	"<span class=""chemical"">malondialdehyde</span>"		D007511	"<span class=""disease"">ischemic</span>"	"The present data indicate that the determination of <span class=""chemical"">malondialdehyde</span>, oxypurines, and nucleosides in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during <span class=""disease"">ischemic</span> phenomena.(ABSTRACT TRUNCATED AT 250 WORDS)"		7710775	7710775_D008315_D007511	bcv_easy_953				
	D009705	"<span class=""chemical"">nucleosides</span>"		D007511	"<span class=""disease"">ischemic</span>"	"The present data indicate that the determination of malondialdehyde, oxypurines, and <span class=""chemical"">nucleosides</span> in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during <span class=""disease"">ischemic</span> phenomena.(ABSTRACT TRUNCATED AT 250 WORDS)"		7710775	7710775_D009705_D007511	bcv_easy_954				
	D003630	"<span class=""chemical"">daunorubicin</span>"		D001855	"<span class=""disease"">myelosuppression</span>"	"Dexrazoxane protects against <span class=""disease"">myelosuppression</span> from the DNA cleavage-enhancing drugs etoposide and <span class=""chemical"">daunorubicin</span> but not doxorubicin."		15897593	15897593_D003630_D001855	bcv_easy_955				
	D005047	"<span class=""chemical"">etoposide</span>"		D001855	"<span class=""disease"">myelosuppression</span>"	"Dexrazoxane protects against <span class=""disease"">myelosuppression</span> from the DNA cleavage-enhancing drugs <span class=""chemical"">etoposide</span> and daunorubicin but not doxorubicin."		15897593	15897593_D005047_D001855	bcv_easy_956				
	D064730	"<span class=""chemical"">Dexrazoxane</span>"		D001855	"<span class=""disease"">myelosuppression</span>"	"<span class=""chemical"">Dexrazoxane</span> protects against <span class=""disease"">myelosuppression</span> from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin."		15897593	15897593_D064730_D001855	bcv_easy_957				
	D004317	"<span class=""chemical"">doxorubicin</span>"		D001855	"<span class=""disease"">myelosuppression</span>"	"Dexrazoxane protects against <span class=""disease"">myelosuppression</span> from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not <span class=""chemical"">doxorubicin</span>."		15897593	15897593_D004317_D001855	bcv_easy_958				
	D003630	"<span class=""chemical"">daunorubicin</span>"		D066126	"<span class=""disease"">cardiac toxicity</span>"	"PURPOSE: The anthracyclines <span class=""chemical"">daunorubicin</span> and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and <span class=""disease"">cardiac toxicity</span> limit their use."		15897593	15897593_D003630_D066126	bcv_easy_959				
	D018943	"<span class=""chemical"">anthracyclines</span>"		D001855	"<span class=""disease"">myelosuppression</span>"	"PURPOSE: The <span class=""chemical"">anthracyclines</span> daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, <span class=""disease"">myelosuppression</span> and cardiac toxicity limit their use."		15897593	15897593_D018943_D001855	bcv_easy_960				
	D011034	"<span class=""chemical"">epipodophyllotoxin</span>"		D001855	"<span class=""disease"">myelosuppression</span>"	"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the <span class=""chemical"">epipodophyllotoxin</span> etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, <span class=""disease"">myelosuppression</span> and cardiac toxicity limit their use."		15897593	15897593_D011034_D001855	bcv_easy_961				
	D003630	"<span class=""chemical"">daunorubicin</span>"		D001855	"<span class=""disease"">myelosuppression</span>"	"PURPOSE: The anthracyclines <span class=""chemical"">daunorubicin</span> and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, <span class=""disease"">myelosuppression</span> and cardiac toxicity limit their use."		15897593	15897593_D003630_D001855	bcv_easy_962				
	D011034	"<span class=""chemical"">epipodophyllotoxin</span>"		D066126	"<span class=""disease"">cardiac toxicity</span>"	"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the <span class=""chemical"">epipodophyllotoxin</span> etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and <span class=""disease"">cardiac toxicity</span> limit their use."		15897593	15897593_D011034_D066126	bcv_easy_963				
	D004317	"<span class=""chemical"">doxorubicin</span>"		D066126	"<span class=""disease"">cardiac toxicity</span>"	"PURPOSE: The anthracyclines daunorubicin and <span class=""chemical"">doxorubicin</span> and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and <span class=""disease"">cardiac toxicity</span> limit their use."		15897593	15897593_D004317_D066126	bcv_easy_964				
	D005047	"<span class=""chemical"">etoposide</span>"		D001855	"<span class=""disease"">myelosuppression</span>"	"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin <span class=""chemical"">etoposide</span> are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, <span class=""disease"">myelosuppression</span> and cardiac toxicity limit their use."		15897593	15897593_D005047_D001855	bcv_easy_965				
	D004317	"<span class=""chemical"">doxorubicin</span>"		D001855	"<span class=""disease"">myelosuppression</span>"	"PURPOSE: The anthracyclines daunorubicin and <span class=""chemical"">doxorubicin</span> and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, <span class=""disease"">myelosuppression</span> and cardiac toxicity limit their use."		15897593	15897593_D004317_D001855	bcv_easy_966				
	D005047	"<span class=""chemical"">etoposide</span>"		D066126	"<span class=""disease"">cardiac toxicity</span>"	"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin <span class=""chemical"">etoposide</span> are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and <span class=""disease"">cardiac toxicity</span> limit their use."		15897593	15897593_D005047_D066126	bcv_easy_967				
	D064730	"<span class=""chemical"">ICRF-187/Dexrazoxane</span>"		D066126	"<span class=""disease"">cardiotoxicity</span>"	"<span class=""chemical"">Dexrazoxane</span> (<span class=""chemical"">ICRF-187</span>) is recommended for protection against anthracycline-induced <span class=""disease"">cardiotoxicity</span>."		15897593	15897593_D064730_D066126	bcv_easy_968				
	D003630	"<span class=""chemical"">daunorubicin</span>"		D006402	"<span class=""disease"">hematologic toxicity</span>"	"EXPERIMENTAL DESIGN: Because of their widespread use, the <span class=""disease"">hematologic toxicity</span> following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, <span class=""chemical"">daunorubicin</span>, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays."		15897593	15897593_D003630_D006402	bcv_easy_969				
	D005047	"<span class=""chemical"">etoposide</span>"		D006402	"<span class=""disease"">hematologic toxicity</span>"	"EXPERIMENTAL DESIGN: Because of their widespread use, the <span class=""disease"">hematologic toxicity</span> following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to <span class=""chemical"">etoposide</span>, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays."		15897593	15897593_D005047_D006402	bcv_easy_970				
	D004317	"<span class=""chemical"">doxorubicin</span>"		D006402	"<span class=""disease"">hematologic toxicity</span>"	"EXPERIMENTAL DESIGN: Because of their widespread use, the <span class=""disease"">hematologic toxicity</span> following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and <span class=""chemical"">doxorubicin</span> +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays."		15897593	15897593_D004317_D006402	bcv_easy_971				
	D064730	"<span class=""chemical"">dexrazoxane</span>"		D006402	"<span class=""disease"">hematologic toxicity</span>"	"EXPERIMENTAL DESIGN: Because of their widespread use, the <span class=""disease"">hematologic toxicity</span> following coadministration of <span class=""chemical"">dexrazoxane</span> and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- <span class=""chemical"">dexrazoxane</span> was determined in granulocyte-macrophage colony forming assays."		15897593	15897593_D064730_D006402	bcv_easy_972				
	D005047	"<span class=""chemical"">etoposide</span>"		D064420	"<span class=""disease"">cytotoxicity</span>"	"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and <span class=""chemical"">etoposide</span> in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro <span class=""disease"">cytotoxicity</span> from doxorubicin."		15897593	15897593_D005047_D064420	bcv_easy_973				
	D004317	"<span class=""chemical"">doxorubicin</span>"		D064420	"<span class=""disease"">cytotoxicity</span>"	"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro <span class=""disease"">cytotoxicity</span> from <span class=""chemical"">doxorubicin</span>."		15897593	15897593_D004317_D064420	bcv_easy_974				
	D064730	"<span class=""chemical"">dexrazoxane</span>"		D001855	"<span class=""disease"">myelosuppression</span>"	"RESULTS: Nontoxic doses of <span class=""chemical"">dexrazoxane</span> reduced <span class=""disease"">myelosuppression</span> and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, <span class=""chemical"">dexrazoxane</span> neither reduced <span class=""disease"">myelosuppression</span>, weight loss, nor the in vitro cytotoxicity from doxorubicin."		15897593	15897593_D064730_D001855	bcv_easy_975				
	D064730	"<span class=""chemical"">dexrazoxane</span>"		D015431	"<span class=""disease"">weight loss</span>"	"RESULTS: Nontoxic doses of <span class=""chemical"">dexrazoxane</span> reduced myelosuppression and <span class=""disease"">weight loss</span> from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, <span class=""chemical"">dexrazoxane</span> neither reduced myelosuppression, <span class=""disease"">weight loss</span>, nor the in vitro cytotoxicity from doxorubicin."		15897593	15897593_D064730_D015431	bcv_easy_976				
	D003630	"<span class=""chemical"">daunorubicin</span>"		D001855	"<span class=""disease"">myelosuppression</span>"	"RESULTS: Nontoxic doses of dexrazoxane reduced <span class=""disease"">myelosuppression</span> and weight loss from <span class=""chemical"">daunorubicin</span> and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced <span class=""disease"">myelosuppression</span>, weight loss, nor the in vitro cytotoxicity from doxorubicin."		15897593	15897593_D003630_D001855	bcv_easy_977				
	D005047	"<span class=""chemical"">etoposide</span>"		D001855	"<span class=""disease"">myelosuppression</span>"	"RESULTS: Nontoxic doses of dexrazoxane reduced <span class=""disease"">myelosuppression</span> and weight loss from daunorubicin and <span class=""chemical"">etoposide</span> in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced <span class=""disease"">myelosuppression</span>, weight loss, nor the in vitro cytotoxicity from doxorubicin."		15897593	15897593_D005047_D001855	bcv_easy_978				
	D004317	"<span class=""chemical"">doxorubicin</span>"		D015431	"<span class=""disease"">weight loss</span>"	"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and <span class=""disease"">weight loss</span> from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, <span class=""disease"">weight loss</span>, nor the in vitro cytotoxicity from <span class=""chemical"">doxorubicin</span>."		15897593	15897593_D004317_D015431	bcv_easy_979				
	D004317	"<span class=""chemical"">doxorubicin</span>"		D001855	"<span class=""disease"">myelosuppression</span>"	"RESULTS: Nontoxic doses of dexrazoxane reduced <span class=""disease"">myelosuppression</span> and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced <span class=""disease"">myelosuppression</span>, weight loss, nor the in vitro cytotoxicity from <span class=""chemical"">doxorubicin</span>."		15897593	15897593_D004317_D001855	bcv_easy_980				
	D064730	"<span class=""chemical"">dexrazoxane</span>"		D064420	"<span class=""disease"">cytotoxicity</span>"	"RESULTS: Nontoxic doses of <span class=""chemical"">dexrazoxane</span> reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, <span class=""chemical"">dexrazoxane</span> neither reduced myelosuppression, weight loss, nor the in vitro <span class=""disease"">cytotoxicity</span> from doxorubicin."		15897593	15897593_D064730_D064420	bcv_easy_981				
	D003630	"<span class=""chemical"">daunorubicin</span>"		D064420	"<span class=""disease"">cytotoxicity</span>"	"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from <span class=""chemical"">daunorubicin</span> and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro <span class=""disease"">cytotoxicity</span> from doxorubicin."		15897593	15897593_D003630_D064420	bcv_easy_982				
	D003630	"<span class=""chemical"">daunorubicin</span>"		D015431	"<span class=""disease"">weight loss</span>"	"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and <span class=""disease"">weight loss</span> from <span class=""chemical"">daunorubicin</span> and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, <span class=""disease"">weight loss</span>, nor the in vitro cytotoxicity from doxorubicin."		15897593	15897593_D003630_D015431	bcv_easy_983				
	D005047	"<span class=""chemical"">etoposide</span>"		D015431	"<span class=""disease"">weight loss</span>"	"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and <span class=""disease"">weight loss</span> from daunorubicin and <span class=""chemical"">etoposide</span> in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, <span class=""disease"">weight loss</span>, nor the in vitro cytotoxicity from doxorubicin."		15897593	15897593_D005047_D015431	bcv_easy_984				
	D064730	"<span class=""chemical"">dexrazoxane</span>"		D009362	"<span class=""disease"">metastases</span>"	"Clinical trials in patients with brain <span class=""disease"">metastases</span> combining <span class=""chemical"">dexrazoxane</span> and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity."		15897593	15897593_D064730_D009362	bcv_easy_985				
	D064730	"<span class=""chemical"">dexrazoxane</span>"		D006402	"<span class=""disease"">hematologic toxicity</span>"	"Clinical trials in patients with brain metastases combining <span class=""chemical"">dexrazoxane</span> and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating <span class=""disease"">hematologic toxicity</span>."		15897593	15897593_D064730_D006402	bcv_easy_986				
	D005047	"<span class=""chemical"">etoposide</span>"		D006402	"<span class=""disease"">hematologic toxicity</span>"	"Clinical trials in patients with brain metastases combining dexrazoxane and high doses of <span class=""chemical"">etoposide</span> is ongoing with the aim of improving efficacy without aggravating <span class=""disease"">hematologic toxicity</span>."		15897593	15897593_D005047_D006402	bcv_easy_987				
	D005047	"<span class=""chemical"">etoposide</span>"		D009362	"<span class=""disease"">metastases</span>"	"Clinical trials in patients with brain <span class=""disease"">metastases</span> combining dexrazoxane and high doses of <span class=""chemical"">etoposide</span> is ongoing with the aim of improving efficacy without aggravating hematologic toxicity."		15897593	15897593_D005047_D009362	bcv_easy_988				
	D000086	"<span class=""chemical"">acetazolamide</span>"		D007674	"<span class=""disease"">renal impairment</span>"	"Acute confusion induced by <span class=""chemical"">acetazolamide</span> is a well known adverse drug reaction in patients with <span class=""disease"">renal impairment</span>."		10692744	10692744_D000086_D007674	bcv_easy_989				
	D000086	"<span class=""chemical"">acetazolamide</span>"		D003221	"<span class=""disease"">confusion</span>"	"Acute <span class=""disease"">confusion</span> induced by <span class=""chemical"">acetazolamide</span> is a well known adverse drug reaction in patients with renal impairment."		10692744	10692744_D000086_D003221	bcv_easy_990				
	D003975	"<span class=""chemical"">Diazepam</span>"		D006212	"<span class=""disease"">hallucinations</span>"	"<span class=""chemical"">Diazepam</span>, unless contraindicated or risky, remains the only necessary complementary drug to ketamine as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative <span class=""disease"">hallucinations</span>."		12091028	12091028_D003975_D006212	bcv_easy_991				
	D007649	"<span class=""chemical"">ketamine</span>"		D006212	"<span class=""disease"">hallucinations</span>"	"Diazepam, unless contraindicated or risky, remains the only necessary complementary drug to <span class=""chemical"">ketamine</span> as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative <span class=""disease"">hallucinations</span>."		12091028	12091028_D007649_D006212	bcv_easy_992				
	D005472	"<span class=""chemical"">5-fluorouracil</span>"		D066126	"<span class=""disease"">Cardiac toxicity</span>"	"<span class=""disease"">Cardiac toxicity</span> of <span class=""chemical"">5-fluorouracil</span>. Report of a case of spontaneous angina."		3952818	3952818_D005472_D066126	bcv_easy_993				
	D005472	"<span class=""chemical"">5-fluorouracil</span>"		D000787	"<span class=""disease"">angina</span>"	"Cardiac toxicity of <span class=""chemical"">5-fluorouracil</span>. Report of a case of spontaneous <span class=""disease"">angina</span>."		3952818	3952818_D005472_D000787	bcv_easy_994				
	D005472	"<span class=""chemical"">5-FU/5-fluorouracil</span>"		D003110	"<span class=""disease"">colon carcinoma</span>"	"We report a case of a patient with <span class=""disease"">colon carcinoma</span> and liver metastasis who presented chest pain after <span class=""chemical"">5-fluorouracil</span> (<span class=""chemical"">5-FU</span>) administration."		3952818	3952818_D005472_D003110	bcv_easy_995				
	D005472	"<span class=""chemical"">5-FU/5-fluorouracil</span>"		D009362	"<span class=""disease"">metastasis</span>"	"We report a case of a patient with colon carcinoma and liver <span class=""disease"">metastasis</span> who presented chest pain after <span class=""chemical"">5-fluorouracil</span> (<span class=""chemical"">5-FU</span>) administration."		3952818	3952818_D005472_D009362	bcv_easy_996				
	D005472	"<span class=""chemical"">5-FU/5-fluorouracil</span>"		D002637	"<span class=""disease"">chest pain</span>"	"We report a case of a patient with colon carcinoma and liver metastasis who presented <span class=""disease"">chest pain</span> after <span class=""chemical"">5-fluorouracil</span> (<span class=""chemical"">5-FU</span>) administration."		3952818	3952818_D005472_D002637	bcv_easy_997				
	D009543	"<span class=""chemical"">nifedipine</span>"		D002637	"<span class=""disease"">chest pain</span>"	"Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and <span class=""disease"">chest pain</span> promptly resolved with <span class=""chemical"">nifedipine</span>."		3952818	3952818_D009543_D002637	bcv_easy_998				
	D009543	"<span class=""chemical"">nifedipine</span>"		D000788	"<span class=""disease"">Prinzmetal's angina</span>"	"Clinical electrocardiographic evolution was similar to that observed in <span class=""disease"">Prinzmetal's angina</span>, and chest pain promptly resolved with <span class=""chemical"">nifedipine</span>."		3952818	3952818_D009543_D000788	bcv_easy_999				
	D005472	"<span class=""chemical"">5-FU</span>"		D066126	"<span class=""disease"">cardiotoxicity</span>"	"These data suggest that coronary spasm may be the cause of <span class=""disease"">cardiotoxicity</span> due to <span class=""chemical"">5-FU</span>, and that calcium antagonists may probably be used in the prevention or treatment of <span class=""chemical"">5-FU</span> <span class=""disease"">cardiotoxicity</span>."		3952818	3952818_D005472_D066126	bcv_easy_1000				
	D002118	"<span class=""chemical"">calcium</span>"		D066126	"<span class=""disease"">cardiotoxicity</span>"	"These data suggest that coronary spasm may be the cause of <span class=""disease"">cardiotoxicity</span> due to 5-FU, and that <span class=""chemical"">calcium</span> antagonists may probably be used in the prevention or treatment of 5-FU <span class=""disease"">cardiotoxicity</span>."		3952818	3952818_D002118_D066126	bcv_easy_1001				
	D002118	"<span class=""chemical"">calcium</span>"		D003329	"<span class=""disease"">coronary spasm</span>"	"These data suggest that <span class=""disease"">coronary spasm</span> may be the cause of cardiotoxicity due to 5-FU, and that <span class=""chemical"">calcium</span> antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity."		3952818	3952818_D002118_D003329	bcv_easy_1002				
	D005472	"<span class=""chemical"">5-FU</span>"		D003329	"<span class=""disease"">coronary spasm</span>"	"These data suggest that <span class=""disease"">coronary spasm</span> may be the cause of cardiotoxicity due to <span class=""chemical"">5-FU</span>, and that calcium antagonists may probably be used in the prevention or treatment of <span class=""chemical"">5-FU</span> cardiotoxicity."		3952818	3952818_D005472_D003329	bcv_easy_1003				
	C047781	"<span class=""chemical"">Lamotrigine</span>"		C562694	"<span class=""disease"">idiopathic generalized epilepsies</span>"	"<span class=""chemical"">Lamotrigine</span> associated with exacerbation or de novo myoclonus in <span class=""disease"">idiopathic generalized epilepsies</span>."		16157917	16157917_C047781_C562694	bcv_easy_1004				
	C047781	"<span class=""chemical"">Lamotrigine</span>"		D009207	"<span class=""disease"">myoclonus</span>"	"<span class=""chemical"">Lamotrigine</span> associated with exacerbation or de novo <span class=""disease"">myoclonus</span> in idiopathic generalized epilepsies."		16157917	16157917_C047781_D009207	bcv_easy_1005				
	C047781	"<span class=""chemical"">LTG/lamotrigine</span>"		C562694	"<span class=""disease"">IGE/idiopathic generalized epilepsies</span>"	"Five patients with <span class=""disease"">idiopathic generalized epilepsies</span> (<span class=""disease"">IGE</span>) treated with <span class=""chemical"">lamotrigine</span> (<span class=""chemical"">LTG</span>) experienced exacerbation or de novo appearance of myoclonic jerks (MJ)."		16157917	16157917_C047781_C562694	bcv_easy_1006				
	C047781	"<span class=""chemical"">LTG/lamotrigine</span>"		D009207	"<span class=""disease"">myoclonic jerks/MJ</span>"	"Five patients with idiopathic generalized epilepsies (IGE) treated with <span class=""chemical"">lamotrigine</span> (<span class=""chemical"">LTG</span>) experienced exacerbation or de novo appearance of <span class=""disease"">myoclonic jerks</span> (<span class=""disease"">MJ</span>)."		16157917	16157917_C047781_D009207	bcv_easy_1007				
	C047781	"<span class=""chemical"">LTG</span>"		D009207	"<span class=""disease"">MJ</span>"	"In three patients, <span class=""chemical"">LTG</span> exacerbated <span class=""disease"">MJ</span> in a dose-dependent manner with early aggravation during titration."		16157917	16157917_C047781_D009207	bcv_easy_1008				
	C047781	"<span class=""chemical"">LTG</span>"		D009207	"<span class=""disease"">MJ</span>"	"<span class=""disease"">MJ</span> disappeared when <span class=""chemical"">LTG</span> dose was decreased by 25 to 50%."		16157917	16157917_C047781_D009207	bcv_easy_1009				
	C047781	"<span class=""chemical"">LTG</span>"		D009207	"<span class=""disease"">myoclonic status/MJ</span>"	"In two patients, <span class=""chemical"">LTG</span> exacerbated <span class=""disease"">MJ</span> in a delayed but more severe manner, with <span class=""disease"">myoclonic status</span> that only ceased after <span class=""chemical"">LTG</span> withdrawal."		16157917	16157917_C047781_D009207	bcv_easy_1010				
	D000638	"<span class=""chemical"">amiodarone</span>"		D017180	"<span class=""disease"">ventricular tachycardia</span>"	"Long-term efficacy and toxicity of high-dose <span class=""chemical"">amiodarone</span> therapy for <span class=""disease"">ventricular tachycardia</span> or ventricular fibrillation."		6637851	6637851_D000638_D017180	bcv_easy_1011				
	D000638	"<span class=""chemical"">amiodarone</span>"		D064420	"<span class=""disease"">toxicity</span>"	"Long-term efficacy and <span class=""disease"">toxicity</span> of high-dose <span class=""chemical"">amiodarone</span> therapy for ventricular tachycardia or ventricular fibrillation."		6637851	6637851_D000638_D064420	bcv_easy_1012				
	D000638	"<span class=""chemical"">amiodarone</span>"		D014693	"<span class=""disease"">ventricular fibrillation</span>"	"Long-term efficacy and toxicity of high-dose <span class=""chemical"">amiodarone</span> therapy for ventricular tachycardia or <span class=""disease"">ventricular fibrillation</span>."		6637851	6637851_D000638_D014693	bcv_easy_1013				
	D000638	"<span class=""chemical"">Amiodarone</span>"		D017180	"<span class=""disease"">VT/ventricular tachycardia</span>"	"<span class=""chemical"">Amiodarone</span> was administered to 154 patients who had sustained, symptomatic <span class=""disease"">ventricular tachycardia</span> (<span class=""disease"">VT</span>) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs."		6637851	6637851_D000638_D017180	bcv_easy_1014				
	D000638	"<span class=""chemical"">Amiodarone</span>"		D006323	"<span class=""disease"">cardiac arrest</span>"	"<span class=""chemical"">Amiodarone</span> was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a <span class=""disease"">cardiac arrest</span> (n = 36) and who were refractory to conventional antiarrhythmic drugs."		6637851	6637851_D000638_D006323	bcv_easy_1015				
	D000638	"<span class=""chemical"">amiodarone</span>"		D017180	"<span class=""disease"">VT</span>"	"Sixty-nine percent of patients continued treatment with <span class=""chemical"">amiodarone</span> and had no recurrence of symptomatic <span class=""disease"">VT</span> or ventricular fibrillation (VF) over a follow-up of 6 to 52 months (mean +/- standard deviation 14.2 +/- 8.2)."		6637851	6637851_D000638_D017180	bcv_easy_1016				
	D000638	"<span class=""chemical"">amiodarone</span>"		D014693	"<span class=""disease"">ventricular fibrillation/VF</span>"	"Sixty-nine percent of patients continued treatment with <span class=""chemical"">amiodarone</span> and had no recurrence of symptomatic VT or <span class=""disease"">ventricular fibrillation</span> (<span class=""disease"">VF</span>) over a follow-up of 6 to 52 months (mean +/- standard deviation 14.2 +/- 8.2)."		6637851	6637851_D000638_D014693	bcv_easy_1017				
	D000638	"<span class=""chemical"">amiodarone</span>"		D017180	"<span class=""disease"">VT</span>"	"Six percent of the patients had a nonfatal recurrence of <span class=""disease"">VT</span> and were successfully managed by continuing <span class=""chemical"">amiodarone</span> at a higher dose or by the addition of a conventional antiarrhythmic drug."		6637851	6637851_D000638_D017180	bcv_easy_1018				
	D000638	"<span class=""chemical"">amiodarone</span>"		D017180	"<span class=""disease"">VT</span>"	"Although large-dose <span class=""chemical"">amiodarone</span> is highly effective in the long-term treatment of <span class=""disease"">VT</span> or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients."		6637851	6637851_D000638_D017180	bcv_easy_1019				
	D000638	"<span class=""chemical"">amiodarone</span>"		D064420	"<span class=""disease"">toxicity</span>"	"Although large-dose <span class=""chemical"">amiodarone</span> is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant <span class=""disease"">toxicity</span> in approximately 50% of patients."		6637851	6637851_D000638_D064420	bcv_easy_1020				
	D000638	"<span class=""chemical"">amiodarone</span>"		D014693	"<span class=""disease"">VF</span>"	"Although large-dose <span class=""chemical"">amiodarone</span> is highly effective in the long-term treatment of VT or <span class=""disease"">VF</span> refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients."		6637851	6637851_D000638_D014693	bcv_easy_1021				
	D000638	"<span class=""chemical"">amiodarone</span>"		D017180	"<span class=""disease"">VT</span>"	"However, when the dose is adjusted based on clinical response or the development of adverse effects, 75% of patients with <span class=""disease"">VT</span> or VF can be successfully managed with <span class=""chemical"">amiodarone</span>."		6637851	6637851_D000638_D017180	bcv_easy_1022				
	D000638	"<span class=""chemical"">amiodarone</span>"		D014693	"<span class=""disease"">VF</span>"	"However, when the dose is adjusted based on clinical response or the development of adverse effects, 75% of patients with VT or <span class=""disease"">VF</span> can be successfully managed with <span class=""chemical"">amiodarone</span>."		6637851	6637851_D000638_D014693	bcv_easy_1023				
	D020927	"<span class=""chemical"">Dexmedetomidine</span>"		D009203	"<span class=""disease"">myocardial infarction</span>"	"<span class=""chemical"">Dexmedetomidine</span> was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal <span class=""disease"">myocardial infarction</span> (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36)."		18086064	18086064_D020927_D009203	bcv_easy_1024				
	D020927	"<span class=""chemical"">Dexmedetomidine</span>"		D017202	"<span class=""disease"">myocardial ischaemia</span>"	"<span class=""chemical"">Dexmedetomidine</span> was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and <span class=""disease"">myocardial ischaemia</span> (OR 0.65, 95% CI 0.26-1.63, p = 0.36)."		18086064	18086064_D020927_D017202	bcv_easy_1025				
	D014031	"<span class=""chemical"">tobramicyn</span>"		D064420	"<span class=""disease"">toxicity</span>"	"OBJECTIVE: To evaluate the effect of dosage regimen (once-daily vs. twice-daily) of <span class=""chemical"">tobramicyn</span> on steady-state serum concentrations and <span class=""disease"">toxicity</span>."		9875685	9875685_D014031_D064420	bcv_easy_1026				
	D003404	"<span class=""chemical"">creatinine</span>"		D007674	"<span class=""disease"">nephrotoxicity</span>"	"Increased serum <span class=""chemical"">creatinine</span> was observed in 73% of patients in OD versus 57% of patients in TD, without evidence of <span class=""disease"">nephrotoxicity</span>."		9875685	9875685_D003404_D007674	bcv_easy_1027				
	D012701	"<span class=""chemical"">serotonin</span>"		D062788	"<span class=""disease"">adenomyosis</span>"	"A murine model of <span class=""disease"">adenomyosis</span>: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective <span class=""chemical"">serotonin</span> reuptake inhibitor, on <span class=""disease"">adenomyosis</span> induction in Wistar albino rats."		9098464	9098464_D012701_D062788	bcv_easy_1028				
	D005473	"<span class=""chemical"">fluoxetine hydrochloride</span>"		D062788	"<span class=""disease"">adenomyosis</span>"	"A murine model of <span class=""disease"">adenomyosis</span>: the effects of hyperprolactinemia induced by <span class=""chemical"">fluoxetine hydrochloride</span>, a selective serotonin reuptake inhibitor, on <span class=""disease"">adenomyosis</span> induction in Wistar albino rats."		9098464	9098464_D005473_D062788	bcv_easy_1029				
	D012701	"<span class=""chemical"">serotonin</span>"		D006966	"<span class=""disease"">hyperprolactinemia</span>"	"A murine model of adenomyosis: the effects of <span class=""disease"">hyperprolactinemia</span> induced by fluoxetine hydrochloride, a selective <span class=""chemical"">serotonin</span> reuptake inhibitor, on adenomyosis induction in Wistar albino rats."		9098464	9098464_D012701_D006966	bcv_easy_1030				
	D005473	"<span class=""chemical"">fluoxetine hydrochloride</span>"		D006966	"<span class=""disease"">hyperprolactinemia</span>"	"A murine model of adenomyosis: the effects of <span class=""disease"">hyperprolactinemia</span> induced by <span class=""chemical"">fluoxetine hydrochloride</span>, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats."		9098464	9098464_D005473_D006966	bcv_easy_1031				
	D005473	"<span class=""chemical"">fluoxetine</span>"		D006966	"<span class=""disease"">hyperprolactinemia</span>"	"OBJECTIVE: The aim of this study was to investigate whether <span class=""chemical"">fluoxetine</span> given to castrated and noncastrated rats caused <span class=""disease"">hyperprolactinemia</span> and its effects with respect to adenomyosis."		9098464	9098464_D005473_D006966	bcv_easy_1032				
	D005473	"<span class=""chemical"">fluoxetine</span>"		D062788	"<span class=""disease"">adenomyosis</span>"	"OBJECTIVE: The aim of this study was to investigate whether <span class=""chemical"">fluoxetine</span> given to castrated and noncastrated rats caused hyperprolactinemia and its effects with respect to <span class=""disease"">adenomyosis</span>."		9098464	9098464_D005473_D062788	bcv_easy_1033				
	D005473	"<span class=""chemical"">Fluoxetine</span>"		D006966	"<span class=""disease"">hyperprolactinemia</span>"	"DESIGN: <span class=""chemical"">Fluoxetine</span>, a serotonin reuptake inhibitor, was given to Wistar Albino rats for 98 days to produce <span class=""disease"">hyperprolactinemia</span>."		9098464	9098464_D005473_D006966	bcv_easy_1034				
	D012701	"<span class=""chemical"">serotonin</span>"		D006966	"<span class=""disease"">hyperprolactinemia</span>"	"DESIGN: Fluoxetine, a <span class=""chemical"">serotonin</span> reuptake inhibitor, was given to Wistar Albino rats for 98 days to produce <span class=""disease"">hyperprolactinemia</span>."		9098464	9098464_D012701_D006966	bcv_easy_1035				
	D005473	"<span class=""chemical"">fluoxetine</span>"		D062788	"<span class=""disease"">adenomyosis</span>"	"Histological studies revealed 11 cases of <span class=""disease"">adenomyosis</span>, all within the noncastrated group receiving <span class=""chemical"">fluoxetine</span>."		9098464	9098464_D005473_D062788	bcv_easy_1036				
	D002217	"<span class=""chemical"">carbachol</span>"		D014202	"<span class=""disease"">tremor</span>"	"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, <span class=""disease"">tremor</span> and clonic-tonic convulsions produced by <span class=""chemical"">carbachol</span> and eserine injected similarly was investigated."		6892185	6892185_D002217_D014202	bcv_easy_1037				
	D002217	"<span class=""chemical"">carbachol</span>"		D004830	"<span class=""disease"">clonic-tonic convulsions</span>"	"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and <span class=""disease"">clonic-tonic convulsions</span> produced by <span class=""chemical"">carbachol</span> and eserine injected similarly was investigated."		6892185	6892185_D002217_D004830	bcv_easy_1038				
	D002122	"<span class=""chemical"">calcium chloride</span>"		D015878	"<span class=""disease"">mydriasis</span>"	"The effect of <span class=""chemical"">calcium chloride</span> injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), <span class=""disease"">mydriasis</span>, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated."		6892185	6892185_D002122_D015878	bcv_easy_1039				
	D010830	"<span class=""chemical"">eserine</span>"		D015878	"<span class=""disease"">mydriasis</span>"	"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), <span class=""disease"">mydriasis</span>, tremor and clonic-tonic convulsions produced by carbachol and <span class=""chemical"">eserine</span> injected similarly was investigated."		6892185	6892185_D010830_D015878	bcv_easy_1040				
	D010830	"<span class=""chemical"">eserine</span>"		D014202	"<span class=""disease"">tremor</span>"	"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, <span class=""disease"">tremor</span> and clonic-tonic convulsions produced by carbachol and <span class=""chemical"">eserine</span> injected similarly was investigated."		6892185	6892185_D010830_D014202	bcv_easy_1041				
	D002217	"<span class=""chemical"">carbachol</span>"		D015878	"<span class=""disease"">mydriasis</span>"	"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), <span class=""disease"">mydriasis</span>, tremor and clonic-tonic convulsions produced by <span class=""chemical"">carbachol</span> and eserine injected similarly was investigated."		6892185	6892185_D002217_D015878	bcv_easy_1042				
	D010830	"<span class=""chemical"">eserine</span>"		D004830	"<span class=""disease"">clonic-tonic convulsions</span>"	"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and <span class=""disease"">clonic-tonic convulsions</span> produced by carbachol and <span class=""chemical"">eserine</span> injected similarly was investigated."		6892185	6892185_D010830_D004830	bcv_easy_1043				
	D002122	"<span class=""chemical"">calcium chloride</span>"		D014202	"<span class=""disease"">tremor</span>"	"The effect of <span class=""chemical"">calcium chloride</span> injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, <span class=""disease"">tremor</span> and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated."		6892185	6892185_D002122_D014202	bcv_easy_1044				
	D002122	"<span class=""chemical"">calcium chloride</span>"		D004830	"<span class=""disease"">clonic-tonic convulsions</span>"	"The effect of <span class=""chemical"">calcium chloride</span> injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and <span class=""disease"">clonic-tonic convulsions</span> produced by carbachol and eserine injected similarly was investigated."		6892185	6892185_D002122_D004830	bcv_easy_1045				
	D002122	"<span class=""chemical"">calcium chloride</span>"		D014202	"<span class=""disease"">tremor</span>"	"On the other hand, mydriasis, <span class=""disease"">tremor</span> and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by <span class=""chemical"">calcium chloride</span>."		6892185	6892185_D002122_D014202	bcv_easy_1046				
	D002217	"<span class=""chemical"">carbachol</span>"		D014202	"<span class=""disease"">tremor</span>"	"On the other hand, mydriasis, <span class=""disease"">tremor</span> and clonic-tonic convulsions evoked by <span class=""chemical"">carbachol</span> and eserine were not significantly changed by calcium chloride."		6892185	6892185_D002217_D014202	bcv_easy_1047				
	D002217	"<span class=""chemical"">carbachol</span>"		D004830	"<span class=""disease"">clonic-tonic convulsions</span>"	"On the other hand, mydriasis, tremor and <span class=""disease"">clonic-tonic convulsions</span> evoked by <span class=""chemical"">carbachol</span> and eserine were not significantly changed by calcium chloride."		6892185	6892185_D002217_D004830	bcv_easy_1048				
	D002122	"<span class=""chemical"">calcium chloride</span>"		D015878	"<span class=""disease"">mydriasis</span>"	"On the other hand, <span class=""disease"">mydriasis</span>, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by <span class=""chemical"">calcium chloride</span>."		6892185	6892185_D002122_D015878	bcv_easy_1049				
	D010830	"<span class=""chemical"">eserine</span>"		D015878	"<span class=""disease"">mydriasis</span>"	"On the other hand, <span class=""disease"">mydriasis</span>, tremor and clonic-tonic convulsions evoked by carbachol and <span class=""chemical"">eserine</span> were not significantly changed by calcium chloride."		6892185	6892185_D010830_D015878	bcv_easy_1050				
	D010830	"<span class=""chemical"">eserine</span>"		D014202	"<span class=""disease"">tremor</span>"	"On the other hand, mydriasis, <span class=""disease"">tremor</span> and clonic-tonic convulsions evoked by carbachol and <span class=""chemical"">eserine</span> were not significantly changed by calcium chloride."		6892185	6892185_D010830_D014202	bcv_easy_1051				
	D002217	"<span class=""chemical"">carbachol</span>"		D015878	"<span class=""disease"">mydriasis</span>"	"On the other hand, <span class=""disease"">mydriasis</span>, tremor and clonic-tonic convulsions evoked by <span class=""chemical"">carbachol</span> and eserine were not significantly changed by calcium chloride."		6892185	6892185_D002217_D015878	bcv_easy_1052				
	D010830	"<span class=""chemical"">eserine</span>"		D004830	"<span class=""disease"">clonic-tonic convulsions</span>"	"On the other hand, mydriasis, tremor and <span class=""disease"">clonic-tonic convulsions</span> evoked by carbachol and <span class=""chemical"">eserine</span> were not significantly changed by calcium chloride."		6892185	6892185_D010830_D004830	bcv_easy_1053				
	D002122	"<span class=""chemical"">calcium chloride</span>"		D004830	"<span class=""disease"">clonic-tonic convulsions</span>"	"On the other hand, mydriasis, tremor and <span class=""disease"">clonic-tonic convulsions</span> evoked by carbachol and eserine were not significantly changed by <span class=""chemical"">calcium chloride</span>."		6892185	6892185_D002122_D004830	bcv_easy_1054				
	D002217	"<span class=""chemical"">carbachol</span>"		D014202	"<span class=""disease"">tremor</span>"	"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, <span class=""disease"">tremor</span> and clonic-tonic convulsions caused by <span class=""chemical"">carbachol</span> and eserine."		6892185	6892185_D002217_D014202	bcv_easy_1055				
	D002217	"<span class=""chemical"">carbachol</span>"		D004830	"<span class=""disease"">clonic-tonic convulsions</span>"	"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and <span class=""disease"">clonic-tonic convulsions</span> caused by <span class=""chemical"">carbachol</span> and eserine."		6892185	6892185_D002217_D004830	bcv_easy_1056				
	D002122	"<span class=""chemical"">calcium chloride</span>"		D015878	"<span class=""disease"">mydriasis</span>"	"It is apparent that <span class=""chemical"">calcium chloride</span> can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as <span class=""disease"">mydriasis</span>, tremor and clonic-tonic convulsions caused by carbachol and eserine."		6892185	6892185_D002122_D015878	bcv_easy_1057				
	D010830	"<span class=""chemical"">eserine</span>"		D015878	"<span class=""disease"">mydriasis</span>"	"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as <span class=""disease"">mydriasis</span>, tremor and clonic-tonic convulsions caused by carbachol and <span class=""chemical"">eserine</span>."		6892185	6892185_D010830_D015878	bcv_easy_1058				
	D010830	"<span class=""chemical"">eserine</span>"		D014202	"<span class=""disease"">tremor</span>"	"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, <span class=""disease"">tremor</span> and clonic-tonic convulsions caused by carbachol and <span class=""chemical"">eserine</span>."		6892185	6892185_D010830_D014202	bcv_easy_1059				
	D002217	"<span class=""chemical"">carbachol</span>"		D015878	"<span class=""disease"">mydriasis</span>"	"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as <span class=""disease"">mydriasis</span>, tremor and clonic-tonic convulsions caused by <span class=""chemical"">carbachol</span> and eserine."		6892185	6892185_D002217_D015878	bcv_easy_1060				
	D010830	"<span class=""chemical"">eserine</span>"		D004830	"<span class=""disease"">clonic-tonic convulsions</span>"	"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and <span class=""disease"">clonic-tonic convulsions</span> caused by carbachol and <span class=""chemical"">eserine</span>."		6892185	6892185_D010830_D004830	bcv_easy_1061				
	D002122	"<span class=""chemical"">calcium chloride</span>"		D014202	"<span class=""disease"">tremor</span>"	"It is apparent that <span class=""chemical"">calcium chloride</span> can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, <span class=""disease"">tremor</span> and clonic-tonic convulsions caused by carbachol and eserine."		6892185	6892185_D002122_D014202	bcv_easy_1062				
	D002122	"<span class=""chemical"">calcium chloride</span>"		D004830	"<span class=""disease"">clonic-tonic convulsions</span>"	"It is apparent that <span class=""chemical"">calcium chloride</span> can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and <span class=""disease"">clonic-tonic convulsions</span> caused by carbachol and eserine."		6892185	6892185_D002122_D004830	bcv_easy_1063				
	D006514	"<span class=""chemical"">hepatitis B surface antigen</span>"		D012409	"<span class=""disease"">rubella</span>"	"Assessment was done on the following: prenatal screening for hepatitis B and <span class=""disease"">rubella</span>, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to <span class=""chemical"">hepatitis B surface antigen</span>-positive mothers, <span class=""disease"">rubella</span> immunity, and administration of in-hospital postpartum <span class=""disease"">rubella</span> vaccine to <span class=""disease"">rubella</span> nonimmune women."		15867025	15867025_D006514_D012409	bcv_easy_1064				
	D006514	"<span class=""chemical"">hepatitis B surface antigen</span>"		D006509	"<span class=""disease"">hepatitis B</span>"	"Assessment was done on the following: prenatal screening for <span class=""disease"">hepatitis B</span> and rubella, administration of the <span class=""disease"">hepatitis B</span> vaccine birth dose to all infants, administration of <span class=""disease"">hepatitis B</span> immune globulin to infants who were born to <span class=""chemical"">hepatitis B surface antigen</span>-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women."		15867025	15867025_D006514_D006509	bcv_easy_1065				
	D006514	"<span class=""chemical"">hepatitis B surface antigen</span>"		D006509	"<span class=""disease"">hepatitis B</span>"	"All infants who were born to <span class=""chemical"">hepatitis B surface antigen</span>-positive mothers also received <span class=""disease"">hepatitis B</span> immune globulin."		15867025	15867025_D006514_D006509	bcv_easy_1066				
	D006493	"<span class=""chemical"">heparin</span>"		D013924	"<span class=""disease"">thrombophlebitis</span>"	"The disease occurred subsequent to the initiation of <span class=""chemical"">heparin</span> therapy for suspected pelvic <span class=""disease"">thrombophlebitis</span> and cleared rapidly subsequent to its discontinuation."		1255900	1255900_D006493_D013924	bcv_easy_1067				
	D011224	"<span class=""chemical"">prazosin</span>"		D006973	"<span class=""disease"">hypertensive</span>"	"Orthostatic hypotension occurs following alpha 2-adrenoceptor blockade in chronic <span class=""chemical"">prazosin</span>-pretreated conscious spontaneously <span class=""disease"">hypertensive</span> rats."		1355091	1355091_D011224_D006973	bcv_easy_1068				
	D011224	"<span class=""chemical"">prazosin</span>"		D007024	"<span class=""disease"">Orthostatic hypotension</span>"	"<span class=""disease"">Orthostatic hypotension</span> occurs following alpha 2-adrenoceptor blockade in chronic <span class=""chemical"">prazosin</span>-pretreated conscious spontaneously hypertensive rats."		1355091	1355091_D011224_D007024	bcv_easy_1069				
	D011224	"<span class=""chemical"">prazosin</span>"		D006973	"<span class=""disease"">hypertensive</span>"	"Studies were performed to evaluate whether chronic <span class=""chemical"">prazosin</span> treatment alters the alpha 2-adrenoceptor function for orthostatic control of arterial blood pressure in conscious spontaneously <span class=""disease"">hypertensive</span> rats (SHR)."		1355091	1355091_D011224_D006973	bcv_easy_1070				
	D015016	"<span class=""chemical"">rauwolscine</span>"		D007024	"<span class=""disease"">orthostatic hypotension</span>"	"However, the head-up tilt induced <span class=""disease"">orthostatic hypotension</span> in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with <span class=""chemical"">rauwolscine</span> (less than +2% MAP, n = 6)."		1355091	1355091_D015016_D007024	bcv_easy_1071				
	D011224	"<span class=""chemical"">prazosin</span>"		D007024	"<span class=""disease"">orthostatic hypotension</span>"	"However, the head-up tilt induced <span class=""disease"">orthostatic hypotension</span> in the SHR treated with <span class=""chemical"">prazosin</span> (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6)."		1355091	1355091_D011224_D007024	bcv_easy_1072				
	D011224	"<span class=""chemical"">prazosin</span>"		D007024	"<span class=""disease"">orthostatic hypotension</span>"	"Head-up tilts in these rats did not produce <span class=""disease"">orthostatic hypotension</span> when performed either prior to or after acute dosing of <span class=""chemical"">prazosin</span> (0.1 mg kg-1 i.p.)."		1355091	1355091_D011224_D007024	bcv_easy_1073				
	C056299	"<span class=""chemical"">Abbott-53693</span>"		D001919	"<span class=""disease"">bradycardia</span>"	"The pressor responses and <span class=""disease"">bradycardia</span> to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist <span class=""chemical"">Abbott-53693</span> (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment."		1355091	1355091_C056299_D001919	bcv_easy_1074				
	D011224	"<span class=""chemical"">prazosin</span>"		D001919	"<span class=""disease"">bradycardia</span>"	"The pressor responses and <span class=""disease"">bradycardia</span> to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic <span class=""chemical"">prazosin</span> pretreatment."		1355091	1355091_D011224_D001919	bcv_easy_1075				
	D009638	"<span class=""chemical"">noradrenaline</span>"		D001919	"<span class=""disease"">bradycardia</span>"	"The pressor responses and <span class=""disease"">bradycardia</span> to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and <span class=""chemical"">noradrenaline</span> (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment."		1355091	1355091_D009638_D001919	bcv_easy_1076				
	C014282	"<span class=""chemical"">cirazoline</span>"		D001919	"<span class=""disease"">bradycardia</span>"	"The pressor responses and <span class=""disease"">bradycardia</span> to the alpha 1-agonist <span class=""chemical"">cirazoline</span> (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment."		1355091	1355091_C014282_D001919	bcv_easy_1077				
	D011224	"<span class=""chemical"">prazosin</span>"		D001919	"<span class=""disease"">bradycardia</span>"	"Both the pressor and <span class=""disease"">bradycardia</span> effects of cirazoline were abolished in chronic <span class=""chemical"">prazosin</span> treated SHR (n = 4) as compared to the untreated SHR (n = 4)."		1355091	1355091_D011224_D001919	bcv_easy_1078				
	C014282	"<span class=""chemical"">cirazoline</span>"		D001919	"<span class=""disease"">bradycardia</span>"	"Both the pressor and <span class=""disease"">bradycardia</span> effects of <span class=""chemical"">cirazoline</span> were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4)."		1355091	1355091_C014282_D001919	bcv_easy_1079				
	D011224	"<span class=""chemical"">prazosin</span>"		D001919	"<span class=""disease"">bradycardia</span>"	"On the other hand, the pressor effects of Abbott-53693 were similar in both groups of SHR, but the accompanying <span class=""disease"">bradycardia</span> was greater in SHR with chronic <span class=""chemical"">prazosin</span> treatment than without such treatment."		1355091	1355091_D011224_D001919	bcv_easy_1080				
	C056299	"<span class=""chemical"">Abbott-53693</span>"		D001919	"<span class=""disease"">bradycardia</span>"	"On the other hand, the pressor effects of <span class=""chemical"">Abbott-53693</span> were similar in both groups of SHR, but the accompanying <span class=""disease"">bradycardia</span> was greater in SHR with chronic prazosin treatment than without such treatment."		1355091	1355091_C056299_D001919	bcv_easy_1081				
	D011224	"<span class=""chemical"">prazosin</span>"		D001919	"<span class=""disease"">bradycardia</span>"	"Furthermore, the <span class=""disease"">bradycardia</span> that accompanied the noradrenaline-induced pressor effect in SHR was similar with and without chronic <span class=""chemical"">prazosin</span> treatment despite a 47-71% reduction of the pressor effect in chronic alpha 1-receptor blocked SHR.(ABSTRACT TRUNCATED AT 400 WORDS)"		1355091	1355091_D011224_D001919	bcv_easy_1082				
	D009638	"<span class=""chemical"">noradrenaline</span>"		D001919	"<span class=""disease"">bradycardia</span>"	"Furthermore, the <span class=""disease"">bradycardia</span> that accompanied the <span class=""chemical"">noradrenaline</span>-induced pressor effect in SHR was similar with and without chronic prazosin treatment despite a 47-71% reduction of the pressor effect in chronic alpha 1-receptor blocked SHR.(ABSTRACT TRUNCATED AT 400 WORDS)"		1355091	1355091_D009638_D001919	bcv_easy_1083				
	D008775	"<span class=""chemical"">methylprednisolone</span>"		D007022	"<span class=""disease"">Hypotension</span>"	"<span class=""disease"">Hypotension</span>, bradycardia, and asystole after high-dose intravenous <span class=""chemical"">methylprednisolone</span> in a monitored patient."		10074612	10074612_D008775_D007022	bcv_easy_1084				
	D008775	"<span class=""chemical"">methylprednisolone</span>"		D006323	"<span class=""disease"">asystole</span>"	"Hypotension, bradycardia, and <span class=""disease"">asystole</span> after high-dose intravenous <span class=""chemical"">methylprednisolone</span> in a monitored patient."		10074612	10074612_D008775_D006323	bcv_easy_1085				
	D008775	"<span class=""chemical"">methylprednisolone</span>"		D001919	"<span class=""disease"">bradycardia</span>"	"Hypotension, <span class=""disease"">bradycardia</span>, and asystole after high-dose intravenous <span class=""chemical"">methylprednisolone</span> in a monitored patient."		10074612	10074612_D008775_D001919	bcv_easy_1086				
	D008775	"<span class=""chemical"">methylprednisolone</span>"		D007022	"<span class=""disease"">hypotension</span>"	"We report a case of <span class=""disease"">hypotension</span>, bradycardia, and asystole after intravenous administration of high-dose <span class=""chemical"">methylprednisolone</span> in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode."		10074612	10074612_D008775_D007022	bcv_easy_1087				
	D008775	"<span class=""chemical"">methylprednisolone</span>"		D006323	"<span class=""disease"">asystole</span>"	"We report a case of hypotension, bradycardia, and <span class=""disease"">asystole</span> after intravenous administration of high-dose <span class=""chemical"">methylprednisolone</span> in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode."		10074612	10074612_D008775_D006323	bcv_easy_1088				
	D008775	"<span class=""chemical"">methylprednisolone</span>"		D001919	"<span class=""disease"">bradycardia</span>"	"We report a case of hypotension, <span class=""disease"">bradycardia</span>, and asystole after intravenous administration of high-dose <span class=""chemical"">methylprednisolone</span> in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode."		10074612	10074612_D008775_D001919	bcv_easy_1089				
	D008775	"<span class=""chemical"">IVMP/methylprednisolone</span>"		D003645	"<span class=""disease"">sudden death</span>"	"This study reviews the current proposed mechanisms of <span class=""disease"">sudden death</span> after a high dose of intravenous <span class=""chemical"">methylprednisolone</span> (<span class=""chemical"">IVMP</span>)."		10074612	10074612_D008775_D003645	bcv_easy_1090				
	D012964	"<span class=""chemical"">sodium</span>"		D004487	"<span class=""disease"">edema</span>"	"Nephrotic syndrome is often accompanied by <span class=""chemical"">sodium</span> retention and generalized <span class=""disease"">edema</span>."		15075188	15075188_D012964_D004487	bcv_easy_1091				
	D012964	"<span class=""chemical"">sodium</span>"		D009404	"<span class=""disease"">Nephrotic syndrome</span>"	"<span class=""disease"">Nephrotic syndrome</span> is often accompanied by <span class=""chemical"">sodium</span> retention and generalized edema."		15075188	15075188_D012964_D009404	bcv_easy_1092				
	D011692	"<span class=""chemical"">PAN</span>"		D011507	"<span class=""disease"">proteinuria</span>"	"After 7 days, <span class=""chemical"">PAN</span> treatment induced significant <span class=""disease"">proteinuria</span>, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites."		15075188	15075188_D011692_D011507	bcv_easy_1093				
	D011692	"<span class=""chemical"">PAN</span>"		D034141	"<span class=""disease"">hypoalbuminemia</span>"	"After 7 days, <span class=""chemical"">PAN</span> treatment induced significant proteinuria, <span class=""disease"">hypoalbuminemia</span>, decreased urinary sodium excretion, and extensive ascites."		15075188	15075188_D011692_D034141	bcv_easy_1094				
	D011692	"<span class=""chemical"">PAN</span>"		D001201	"<span class=""disease"">ascites</span>"	"After 7 days, <span class=""chemical"">PAN</span> treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive <span class=""disease"">ascites</span>."		15075188	15075188_D011692_D001201	bcv_easy_1095				
	D012964	"<span class=""chemical"">sodium</span>"		D011507	"<span class=""disease"">proteinuria</span>"	"After 7 days, PAN treatment induced significant <span class=""disease"">proteinuria</span>, hypoalbuminemia, decreased urinary <span class=""chemical"">sodium</span> excretion, and extensive ascites."		15075188	15075188_D012964_D011507	bcv_easy_1096				
	D012964	"<span class=""chemical"">sodium</span>"		D034141	"<span class=""disease"">hypoalbuminemia</span>"	"After 7 days, PAN treatment induced significant proteinuria, <span class=""disease"">hypoalbuminemia</span>, decreased urinary <span class=""chemical"">sodium</span> excretion, and extensive ascites."		15075188	15075188_D012964_D034141	bcv_easy_1097				
	D012964	"<span class=""chemical"">sodium</span>"		D001201	"<span class=""disease"">ascites</span>"	"After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary <span class=""chemical"">sodium</span> excretion, and extensive <span class=""disease"">ascites</span>."		15075188	15075188_D012964_D001201	bcv_easy_1098				
	D012964	"<span class=""chemical"">sodium</span>"		D009404	"<span class=""disease"">nephrotic syndrome</span>"	"In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the <span class=""chemical"">sodium</span> retention associated with PAN-induced <span class=""disease"">nephrotic syndrome</span>."		15075188	15075188_D012964_D009404	bcv_easy_1099				
	D014191	"<span class=""chemical"">tranylcypromine</span>"		D020230	"<span class=""disease"">Serotonin syndrome</span>"	"<span class=""disease"">Serotonin syndrome</span> from venlafaxine-<span class=""chemical"">tranylcypromine</span> interaction."		8888541	8888541_D014191_D020230	bcv_easy_1100				
	C047426	"<span class=""chemical"">venlafaxine</span>"		D020230	"<span class=""disease"">Serotonin syndrome</span>"	"<span class=""disease"">Serotonin syndrome</span> from <span class=""chemical"">venlafaxine</span>-tranylcypromine interaction."		8888541	8888541_C047426_D020230	bcv_easy_1101				
	D012701	"<span class=""chemical"">serotonin</span>"		D003221	"<span class=""disease"">confusion</span>"	"Excessive stimulation of <span class=""chemical"">serotonin</span> 5HT1A receptors causes a syndrome of <span class=""chemical"">serotonin</span> excess that consists of shivering, muscle rigidity, salivation, <span class=""disease"">confusion</span>, agitation and hyperthermia."		8888541	8888541_D012701_D003221	bcv_easy_1102				
	D012701	"<span class=""chemical"">serotonin</span>"		D012798	"<span class=""disease"">salivation</span>"	"Excessive stimulation of <span class=""chemical"">serotonin</span> 5HT1A receptors causes a syndrome of <span class=""chemical"">serotonin</span> excess that consists of shivering, muscle rigidity, <span class=""disease"">salivation</span>, confusion, agitation and hyperthermia."		8888541	8888541_D012701_D012798	bcv_easy_1103				
	D012701	"<span class=""chemical"">serotonin</span>"		D005334	"<span class=""disease"">hyperthermia</span>"	"Excessive stimulation of <span class=""chemical"">serotonin</span> 5HT1A receptors causes a syndrome of <span class=""chemical"">serotonin</span> excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and <span class=""disease"">hyperthermia</span>."		8888541	8888541_D012701_D005334	bcv_easy_1104				
	D012701	"<span class=""chemical"">serotonin</span>"		D009127	"<span class=""disease"">muscle rigidity</span>"	"Excessive stimulation of <span class=""chemical"">serotonin</span> 5HT1A receptors causes a syndrome of <span class=""chemical"">serotonin</span> excess that consists of shivering, <span class=""disease"">muscle rigidity</span>, salivation, confusion, agitation and hyperthermia."		8888541	8888541_D012701_D009127	bcv_easy_1105				
	D012701	"<span class=""chemical"">serotonin</span>"		D011595	"<span class=""disease"">agitation</span>"	"Excessive stimulation of <span class=""chemical"">serotonin</span> 5HT1A receptors causes a syndrome of <span class=""chemical"">serotonin</span> excess that consists of shivering, muscle rigidity, salivation, confusion, <span class=""disease"">agitation</span> and hyperthermia."		8888541	8888541_D012701_D011595	bcv_easy_1106				
	D014191	"<span class=""chemical"">tranylcypromine</span>"		D003866	"<span class=""disease"">depression</span>"	"We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking <span class=""chemical"">tranylcypromine</span> for <span class=""disease"">depression</span>."		8888541	8888541_D014191_D003866	bcv_easy_1107				
	C047426	"<span class=""chemical"">venlafaxine</span>"		D003866	"<span class=""disease"">depression</span>"	"We report a <span class=""chemical"">venlafaxine</span>-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for <span class=""disease"">depression</span>."		8888541	8888541_C047426_D003866	bcv_easy_1108				
	D014191	"<span class=""chemical"">tranylcypromine</span>"		D020230	"<span class=""disease"">serotonin syndrome</span>"	"We report a venlafaxine-MAOI interaction that resulted in the <span class=""disease"">serotonin syndrome</span> in a 23-y-old male who was taking <span class=""chemical"">tranylcypromine</span> for depression."		8888541	8888541_D014191_D020230	bcv_easy_1109				
	C047426	"<span class=""chemical"">venlafaxine</span>"		D020230	"<span class=""disease"">serotonin syndrome</span>"	"We report a <span class=""chemical"">venlafaxine</span>-MAOI interaction that resulted in the <span class=""disease"">serotonin syndrome</span> in a 23-y-old male who was taking tranylcypromine for depression."		8888541	8888541_C047426_D020230	bcv_easy_1110				
	D003975	"<span class=""chemical"">diazepam</span>"		D009127	"<span class=""disease"">muscle rigidity</span>"	"After 180 mg of <span class=""chemical"">diazepam</span> i.v. he remained tremulous with <span class=""disease"">muscle rigidity</span> and clenched jaws."		8888541	8888541_D003975_D009127	bcv_easy_1111				
	D015632	"<span class=""chemical"">MPTP</span>"		D004409	"<span class=""disease"">dyskinesias</span>"	"Effect of nondopaminergic drugs on L-dopa-induced <span class=""disease"">dyskinesias</span> in <span class=""chemical"">MPTP</span>-treated monkeys."		8106150	8106150_D015632_D004409	bcv_easy_1112				
	D015632	"<span class=""chemical"">MPTP</span>"		D020734	"<span class=""disease"">parkinsonian</span>"	"A group of four monkeys was rendered <span class=""disease"">parkinsonian</span> with the toxin <span class=""chemical"">MPTP</span>."		8106150	8106150_D015632_D020734	bcv_easy_1113				
	D004298	"<span class=""chemical"">dopamine</span>"		D004409	"<span class=""disease"">dyskinetic</span>"	"A series of agents acting primarily on neurotransmitters other than <span class=""chemical"">dopamine</span> were then tested in combination with L-DOPA to see if the <span class=""disease"">dyskinetic</span> movements would be modified."		8106150	8106150_D004298_D004409	bcv_easy_1114				
	D008784	"<span class=""chemical"">methysergide</span>"		D020734	"<span class=""disease"">parkinsonian</span>"	"Several drugs, including clonidine, physostigmine, <span class=""chemical"">methysergide</span>, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of <span class=""disease"">parkinsonian</span> symptomatology."		8106150	8106150_D008784_D020734	bcv_easy_1115				
	D008784	"<span class=""chemical"">methysergide</span>"		D004409	"<span class=""disease"">dyskinetic</span>"	"Several drugs, including clonidine, physostigmine, <span class=""chemical"">methysergide</span>, 5-MDOT, propranolol, and MK-801, markedly reduced the <span class=""disease"">dyskinetic</span> movements but at the cost of a return of parkinsonian symptomatology."		8106150	8106150_D008784_D004409	bcv_easy_1116				
	D011433	"<span class=""chemical"">propranolol</span>"		D004409	"<span class=""disease"">dyskinetic</span>"	"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, <span class=""chemical"">propranolol</span>, and MK-801, markedly reduced the <span class=""disease"">dyskinetic</span> movements but at the cost of a return of parkinsonian symptomatology."		8106150	8106150_D011433_D004409	bcv_easy_1117				
	D011433	"<span class=""chemical"">propranolol</span>"		D020734	"<span class=""disease"">parkinsonian</span>"	"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, <span class=""chemical"">propranolol</span>, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of <span class=""disease"">parkinsonian</span> symptomatology."		8106150	8106150_D011433_D020734	bcv_easy_1118				
	D016291	"<span class=""chemical"">MK-801</span>"		D020734	"<span class=""disease"">parkinsonian</span>"	"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and <span class=""chemical"">MK-801</span>, markedly reduced the dyskinetic movements but at the cost of a return of <span class=""disease"">parkinsonian</span> symptomatology."		8106150	8106150_D016291_D020734	bcv_easy_1119				
	D016291	"<span class=""chemical"">MK-801</span>"		D004409	"<span class=""disease"">dyskinetic</span>"	"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and <span class=""chemical"">MK-801</span>, markedly reduced the <span class=""disease"">dyskinetic</span> movements but at the cost of a return of parkinsonian symptomatology."		8106150	8106150_D016291_D004409	bcv_easy_1120				
	D010830	"<span class=""chemical"">physostigmine</span>"		D004409	"<span class=""disease"">dyskinetic</span>"	"Several drugs, including clonidine, <span class=""chemical"">physostigmine</span>, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the <span class=""disease"">dyskinetic</span> movements but at the cost of a return of parkinsonian symptomatology."		8106150	8106150_D010830_D004409	bcv_easy_1121				
	D003000	"<span class=""chemical"">clonidine</span>"		D020734	"<span class=""disease"">parkinsonian</span>"	"Several drugs, including <span class=""chemical"">clonidine</span>, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of <span class=""disease"">parkinsonian</span> symptomatology."		8106150	8106150_D003000_D020734	bcv_easy_1122				
	D010830	"<span class=""chemical"">physostigmine</span>"		D020734	"<span class=""disease"">parkinsonian</span>"	"Several drugs, including clonidine, <span class=""chemical"">physostigmine</span>, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of <span class=""disease"">parkinsonian</span> symptomatology."		8106150	8106150_D010830_D020734	bcv_easy_1123				
	D003000	"<span class=""chemical"">clonidine</span>"		D004409	"<span class=""disease"">dyskinetic</span>"	"Several drugs, including <span class=""chemical"">clonidine</span>, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the <span class=""disease"">dyskinetic</span> movements but at the cost of a return of parkinsonian symptomatology."		8106150	8106150_D003000_D004409	bcv_easy_1124				
	D008614	"<span class=""chemical"">meperidine</span>"		D004409	"<span class=""disease"">dyskinetic</span>"	"However, yohimbine and <span class=""chemical"">meperidine</span> reduced predominantly the <span class=""disease"">dyskinetic</span> movements."		8106150	8106150_D008614_D004409	bcv_easy_1125				
	D015016	"<span class=""chemical"">yohimbine</span>"		D004409	"<span class=""disease"">dyskinetic</span>"	"However, <span class=""chemical"">yohimbine</span> and meperidine reduced predominantly the <span class=""disease"">dyskinetic</span> movements."		8106150	8106150_D015016_D004409	bcv_easy_1126				
	D001418	"<span class=""chemical"">Baclofen</span>"		D020821	"<span class=""disease"">dystonic</span>"	"<span class=""chemical"">Baclofen</span> was also useful in one monkey against a more <span class=""disease"">dystonic</span> form of dyskinesia."		8106150	8106150_D001418_D020821	bcv_easy_1127				
	D001418	"<span class=""chemical"">Baclofen</span>"		D004409	"<span class=""disease"">dyskinesia</span>"	"<span class=""chemical"">Baclofen</span> was also useful in one monkey against a more dystonic form of <span class=""disease"">dyskinesia</span>."		8106150	8106150_D001418_D004409	bcv_easy_1128				
	D001285	"<span class=""chemical"">Atropine</span>"		D002819	"<span class=""disease"">chorea</span>"	"<span class=""chemical"">Atropine</span> converted the dystonic movements into <span class=""disease"">chorea</span>."		8106150	8106150_D001285_D002819	bcv_easy_1129				
	D001285	"<span class=""chemical"">Atropine</span>"		D020821	"<span class=""disease"">dystonic</span>"	"<span class=""chemical"">Atropine</span> converted the <span class=""disease"">dystonic</span> movements into chorea."		8106150	8106150_D001285_D020821	bcv_easy_1130				
	D008094	"<span class=""chemical"">lithium</span>"		D013959	"<span class=""disease"">thyroid disease</span>"	"These were evaluated with respect to the duration of <span class=""chemical"">lithium</span> therapy, age, sex, and family history (whether or not the patient had a first-degree relative with <span class=""disease"">thyroid disease</span>)."		10354657	10354657_D008094_D013959	bcv_easy_1131				
	D008094	"<span class=""chemical"">lithium</span>"		D001714	"<span class=""disease"">bipolar disorder</span>"	"PATIENTS: One hundred and one patients (28 men and 73 women) with <span class=""disease"">bipolar disorder</span> receiving <span class=""chemical"">lithium</span> maintenance therapy ranging from 1 year's to 32 years' duration."		10354657	10354657_D008094_D001714	bcv_easy_1132				
	D008094	"<span class=""chemical"">lithium</span>"		D007037	"<span class=""disease"">hypothyroidism</span>"	"All patients having first-degree relatives affected by thyroid illness had accelerated onset of <span class=""disease"">hypothyroidism</span> (3.7 years after onset of <span class=""chemical"">lithium</span> therapy) compared with patients without a family history (8.6 years after onset of <span class=""chemical"">lithium</span> therapy)."		10354657	10354657_D008094_D007037	bcv_easy_1133				
	D008094	"<span class=""chemical"">lithium</span>"		D013959	"<span class=""disease"">thyroid illness</span>"	"All patients having first-degree relatives affected by <span class=""disease"">thyroid illness</span> had accelerated onset of hypothyroidism (3.7 years after onset of <span class=""chemical"">lithium</span> therapy) compared with patients without a family history (8.6 years after onset of <span class=""chemical"">lithium</span> therapy)."		10354657	10354657_D008094_D013959	bcv_easy_1134				
	D008094	"<span class=""chemical"">lithium</span>"		D007037	"<span class=""disease"">hypothyroidism</span>"	"CONCLUSIONS: Familial thyroid illness is a risk factor for <span class=""disease"">hypothyroidism</span> and hypercalcemia during <span class=""chemical"">lithium</span> therapy."		10354657	10354657_D008094_D007037	bcv_easy_1135				
	D008094	"<span class=""chemical"">lithium</span>"		D006934	"<span class=""disease"">hypercalcemia</span>"	"CONCLUSIONS: Familial thyroid illness is a risk factor for hypothyroidism and <span class=""disease"">hypercalcemia</span> during <span class=""chemical"">lithium</span> therapy."		10354657	10354657_D008094_D006934	bcv_easy_1136				
	D008094	"<span class=""chemical"">lithium</span>"		D013959	"<span class=""disease"">thyroid illness</span>"	"CONCLUSIONS: Familial <span class=""disease"">thyroid illness</span> is a risk factor for hypothyroidism and hypercalcemia during <span class=""chemical"">lithium</span> therapy."		10354657	10354657_D008094_D013959	bcv_easy_1137				
	D014640	"<span class=""chemical"">Vancomycin</span>"		D007239	"<span class=""disease"">infection</span>"	"<span class=""chemical"">Vancomycin</span> was curative in 95% of 43 patients with proven <span class=""disease"">infection</span>."		3934126	3934126_D014640_D007239	bcv_easy_1138				
	D014640	"<span class=""chemical"">vancomycin</span>"		D013924	"<span class=""disease"">Thrombophlebitis</span>"	"<span class=""disease"">Thrombophlebitis</span> occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus <span class=""chemical"">vancomycin</span>."		3934126	3934126_D014640_D013924	bcv_easy_1139				
	D000617	"<span class=""chemical"">aminoglycoside</span>"		D007674	"<span class=""disease"">nephrotoxicity</span>"	"Thrombophlebitis occurred only with infusion through peripheral cannulae; <span class=""disease"">nephrotoxicity</span> and ototoxicity were confined to patients receiving an <span class=""chemical"">aminoglycoside</span> plus vancomycin."		3934126	3934126_D000617_D007674	bcv_easy_1140				
	D014640	"<span class=""chemical"">vancomycin</span>"		D007674	"<span class=""disease"">nephrotoxicity</span>"	"Thrombophlebitis occurred only with infusion through peripheral cannulae; <span class=""disease"">nephrotoxicity</span> and ototoxicity were confined to patients receiving an aminoglycoside plus <span class=""chemical"">vancomycin</span>."		3934126	3934126_D014640_D007674	bcv_easy_1141				
	D000617	"<span class=""chemical"">aminoglycoside</span>"		D006311	"<span class=""disease"">ototoxicity</span>"	"Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and <span class=""disease"">ototoxicity</span> were confined to patients receiving an <span class=""chemical"">aminoglycoside</span> plus vancomycin."		3934126	3934126_D000617_D006311	bcv_easy_1142				
	D000617	"<span class=""chemical"">aminoglycoside</span>"		D013924	"<span class=""disease"">Thrombophlebitis</span>"	"<span class=""disease"">Thrombophlebitis</span> occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an <span class=""chemical"">aminoglycoside</span> plus vancomycin."		3934126	3934126_D000617_D013924	bcv_easy_1143				
	D014640	"<span class=""chemical"">vancomycin</span>"		D006311	"<span class=""disease"">ototoxicity</span>"	"Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and <span class=""disease"">ototoxicity</span> were confined to patients receiving an aminoglycoside plus <span class=""chemical"">vancomycin</span>."		3934126	3934126_D014640_D006311	bcv_easy_1144				
	D014640	"<span class=""chemical"">vancomycin</span>"		D007239	"<span class=""disease"">infections</span>"	"We conclude that <span class=""chemical"">vancomycin</span>, administered appropriately, constitutes safe, effective therapy for <span class=""disease"">infections</span> caused by susceptible bacteria."		3934126	3934126_D014640_D007239	bcv_easy_1145				
	D016861	"<span class=""chemical"">cyclooxygenase inhibitors</span>"		D006333	"<span class=""disease"">heart failure</span>"	"Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and <span class=""disease"">heart failure</span> during treatment with <span class=""chemical"">cyclooxygenase inhibitors</span>."		16586083	16586083_D016861_D006333	bcv_easy_1146				
	D016861	"<span class=""chemical"">cyclooxygenase inhibitors</span>"		D020521	"<span class=""disease"">stroke</span>"	"Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, <span class=""disease"">stroke</span>, hypertension and heart failure during treatment with <span class=""chemical"">cyclooxygenase inhibitors</span>."		16586083	16586083_D016861_D020521	bcv_easy_1147				
	D016861	"<span class=""chemical"">cyclooxygenase inhibitors</span>"		D006973	"<span class=""disease"">hypertension</span>"	"Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, <span class=""disease"">hypertension</span> and heart failure during treatment with <span class=""chemical"">cyclooxygenase inhibitors</span>."		16586083	16586083_D016861_D006973	bcv_easy_1148				
	D016861	"<span class=""chemical"">cyclooxygenase inhibitors</span>"		D009203	"<span class=""disease"">myocardial infarction</span>"	"Randomised clinical trials and observational studies have shown an increased risk of <span class=""disease"">myocardial infarction</span>, stroke, hypertension and heart failure during treatment with <span class=""chemical"">cyclooxygenase inhibitors</span>."		16586083	16586083_D016861_D009203	bcv_easy_1149				
	C109794	"<span class=""chemical"">NT-proBNP/N-terminal pro brain natriuretic peptide</span>"		D002318	"<span class=""disease"">cardiovascular toxicity</span>"	"Diagnostic markers such as <span class=""chemical"">N-terminal pro brain natriuretic peptide</span> (<span class=""chemical"">NT-proBNP</span>) or high-sensitive C-reactive protein might help in the early identification of patients at risk, thus avoiding the occurrence of serious <span class=""disease"">cardiovascular toxicity</span>."		16586083	16586083_C109794_D002318	bcv_easy_1150				
	D004317	"<span class=""chemical"">doxorubicin</span>"		D001281	"<span class=""disease"">atrial fibrillation</span>"	"The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden <span class=""disease"">atrial fibrillation</span> following one cycle of <span class=""chemical"">doxorubicin</span>-based chemotherapy in the same patient."		15042318	15042318_D004317_D001281	bcv_easy_1151				
	D004317	"<span class=""chemical"">doxorubicin</span>"		C535648	"<span class=""disease"">gastric lymphoma</span>"	"The authors describe the unusual association between diffuse B-cell <span class=""disease"">gastric lymphoma</span> and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of <span class=""chemical"">doxorubicin</span>-based chemotherapy in the same patient."		15042318	15042318_D004317_C535648	bcv_easy_1152				
	D004317	"<span class=""chemical"">doxorubicin</span>"		D009223	"<span class=""disease"">myotonic dystrophy</span>"	"The authors describe the unusual association between diffuse B-cell gastric lymphoma and <span class=""disease"">myotonic dystrophy</span>, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of <span class=""chemical"">doxorubicin</span>-based chemotherapy in the same patient."		15042318	15042318_D004317_D009223	bcv_easy_1153				
	D004317	"<span class=""chemical"">doxorubicin</span>"		D009136	"<span class=""disease"">muscular dystrophy</span>"	"The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult <span class=""disease"">muscular dystrophy</span>, and sudden atrial fibrillation following one cycle of <span class=""chemical"">doxorubicin</span>-based chemotherapy in the same patient."		15042318	15042318_D004317_D009136	bcv_easy_1154				
	D011802	"<span class=""chemical"">Quinidine</span>"		D056486	"<span class=""disease"">hepatitis</span>"	"<span class=""chemical"">Quinidine</span> <span class=""disease"">hepatitis</span>."		48362	48362_D011802_D056486	bcv_easy_1155				
	D011802	"<span class=""chemical"">quinidine</span>"		D056486	"<span class=""disease"">hepatotoxicity</span>"	"We concluded that this patient had <span class=""chemical"">quinidine</span> <span class=""disease"">hepatotoxicity</span> and believe that this is the first case reported with liver biopsy documentation."		48362	48362_D011802_D056486	bcv_easy_1156				
	D000728	"<span class=""chemical"">androgen</span>"		D020181	"<span class=""disease"">obstructive sleep apnea syndrome</span>"	"Induction of the <span class=""disease"">obstructive sleep apnea syndrome</span> in a woman by exogenous <span class=""chemical"">androgen</span> administration."		6732043	6732043_D000728_D020181	bcv_easy_1157				
	D000728	"<span class=""chemical"">androgens</span>"		D020181	"<span class=""disease"">syndrome of obstructive sleep apnea</span>"	"We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54-yr-old woman who had developed physical changes and the <span class=""disease"">syndrome of obstructive sleep apnea</span> while being administered exogenous <span class=""chemical"">androgens</span>."		6732043	6732043_D000728_D020181	bcv_easy_1158				
	D000728	"<span class=""chemical"">androgen</span>"		D020181	"<span class=""disease"">obstructive sleep apnea</span>"	"A rechallenge with <span class=""chemical"">androgen</span> produced symptoms of <span class=""disease"">obstructive sleep apnea</span> that abated upon withdrawal of the hormone."		6732043	6732043_D000728_D020181	bcv_easy_1159				
	D000728	"<span class=""chemical"">androgens</span>"		D012891	"<span class=""disease"">sleep apnea</span>"	"Previous reports have favored a role of <span class=""chemical"">androgens</span> in the pathogenesis of <span class=""disease"">sleep apnea</span>."		6732043	6732043_D000728_D012891	bcv_easy_1160				
	D000728	"<span class=""chemical"">androgen</span>"		D020181	"<span class=""disease"">obstructive sleep apnea syndrome</span>"	"Development of the <span class=""disease"">obstructive sleep apnea syndrome</span> must be considered a possible side effect of <span class=""chemical"">androgen</span> therapy."		6732043	6732043_D000728_D020181	bcv_easy_1161				
	D011224	"<span class=""chemical"">prazosin</span>"		D009127	"<span class=""disease"">muscular rigidity</span>"	"Such an induced <span class=""disease"">muscular rigidity</span> by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha-adrenoceptor blocker, <span class=""chemical"">prazosin</span>."		2564649	2564649_D011224_D009127	bcv_easy_1162				
	D004456	"<span class=""chemical"">echothiophate iodide</span>"		D064420	"<span class=""disease"">toxicity</span>"	"Cholinergic <span class=""disease"">toxicity</span> resulting from ocular instillation of <span class=""chemical"">echothiophate iodide</span> eye drops."		7650771	7650771_D004456_D064420	bcv_easy_1163				
	D004456	"<span class=""chemical"">echothiophate iodide</span>"		D009157	"<span class=""disease"">myasthenia gravis</span>"	"A patient developed a severe cholinergic syndrome from the use of <span class=""chemical"">echothiophate iodide</span> ophthalmic drops, presented with profound muscle weakness and was initially given the diagnosis of <span class=""disease"">myasthenia gravis</span>."		7650771	7650771_D004456_D009157	bcv_easy_1164				
	D004456	"<span class=""chemical"">echothiophate iodide</span>"		D018908	"<span class=""disease"">muscle weakness</span>"	"A patient developed a severe cholinergic syndrome from the use of <span class=""chemical"">echothiophate iodide</span> ophthalmic drops, presented with profound <span class=""disease"">muscle weakness</span> and was initially given the diagnosis of myasthenia gravis."		7650771	7650771_D004456_D018908	bcv_easy_1165				
	D005277	"<span class=""chemical"">fenfluramine</span>"		D006349	"<span class=""disease"">valvular heart disease</span>"	"Risk for <span class=""disease"">valvular heart disease</span> among users of <span class=""chemical"">fenfluramine</span> and dexfenfluramine who underwent echocardiography before use of medication."		9867728	9867728_D005277_D006349	bcv_easy_1166				
	D020372	"<span class=""chemical"">dexfenfluramine</span>"		D006349	"<span class=""disease"">valvular heart disease</span>"	"Risk for <span class=""disease"">valvular heart disease</span> among users of fenfluramine and <span class=""chemical"">dexfenfluramine</span> who underwent echocardiography before use of medication."		9867728	9867728_D020372_D006349	bcv_easy_1167				
	D005277	"<span class=""chemical"">fenfluramine</span>"		D006349	"<span class=""disease"">valvular disease</span>"	"BACKGROUND: Because uncontrolled echocardiographic surveys suggested that up to 30% to 38% of users of <span class=""chemical"">fenfluramine</span> and dexfenfluramine had <span class=""disease"">valvular disease</span>, these drugs were withdrawn from the market."		9867728	9867728_D005277_D006349	bcv_easy_1168				
	D020372	"<span class=""chemical"">dexfenfluramine</span>"		D006349	"<span class=""disease"">valvular disease</span>"	"BACKGROUND: Because uncontrolled echocardiographic surveys suggested that up to 30% to 38% of users of fenfluramine and <span class=""chemical"">dexfenfluramine</span> had <span class=""disease"">valvular disease</span>, these drugs were withdrawn from the market."		9867728	9867728_D020372_D006349	bcv_easy_1169				
	D005277	"<span class=""chemical"">fenfluramine</span>"		D006349	"<span class=""disease"">valvular abnormalities</span>"	"OBJECTIVE: To determine the risk for new or worsening <span class=""disease"">valvular abnormalities</span> among users of <span class=""chemical"">fenfluramine</span> or dexfenfluramine who underwent echocardiography before they began to take these medications."		9867728	9867728_D005277_D006349	bcv_easy_1170				
	D020372	"<span class=""chemical"">dexfenfluramine</span>"		D006349	"<span class=""disease"">valvular abnormalities</span>"	"OBJECTIVE: To determine the risk for new or worsening <span class=""disease"">valvular abnormalities</span> among users of fenfluramine or <span class=""chemical"">dexfenfluramine</span> who underwent echocardiography before they began to take these medications."		9867728	9867728_D020372_D006349	bcv_easy_1171				
	D005277	"<span class=""chemical"">fenfluramine</span>"		D006349	"<span class=""disease"">valvular heart disease</span>"	"RESULTS: Two patients (4.3% [95% CI, 0.6% to 14.8%]) receiving <span class=""chemical"">fenfluramine</span>-phentermine developed <span class=""disease"">valvular heart disease</span>."		9867728	9867728_D005277_D006349	bcv_easy_1172				
	D010645	"<span class=""chemical"">phentermine</span>"		D006349	"<span class=""disease"">valvular heart disease</span>"	"RESULTS: Two patients (4.3% [95% CI, 0.6% to 14.8%]) receiving fenfluramine-<span class=""chemical"">phentermine</span> developed <span class=""disease"">valvular heart disease</span>."		9867728	9867728_D010645_D006349	bcv_easy_1173				
	D017311	"<span class=""chemical"">amlodipine</span>"		D006973	"<span class=""disease"">hypertension</span>"	"This is a case report on a 45-year old African-American female with newly diagnosed <span class=""disease"">hypertension</span>, who was started on a combination pill of <span class=""chemical"">amlodipine</span>/benazapril 10/5 mg."		17285209	17285209_D017311_D006973	bcv_easy_1174				
	C044946	"<span class=""chemical"">benazapril</span>"		D006973	"<span class=""disease"">hypertension</span>"	"This is a case report on a 45-year old African-American female with newly diagnosed <span class=""disease"">hypertension</span>, who was started on a combination pill of amlodipine/<span class=""chemical"">benazapril</span> 10/5 mg."		17285209	17285209_C044946_D006973	bcv_easy_1175				
	D000809	"<span class=""chemical"">angiotensin</span>"		D007410|D000799	"<span class=""disease"">intestinal angioedema</span>"	"The recognition of <span class=""chemical"">angiotensin</span>-converting enzyme (ACE) and <span class=""chemical"">angiotensin</span> receptor blocker (ARB) <span class=""disease"">intestinal angioedema</span> constitutes a challenge to primary care physicians, internists, emergency room personal and surgeons."		17285209	17285209_D000809_D007410|D000799	bcv_easy_1176				
	D016666	"<span class=""chemical"">fluvoxamine</span>"		D006948	"<span class=""disease"">hyperactivity</span>"	"A repeated treatment with <span class=""chemical"">fluvoxamine</span> (twice daily for 14 days) potentiated in mice and in rats (weaker) the amphetamine-induced <span class=""disease"">hyperactivity</span>."		2576810	2576810_D016666_D006948	bcv_easy_1177				
	D009627	"<span class=""chemical"">nomifensine</span>"		D006948	"<span class=""disease"">hyperactivity</span>"	"The <span class=""disease"">hyperactivity</span> induced by <span class=""chemical"">nomifensine</span> in mice remained unaffected by fluvoxamine."		2576810	2576810_D009627_D006948	bcv_easy_1178				
	D016666	"<span class=""chemical"">fluvoxamine</span>"		D006948	"<span class=""disease"">hyperactivity</span>"	"The <span class=""disease"">hyperactivity</span> induced by nomifensine in mice remained unaffected by <span class=""chemical"">fluvoxamine</span>."		2576810	2576810_D016666_D006948	bcv_easy_1179				
	D004317	"<span class=""chemical"">doxorubicin</span>"		D009401	"<span class=""disease"">nephrosis</span>"	"Mitochondrial DNA and its respiratory chain products are defective in <span class=""chemical"">doxorubicin</span> <span class=""disease"">nephrosis</span>."		14736955	14736955_D004317_D009401	bcv_easy_1180				
	C102006	"<span class=""chemical"">citrate</span>"		D007674	"<span class=""disease"">glomerular and tubular lesions</span>"	"RESULTS: The 'long-term' group had significant <span class=""disease"">glomerular and tubular lesions</span>, depressed activities of mtDNA-encoded NADH dehydrogenase and cytochrome-c oxidase (COX) and increased <span class=""chemical"">citrate</span> synthase activity."		14736955	14736955_C102006_D007674	bcv_easy_1181				
	D013481	"<span class=""chemical"">superoxide</span>"		D007674	"<span class=""disease"">renal lesions</span>"	"CONCLUSIONS: These results suggest an important role for quantitative and qualitative mtDNA alterations through the reduction of mtDNA-encoded respiratory chain function and induction of <span class=""chemical"">superoxide</span> in doxorubicin-induced <span class=""disease"">renal lesions</span>."		14736955	14736955_D013481_D007674	bcv_easy_1182				
	D014859	"<span class=""chemical"">warfarin</span>"		D012871	"<span class=""disease"">skin eruptions</span>"	"All 4 patients presented with <span class=""disease"">skin eruptions</span> that developed after receiving <span class=""chemical"">warfarin</span> for several years."		16047871	16047871_D014859_D012871	bcv_easy_1183				
	D014859	"<span class=""chemical"">warfarin</span>"		D018366	"<span class=""disease"">LV Cutaneous lesions</span>"	"The results of skin lesion biopsies were available in 3 patients, confirming <span class=""disease"">LV Cutaneous lesions</span> resolved in all patients after <span class=""chemical"">warfarin</span> was discontinued."		16047871	16047871_D014859_D018366	bcv_easy_1184				
	D014859	"<span class=""chemical"">warfarin</span>"		D012871	"<span class=""disease"">skin lesion</span>"	"The results of <span class=""disease"">skin lesion</span> biopsies were available in 3 patients, confirming LV Cutaneous lesions resolved in all patients after <span class=""chemical"">warfarin</span> was discontinued."		16047871	16047871_D014859_D012871	bcv_easy_1185				
	D008790	"<span class=""chemical"">metoprolol</span>"		D017202	"<span class=""disease"">myocardial ischemia</span>"	"Effect of intravenous <span class=""chemical"">metoprolol</span> or intravenous <span class=""chemical"">metoprolol</span> plus glucagon on dobutamine-induced <span class=""disease"">myocardial ischemia</span>."		11079278	11079278_D008790_D017202	bcv_easy_1186				
	D008790	"<span class=""chemical"">metoprolol</span>"		D017202	"<span class=""disease"">myocardial ischemia</span>"	"CONCLUSION: During dobutamine stress testing, <span class=""chemical"">metoprolol</span> attenuates or eliminates evidence of <span class=""disease"">myocardial ischemia</span>."		11079278	11079278_D008790_D017202	bcv_easy_1187				
	D002216	"<span class=""chemical"">captopril</span>"		D006973	"<span class=""disease"">hypertensive</span>"	"Contribution of the sympathetic nervous system to salt-sensitivity in lifetime <span class=""chemical"">captopril</span>-treated spontaneously <span class=""disease"">hypertensive</span> rats."		8586822	8586822_D002216_D006973	bcv_easy_1188				
	D002216	"<span class=""chemical"">captopril</span>"		D006973	"<span class=""disease"">hypertensive</span>"	"OBJECTIVE: To test the hypothesis that, in lifetime <span class=""chemical"">captopril</span>-treated spontaneously <span class=""disease"">hypertensive</span> rats (SHR), the sympathetic nervous system contributes importantly to the <span class=""disease"">hypertensive</span> effect of dietary sodium chloride supplementation."		8586822	8586822_D002216_D006973	bcv_easy_1189				
	D018738	"<span class=""chemical"">hexamethonium</span>"		D006973	"<span class=""disease"">increase in MAP</span>"	"Intravenous infusion of the ganglionic blocker <span class=""chemical"">hexamethonium</span> resulted in a rapid decline in MAP that eliminated the dietary sodium chloride-induced <span class=""disease"">increase in MAP</span> in both groups."		8586822	8586822_D018738_D006973	bcv_easy_1190				
	D006220	"<span class=""chemical"">haloperidol</span>"		D003072	"<span class=""disease"">cognitive impairment</span>"	"Absence of effect of sertraline on time-based sensitization of <span class=""disease"">cognitive impairment</span> with <span class=""chemical"">haloperidol</span>."		8617710	8617710_D006220_D003072	bcv_easy_1191				
	D020280	"<span class=""chemical"">sertraline</span>"		D003072	"<span class=""disease"">cognitive impairment</span>"	"Absence of effect of <span class=""chemical"">sertraline</span> on time-based sensitization of <span class=""disease"">cognitive impairment</span> with haloperidol."		8617710	8617710_D020280_D003072	bcv_easy_1192				
	D006220	"<span class=""chemical"">haloperidol</span>"		D003072	"<span class=""disease"">Impairment of cognitive function</span>"	"RESULTS: <span class=""disease"">Impairment of cognitive function</span> was observed 6 to 8 hours after administration of <span class=""chemical"">haloperidol</span> on Day 2 but was not evident 23 hours after dosing."		8617710	8617710_D006220_D003072	bcv_easy_1193				
	D006220	"<span class=""chemical"">Haloperidol</span>"		D003072	"<span class=""disease"">cognitive impairment</span>"	"CONCLUSION: <span class=""chemical"">Haloperidol</span> produced a clear profile of <span class=""disease"">cognitive impairment</span> that was not worsened by concomitant sertraline administration."		8617710	8617710_D006220_D003072	bcv_easy_1194				
	D020280	"<span class=""chemical"">sertraline</span>"		D003072	"<span class=""disease"">cognitive impairment</span>"	"CONCLUSION: Haloperidol produced a clear profile of <span class=""disease"">cognitive impairment</span> that was not worsened by concomitant <span class=""chemical"">sertraline</span> administration."		8617710	8617710_D020280_D003072	bcv_easy_1195				
	D016685	"<span class=""chemical"">mitomycin C</span>"		D066126	"<span class=""disease"">cardiotoxicity</span>"	"A prospective study on the dose dependency of <span class=""disease"">cardiotoxicity</span> induced by <span class=""chemical"">mitomycin C</span>."		3137399	3137399_D016685_D066126	bcv_easy_1196				
	D004317	"<span class=""chemical"">doxorubicin</span>"		D066126	"<span class=""disease"">cardiotoxic</span>"	"Since 1975 mitomycin C (MMC) has been suggested to be <span class=""disease"">cardiotoxic</span>, especially when combined with or given following <span class=""chemical"">doxorubicin</span>."		3137399	3137399_D004317_D066126	bcv_easy_1197				
	D016685	"<span class=""chemical"">MMC/mitomycin C</span>"		D066126	"<span class=""disease"">cardiotoxic</span>"	"Since 1975 <span class=""chemical"">mitomycin C</span> (<span class=""chemical"">MMC</span>) has been suggested to be <span class=""disease"">cardiotoxic</span>, especially when combined with or given following doxorubicin."		3137399	3137399_D016685_D066126	bcv_easy_1198				
	D004317	"<span class=""chemical"">doxorubicin</span>"		D006333	"<span class=""disease"">cardiac failure</span>"	"One of the patients developed <span class=""disease"">cardiac failure</span> after 30 mg m-2 MMC and only 150 mg m-2 <span class=""chemical"">doxorubicin</span>."		3137399	3137399_D004317_D006333	bcv_easy_1199				
	D016685	"<span class=""chemical"">MMC</span>"		D006333	"<span class=""disease"">cardiac failure</span>"	"One of the patients developed <span class=""disease"">cardiac failure</span> after 30 mg m-2 <span class=""chemical"">MMC</span> and only 150 mg m-2 doxorubicin."		3137399	3137399_D016685_D006333	bcv_easy_1200				
	D004317	"<span class=""chemical"">doxorubicin</span>"		D066126	"<span class=""disease"">cardiotoxicity</span>"	"Based on the combined data from the present study and the literature, we suggest that MMC-related <span class=""disease"">cardiotoxicity</span> is dose dependent, occurring at cumulative dose levels of 30 mg m-2 or more, mainly in patients also (previously or simultaneously) treated with <span class=""chemical"">doxorubicin</span>."		3137399	3137399_D004317_D066126	bcv_easy_1201				
	D016685	"<span class=""chemical"">MMC</span>"		D066126	"<span class=""disease"">cardiotoxicity</span>"	"Based on the combined data from the present study and the literature, we suggest that <span class=""chemical"">MMC</span>-related <span class=""disease"">cardiotoxicity</span> is dose dependent, occurring at cumulative dose levels of 30 mg m-2 or more, mainly in patients also (previously or simultaneously) treated with doxorubicin."		3137399	3137399_D016685_D066126	bcv_easy_1202				
	D010634	"<span class=""chemical"">phenobarbital</span>"		D002761	"<span class=""disease"">cholangitis</span>"	"Hepatonecrosis and <span class=""disease"">cholangitis</span> related to long-term <span class=""chemical"">phenobarbital</span> therapy: an autopsy report of two patients."		17574447	17574447_D010634_D002761	bcv_easy_1203				
	D010634	"<span class=""chemical"">PB/Phenobarbital</span>"		D008107	"<span class=""disease"">liver disease</span>"	"<span class=""chemical"">Phenobarbital</span> (<span class=""chemical"">PB</span>) has a reputation for safety, and it is commonly believed that <span class=""chemical"">PB</span>-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic <span class=""disease"">liver disease</span>."		17574447	17574447_D010634_D008107	bcv_easy_1204				
	D010634	"<span class=""chemical"">PB</span>"		D004827	"<span class=""disease"">epilepsy</span>"	"Here we report of two adult patients with a long history of <span class=""disease"">epilepsy</span> treated with <span class=""chemical"">PB</span> who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia."		17574447	17574447_D010634_D004827	bcv_easy_1205				
	D010634	"<span class=""chemical"">PB</span>"		D001996	"<span class=""disease"">bronchopneumonia</span>"	"Here we report of two adult patients with a long history of epilepsy treated with <span class=""chemical"">PB</span> who died suddenly: one as consequence of cardiac arrest, the other of acute <span class=""disease"">bronchopneumonia</span>."		17574447	17574447_D010634_D001996	bcv_easy_1206				
	D010634	"<span class=""chemical"">PB</span>"		D006323	"<span class=""disease"">cardiac arrest</span>"	"Here we report of two adult patients with a long history of epilepsy treated with <span class=""chemical"">PB</span> who died suddenly: one as consequence of <span class=""disease"">cardiac arrest</span>, the other of acute bronchopneumonia."		17574447	17574447_D010634_D006323	bcv_easy_1207				
	D010634	"<span class=""chemical"">PB</span>"		D008107	"<span class=""disease"">liver damage</span>"	"Our findings illustrate that <span class=""chemical"">PB</span> may be associated with chronic <span class=""disease"">liver damage</span>, which may lead to more serious and deleterious consequences."		17574447	17574447_D010634_D008107	bcv_easy_1208				
	D010634	"<span class=""chemical"">PB</span>"		D056487	"<span class=""disease"">chronic hepatic enzyme dysfunction</span>"	"For this reason, each clinician should recognize this entity in the differential diagnosis of <span class=""chemical"">PB</span>-related asymptomatic <span class=""disease"">chronic hepatic enzyme dysfunction</span>."		17574447	17574447_D010634_D056487	bcv_easy_1209				
	D007741	"<span class=""chemical"">dilevalol</span>"		D004342	"<span class=""disease"">Hypersensitivity</span>"	"<span class=""disease"">Hypersensitivity</span> immune reaction as a mechanism for <span class=""chemical"">dilevalol</span>-associated hepatitis."		1504402	1504402_D007741_D004342	bcv_easy_1210				
	D013866	"<span class=""chemical"">6-thioguanine</span>"		D006504	"<span class=""disease"">Hepatic veno-occlusive disease</span>"	"<span class=""disease"">Hepatic veno-occlusive disease</span> caused by <span class=""chemical"">6-thioguanine</span>."		7053705	7053705_D013866_D006504	bcv_easy_1211				
	D013866	"<span class=""chemical"">6-thioguanine</span>"		D054198	"<span class=""disease"">acute lymphocytic leukemia</span>"	"Clinically reversible veno-occlusive disease of the liver developed in a 23-year-old man with <span class=""disease"">acute lymphocytic leukemia</span> after 10 months of maintenance therapy with <span class=""chemical"">6-thioguanine</span>."		7053705	7053705_D013866_D054198	bcv_easy_1212				
	D013866	"<span class=""chemical"">6-thioguanine</span>"		D006504	"<span class=""disease"">veno-occlusive disease of the liver</span>"	"Clinically reversible <span class=""disease"">veno-occlusive disease of the liver</span> developed in a 23-year-old man with acute lymphocytic leukemia after 10 months of maintenance therapy with <span class=""chemical"">6-thioguanine</span>."		7053705	7053705_D013866_D006504	bcv_easy_1213				
	D013866	"<span class=""chemical"">6-thioguanine</span>"		D006504	"<span class=""disease"">hepatic veno-occlusive disease</span>"	"This case presented a unique opportunity to observe the histologic features of clinically reversible <span class=""disease"">hepatic veno-occlusive disease</span> over time, and may be the first case of veno-occlusive related solely to <span class=""chemical"">6-thioguanine</span>."		7053705	7053705_D013866_D006504	bcv_easy_1214				
	C033457	"<span class=""chemical"">Quinidine phenylethylbarbiturate</span>"		D056486	"<span class=""disease"">hepatitis</span>"	"<span class=""chemical"">Quinidine phenylethylbarbiturate</span>-induced fulminant <span class=""disease"">hepatitis</span> in a pregnant woman. A case report."		3411101	3411101_C033457_D056486	bcv_easy_1215				
	C033457	"<span class=""chemical"">quinidine phenylethylbarbiturate</span>"		D056486	"<span class=""disease"">hepatitis</span>"	"We report the case of a 19-year-old Laotian patient affected by fulminant <span class=""disease"">hepatitis</span> during the third trimester of her pregnancy after a 1-month administration of <span class=""chemical"">quinidine phenylethylbarbiturate</span>."		3411101	3411101_C033457_D056486	bcv_easy_1216				
	C033457	"<span class=""chemical"">phenylethylbarbiturate</span>"		D056486	"<span class=""disease"">hepatitis</span>"	"Quinidine itself or <span class=""chemical"">phenylethylbarbiturate</span> may be responsible for fulminant <span class=""disease"">hepatitis</span> in this patient."		3411101	3411101_C033457_D056486	bcv_easy_1217				
	D011802	"<span class=""chemical"">Quinidine</span>"		D056486	"<span class=""disease"">hepatitis</span>"	"<span class=""chemical"">Quinidine</span> itself or phenylethylbarbiturate may be responsible for fulminant <span class=""disease"">hepatitis</span> in this patient."		3411101	3411101_D011802_D056486	bcv_easy_1218				
	D010862	"<span class=""chemical"">pilocarpine</span>"		D004833	"<span class=""disease"">temporal lobe epilepsy</span>"	"Neuropeptide-Y immunoreactivity in the <span class=""chemical"">pilocarpine</span> model of <span class=""disease"">temporal lobe epilepsy</span>."		9305828	9305828_D010862_D004833	bcv_easy_1219				
	D010862	"<span class=""chemical"">pilocarpine/PILO</span>"		D001930	"<span class=""disease"">brain damage</span>"	"The <span class=""chemical"">pilocarpine</span> (<span class=""chemical"">PILO</span>) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related <span class=""disease"">brain damage</span>."		9305828	9305828_D010862_D001930	bcv_easy_1220				
	D010862	"<span class=""chemical"">pilocarpine/PILO</span>"		D013226	"<span class=""disease"">status epilepticus</span>"	"The <span class=""chemical"">pilocarpine</span> (<span class=""chemical"">PILO</span>) model of epilepsy is characterized by an acute period of <span class=""disease"">status epilepticus</span> followed by spontaneous recurrent seizures and related brain damage."		9305828	9305828_D010862_D013226	bcv_easy_1221				
	D010862	"<span class=""chemical"">pilocarpine/PILO</span>"		D012640	"<span class=""disease"">seizures</span>"	"The <span class=""chemical"">pilocarpine</span> (<span class=""chemical"">PILO</span>) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent <span class=""disease"">seizures</span> and related brain damage."		9305828	9305828_D010862_D012640	bcv_easy_1222				
	D010862	"<span class=""chemical"">pilocarpine/PILO</span>"		D004827	"<span class=""disease"">epilepsy</span>"	"The <span class=""chemical"">pilocarpine</span> (<span class=""chemical"">PILO</span>) model of <span class=""disease"">epilepsy</span> is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage."		9305828	9305828_D010862_D004827	bcv_easy_1223				
	D010862	"<span class=""chemical"">PILO</span>"		D004833	"<span class=""disease"">TLE</span>"	"The results demonstrate that changes in NPY expression, including expression in the granule cells and mossy fibres and the loss of vulnerable NPY neurons, are present in the <span class=""chemical"">PILO</span> model of <span class=""disease"">TLE</span>."		9305828	9305828_D010862_D004833	bcv_easy_1224				
	D015742	"<span class=""chemical"">propofol</span>"		D008305	"<span class=""disease"">malignant hyperthermia</span>"	"Anesthesia was continued uneventfully with <span class=""chemical"">propofol</span> infusion while all facilities were available to detect and treat <span class=""disease"">malignant hyperthermia</span>."		15893386	15893386_D015742_D008305	bcv_easy_1225				
	D013256	"<span class=""chemical"">Steroid</span>"		D000647	"<span class=""disease"">amnesic</span>"	"<span class=""chemical"">Steroid</span> structure and pharmacological properties determine the anti-<span class=""disease"">amnesic</span> effects of pregnenolone sulphate in the passive avoidance task in rats."		11860495	11860495_D013256_D000647	bcv_easy_1226				
	C018370	"<span class=""chemical"">pregnenolone sulphate</span>"		D000647	"<span class=""disease"">amnesic</span>"	"Steroid structure and pharmacological properties determine the anti-<span class=""disease"">amnesic</span> effects of <span class=""chemical"">pregnenolone sulphate</span> in the passive avoidance task in rats."		11860495	11860495_C018370_D000647	bcv_easy_1227				
	D005680	"<span class=""chemical"">GABA</span>"		D000647	"<span class=""disease"">amnesic</span>"	"Moreover, PREGS is able to reverse the <span class=""disease"">amnesic</span>-like effects of NMDAR and <span class=""chemical"">GABA</span>(A)R ligands."		11860495	11860495_D005680_D000647	bcv_easy_1228				
	C018370	"<span class=""chemical"">PREGS</span>"		D000647	"<span class=""disease"">amnesic</span>"	"Moreover, <span class=""chemical"">PREGS</span> is able to reverse the <span class=""disease"">amnesic</span>-like effects of NMDAR and GABA(A)R ligands."		11860495	11860495_C018370_D000647	bcv_easy_1229				
	C018370	"<span class=""chemical"">PREGS</span>"		D000647	"<span class=""disease"">amnesia</span>"	"The memory-enhancing effects of <span class=""chemical"">PREGS</span> and its analogs were tested in the passive avoidance task using the model of scopolamine-induced <span class=""disease"">amnesia</span>."		11860495	11860495_C018370_D000647	bcv_easy_1230				
	C018370	"<span class=""chemical"">PREGS</span>"		D000647	"<span class=""disease"">amnesia</span>"	"Moreover, enantioselectivity was demonstrated by the ability of natural <span class=""chemical"">PREGS</span> to be an order of magnitude more effective than its synthetic enantiomer in reversing scopolamine-induced <span class=""disease"">amnesia</span>."		11860495	11860495_C018370_D000647	bcv_easy_1231				
	D018698	"<span class=""chemical"">glutamate</span>"		D010300	"<span class=""disease"">Parkinson's disease</span>"	"Metabotropic <span class=""chemical"">glutamate</span> 7 receptor subtype modulates motor symptoms in rodent models of <span class=""disease"">Parkinson's disease</span>."		19940105	19940105_D018698_D010300	bcv_easy_1232				
	D018698	"<span class=""chemical"">glutamate</span>"		D010300	"<span class=""disease"">Parkinson's disease/PD</span>"	"Metabotropic <span class=""chemical"">glutamate</span> (mGlu) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of <span class=""disease"">Parkinson's disease</span> (<span class=""disease"">PD</span>)."		19940105	19940105_D018698_D010300	bcv_easy_1233				
	C507346	"<span class=""chemical"">AMN082/N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride</span>"		D010300	"<span class=""disease"">PD</span>"	"The effects of <span class=""chemical"">N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride</span> (<span class=""chemical"">AMN082</span>), the first selective allosteric activator of mGlu7 receptors, were thus tested in different rodent models of <span class=""disease"">PD</span>."		19940105	19940105_C507346_D010300	bcv_easy_1234				
	C507346	"<span class=""chemical"">AMN082</span>"		D002375	"<span class=""disease"">catalepsy</span>"	"Here, we show that oral (5 mg/kg) or intrastriatal administration (0.1 and 0.5 nmol) of <span class=""chemical"">AMN082</span> reverses haloperidol-induced <span class=""disease"">catalepsy</span> in rats."		19940105	19940105_C507346_D002375	bcv_easy_1235				
	D016627	"<span class=""chemical"">6-OHDA</span>"		D010300	"<span class=""disease"">PD</span>"	"In a more complex task commonly used to evaluate major akinetic symptoms of <span class=""disease"">PD</span> patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral <span class=""chemical"">6-OHDA</span>-lesioned rats."		19940105	19940105_D016627_D010300	bcv_easy_1236				
	D016627	"<span class=""chemical"">6-OHDA</span>"		D018476	"<span class=""disease"">akinetic</span>"	"In a more complex task commonly used to evaluate major <span class=""disease"">akinetic</span> symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral <span class=""chemical"">6-OHDA</span>-lesioned rats."		19940105	19940105_D016627_D018476	bcv_easy_1237				
	C507346	"<span class=""chemical"">AMN082</span>"		D018476	"<span class=""disease"">akinetic</span>"	"In a more complex task commonly used to evaluate major <span class=""disease"">akinetic</span> symptoms of PD patients, 5 mg/kg <span class=""chemical"">AMN082</span> reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats."		19940105	19940105_C507346_D018476	bcv_easy_1238				
	C507346	"<span class=""chemical"">AMN082</span>"		D010300	"<span class=""disease"">PD</span>"	"In a more complex task commonly used to evaluate major akinetic symptoms of <span class=""disease"">PD</span> patients, 5 mg/kg <span class=""chemical"">AMN082</span> reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats."		19940105	19940105_C507346_D010300	bcv_easy_1239				
	C507346	"<span class=""chemical"">AMN082</span>"		D002375	"<span class=""disease"">catalepsy</span>"	"In addition, <span class=""chemical"">AMN082</span> reduces the duration of haloperidol-induced <span class=""disease"">catalepsy</span> in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice."		19940105	19940105_C507346_D002375	bcv_easy_1240				
	C507346	"<span class=""chemical"">AMN082</span>"		D010300	"<span class=""disease"">PD</span>"	"Higher doses of <span class=""chemical"">AMN082</span> (10 and 20 mg/kg p.o.) have no effect on the same models of <span class=""disease"">PD</span>."		19940105	19940105_C507346_D010300	bcv_easy_1241				
	D003915	"<span class=""chemical"">dextromethorphan</span>"		D003072	"<span class=""disease"">Cognitive deterioration</span>"	"<span class=""disease"">Cognitive deterioration</span> from long-term abuse of <span class=""chemical"">dextromethorphan</span>: a case report."		7803371	7803371_D003915_D003072	bcv_easy_1242				
	D003915	"<span class=""chemical"">DM</span>"		D003072	"<span class=""disease"">cognitive deterioration</span>"	"This report describes a case of <span class=""disease"">cognitive deterioration</span> resulting from prolonged use of <span class=""chemical"">DM</span>."		7803371	7803371_D003915_D003072	bcv_easy_1243				
	D009288	"<span class=""chemical"">naproxen</span>"		D007681	"<span class=""disease"">Renal papillary necrosis</span>"	"<span class=""disease"">Renal papillary necrosis</span> due to <span class=""chemical"">naproxen</span>."		6699841	6699841_D009288_D007681	bcv_easy_1244				
	D006046	"<span class=""chemical"">gold</span>"		D001172	"<span class=""disease"">rheumatoid arthritis</span>"	"A 31-year-old man with <span class=""disease"">rheumatoid arthritis</span>, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and <span class=""chemical"">gold</span> salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy."		6699841	6699841_D006046_D001172	bcv_easy_1245				
	D005279	"<span class=""chemical"">fenoprofen calcium</span>"		D007681	"<span class=""disease"">renal papillary necrosis/RPN</span>"	"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, <span class=""chemical"">fenoprofen calcium</span>, high dose salicylates and gold salts, developed <span class=""disease"">renal papillary necrosis</span> (<span class=""disease"">RPN</span>) 4 months after institution of naproxen therapy."		6699841	6699841_D005279_D007681	bcv_easy_1246				
	D012459	"<span class=""chemical"">salicylates</span>"		D007681	"<span class=""disease"">renal papillary necrosis/RPN</span>"	"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose <span class=""chemical"">salicylates</span> and gold salts, developed <span class=""disease"">renal papillary necrosis</span> (<span class=""disease"">RPN</span>) 4 months after institution of naproxen therapy."		6699841	6699841_D012459_D007681	bcv_easy_1247				
	D012459	"<span class=""chemical"">salicylates</span>"		D001172	"<span class=""disease"">rheumatoid arthritis</span>"	"A 31-year-old man with <span class=""disease"">rheumatoid arthritis</span>, who had previously been treated with sulindac, fenoprofen calcium, high dose <span class=""chemical"">salicylates</span> and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy."		6699841	6699841_D012459_D001172	bcv_easy_1248				
	D013467	"<span class=""chemical"">sulindac</span>"		D007681	"<span class=""disease"">renal papillary necrosis/RPN</span>"	"A 31-year-old man with rheumatoid arthritis, who had previously been treated with <span class=""chemical"">sulindac</span>, fenoprofen calcium, high dose salicylates and gold salts, developed <span class=""disease"">renal papillary necrosis</span> (<span class=""disease"">RPN</span>) 4 months after institution of naproxen therapy."		6699841	6699841_D013467_D007681	bcv_easy_1249				
	D013467	"<span class=""chemical"">sulindac</span>"		D001172	"<span class=""disease"">rheumatoid arthritis</span>"	"A 31-year-old man with <span class=""disease"">rheumatoid arthritis</span>, who had previously been treated with <span class=""chemical"">sulindac</span>, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy."		6699841	6699841_D013467_D001172	bcv_easy_1250				
	D006046	"<span class=""chemical"">gold</span>"		D007681	"<span class=""disease"">renal papillary necrosis/RPN</span>"	"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and <span class=""chemical"">gold</span> salts, developed <span class=""disease"">renal papillary necrosis</span> (<span class=""disease"">RPN</span>) 4 months after institution of naproxen therapy."		6699841	6699841_D006046_D007681	bcv_easy_1251				
	D005279	"<span class=""chemical"">fenoprofen calcium</span>"		D001172	"<span class=""disease"">rheumatoid arthritis</span>"	"A 31-year-old man with <span class=""disease"">rheumatoid arthritis</span>, who had previously been treated with sulindac, <span class=""chemical"">fenoprofen calcium</span>, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy."		6699841	6699841_D005279_D001172	bcv_easy_1252				
	D009288	"<span class=""chemical"">naproxen</span>"		D007681	"<span class=""disease"">renal papillary necrosis/RPN</span>"	"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed <span class=""disease"">renal papillary necrosis</span> (<span class=""disease"">RPN</span>) 4 months after institution of <span class=""chemical"">naproxen</span> therapy."		6699841	6699841_D009288_D007681	bcv_easy_1253				
	D009288	"<span class=""chemical"">naproxen</span>"		D001172	"<span class=""disease"">rheumatoid arthritis</span>"	"A 31-year-old man with <span class=""disease"">rheumatoid arthritis</span>, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of <span class=""chemical"">naproxen</span> therapy."		6699841	6699841_D009288_D001172	bcv_easy_1254				
	D013467	"<span class=""chemical"">sulindac</span>"		D007674	"<span class=""disease"">renal toxicity</span>"	"We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of <span class=""chemical"">sulindac</span> in patients who have experienced <span class=""disease"">renal toxicity</span> from other antiinflammatory agents."		6699841	6699841_D013467_D007674	bcv_easy_1255				
	D013467	"<span class=""chemical"">sulindac</span>"		D007681	"<span class=""disease"">RPN</span>"	"We review previous reports linking <span class=""disease"">RPN</span> to antiinflammatory drug use and discuss possible advantages of <span class=""chemical"">sulindac</span> in patients who have experienced renal toxicity from other antiinflammatory agents."		6699841	6699841_D013467_D007681	bcv_easy_1256				
	D003907	"<span class=""chemical"">dexamethasone</span>"		D009422	"<span class=""disease"">neurological dysfunction</span>"	"Minor <span class=""disease"">neurological dysfunction</span>, cognitive development, and somatic development at the age of 3 to 7 years after <span class=""chemical"">dexamethasone</span> treatment in very-low birth-weight infants."		15814210	15814210_D003907_D009422	bcv_easy_1257				
	D003907	"<span class=""chemical"">dexamethasone</span>"		D009422	"<span class=""disease"">neurological dysfunction</span>"	"The objective of this study was to assess minor <span class=""disease"">neurological dysfunction</span>, cognitive development, and somatic development after <span class=""chemical"">dexamethasone</span> therapy in very-low-birthweight infants."		15814210	15814210_D003907_D009422	bcv_easy_1258				
	D003907	"<span class=""chemical"">dexamethasone</span>"		D009422	"<span class=""disease"">neurological dysfunctions</span>"	"After <span class=""chemical"">dexamethasone</span> treatment, children showed a higher rate of minor <span class=""disease"">neurological dysfunctions</span>."		15814210	15814210_D003907_D009422	bcv_easy_1259				
	C005435	"<span class=""chemical"">edaravone</span>"		D015837	"<span class=""disease"">vestibulotoxicity</span>"	"Protective effect of <span class=""chemical"">edaravone</span> against streptomycin-induced <span class=""disease"">vestibulotoxicity</span> in the guinea pig."		12600698	12600698_C005435_D015837	bcv_easy_1260				
	C005435	"<span class=""chemical"">edaravone</span>"		D015837	"<span class=""disease"">vestibulotoxicity</span>"	"This study investigated alleviation of streptomycin-induced <span class=""disease"">vestibulotoxicity</span> by <span class=""chemical"">edaravone</span> in guinea pigs."		12600698	12600698_C005435_D015837	bcv_easy_1261				
	C005435	"<span class=""chemical"">Edaravone</span>"		D002544	"<span class=""disease"">cerebral infarction</span>"	"<span class=""chemical"">Edaravone</span>, a free radical scavenger, has potent free radical quenching action and is used in clinical practice to treat <span class=""disease"">cerebral infarction</span>."		12600698	12600698_C005435_D002544	bcv_easy_1262				
	C005435	"<span class=""chemical"">edaravone</span>"		D015837	"<span class=""disease"">vestibulotoxicity</span>"	"These results suggest that <span class=""chemical"">edaravone</span> suppresses streptomycin-induced <span class=""disease"">vestibulotoxicity</span>."		12600698	12600698_C005435_D015837	bcv_easy_1263				
	D004298	"<span class=""chemical"">Dopamine</span>"		D020258	"<span class=""disease"">neurotoxicity</span>"	"<span class=""chemical"">Dopamine</span> is not essential for the development of methamphetamine-induced <span class=""disease"">neurotoxicity</span>."		20533999	20533999_D004298_D020258	bcv_easy_1264				
	D004298	"<span class=""chemical"">DA/dopamine</span>"		D064420	"<span class=""disease"">toxicity</span>"	"It is widely believed that <span class=""chemical"">dopamine</span> (<span class=""chemical"">DA</span>) mediates methamphetamine (METH)-induced <span class=""disease"">toxicity</span> to brain dopaminergic neurons, because drugs that interfere with <span class=""chemical"">DA</span> neurotransmission decrease <span class=""disease"">toxicity</span>, whereas drugs that increase <span class=""chemical"">DA</span> neurotransmission enhance <span class=""disease"">toxicity</span>."		20533999	20533999_D004298_D064420	bcv_easy_1265				
	D007980	"<span class=""chemical"">L-dihydroxyphenylalanine</span>"		D020258	"<span class=""disease"">neurotoxicity</span>"	"Here we show that the recently reported ability of <span class=""chemical"">L-dihydroxyphenylalanine</span> to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA <span class=""disease"">neurotoxicity</span> is also confounded by drug effects on body temperature."		20533999	20533999_D007980_D020258	bcv_easy_1266				
	D004298	"<span class=""chemical"">DA</span>"		D020258	"<span class=""disease"">neurotoxicity</span>"	"Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced <span class=""chemical"">DA</span> <span class=""disease"">neurotoxicity</span> is also confounded by drug effects on body temperature."		20533999	20533999_D004298_D020258	bcv_easy_1267				
	D019805	"<span class=""chemical"">alpha-methyl-para-tyrosine</span>"		D020258	"<span class=""disease"">neurotoxicity</span>"	"Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of <span class=""chemical"">alpha-methyl-para-tyrosine</span> on METH-induced DA <span class=""disease"">neurotoxicity</span> is also confounded by drug effects on body temperature."		20533999	20533999_D019805_D020258	bcv_easy_1268				
	D004298	"<span class=""chemical"">DA</span>"		D020258	"<span class=""disease"">neurotoxicity</span>"	"Further, we show that mice genetically engineered to be deficient in brain <span class=""chemical"">DA</span> develop METH <span class=""disease"">neurotoxicity</span>, as long as the thermic effects of METH are preserved."		20533999	20533999_D004298_D020258	bcv_easy_1269				
	D004298	"<span class=""chemical"">DA</span>"		D009461	"<span class=""disease"">dopaminergic deficits</span>"	"In addition, we demonstrate that mice genetically engineered to have unilateral brain <span class=""chemical"">DA</span> deficits develop METH-induced <span class=""disease"">dopaminergic deficits</span> that are of comparable magnitude on both sides of the brain."		20533999	20533999_D004298_D009461	bcv_easy_1270				
	D004298	"<span class=""chemical"">DA</span>"		D020258	"<span class=""disease"">neurotoxicity</span>"	"Taken together, these findings demonstrate that <span class=""chemical"">DA</span> is not essential for the development of METH-induced dopaminergic <span class=""disease"">neurotoxicity</span> and suggest that mechanisms independent of <span class=""chemical"">DA</span> warrant more intense investigation."		20533999	20533999_D004298_D020258	bcv_easy_1271				
	D006220	"<span class=""chemical"">haloperidol</span>"		D011595	"<span class=""disease"">agitation</span>"	"If <span class=""disease"">agitation</span> becomes marked, high-potency neuroleptics (i.e., <span class=""chemical"">haloperidol</span>) may be effective."		8111719	8111719_D006220_D011595	bcv_easy_1272				
	D006493	"<span class=""chemical"">Heparin</span>"		D006470	"<span class=""disease"">hemorrhage</span>"	"<span class=""chemical"">Heparin</span>-induced thrombocytopenia, thrombosis, and <span class=""disease"">hemorrhage</span>."		6615052	6615052_D006493_D006470	bcv_easy_1273				
	D006493	"<span class=""chemical"">Heparin</span>"		D013927	"<span class=""disease"">thrombosis</span>"	"<span class=""chemical"">Heparin</span>-induced thrombocytopenia, <span class=""disease"">thrombosis</span>, and hemorrhage."		6615052	6615052_D006493_D013927	bcv_easy_1274				
	D006493	"<span class=""chemical"">heparin</span>"		D013923	"<span class=""disease"">thromboembolic</span>"	"Clinical manifestations of this disorder include hemorrhage or, more frequently, <span class=""disease"">thromboembolic</span> events in patients receiving <span class=""chemical"">heparin</span>."		6615052	6615052_D006493_D013923	bcv_easy_1275				
	D006493	"<span class=""chemical"">heparin</span>"		D006470	"<span class=""disease"">hemorrhage</span>"	"Clinical manifestations of this disorder include <span class=""disease"">hemorrhage</span> or, more frequently, thromboembolic events in patients receiving <span class=""chemical"">heparin</span>."		6615052	6615052_D006493_D006470	bcv_easy_1276				
	D006493	"<span class=""chemical"">heparin</span>"		D001791	"<span class=""disease"">a falling platelet count</span>"	"Laboratory testing has revealed <span class=""disease"">a falling platelet count</span>, increased resistance to <span class=""chemical"">heparin</span>, and aggregation of platelets by the patient's plasma when <span class=""chemical"">heparin</span> is added."		6615052	6615052_D006493_D001791	bcv_easy_1277				
	D006493	"<span class=""chemical"">heparin</span>"		D001791	"<span class=""disease"">platelet aggregation</span>"	"If the platelet count falls to less than 100,000/mm3, while the patient is receiving <span class=""chemical"">heparin</span>, <span class=""disease"">platelet aggregation</span> testing, using the patient's plasma, is indicated."		6615052	6615052_D006493_D001791	bcv_easy_1278				
